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Résumé 
 Cette thèse se compose en deux parties: 
 
 Première Partie: La conception et la synthèse d’analogues pyrrolidiniques, utilisés 
comme agents anticancéreux, dérivés du FTY720. 
 
 FTY720 est actuellement commercialisé comme médicament (GilenyaTM) pour le 
traitement de la sclérose en plaques rémittente-récurrente. Il agit comme immunosuppresseur 
en raison de son effet sur les récepteurs de la sphingosine-1-phosphate. A fortes doses, 
FTY720 présente un effet antinéoplasique. Cependant, à de telles doses, un des effets 
secondaires observé est la bradycardie dû à l’activation des récepteurs S1P1 et S1P3. Ceci 
limite son potentiel d’utilisation lors de chimiothérapie. 
 
 Nos précédentes études ont montré que des analogues pyrrolidiniques dérivés du 
FTY720 présentaient une activité anticancéreuse mais aucune sur les récepteurs S1P1 et S1P3. 
Nous avons soumis l’idée qu’une étude relation structure-activité (SARs) pourrait nous 
conduire à la découverte de nouveaux agents anti tumoraux. Ainsi, deux séries de composés 
pyrrolidiniques (O-arylmethyl substitué et C-arylmethyl substitué) ont pu être envisagés et 
synthétisés (Chapitre 1). Ces analogues ont montré d’excellentes activités cytotoxiques contre 
diverses cellules cancéreuses humaines (prostate, colon, sein, pancréas et leucémie), plus  
particulièrement les analogues actifs qui ne peuvent pas être phosphorylés par SphK, 
présentent un plus grand potentiel pour le traitement du cancer sans effet secondaire comme la 
bradycardie. 
 
 Les études mécanistiques suggèrent que ces analogues de déclencheurs de régulation 
négative sur les transporteurs de nutriments induisent une crise bioénergétique en affamant les 
cellules cancéreuses. Afin d’approfondir nos connaissances sur les récepteurs cibles, nous 
avons conçu et synthétisé des sondes diazirine basées sur le marquage d’affinité aux photons 
(méthode PAL: Photo-Affinity Labeling) (Chapitre 2). En s’appuyant sur la méthode PAL, il 
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est possible de récolter des informations sur les récepteurs cibles à travers l’analyse 
LC/MS/MS de la protéine. Ces tests sont en cours et les résultats sont prometteurs. 
 
 Deuxième partie: Coordination métallique et catalyse di fonctionnelle de dérivés β-
hydroxy cétones tertiaires. 
 
 Les réactions de Barbier et de Grignard sont des méthodes classiques pour former des 
liaisons carbone-carbone, et généralement utilisées pour la préparation d’alcools secondaires 
et tertiaires. En vue d’améliorer la réaction de Grignard avec le 1-iodobutane dans les 
conditions « one-pot » de Barbier, nous avons obtenu comme produit majoritaire la β-hydroxy 
cétone provenant de l’auto aldolisation de la 5-hexen-2-one, plutôt que le produit attendu 
d’addition de l’alcool (Chapitre 3). La formation inattendue de la β-hydroxy cétone a 
également été observée en utilisant d’autres dérivés méthyl cétone. Étonnement dans la 
réaction intramoléculaire d’une tricétone, connue pour former la cétone Hajos-Parrish, le 
produit majoritaire est rarement la β-hydroxy cétone présentant la fonction alcool en position 
axiale. Intrigué par ces résultats et après l’étude systématique des conditions de réaction, nous 
avons développé deux nouvelles méthodes à travers la synthèse sélective et catalytique de β-
hydroxy cétones spécifiques par cyclisation intramoléculaire avec des rendements élevés 
(Chapitre 4). La réaction peut être catalysée soit par une base adaptée et du bromure de lithium 
comme additif en passant par un état de transition coordonné au lithium, ou bien soit à l’aide 
d’un catalyseur TBD di fonctionnel, via un état de transition médiée par une coordination 
bidenté au TBD. Les mécanismes proposés ont été corroborés par calcul DFT. Ces réactions 
catalytiques ont également été appliquées à d’autres substrats comme les tricétones et les 
dicétones. Bien que les efforts préliminaires afin d’obtenir une enantioselectivité se sont 
révélés sans succès, la synthèse et la recherche de nouveaux catalyseurs chiraux sont en cours. 
 
Mots-clés: FTY720, cancer, cycle rigide, pyrrolidine, sondes diazirine basées sur le marquage 
d’affinité aux photons (PAL), diazirine, réaction de Barbier, réaction de Grignard, réaction 
d’auto aldolisation, β-hydroxy cétone, catalyse. 
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Abstract 
This thesis consists of two parts: 
 
Part 1: Design and synthesis of constrained azacyclic pyrrolidine analogues of 
FTY720 as anticancer agents 
 
FTY720 is presently marketed as a drug (GilenyaTM) for the treatment of relapsing-
remitting multiple sclerosis. It functions as an immunosuppressant due to its effect on 
sphingosine-1-phosphate (S1P) receptors. At higher doses, FTY720 also has antineoplastic 
actions. However, at such doses it induces bradycardia due to the activation of the S1P1 and 
S1P3 receptors. This limits its potentical to be used as a cancer therapy in humans. 
 
Our previous studies have shown that some constrained pyrrolidine analogues of 
FTY720 have anticancer activity but no activity toward S1P1 and S1P3 receptors. We reasoned 
that a study of the structure-activity relationships (SARs) could lead to the discovery of new 
effective antitumor agents. Thus, two series of constrained analogues (O-arylmethyl-
substituted pyrrolidines and C-aryl-substituted pyrrolidines) were designed and synthesized 
(Chapter 1). These analogues showed excellent cytotoxic activity against various human 
cancer cells (prostate, colon, breast, pancreas and leukemia). Especially, several active 
analogues, which cannot be phosphorylated by SphK, have the potency to be further studied in 
the treatment of cancer without inducing bradycardia.  
 
Mechanistic studies suggest that these constrained analogues trigger down-regulation 
of nutrient transporters, which induce a bioenergetic crisis and the cancer cells starve to death. 
To further investigate their target receptors, we have designed and synthesized diazirine based 
photo-affinity labeling (PAL) probes (Chapter 2). Aided by the PAL technique, information 
regarding the target receptor could be obtained through LC/MS/MS protein analysis. These 
tests are in progress and the preliminary results appear promising. 
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Part 2: Metal coordination-controlled and bifunctional catalysis toward tertiary β-
ketols 
 
The Barbier and Grignard reactions are classical methods to form carbon-carbon 
bonds, and generally used to prepare secondary or tertiary alcohols. In an attempt to perform a 
Grignard reaction with n-butyl iodide under Barbier one-pot conditions, we obtained major 
product β-hydroxyl ketol from the self-aldol reaction of 5-hexen-2-one, rather than the 
expected addition alcohol product (Chapter 3). The unusual β-ketol formation was also 
observed using other methyl ketone substrates. Interestingly, in an intramolecular reaction of a 
triketone substrate, which is well known to give the Hajos-Parrish ketone, the favored product 
was a rarely studied β-ketol with the hydroxyl group at axial position. Intrigued by these 
results, after systematic reaction condition studies, we developed two new methods toward the 
catalytic synthesis of specific β-ketols by intramolecular cylcization in high yield and 
selectivity (Chapter 4). The reaction can be catalyzed either by a suitable base and lithium 
bromide as the additive, through a lithium pre-organized transition state or by a bifunctional 
catalyst TBD (triazabicyclodecene), through a TBD mediated bidentate transition state. The 
proposed mechanisms were corroborated by DFT computation. These catalytic reactions were 
also extended to other triketone and diketone substrates. Although the initial efforts to achieve 
enantioselectivity were not successful, they merit further study of the synthesis and 
investigation of new chiral catalysts. 
 
Keywords: FTY720, cancer, constrained analogue, pyrrolidine, photoaffinity labeling (PAL), 
diazirine, Barbier reaction, Grignard reaction, self-aldol reaction, β-ketols, catalysis. 
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Chapter 1: Design and Synthesis of Constrained Azacyclic 
Pyrrolidine Analogues of FTY720 as Anticancer Agents 
 
1-1 Introduction 
1-1-1 Discovery of FTY720 
 Organ transplantation is one of the most challenging medical procedures. One of the 
major problems being transplant rejection due to immune response from the patient. During 
the 1970s and 1980s, the discovery and development of immunosuppressive drugs, such as 
rapamycin 1 , 2  (isolated from a soil sample collected from Rapa Nui) (Figure 1, 1.1), 
cyclosporin A3-5 (isolated from fungus Trichoderma polysporum) 1.2, and FK5066,7 (isolated 
from bacterium Streptomyces tsukubaensis) 1.3, have enhanced greatly the survival rate of 
organ transplant recipients, and inspired efforts of many scientists to find new 
immunosuppressant drugs from fungi and other microorganisms, as well as to synthetize 
derivatives. 
 
 In 1994, Tetsuro Fujita and coworkers reported a potent immunosuppressive agent, 
(2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2-hydroxymethyl-14-oxoeicos-6-enoic acid, termed as 
ISP-I, which was isolated from the fermentation broth of the fungus Isaria sinclairii (ATCC 
24400) (Figure 1, 1.4).8 The structure of ISP-1 (1.4) was found to be identical to the known 
antifungal agents myriocin9 (isolated from Myriococcum albomyces) and thermozymocidin10 
(isolated from Mycelia sterilia). Also, Fujita et al. found for the first time that ISP-I (1.4) had 
strong immunosuppressive activity, being 5-10 fold more potent than cyclosporin A (1.2), 
suppressing the proliferation of lymphocytes in mouse allogeneic mixed lymphocyte reaction 
(MLR) assays in vitro,8 and prolonging rat skin graft survival time in vivo at 0.1 mg / kg 
compared to 1.0 mg / kg of cyclosporin A (1.2).11 However, ISP-I (1.4) was not suitable for 
clinical application due to its toxicity and poor solubility.  
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Figure 1. Structure of rapamycin (1.1), cyclosporin A (1.2), FK506 (1.3) and ISP-I (myriocin, 
thermozymocidin, 1.4). 
 
 Optimization of ISP-I (1.4) was carefully performed and guided by structure-activity 
relationship (SAR) studies to simplify the structure and improve the physicochemical and 
biological properties. The first important analogue, ISP-I-28 (Figure 2, 1.5),11 from the 
reduction of ISP-I (1.4), exhibited reduced toxicity (100 mg / kg compared to 1 mg / kg (ISP-I 
(1.4)) using in vivo rat skin graft assay),12 and increased solubility compared to ISP-I (1.4).11,12 
ISP-I-28 prolonged rat skin graft survival time compared to cyclosporin A (1.2).11,12 In the 
MLR assay, the activity of ISP-I-28 was however dramatically diminished (IC50 : ISP-I-28 
(1.5) 1630 nM compared to ISP-I (1.4) 3 ~ 8 nM).12,13  
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 Further modification of ISP-I-28 (1.5) led to a more simplified achiral compound ISP-
I-36 (Figure 2, 1.6) by removing the three secondary alcohols.14 This analogue showed good 
immunosuppressive activity in the MLR assay (IC50 : 12 nM)11 and was more effective in 
prolonging rat skin graft survival time compared to ISP-I-28 (1.5).11 Modification of the 18-
carbon aliphatic side-chain to a shorter 14-carbon alkyl chain generated analogue ISP-I-55 
(Figure 2, 1.7),11,14 which further improved the activities in vitro and in vivo compared to ISP-
I-36 (1.6).11,14 At this stage, it was clear that the 2-amino-propane-1,3-diol hydrophilic head 
was crucial to maintain the activity, however, the lipophilic tail chain could be further 
optimized. 
 
 Further optimization led to FTY720 (Figure 2, 1.8),15,16 which was obtained by 
introducing a phenyl moiety into the side-chain with the intention to restrict the conformation 
of the hydrophobic alkyl appendage. This modification facilitated to analytical detection 
compared to non-aromatic analogues in biological testing and future clinical studies. FTY720 
(1.8) was active in vitro (IC50 : 6.1 nM in (MLR) assay),15 and prolonged significantly survival 
time in the rat skin allograft assay in vivo.15,17 It was also more favorable in terms of 
toxicology (less toxic) and physical properties (better solubility) compared to ISP-1 (1.4).15,17 
It should be noted that the activity was dependent on the position of the phenyl ring. 
Analogues bearing a phenyl group at other positions of the side-chain were less active than 
FTY720 (1.8).15,17  
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Figure 2. Optimization of ISP-I (1.4) to FTY720 (1.8) 
 
1-1-2 FTY720 in immunosuppression 
1-1-2-1 Mechanism of FTY720 in immunosuppression 
 During the discovery of FTY720 (1.8), the immunosuppressive ability of analogues 
was always evaluated by the MLR assay in vitro and the rat skin allograft assay in vivo, which 
were later found to be a crucial and fortunate choices that enabled the development of FTY720 
as a drug. The serine palmitoyl-transferase (SPT) inhibition assay is used commonly for 
measuring the activity of immunosuppressants in vitro based on inhibition of serine 
palmitoyltransferase, which is an enzyme participating in the first step of sphingosine and 
sphingolipid biosynthesis. The lead compound ISP-I (1.4) had activity in the MLR assay8 and 
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was also reported to inhibit SPT in 1995.18 However, the analogues FTY720 (1.8) and ISI-55 
(1.7) were found to only be active in the MLR assay, and not in the SPT assay.12,17 This 
indicates that the mechanism of immunosuppression has changed at some stage of the 
structural modification, and there is another mechanism responsible for the activity of FTY720 
(1.8). Thus, it is fortunate that all the analogues were screened by MLR assay; otherwise, 
FTY720 (1.8) may not have been discovered. 
   
 Since the discovery of FTY720 (1.8), efforts have been made to elucidate its 
mechanism of action. In 1996, Chiba, Fujita and coworkers noticed initially that FTY720 (1.8) 
induced a remarkable decrease of the number of peripheral blood lymphocytes (PBL), 
especially T cells, at doses that prolong allograft survival.19,20 At first, they hypothesized that 
the decrease of PBL was caused by the apoptosis of lymphocytes induced by FTY720 (1.8).21 
After realizing the blood concentration of FTY720 (1.8) was too low to induce the cell death 
of PBL, they focused on the lymphocyte recirculation.22  Lymphocytes are mobile and 
continuously travel in the body from the blood to the secondary lymphoid organs (spleen, 
lymph node), and return to the blood to complete circulation and maintain the immune system. 
Thus, the number of PBL could decrease without apoptosis of lymphocytes if FTY720 (1.8) 
modulated lymphocyte homing. This hypothesis was proven by an experiment in which single 
oral administration of FTY720 (1.8), at 0.1 to 1 mg/ kg, to rats caused the number of PBL to 
decrease significantly, while the number of lymphocytes in the lymph nodes was markedly 
increased.22 Further experiments 23 - 26  illustrated a more acceptable mechanism for the 
immunosuppressive ability of FTY720 (1.8) involving induction of the sequestration of mature 
lymphocytes into the secondary lymphoid organs, resulting in a decrease in the number of 
lymphocytes circulating in the blood, and reduced autoimmune response to the grafted organs 
and inflamed tissues. The function of lymphocytes (including the activation and proliferation 
of T cells) was not impaired in this process, making FTY720 (1.8) potentially more 
advantageous and promising as an immunosuppressant compared to other immunosuppressive 
drugs that act via inhibition of mTOR (e.g., rapamycin (1.1)2) and calcineurin (e.g., 
cyclosporin A (1.2)27,28, FK506 (1.3)27,29), blocking the activation of T cells.  
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 Although FTY720 (1.8) could induce redistribution of lymphocytes, the mechanism of 
action of FTY720 (1.8) was still not clear. Lymphocyte trafficking regulates lymphocyte 
recirculation via the lymphocyte-homing receptor. However, the lymphocyte-homing receptor 
was not required for FTY720 (1.8) to redistribute the recirculation of lymphocytes,30 and its 
real target of was unclear. Researchers observed and surmised that FTY720 (1.8) targets 
possibly G-protein-coupled receptors (GPCRs).26, 31  Based on this hypothesis, and the 
structural similarity of FTY720 (1.8) with sphingosine (Scheme 1), two groups32,33 discovered 
independently that FTY720 (1.8) targeted sphingosine 1-phosphate receptors. 
   
 Sphingosine (2-amino-4-octadecene-1,3-diol) is the backbone of sphingolipids. 
Sphingolipids and their metabolites [e.g., ceramide, sphingosine and sphingosine-1-phosphate 
(S1P) (Scheme 1)] are important signaling lipid molecules participating in a variety of cellular 
processes. In the sphingolipid metabolism (Scheme 1), sphingosine is generated from the N-
deacylation of ceramide by ceramidase. Whereas ceramide can be formed thorough either 
degradation of sphingomyelin or de novo biosynthesis starting from palmitoyl-CoA and L-
serine, sphingosine can be phosphorylated in vivo via sphingosine kinases (SphK1, 2) to give 
sphingosine-1-phosphate (S1P),34,35 which functions as an activator for five different cell 
surface GPCRs, termed as S1P1-5. These receptors are ubiquitously expressed and regulate 
diverse biological processes.35,36 S1P1-3 are widely expressed in heart, lung, brain, spleen, 
liver, thymus, kidney, adipose and other tissues.37 , 38  Specifically, S1P1 is essential for 
lymphocyte trafficking. It regulates lymphocyte egress from both the thymus and peripheral 
lymphoid organs;39,40 S1P3 is also expressed in the heart and help regulate heart rate.39 
Expressing of S1P4-5 is relatively restricted to the immune and nervous systems.38,41  
  
 As per the mechanism discovered in 2002,32,33 FTY720 (1.8) is structurally close to 
sphingosine, and can be phosphorylated by sphingosine kinases (primarily by SphK2)42 in vivo 
to form (S)-FTY720 phosphate43 (Scheme 1). This phosphate is the biologically active 
molecule, rather than FTY720 (1.8), and acts as an agonist towards four of five S1P receptors 
(S1P1, 3, 4, 5) with high affinity (Table 1).32,33  
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Scheme 1. FTY720 (1.8) and sphingolipid metabolism. 
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Table 1. Binding affinities (nM) to S1P receptors.32  
 
 S1P1 S1P2 S1P3 S1P4 S1P5 
S1P 0.47 ± 0.34 0.31 ± 0.02 0.17 ± 0.05 95 ± 25 0.61 ± 0.39 
(S)-FTY720-P 0.21 ± 0.17 > 10000 5.0 ± 2.7 5.9 ± 2.3 0.59 ± 0.27 
FTY720 300 ± 51 > 10000 > 10000 > 5000 2623 ± 317 
IC50 measurements determined by competition of S1P binding to membranes prepared from stably transfected 
CHO cells expressing the indicated S1P receptor.30 
 
  Further studies44-48 suggest that (S)-FTY720 phosphate serves as both an agonist, and 
operates as a functional antagonist. Internalization, followed by degradation of S1P1 on 
lymphocytes, results in the inhibition of S1P-S1P1 signaling-dependent lymphocyte’s egress 
from the thymus and secondary lymphoid organs (Figure 3). S1P, on the other hand, 
internalizes with S1P1, followed by recycling of the receptor without degradation.49 This 
mechanism explains the previously reported observation that FTY720 (1.8) induced a decrease 
in the number of lymphocytes in the blood, while increasing their numbers in the lymph 
nodes.22 Expression of S1P1 on the surface of lymphocytes is dependent on the concentration 
of S1P, which is stringently regulated in vivo. S1P is abundant in blood and lymph. In the 
secondary lymphoid tissues, S1P is found in low concentrations due to regulation by S1P-
degradating enzyme (S1P lyase). Therefore, the concentration gradient of S1P causes S1P1 
expression in lymphocytes to be down-regulated in blood but up-regulated in secondary 
lymphoid tissues. Lymphocyte egress from the secondary lymphoid organs is suggested to be 
mediated by S1P gradients, which are regulated by S1P lyase.50-52 Therefore, targeting this 
enzyme may lead to new immunosuppressive agents.51,52  
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Diagram from Kunitomo Adachi et al. 16a 
 
Figure 3. (S)-FTY720 phosphate inhibits S1P/S1P1-dependent lymphocyte egress from 
lymphoid tissues by long-term internalization and degradation of S1P1. 
 Based on all the accumulated evidence, the generally recognized immunosuppressive 
mechanism is that FTY720 (1.8) is first phosphorylated by SphK2 in vivo to yield (S)-FTY720 
phosphate. Then this phosphate mimics S1P, and activates the S1P1 receptor on lymphocytes, 
which is followed by long-term internalization and degradation of the S1P1 receptors, which 
resulting in a temporary state without S1P1 at the surface of lymphocyte. These lymphocytes 
cells are then unable to sense the S1P gradient between lymphoid tissues and blood or lymph, 
which ultimately prevents lymphocytes from egressing out of the secondary lymphoid organs 
(Figure 3). 
1-1-2-2 FTY720 in the treatment of multiple sclerosis (MS) 
 Since its discovery, FTY720 (1.8) has shown good immunosuppressive ability and 
potential to be used in organ transplantation. Early preclinical studies demonstrated that 
FTY720 (1.8), (daily dose from 0.1 ~ 10 mg / kg) prolonged remarkably skin and cardiac 
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allograft survival, as well as and host survival in rats.19,20,53,54 A synergistic effect was obtained 
in combination therapy of FTY720 (1.8) with subtherapeutic doses of cyclosporin A (1.2) or 
FK506 (1.3) on canine renal allograft, as well as rat skin and cardiac allografts.21,23,24,54 -57 In 
experimental autoimmune encephalomyelitis (EAE), an animal model of human MS, FTY720 
(1.8) was also highly advantageous (in the doses of 0.1 ~ 0.3 mg/Kg per day) for suppressing 
the development of EAE.31,58 Being promising in animal models of organ transplantation, 
FTY720 (1.8) was advanced to clinical studies. In the phase I clinical trials for renal 
transplantation, FTY720 (1.8) showed a good safety profile (no serious side effects except for 
transient asymptomatic bradycardia when given at high does to patient).59,60 However, in phase 
II and III trials in de novo renal transplantation, combination therapy using FTY720 (1.8) and 
Neoral™ (cyclosporine A (1.2) microemulsion, Novartis) failed to show a clear advantage 
compared to the existing standard therapy (mycophenolate mofetil (MMF) and Neoral) for 
preventing acute allograft rejection in terms of efficacy, or adverse effects (bradycardia and 
other unexpected side effects including impairment of renal function and macula oedema).61-64 
After discontinuation of FTY720 (1.8) in trials in renal transplantation, the potential of 
FTY720 (1.8) was explored in the treatment of MS. 
   
 Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system 
(CNS, including brain and spinal cord). First reported in 1868,65 there were about 2.5 million 
MS patients all over the world in 2008.66 MS is unpredictable, and its causes are still not clear. 
Most people are first affected by MS when they are 20 ~ 40 years old (women twice as often 
as men).67 Studies show that MS is an inflammatory disease caused by myelin being attacked 
by the immune system. Myelin covers and protects nerves of the brain and spinal cord. 
Frequent demyelination and remyelination lead to scarring of axons, which leads to electrical 
signals being unable to conduct effectively.67, 68  Generally, there are four types of MS 
depending on the pattern of disease: relapsing-remitting MS (RR-MS), secondary progressive 
MS (SP-MS), primary progressive MS (PP-MS) and progressive relapsing MS (PR-MS).69 It 
is noteworthy that 85% of patients have RR-MS.70  
   
  11 
 Although MS usually progresses slowly, to date there is no cure. Current therapies are 
focused on suppressing and slowing down the development of MS by reducing relapses and 
managing symptoms at the same time. Disease modifying therapies (DMTs) are the most 
common therapies used in the treatment of MS. Before 2010, the classic immunomodulator 
drugs for DMTs were interferon-β (IFN-β) products (Avonex®, Betaseron®, Extavia® and 
Rebif®), glatiramer acetate (Copaxone®) and natalizumab (Tysabri®). These medications 
need to be administered by injection or intravenous (iv) infusion. They are limited due to their 
modest efficacy and side-effects. The discovery and development of more effective therapies 
for MS remains an important topic in drug discovery. In 2010, FTY720 (Gilenya™) (1.8) was 
approved by the Food and Drug Administration (FDA) as the first oral drug for treating MS. 
Then in 2014, two new oral drugs, Teriflunomide (Aubagio®) and dimethyl fumarate 
(Tecfidera™) were approved, as well as Alemtuzumab (Lemtrada™), which is given by iv 
infusion.  
   
 FTY720 (1.8) has significantly improved the efficacy in reducing relapse rate 
compared to a common therapy, IFN-β-1a (Avonex®), in phase III clinic trials.71 Mechanistic 
studies have demonstrated that, as an immunomodulator, FTY720 (Gilenya™) (1.8) works 
through sequestering lymphocytes in lymph tissues; therefore, there are less immune cells to 
infiltrate and attack the CNS causing autoimmune responses, and the resulting relapses are 
reduced.72 The immune system of the patient is not affected by the administration of FTY720 
(1.8), and can still respond to other infections, because FTY720 (1.8) does not impair the 
function of lymphocytes,73 Besides effects on the immune system through phosphorylation, 
FTY720 (1.8) can also cross the blood–brain barrier (BBB),74 and directly act on the CNS, 
which may contribute to its efficacy in the treatment of MS.73,75  
   
 Although FTY720 (Gilenya™) (1.8) has been approved for the treatment of MS, it can 
induce bradycardia,71, 76  a potentially fatal side-effect. Thus, it is advised that the first 
administration should be conducted and monitored in a hospital. Bradycardia, the decreasing 
of heart rate, is probably caused by FTY720-phosphate activating S1P3 receptors which 
regulate heart rate.39 However, recent studies have suggested that bradycardia is mediated by 
S1P1,77 and may not be avoided, because S1P1 is targeted by FTY720 (1.8). Safety and 
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tolerability studies in clinical trials have deemed FTY720 (1.8) safe and promising as therapy 
for MS.71,76  
1-1-3 FTY720 in cancer therapy 
 FTY720 (1.8) is not only an immunomodulator, but also an efficient antitumor agent.78 
FTY720 (1.8) has been evaluated in multiple cancer cell lines in vitro and in vivo. For 
example, it acts against human glioma cell line T98G with an ED50 of 1~10 µg/mL,79 and 
markedly suppressed the proliferation of two glioblastoma cancel cell lines (U251MG and 
U87MG) at concentrations above 7 µM.80 In breast cancer studies, it killed 80% of mouse 
breast cancer JygMC(A) cells in vitro at 10 µM after 12 h and significantly inhibited tumor 
growth in vivo at 5 mg/kg per day or higher doses without any notable adverse effects.81 In test 
with three human breast cancer cell lines (MCF-7, MDA-MB-231 and Sk-Br-3), it also 
showed good antitumor activity with IC50 5~7 µM.82 For human colon cancer cell lines (HCT-
116 and SW620), it also maintained activity with IC50 5~7 µM.82 FTY720 (1.8) has been 
evaluated against prostatic cancer shortly after it was discovered. In 1999, researchers found it 
induced rapid death of a human prostatic carcinoma cell line DU145 in vitro at concentrations 
of 20 µM or more.83 The following in vitro studies with another human prostate cancer cell 
line (PC3), as well as DU145, indicated FTY720 (1.8) exhibited very strong anticancer ability 
(IC50: 1.48, 1.50 µM respectively),84 and suppressed the growth of human prostate cancer 
LNCaP-AI cells.85 In in vivo studies with nude mice xenografted with human prostate cancer 
cells CWR22R, the growth of tumor was significantly inhibited by treatment with FTY720 
(1.8) at 10 mg/kg/day for 20 days, without notable side effects.86 FTY720 (1.8) exhibits the 
potential to treat various forms of leukemia, such as acute lymphoblastic leukemia (ALL),87,88 
chronic lymphocytic leukemia (CLL)87 and chronic myelogenous leukemia (CML). 89  It 
inhibits the proliferation of B-cell lines in vitro, including two ALL cell lines (697, RS4;11) 
and CLL B cells from CLL patients, MEC-1 CLL cells, and Burkitt lymphoma cell lines (Raji, 
Ramos).87 In in vivo tests of FTY720 (1.8) using xenografted mice, a model of disseminated 
B-cell lymphoma/leukemia, it was found that the survival time of the mice was markedly 
prolonged.87 Further studies in ALL indicated FTY720 (1.8) induced apoptosis in both 
Philadelphia positive (Ph+) and native (Ph-) cell lines.88For other blood cancers, FTY720 (1.8) 
also showed potential in the treatment of multiple myeloma,90 lymphoblastic lymphoma87 and 
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mantle cell lymphoma.91 In addition to the cancers mentioned above, many studies have 
demonstrated that FTY720 (1.8) also has antitumor activity in lung cancer, 92 - 95  liver 
cancer,96,97 ovarian cancer,98,99 bladder cancer,100 renal cancer101 and other cancers.78 
   
 Since FTY720 (1.8) acts against a variety of cancers, the anticancer mechanisms 
involved are varied and complicated. It has been noted that FTY720-phosphate, which is 
essential for the immunosuppressive effect, did not inhibit the proliferation of breast cancer 
cells (MCF-7, MDA-MB-231, Sk-Br-3) or colon cancer cell lines (HCT-116, SW620).82 In 
contrast, FTY720-phosphate induced a slight growth of MCF-7 cells at low concentration,82 
thus indicating that phosphorylation of FTY720 (1.8) is not responsible for the anticancer 
activity. Further studies, in 2010, found that both FTY720 (1.8) and one of its analogues, (S)-
FTY720 vinylphosphonate induced apoptosis of MCF-7 and LNCaP-AI cancer cells due to 
inhibition followed by degradation of SphK1.102,103 As discussed previously (Scheme 1), there 
are two types of sphingosine kinases (SphKs). FTY720 (1.8) is phosphorylated most by 
SphK2 to yield immunosuppressant FTY720-phosphate, while SphK1 is already highly 
recognized in association with various cancers, and it participates in the multiplication, 
migration and impairment of apoptosis in cancer cells.78,104 Thus, FTY720 (1.8), as a SphK1 
inhibitor, disturbs S1P/S1P receptor mediated signaling to induce the apoptosis of cancer 
cells.78 Higher concentrations of FTY720 (1.8), and the related S1P receptor expression in 
tissues, may cause the former to act as an antitumor agent rather than as an 
immunomodulator.78 In addition to SphK1, many other targets have been proposed, such as B-
cell lymphoma 2 (Bcl-2), reactive oxygen species (ROS), protein phosphatase 2A (PP2A), 
extracellular-signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), 
PI3K/AKT/mTOR signaling pathway, phosphatase and tensin homolog (PTEN), Cyclin D1 
and 14-3-3 proteins.78 By activating these molecular targets, FTY720 (1.8) induces apoptosis 
and cancer cell death.78  
   
 Besides apoptosis of cancer cells through a caspase-dependent pathway or caspase-
independent cell death, autophagy was also found to contribute to the anticancer activity of 
FTY720 (1.8).78 Autophagy is a term for cell self-degradation through lysosomes to remove 
unnecessary cytoplasmic components.105 It’s a survival process for cells to balance the energy 
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levels when they are under nutrient stress.105 However, autophagy could also lead to cell death 
under excessive activation.106 Autophagy has been reported to be induced by FTY720 (1.8) in 
cancer cells, such as ALL cell lines,88 ovarian cancer cells,98,99 and multiple myeloma U266 
cell lines.107 Cancer cell survival may be dependant on the type of cell. For example, FTY720 
(1.8)-induced autophagy promoted the apoptosis of the multiple myeloma U266 cell line.107 In 
ALL,88 and ovarian cancer cells,98,99 inhibition of induced autophagy protected cells from 
death resulting enhanced anticancer activity.98,99 In addition, Edinger108 reported that FTY720 
(1.8) induced cell starvation in the presence of abundant nutrients by down regulating nutrient 
transporter proteins, which resulted in autophagy for self-protection. Cancer cells starved to 
death but normal cells can adapt to the nutrient stress and survive.108 Meanwhile, this 
bioenergetic stress led to apoptosis even if it’s found to be not necessary, because the nutrient 
stress was severe enough to kill cancer cells when apoptosis was block. Thus, FTY720 (1.8) 
can effectively and selectively starve cancer cells to death.108  FTY720 (1.8) induced 
autophagy, and induced blockage of autophagy to enhance the anticancer efficacy of 
milatuzumab in mantle cell lymphoma.109,110 Therefore, the autophagy and apoptosis induced 
by FTY720 (1.8) involved in its antitumor mechanisms are complicated. Although many 
targets and mechanisms have been proposed, the anticancer effects of FTY720 (1.8) remain 
unclear. 
 
 Bradycardia is a known side-effect of FTY720 (1.8) when used to treat MS, so the 
recommended dose is only 0.5 mg per day. Although FTY720 has anticancer activity against 
various cancers, the required dose for in vivo studies on mice generally are 5~10 mg per 
day,81,86 which are much higher than those needed for immunosuppressive treatment. Even if 
no notable side effects were observed in mice at such high does,81,86 the increased chance of 
triggering bradycardia, and other potential adverse effects, limited the use of FTY720 (1.8) in 
human cancer treatment. Therefore, finding the right FTY720 (1.8) analogues lacking dose-
limiting toxicity, but maintaining good anticancer proprieties, has attracted the attention of 
many scientists and has already shown promise in the discovery of new anticancer drugs. For 
example, AAL-149,33,111 an analogue of FTY720 (1.8) tested by Edinger,108 killed human ALL 
Sup-B15 cells by down-regulating nutrient transporter proteins, but does not induce 
bradycardia due to its inability to be phosphorylated and activate S1P receptors. 
  15 
1-1-4 Constrained analogues of FTY720 in S1P receptors studies 
 As a prodrug,  FTY720 (1.8) can be phosphorylated to generate FTY720-phosphate, 
which binds non-selectively to four of the five S1P receptors.32,33 In general, in order to bind 
to a receptor, a ligand needs to change its conformation to adapt itself to a certain shape 
(bioactive conformation), which can fit the binding pocket of the receptor to be recognized. 
FTY720 (1.8) bears a lipophilic long alkyl chain and a hydrophilic amino-diol, which are 
linked by a phenylene group in a 1,4-configuration. This structure affords a high level of 
flexibility, even for the phosphorylated product, FTY720-phosphate. Thus, to understand how 
the conformations of FTY720 (1.8) affect these receptors, and further develop new FTY720 
(1.8) analogues that can selectively target S1P receptors, constrained analogues were of 
particular interest. For instance, MacDonald and coworkers reported a series of constrained 
analogues based on modification of the polar moiety of FTY720 (1.8) (Figure 4), including 
bond 1-constrained analogues 1.9a-d, 112  bond 2-constrained analogue 1.10,112 bond 3-
constrained analogue 1.11,112 bond 1,2-constrained analogues 1.12a,112 1.12b,113 1.12c and 
1.12d,114 bond 2,3-constrained analogue 1.13112,115  and variety of heterocyclic analogues 
(1.14a,116 1.14b117,118). It became clear that the constrained chemical space had a great 
influence on the biological activity. For example, 1.9b and 1.9c can be phosphorylated by 
SphK in vivo, while 1.10, 1.11 and 1.12a cannot be phosphorylated.112 The phosphate of 1.9b 
is an agonist for S1P1, 3 receptors,112 but 1.12b-phosphate is a selective S1P1,3 antagonist.113 
The phosphates of 1.12c and 1.12d are S1P1 agonists, but 1.12c-phosphate is an antagonist of 
S1P3 receptors. The indane-based analog 1.13a cannot be phosphorylated, but the tetralin-
based analog 1.13b is phosphorylated by SphK2 and is a potent agonist for S1P1.112,115 
Phenylimidazole-based analogue 1.14a is a selective S1P4 agonist,116 while the oxazole and 
oxadiazole heterocyclic compounds (e.g.,1.14b-f) are good substrates for SphK, and their 
phosphates have better S1P1 / S1P3 selectivity compared to FTY720-phosphate.117,118 By 
evaluating these analogues, potential S1P ligands were discovered, and the structural 
requirements of the S1P receptors were better understood. 
 
  16 
 
Figure 4. Examples of constrained analogues reported by Macdonald.112-113114115116117118 
 
 Our group has a long-standing interest in the design and synthesis of constrained 
analogues of FTY720 (1.8). In 2007, two enantiomeric 2,3,5-trisubstituted pyrrolidines (1.15, 
1.16), were made as constrained azacyclic analogues. 119 The corresponding phosphates (1.17, 
1.18, 1.19, 1.20) were also synthesized (Figure 5).119 Starting from α,β-unsaturated lactam 
1.21, cuprate 1,4-addition generated the aryl bromide 1.22 with good diastereomeric 
selectivity. The alkyl chain was then incorporated by a Suzuki coupling reaction followed by 
hydrogenation, to yield intermediate 1.23. Reduction of the lactam with Super-hydride, 
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followed by trapping as the O-methyl aminal, and titanium-catalyzed allylation, afforded tetra 
substituted pyrrolidine 1.24 as the only diastereomer. With 1.24 in hand, the terminal olefin 
was isomerized to the 1,2-disubstituted alkene, which was then cleaved by ozonolysis and the 
aldehyde was reduced with sodium borohydride to obtain the alcohol 1.25. Finally, 
deprotection with TBAF, followed by treatment with HCl, led to the constrained analogue 
1.15. The same protocol was used to prepare the enatiomeric analogue 1.16.119  
 
  
 
 
Figure 5. Constrained 2,3,5-trisubstituted pyrrolidine analogues. 
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Scheme 2. Synthesis of constrained 2,3,5-trisubstituted pyrrolidine analogue 1.15.  
 
 
 
 The biological activities of enantiomers 1.15 and 1.16 are quite different. Analogue 
1.15 was rapidly phosphorylated by SphK2 in vitro, being 4 times faster than the 
phosphorylation of FTY720 (1.8), but 1.16 was not a substrate for SphK.119 Further evaluation 
in calcium release assays demonstrated significant selective affinities for S1P4 and S1P5 
receptors, over S1P1 and S1P3  receptors for all of the four chemically synthesized phosphates 
(1.17, 1.18, 1.19, 1.20) compared to FTY720-phosphate and S1P. Among these phosphates, 
1.17 and 1.18 were the most efficient agonists for S1P4 and S1P5, and were generated 
enzymatically from 1.15.119 Thus, constraining the conformation of FTY720 (1.8), and 
changing the stereochemistry of the analogues has had significant influence on biological 
proprieties.  
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1-1-5 Design of new constrained pyrrolidine analogues of FTY720 
 Interesting biological results obtained using constrained FTY720 analogues,Error! 
Bookmark not defined. especially the observation of low affinity toward S1P1 and S1P3 for the 
phosphate analogues, indicate a path for lowering the chance of triggering bradycardia to 
enhance the potential for drug development. We decided to continue SAR studies of novel 
constrained analogues of FTY720 (1.8). To evaluate their effects on cancer cell lines, we have 
collaborated with the Edinger group in department of cell & developmental biology at the 
University of California-Irvine. Based on the idea of constraining FTY720 (1.8), we designed 
two new series of pyrrolidine analogues to test if both hydroxymethyl arms were necessary for 
activity (Scheme 3). One of the series was designed bearing O-substituted benzyl ethers to 
simplify the synthetic approach and increase conformational flexibility of the aryl appendage, 
and included substitution on the 2,3-, 2,4-, and 3-positions of the pyrrolidine ring,120 The other 
C-aryl series pursued the design of our pervious studies119 to gain further understanding of the 
influence of stereochemistry and to optimize the molecular structure.   
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Scheme 3. Design of two series of constrained pyrrolidine analogues of FTY720 (1.8). 
 
 
 
1-2 Results and Discussion 
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reaction could be obtained by a simple substitution reaction with 4-bromobenzyl bromide. The 
hydroxypyrrolidine scaffold can be easily accessed, either directly from enantiomerically pure 
natural products that already possess the same stereocenters (e.g. hydroxylproline, 
hydroxylpyrrolidine), or by known procedures.120  
 
Scheme 4. Retrosynthesis of constrained O-arylmethyl-substituted pyrrolidine analogues 
 
 
 
1-2-1-1 Synthesis of 2-hydroxylmethyl-3-O-arylmethylpyrrolidine analogues 
1-2-1-1-1 Synthesis of trans-2-hydroxymethyl-3-O-arylmethylpyrrolidine analogues 
 As per our synthetic protocol (Scheme 4), pyrrolidine intermediate 1.29 was prepared 
by a known procedure starting from D-serine (1.26, Scheme 5).121 Protection of the alcohol as 
a tert-butyldimethylsilyl ether afforded 1.27 in 79 % yield. The carboxylic acid group of 1.27 
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with two equivalents of allylmagnesium bromide to yield an allylketone intermediate, which 
was further reduced by sodium borohydride to give 1.28 as a single diastereomer in 42 % yield 
(two steps). Oxidative cleavage of the terminal olefin of 1.28, followed by cyclization, led to 
an aminal intermediate, which was then reduced using triethylsilane and boron trifluoride to 
afford the required (2R,3S)-2-(tert-butyldimethylsilyl)oxy)methyl-3-hydroxypyrrolidine 
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intermediate 1.29 (14 % yield from 1.29 in 5 steps). With 1.29 in hand, a substitution reaction 
on 4-bromobenzyl bromide furnished aryl bromide intermediate 1.30. The alkyl chain was 
then introduced through a Suzuki coupling reaction followed by hydrogenation to afford 1.31 
in 69% yield (two steps). Finally, global deprotection of 1.31 using hydrogen chloride in 1,4-
dioxane gave the desired (2R,3S)-2-hydroxymethyl-3-O-arylmethylpyrrolidine analogue 1.32 
as the hydrochloride salt in 9 steps from D-serine (1.26), and 6 % overall yield.  
 
Scheme 5. Synthesis of (2R,3S)-2-hydroxymethyl-3-O-arylmethylpyrrolidine 1.32. 
 
 
   
 After successfully synthesizing 1.32, the enantiomer (1.39) was prepared from L-serine 
1.33 via the same route in 7 % overall yield (Scheme 6).  
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Scheme 6. Synthesis of (2S,3R)-2-hydroxymethyl-3-O-arylmethylpyrrolidine 1.39. 
 
 
 
1-2-1-1-2 Synthesis of cis-2-hydroxymethyl-3-O-arylmethylpyrrolidine analogues 
 Starting with the key hydroxypyrrolidine intermediate 1.29, the hydroxyl group was 
oxidized using Dess–Martin periodinane to yield ketone 1.40, which was then reduced by L-
selectride to provide the desired (2R,3R)-2-(tert-butyldimethylsilyl)oxy)methyl-3-
hydroxypyrrolidine intermediate 1.41 as a single isomer. Hydride attack occurred from the 
bottom face of pyrrolidine due to the bulky OTBS group on the top face. With 1.41 in hand, 
we used the same protocol as in our synthesis of the trans-2,3-substituted analogues to afford 
cis-2,3-substituted pyrrolidine analogue 1.44 as the hydrochloride salt (6 steps from 
intermediate 1.29, 41 % overall yield, Scheme 7). In this way, hydroxymethylpyrrolidine 1.49, 
the enantiomer of 1.44, was also prepared starting from the enantiomeric intermediate (2S, 3R) 
-1.36 in 44 % overall yield (Scheme 8).   
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Scheme 7. Synthesis of (2R,3R)-2-hydroxymethyl-3-O-arylmethylpyrrolidine 1.44. 
 
Scheme 8. Synthesis of (2S,3S)-2-hydroxymethyl-3-O-arylmethylpyrrolidine 1.49. 
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1-2-1-2 Synthesis of 2-hydroxymethyl-4-O-arylmethylpyrrolidine analogues 
1-2-1-2-1 Synthesis of trans-2-hydroxymethyl-4-O-arylmethylpyrrolidine analogues 
 trans-2,4-Substituted pyrrolidine analogues were first synthesized by Dr. Rebecca 
Fransson in our group.120 Starting from commercially available trans-4-hydroxy-L-proline 
1.50, protection of the free amine 1.50 as tert-butyl carbamate 1.51, followed by the reduction 
of the carboxylic acid to the primary alcohol 1.52 using ethyl chloroformate to generate a 
mixed anhydride that was reduced by treatment with aqueous sodium borohydride and TBAB 
(as a phase transfer reagent).122 The resulting primary alcohol was then protected as tert-
butyldimethylsilyl ether 1.53, to which was added the side-chain using the previously 
described substitution-coupling-hydrogenation route to give intermediate 1.55. Removal of all 
the protecting groups from 1.55 using TBAF yielded alcohol 1.56, and treatment with 
hydrogen chloride in 1,4-dioxane, led to (2S,4R)-2-hydroxymethyl-4-O-arylmethylpyrrolidine 
analogue 1.57 as the hydrochloride salt (Scheme 9). Similarly, the enantiomer 1.65 was 
prepared from trans-4-hydroxy-D-proline 1.58 (Scheme 10).   
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Scheme 9. Synthesis of (2S,4R)-2-hydroxymethyl-4-O-arylmethylpyrrolidine 1.57. 
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Scheme 10. Synthesis of (2R,4S)-2-hydroxymethyl-4-O-arylmethylpyrrolidine 1.65. 
 
 
 
 With the successful synthesis of trans-2-hydroxymethyl-4-O-arylmethylpyrrolidines 
1.57 and 1.65, we prepared several analogues modifying the hydroxymethyl arm. To prevent 
the analogues from being phosphorylated by cells, the hydroxyl group was removed. 
Protection of alcohol 1.63 as methyl ether 1.66, followed by treatment with hydrogen chloride 
in 1,4-dioxane generated (2R,4S)-2-methoxymethyl-4-O-arylmethylpyrrolidine 1.67 (Scheme 
11). Transformation of the alcohol 1.63 to the methanesulfonate 1.68 by reaction with MsCl 
and Et3N followed by deoxygenation using Super-hydride afforded methyl pyrrolidine 1.69 in 
92 % yield.123,124 Deprotection afforded (2R,4S)-2-methyl-4-O-aryl-methylpyrrolidine 1.70 
(Scheme 12). With the same synthetic strategy, enantiomer 1.73 was prepared from 
intermediate 1.56 (Scheme 13).  
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Scheme 11. Synthesis of (2R,4S)-2-methoxymethyl-4-O-arylmethylpyrrolidine 1.67. 
 
 
 
Scheme 12. Synthesis of (2R,4S)-2-methyl-4-O-arylmethylpyrrolidine 1.70. 
 
 
 
Scheme 13. Synthesis of (2S,4R)-2-methyl-4-O-arylmethylpyrrolidine 1.73. 
 
 
  
 To evaluate the effects on S1P receptors of analogues 1.57 and 1.65, their phosphates 
1.75 and 1.77 were also prepared. Using the protocol that was described in Charron’s work,119 
starting from the 2-hydoxymethyl-4-O-arylmethylpyrrolidine intermediate 1.56. The primary 
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alcohol was converted to a di-tert-butyl phosphite ester using phosphoramidite chemistry, and 
then oxidized using m-CPBA to generate the desired di-tert-butyl phosphate ester 1.74. 
Removal of the Boc protecting group using hydrogen chloride afforded phosphate 1.75 (the 
phosphorylated analogue of 1.57) (Scheme 14). The enantiomeric phosphate analogue 1.77 
was made in the same way from (2R, 4S)-1.64 (Scheme 14). 
 
Scheme 14.Synthesis of (2S,4R)- and (2R,4S)-2-(methyl-dihydrophosphate)-4-O- 
arylmethylpyrrolidines 1.75 and 1.77. 
 
 
 
1-2-1-2-2 Synthesis of cis-2-hydroxylmethyl-4-O-arylmethylpyrrolidine analogues 
 The cis-2-hydroxylmethyl-4-O-arylmethylpyrrolidine analogues were prepared by Dr. 
Rebecca Fransson.120 Among these, analogue 1.83 was synthesized from the relatively cheap 
and commercially available N-Boc-cis-4-hydroxy-D-proline (1.78), Instead of the two steps 
sequence used in the synthesis of trans-analogues 1.56 and 1.65 (Scheme 9 and 10), the 
carboxylic acid of 1.78 was reduced with borane in THF to generate the primary alcohol 1.79. 
With diol 1.79 in hand, the same synthetic protocol used for the synthesis of 1.56 and 1.65 
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(Scheme 9 and 10) was employed to prepare (2R,4R)-2-hydroxymethyl-4-O-
arylmethylpyrrolidine 1.83 as the hydrogen chloride salt (Scheme 15). 
 
Scheme 15. Synthesis of (2R,4R)-2-hydroxymethyl-4-O-arylmethylpyrrolidine 1.83.  
 
 
 
 To avoid using expensive cis-4-hydroxy-L-proline (120 $ / mmol in Aldrich), a 
Mitsunobu reaction was performed on inexpesive N-Boc-trans-4-hydroxy-L-proline methyl 
ester (1.84) (7.5 $ / mmol in Aldrich). The secondary alcohol was inverted to furnish the cis-4-
hydroxyproline methyl ester intermediate, which was reduced using LiBH4 to afford cis-4-
hydroxy-L-prolinol 1.85. (2S,4S)-2-hydroxymethyl-4-O-arylmethylpyrrolidine 1.89 was 
prepared using the same procedure as for 1.83 (Scheme 16). 
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Scheme 16. Synthesis of (2S,4S)-2-hydroxymethyl-4-O-arylmethylpyrrolidine 1.89.  
 
 
 
1-2-1-3 Synthesis of 3-O-arylmethylpyrrolidine analogues 
 Compared to the di-substituted pyrrolidine analogues, the 3-O-arylmethyl substituted 
analogues were easier to prepare. Starting from 3-hydroxy-pyrrolidine (1.90), Boc protection 
of the amine, followed by our previously described procedures to furnish the long alkyl chain 
yielded 1.93, which was deprotected using hydrogen chloride afforded the (R)-3-O-
arylmethylpyrrolidine 1.94 in five steps (Scheme 17). The same route was used for synthesis 
of the enantiomer 1.99 (Scheme 18). These two analogues were also prepared by Dr. Rebecca 
Fransson.120 
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Scheme 17. Synthesis of (R)-3-O-arylmethylpyrrolidine 1.94. 
 
Scheme 18. Synthesis of (S)-3-O-arylmethylpyrrolidine 1.99. 
 
  
 In sum, we prepared a series of constrained O-arylmethyl substituted pyrrolidine 
analogues (Figure 6), including all the diastereomers of 2-hydroxymethyl-3- and -4-
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arylmethylpyrrolidine analogues, 3-O-arylmethylpyrrolidine analogues, and several 2-
substituted-4-O-arylmethylpyrrolidine analogues with a modified 2-hydroxymethyl arm. 
 
Figure 6. List of synthesized constrained O-arylmethylpyrrolidine analogues. 
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1-2-2 Synthesis of constrained C-aryl substituted pyrrolidine analogues 
1-2-2-1 Synthesis of 2,5-bis(hydroxymethyl)-3-arylpyrrolidine analogues 
 Continuing Charron’s research on 2,5-bis(hydroxymethyl)-3-arylpyrrolidine analogues 
1.15 and 1.16 (Figure 5),119 to understand the influence of stereochemistry on these tri-
substituted analogues, two new diastereomers 1.100 and 1.101 were considered (Scheme 19). 
We envisioned that the second hydroxymethyl arm of 1.100 would be accessed from the 
(2S,3S)-2-hydroxymethyl-3-aryl substituted lactam intermediate using the same strategy as in 
the synthesis of 1.15.119 This lactam could be obtained from an α,β-unsaturated lactam by 
hydrogenation, with hydrogen delivery from the opposite face of the bulky OTBDPS ether. 
The unsaturated lactam would be provided on selenoxide installation and elimination from the 
intermediate 1.23, which was previous used in the synthesis of 1.15.119 Both enantiomers 
1.101 and 1.100 could be obtained using the same protocol. 
 
Scheme 19. Retrosynthetic analysis of (2S,3S,5S)-2,5-bis(hydroxymethyl)-3-aryl- 
pyrrolidine 1.100. 
 
 
   
 Starting from 1.23, which was prepared using Charron’s procedure (Scheme 2),119 the 
α-position of the lactam was deprotonated with LiHMDS, and the anion was reacted with 
phenylselenyl bromide to generate the selenide intermediate, which was oxidized with 
hydrogen peroxide to the selenoxide, and eliminated to afford α,β-unsaturated lactam 1.103. 
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Hydrogenation with 1.103 provided the desired cis-2,3-substituted lactam 1.104 as a single 
isomer. With lactam 1.104 in hand, the protocol previous described for synthesizing 1.15 
(Scheme 5), was used to provide (2S,3S,5S)-2,5-bis(hydroxymethyl)-3-arylpyrrolidine 1.100 
as the hydrochloride salt in nine steps from 1.23, and 9 % overall yield, Scheme 20). The 
enantiomer 1.101 was prepared in the same way from intermediate 1.107 (Scheme 21).   
 
Scheme 20. Synthesis of (2S,3S,5S)-2,5-bis(hydroxymethyl)-3-arylpyrrolidine 1.100. 
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Scheme 21. Synthesis of (2R,3R,5R)-2,5-bis(hydroxymethyl)-3-arylpyrrolidine 1.101. 
 
 
 
1-2-2-2 Synthesis of 2,3-substituted C-aryl analogues 
1-2-2-2-1 Synthesis of 2-hydroxylmethyl-3-arylpyrrolidine analogues 
 2,3-Substituted C-aryl pyrrolidine analogues were designed to determine the 
importance of the second hydroxymethyl arm. These analogues were prepared from key 
lactam intermediates by reduction of the lactam. For example, treatment of lactam 1.23 with 
borane dimethyl sulfide complex gave pyrrolidine 1.112. Removal of the TBDPS protecting 
group from 1.112 unveiled the primary alcohol 1.113, and Boc group removal using hydrogen 
chloride afforded 2,3-substituted C-aryl pyrrolidine 1.114 in good yield (Scheme 22). 
Similarly, three other 2,3-substituted C-aryl pyrrolidine diastereomers 1.117, 1.120 and 1.123 
were prepared from the corresponding lactams (Scheme 22). The cis-configuration and 
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bulkiness of the OTBDPS group and the phenyl side chain in 1.118 and 1.121, necessitated 
heating the reaction to 40 °C to cleave the silyl ether. 
 
Scheme 22. Synthesis of 2-hydroxylmethyl-3-arylpyrrolidines 1.114, 1.117, 1.120 and 1.123. 
 
 
 
1-2-2-2-2 Synthesis of 2-hydroxylmethyl-3-aryl-substituted lactam analogues 
 To compare the effects of a lactam to those of a free amine (pyrrolidine), several 
lactams (e.g.,1.124, 1.125, 1.126 and 1.127) were prepared by removing all of the protecting 
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groups from key intermediates (e.g., 1.23, 1.107, 1.104 and 1.109) using a 9:1 mixture of TFA 
and water (Scheme 23).    
 
Scheme 23. Synthesis of 2-hydroxylmethyl-3-aryl-substituted lactams 1.124, 1.125, 1.126 and 
1.127. 
 
 
 
1-2-2-2-3 Synthesis of 2-methoxymethyl- and 2-methyl-3-arylpyrrolidine analogues  
 As described for the constrained O-arylmethyl substituted pyrrolidine analogues (e.g., 
1.67, 1.70 and 1.73, Scheme 11-13), to gauge the importance at the hydroxyl group for 
activity, alcohols 1.113 and 1.116 were converted to methyl ethers 1.129 and 1.131 (Scheme 
24), and the hydroxyl group were removed to afford methyl analogues 1.134 and 1.137 in 
good yield (Scheme 25), employing simlar same synthetic protocols as those described for 
preparing compounds 1.67, 1.70 and 1.73 (Scheme 11-13). 
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Scheme 24. Synthesis of 2-methoxymethyl-3-arylpyrrolidines 1.129 and 1.131. 
 
 
 
Scheme 25. Synthesis of 2-methyl-3-arylpyrrolidines 1.134 and 1.137. 
 
 
 
1-2-2-2-4 Synthesis of phosphates of 2-hydroxylmethyl-3-arylpyrrolidine analogues.  
 In order to probe the effect of phosphorylation, the phosphates of 1.114 and 1.117 were 
prepared. Starting from alcohols 1.113 and 1.116, using the same procedure as described for 
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the synthesis of phosphates 1.75 and 1.77, the corresponding phospahtes 1.139 and 1.141 were 
obtained in moderate yield (Scheme 26).  
 
Scheme 26. Synthesis of 2-methyldihydrophosphate-3-arylpyrrolidines 1.139 and 1.141. 
 
 
 
1-2-2-3 Synthesis of 2-hydroxymethyl-4-arylpyrrolidine analogues 
 As shown in the retrosynthetic analysis, outlined in scheme 27, we envisioned that both 
cis and trans-2-hydroxymethyl-4-arylpyrrolidine analogues could be obtained by the selective 
hydrogenation of unsaturated pyrrolidine intermediates. cis-Diastereomers would be obtained 
by taking advantage of the bulky OR group to direct hydrogen addition from the opposite face. 
A free hydroxyl group may direct hydrogenation to the same face to generate the trans-
diastereomers. The unsaturated pyrrolidine could result from by elimination of a tertiary 
alcohol intermediate, which could be obtained through addition of a phenyl lithium to a 4-
oxopyrrolidine intermediate, derived from the corresponding 4-hydroxy-proline. The 
organolithium reagent could be prepared from 1-bromo-4-octylbenzene, which would be 
produced by a coupling reaction between 1,4-dibromobenzene and octyl magnesium bromide.    
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Scheme 27. Retrosynthetic analysis of 2-hydroxymethyl-4-arylpyrrolidines. 
 
 
 
1-2-2-3-1 Synthesis of cis-2-hydroxymethyl-4-arylpyrrolidine analogues  
 We began with the synthesis of the common intermediate 1-bromo-4-octylbenzene 
1.142, which was prepared by a palladium-catalyzed coupling reaction between 1,4- 
dibromobenzene and octyl magnesium bromide (Scheme 28).125 Protection of cis-4-hydroxyl-
proline (1.143) as tert-butyl carbamate followed by oxidation using trichloroisocyanuric acid 
and TEMPO gave the 4-oxoproline 1.144 in 87 % yield over two steps. To introduce a bulky 
group, carbocyclic acid 1.144 was converted to tert-butyl ester 1.145. Treatment of bromide 
1.142 with n-BuLi generated the corresponding organolithium reagent, which was added to 
ketone 1.145 to give addition product 1.146. Elimination of the tertiary alcohol from 1.146 
using Burgess’s reagent (methyl N-(triethylammoniumsulfonyl)carbamate) 126  led to 
unsaturated pyrrolidine intermediate 1.147 in 68 % yield. With olefin 1.147 in hand, 
hydrogenation catalyzed by palladium-on-activated-charcoal gave the cis-2,4-substituted 
pyrrolidine 1.148, in 94 % yield. The structure of 1.148 was confirmed by X-ray analysis 
(Figure 7). Finally, reduction of ester 1.148 using LiAlH4 generated primary alcohol 1.149, 
which was treated with hydrogen chloride to give (2R,4S)-2-hydroxymethyl-4-aryl-substituted 
pyrrolidine 1.150 in good yield (Scheme 28).  
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Scheme 28. Synthesis of (2R,4S)-2-hydroxymethyl-4-arylpyrrolidine 1.150. 
 
 
 
 
Figure 7. X ray structure of ester 1.148. 
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 Based on the same synthetic strategy, the enantiomer 1.157 was synthesized from 
trans-4-hydroxyl-L-proline (1.50) in eight steps and 8 % overall yield (Scheme 29).  
 
Scheme 29. Synthesis of (2S,4R)-2-hydroxymethyl-4-arylpyrrolidine 1.157. 
 
 
 
 In the syntheses of 1.150 and the enantiomer 1.157, one of the key reactions was the 
addition of an organolithium reagent to oxo-pyrrolidines  1.145 and 1.152. The yield of this 
step was however usually around 30 %. Upon investigating this reaction further (Scheme 30), 
we found that the low yield was due to in part addition on the tert-butyl ester rather than the 
ketone, which increased ultimately the difficulty in the purification. Moreover, another 
diastereomer 1.158, which had not previously been isolated, was obtained as a more polar 
product than 1.146 in up to 19% yield. Treatment of both alcohol isomers under the same 
conditions used to eliminate the tertiary alcohol gave products having the same r.f. and 1H 
NMR spectrum, but opposite optical rotation values, indicating that they were enantiomers.  
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Scheme 30. Studies of the reaction organolithium reagent addition on 1.145. 
 
 
 
 Based on these observations, we proposed that the stereocenter at the 2-position of 
1.158 was epimerized due to the steric hindrance induced by the cis-2,4 configuration of 1.158 
(Scheme 31). In the presence of the Burgess’s reagent in toluene at reflux, 1.158 was 
epimerized at the 2-position, prior to elimination of the hydroxyl group, by the Burgess 
reagent to afford olefin 1.154.  
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Scheme 31. Proposed mechanism of epimerization of 1.158 followed by dehydrogenation. 
 
 
 
1-2-2-3-2 Synthesis of trans-2-hydroxymethyl-4-arylpyrrolidine analogues 
 After successfully achieving the synthesis of cis-2-hydroxymethyl-4-arylpyrrolidines 
1.150 and 1.157, the trans-2-hydroxymethyl-4-arylpyrrolidine analogues were also prepared 
according to the initial plan (Scheme 27). The tert-butyl ester of unsaturated pyrrolidine 1.147 
was reduced to primary alcohol 1.159, which was treated with Carbtree’s catalyst127,128 and 
hydrogen, under hydrogen at 70 psi pressure, for 3 days. As expected, the hydrogenation was 
directed by the primary alcohol to the same face as the hydroxymethyl group of prolinol 1.159 
to give trans-product 1.160 in 72 % yield. A minor amount of cis-isomer 1.149 (9 %) was also 
generated. Finally, the Boc group of 1.160 was removed using hydrogen chloride to afford 
(2R,4R)-2-hydroxylmethyl-4-arylpyrrolidine 1.161 (Scheme 32). The enantiomer 1.164 was 
prepared in the same way from 1.154 (Scheme 33).  
 
 
N CO2tBu
HO
C8H17
Boc
toluene reflux
O N S N
O O O
H O NH
S N
O O O
N CO2tBu
O
C8H17
Boc
1.158
O N S N
O O O
N CO2tBu
HO
C8H17
Boc
+
1.153
N CO2tBu
O
C8H17
Boc
S
O
O
NO
O
H Et3NH
N
C8H17
CO2tBu
Boc
1.154
O N
H
S O
O O O
Et3NH
+
2
4
  46 
Scheme 32. Synthesis of (2R,4R)-2-hydroxylmethyl-4-arylpyrrolidine 1.161. 
 
 
 
Scheme 33. Synthesis of (2S,4S)-2-hydroxylmethyl-4-arylpyrrolidine 1.164. 
 
 
 
1-2-2-4 Synthesis of 3-arylpyrrolidine analogues 
 We envisioned that the side-chain could be installed at a later point in the synthesis by 
our general coupling and hydrogenation strategy (Scheme 34). The 3-(p-bromophenyl)-
pyrrolidine coupling precursor could be generated from a nitroaldehyde by reduction of the 
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nitro group to the amine, followed by cyclization using reductive amination. The 
nitroaldehyde could be obtained by an asymmetric Michael reaction between acetaldehyde and 
trans-4-bromo-β-nitrostyrene, based on the organo-catalytic method reported by List.129  
 
Scheme 34. Retrosynthetic analysis for the synthesis of 3-arylpyrrolidine analogues. 
 
 
 
 The reaction of acetaldehyde and trans-4-bromo-β-nitrostyrene was performed in the 
presence of the Jørgensen−Hayashi-type of silyl ether catalyst, (S)-(–)-α,α-diphenyl-2-
pyrrolidinemethanol trimethylsilyl ether,130,131 to afford the (S)-nitroaldehyde 1.165 in 22 % 
yield (Scheme 35). Treatment of nitroaldehyde 1.165 with Pd(OH)2 under 5 bar pressure of 
hydrogen, as used previously in synthesis of 3-phenylpyrroline,129 gave no reaction; however, 
switching to zinc and aqueous acetic acid132 led to the required 3-substituted pyrrolidine 1.167. 
Protection of 1.167 as the tert-butyl carbamate gave pyrrolidine 1.168, which was ready for a 
Suzuki reaction. The purity of amine 1.168 was established by chiral SFC, which 
demonstrated a good enantiomeric ratio (e.r. = 94.5 5.5) had been obtained. The side-chain 
was installed using our general synthetic protocol to yield 1.169, which was deprotected to 
give the (S)-3-arylpyrrolidine 1.170 as the hydrochloride salt (Scheme 35). The enantiomer 
1.175 was obtained based on the same synthetic strategy employing (R)-(–)-α,α-diphenyl-2-
pyrrolidinemethanol trimethylsilyl ether as catalyst (Scheme 36).  
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Scheme 35. Synthesis of (S)-3-arylpyrrolidine 1.170. 
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Scheme 36. Synthesis of (R)-3-arylpyrrolidine 1.175. 
 
 
   
 In summary, we have prepared a series of constrained C-arylpyrrolidine analogues 
(Figure 8). These include all the diastereomers of the 2-hydroxymethyl-3- and 4-
arylpyrrolidine, 3-arylpyrrolidine, 2-hydroxymethyl-3-aryl-lactam analogues, as well as 
several 2,3-substituted pyrrolidine analogues with modified 2-hydroxymethyl arm. 
 
 
 
 
 
 
 
 
 
 
1) 1-octyne, catecholborane 
    Pd(PPh3)4, NaHCO3
2) H2, Pd/C, EtOAc
 4M HCl in 1,4-dioxane
H
O NO2
+
Br
N
H OTMS
Ph
Ph
CH3CN
(20%)
H NO2
O
Br
25%
N
H
Br
H2O
Zn, HOAc
Boc2O, Et3N
CH2Cl2
N
Br
Boc
N
C8H17
Boc
54% in two steps 52% in two steps
88%
N
H2
C8H17
Cl
1.175
1.171
1.172 1.173 
(e.r. = 94.1 : 5.9)
1.174
(R)
  50 
Figure 8. List of synthesized constrained C-aryl substituted pyrrolidine analogues. 
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1-2-3 Biological evaluations of constrained O-arylmethyl substituted 
pyrrolidine analogues 
 We collaborated with Professor Edinger at the University of California-Irvine to 
evaluate the biological activities of our synthetic compounds (Figure 6) against various cancer 
cell lines. Firstly, the importance of the O-arylmethyl C-8 alkyl chain was studied. A series of 
analogues with modified aliphatic chain moieties were prepared by Dr. Rebecca Fransson 
(Figure 9).120 These analogues were evaluated using cell viability assays with a murine 
hematopoietic FL5.12 cell line (Figure 9). Limiting the flexibility of the C-8 alkyl chain by 
introducing unsaturation (e.g., 1.176), and extending the chain length to a C-10 chain (e.g., 
1.177), led to a slight decrease in activity compared to 1.57. An obvious reduction in activity 
was observed in the shorter C-6 unsaturated chain (e.g., 1.178). Removal of the phenyl group 
(e.g., 1.179) resulted in a dramatic loss of activity. The O-benzyl group tethered to a C-8 alkyl 
chain was thus crucial for maintaining activity.  
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Cell viability was measured by vital dye exclusion and flow cytometry at 72h. 
Figure 9. Cytotoxic action of different alkyl chain substituted L-prolinol analogues on murine 
hematopoietic FL5.12 cells.120  
 
 The constrained O-arylmethylpyrrolidine analogues were then tested in cell viability 
assays using Sup-B15, a Ph+ ALL cell line. All the 2-hydroxymethyl-4-O-
arylmethylpyrrolidine analogues induced leukemia cell death as efficiently as FTY720 (1.8) 
(Figure 10).120 Among these, the trans-analogue 1.65 exhibited a 3-fold increase in efficacy 
compared to FTY720 (1.8), and a 4-fold increase compared to its enantiomer 1.57. cis-
Analogues were less active compared to the trans-isomers, especially 1.89, which showed an 
8-fold decrease in activity compared to 1.65. These results indicated that constrained 
analogues could enhance the anticancer potency compared to FTY720 (1.8). The shape of the 
molecule, due to different stereochemistry of the benzyl ether appendage and the 
hydroxymethyl arm, has great influence on its anti-leukemia ability.  
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 1.8 1.57 1.65 1.83 1.89 
Sup-B15 6.8 ± 0.7 7.7 ± 0.8 2.0 ± 0.2 8.3 ± 0.8 16.7 ± 2.4 
Mean IC50 (in µM +/- SEM). Cell viability was measured by vital dye exclusion and flow cytometry at 72h. 
Figure 10. Cytotoxic action of diastereomeric 2-hydroxymethyl-4-O-arylmethylpyrrolidine 
analogues on Sup-B15 leukemia cells.120  
 
 Next, the 2-hydroxymethyl-3-O-arylmethylpyrrolidine analogues were evaluated 
(Figure 11). These analogues killed Sup-15 cells efficiently, but compared to 1.65, they were 5 
~ 6 fold less active. Interestingly, their stereochemistry did not have much effect on their anti-
leukemia activities as in the previously mentioned 2,4-substituted series. Thus, the high 
activity of 1.65 was caused by its unique structure, stereochemistry, and spatial orientation of 
the benzyl ether appendage and hydroxymethyl group. 
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 1.8 1.65 1.32 1.39 1.44 1.49 
Sup-B15 6.8 ± 0.7 2.0 ± 0.2 13.9 ± 2.2 12.9 ± 1.1 10.7 ± 2.0 11.0 ± 2.0 
Mean IC50 (in µM +/- SEM). Cell viability was measured by vital dye exclusion and flow cytometry at 72h. 
Figure 11. Cytotoxic action of diastereomeric 2-hydroxymethyl-3-O-arylmethylpyrrolidine 
analogues on Sup-B15 leukemia cells.120 
 
 Although the 2-hydroxymethyl constrained analogues (1.32, 1.39, 1.44, 1.49, 1.57, 
1.65, 1.83 and 1.89) showed good activities against Sup-B15 leukemia cells, their in vivo 
anticancer efficacies could be limited due to the chance of phosphorylation to activate S1P1 
and S1P3 receptors, which could induce bradycardia. Taking the two most active analogues 
1.57 and 1.65, a series of analogues with modified hydroxymethyl arms was prepared (Figure 
12). For 1.57, there was almost no detrimental effect for either removal of the hydroxyl group 
(1.73) or the entire removal of the hydroxymethyl group (1.94). For the analogue 1.65, 
protection and removal of the hydroxyl group (1.67, 1.70 and 1.99) reduced activity. These 
results demonstrated that phosphorylation was not necessary to induce the death of Sup-B15 
leukemia cells, In the case of 1.65, a free hydroxyl group gave however the most active 
analogue. Recent results from the Edinger group have revealed that compound 1.77, the 
Cl
N
H2
OH
O
C8H17
1.32
Cl
N
H2
OH
O
C8H17
1.39
Cl
N
H2
OH
O
C8H17
1.44
Cl
N
H2
OH
O
C8H17
1.49
0.1 1 10
0
50
100
Drug concentration (µM)
Pe
rce
nt 
via
ble
 (7
2h
rs)
1.32
1.39
1.49
1.44
1.8
1.65
  55 
phosphate of 1.65, appeared to further enhance the in vitro antileukemic activity without 
causing bradycardia (private communication, see discussion).  
 
 
 
 
 1.57 1.65 1.73 1.67 1.70 1.94 1.99 
Sup-B15 7.7 ± 0.8 2.0 ± 0.2 6.5 ± 0.3 8.1± 1.0 9.0 ± 1.0 8.1 ± 0.9 11.5 ± 0.7 
Mean IC50 (in µM +/- SEM). Cell viability was measured by vital dye exclusion and flow cytometry at 72h. 
Figure 12. Cytotoxic action of 2-methoxylmethyl- and 2-methyl-4-O-arylmethylpyrrolidine 
analogues, and 3-O-arylmethylpyrrolidine analogues on Sup-B15 leukemia cells.120  
 
 Intrigued by the high activity of 1.65, compared to its diastereomeric analogues, 
against Sup-B15 leukemia cells, it was evaluated against several other cancer cell lines (Table 
2),120 and 1.65 proved the most active analogue against another BCR-ABL positive ALL cell 
line, BV173. It also showed the best activity, with a 10-fold increase in activity compared to 
1.57 against cell line BM-P190, a transformed murine bone marrow cell line bearing the BCR-
ABL fusion protein p190. Against the other three non BCR-ABL fused protein expressed ALL 
cell lines (CCRF-CEM, Nalm-6 and Blin-1), 1.65 did not exhibit an obvious advantage 
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compared to the other analogues (1.57, 1.83 and 1.89). In addition, 1.65 was active against the 
prostate cancer cell lines PC3 and DU145, but it was not as efficient as FTY720 (1.8). Thus, 
the effect of 1.65 seems to have a connection with the expression of BCR-ABL-fused protein, 
which was associated with CML and ALL. Several BCR-ABL tyrosine kinase inhibitors have 
been discovered to treat CML,133 such as the well-known Imatinib (Gleevec),134 which 
prolongs the survival of CML significantly. The constrained analogue 1.65 showed the 
potency necessary to be potentially used in clinical studies of BCR-ABL positive ALL.   
 
Table 2. Mean IC50 (in µM +/- SEM) of analogs in cell viability assays in a range of human 
cancer cell lines and BCR-Abl-expressing murine bone marrow (BM).120  
 
 
SupB15 
BM- 
p190 
BV173 
CCRF- 
CEM 
Nalm-6 Blin-1 PC3 DU145 
 Ph+ ALL  Ph+ ALL Ph- ALL Ph- ALL Ph- ALL Prostate Prostate 
1.8 
6.8 ± 0.7 3.3 ± 0.2 6.3 ± 0.4 6.8 ± 0.3 9.6 ± 1.9 5.5 ± 0.1 
9.8 ± 
0.9 
6.5 ± 
0.9 
1.57 
7.7 ± 0.8 5.7 ± 1.1 10.4 ± 0.7 
11.0 ± 
1.3 
15.0 ± 
2.1 
7.5 ± 0.1 
14.3 ± 
1.2 
10.8 ± 
0.4 
1.65 
2.0 ± 0.2 0.5 ± 0.1 3.8 ± 0.4 8.2 ± 0.7 
13.5 ± 
2.4 
6.9 ± 0.3 
13.5 ± 
2.6 
15.1 ± 
1.0 
1.83 8.3 ± 0.8 4.0 ± 0.4 9.7 ± 1.0 8.1 ± 1.4     
1.89 16.7 ± 
2.4 
8.4 ± 1.5 13.8 ± 0.8 
11.6 ± 
1.1 
    
Viability was measured by vital dye exclusion and flow cytometry at 72 h.  
 
 Since the early studies of the anticancer effect of FTY720 (1.8), Edinger has found that 
FTY720 (1.8) could selectively starve cancer cells to death by down regulating nutrient 
transporter proteins.108 Thus, these constrained analogues were also evaluated to see if they 
killed cancer cells through same mechanism as FTY720 (1.8) (Figure 13). In the assay of 
surface expression of 4F2hc, all of the constrained analogues 1.57, 1.65, 1.70, and 1.73, as 
well as FTY720 (1.8), induced rapid down-regulation of the amino acid transporter-associated 
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protein 4F2hc, which indicated that these novel constrained analogues were working through a 
common mechanism involving starving the cancer cells to death.     
 
Figure 13. Diastereomeric 2-hydroxymethyl- and 2-methyl-4-O-arylmethylpyrrolidine (10 
µM) trigger nutrient transporter loss in Sup-B15 leukemia cells. 
 
1-2-4 Biological evaluations of constrained C-aryl substituted pyrrolidine 
analogues 
 Although the constrained O-arylmethylpyrrolidine analogues showed greatly enhanced 
anti-leukemia activities compared to FTY720 (1.8) (Table 2), they were less efficient toward 
other types of cancer cell lines (PC3 and DU145). On the other hand, Charron’s original C-
aryl analogues119 1.15 and 1.16 were active against the prostate cancer cell lines (PC3 and 
DU145). To determine the relationship between stereochemistry and activity, as studied in the 
O-arylmethyl pyrrolidine analogues, two new synthetic 2,5-bis(hydroxymethyl)-3-
arylpyrrolidine analogues (1.100 and 1.101) were synthesized and tested in a Cell Titer Glo 
assay (Figure 14). Compound 1.16, which was shown previously to not be phosphorylated by 
SphK,119 had same activities in both prostate cancer cell lines compared to 1.15. The new 
analogues 1.100 and 1.101 showed similar in vitro activities against prostate cancer cell lines 
as 1.15 and 1.16. Thus, the stereochemistry of 2,3,5-trisubstituted analogues had little effect 
on their activity against prostate cancer cell lines, but the stereochemistry was important for 
the compounds to be phosphorylated by SphK.119   
 
0 20 40 60 80 100
1.73
1.70
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1.8
Ctr
Surface 4F2hc Expression 
(% Control)
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 FTY720 (1.8) 1.15 1.16 1.100 1.101 
PC3 2.6 ± 0.2 7.0 ± 0.3 6.1 ± 1.0 3.4 ± 0.6 4.9 ± 0.6 
DU145 3.2 ± 0.2 7.3 ± 0.8 5.7 ± 0.4 4.1 ± 0.6 5.3 ± 0.2 
Values in µM, Mean +/- SEM is shown, n3. 
Figure 14. IC50 values of 2,5-bis(hydroxymethyl)-3-arylpyrrolidine analogues in prostate 
cancer cell lines.  
 
 Next, the 2-hydroxymethyl-3-arylpyrrolidine analogues were evaluated for activity 
against prostate cancer cell lines (Figure 15). Compared to the 2,3,5-trisubstituted C-aryl 
analogues, these analogues are without a second hydroxymethyl arm. They retained the anti-
prostate cancer activities as for 2,3,5-trisubstituted C-aryl analogues. Although 1.114 and 
1.117 had better activities compared to the other two diastereomers, 1.120 and 1.123, the 
configurations of the members in this series was not as important as in the O-arylmethyl 
substituted pyrrolidine analogues in influencing the anti-cancer activities. 
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 1.114 1.117 1.120 1.123 
PC3 4.0 ± 0.7 3.0 ± 0.4 6.5 ± 0.3 5.5 ± 0.7 
DU145 3.8 ± 0.4 3.7 ± 0.4 5.4 ± 0.3 5.3 ± 0.7 
Values in µM, Mean +/- SEM is shown, n3. 
Figure 15. IC50 values of 2-hydroxymethyl-3-arylpyrrolidine analogues in prostate cancer cell 
lines.  
 
 Meawhile, the corresponding lactams of 2-hydroxymethyl-3-arylpyrrolidine analogues 
were tested to see if the amonium was important for the activity (Figure 16). The anti-prostate 
cancer activities were lost for all the lactams indicating that a charged nitrogen on the 
pyrrolidine ring was crucial for anticancer activity likely through an electrostatic interaction 
with the target receptor .  
 
 
 1.125 1.126 1.127 
PC3 >20 >20 >20 
DU145 >20 >20 >20 
Values in µM, Mean +/- SEM is shown, n3. 
Figure 16. IC50 values of 2-hydroxymethyl-3-aryl-lactam analogues in prostate cancer cell 
lines.  
 
 Considering that 1.114 and 1.117 showed as good anti-prostate cancer activities as 
FTY720 (1.8) (Figure 15), we wanted to know if they could be phosphorylated, and whether 
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their activities were associated with phosphorylation. Preliminary results suggested that 1.114 
was phosphorylated to a similar degree as FTY720 (1.8) in PC3 and SW620 cells. 
Furthermore, analogues 1.114 and 1.117 activated only weakly S1P1, and were not substrates 
for the other S1P2,3,4,5 receptors. Similar losses of activity at S1P receptors were observed in 
tests of the corresponding synthetic phosphates 1.139 and 1.141. In order to eliminate any 
possibility of phosphorylation, a series of new 1.114 and 1.117 analogues (1.129, 1.131, 1.134 
and 1.137) with modified hydroxymethyl groups were evaluated (Figure 17). Methyl ethers 
1.129 and 1.131, and methyl analogues 1.134 and 1.137 exhibited activities against prostate 
cancer cell lines which were as good as compounds 1.114 and 1.117. This indicated further 
that the hydroxyl group and its phosphorylation were not crucial for the anti-cancer activity.  
 
 
 1.129 1.131 1.134 1.137 
PC3 6.3 ± 0.3 1.9 ± 0.3 4.4 ± 0.6 4.1 ± 0.4 
DU145 5.9 ± 0.3 5.6 ± 0.1 5.1 ± 0.6 5.0 ± 0.1 
Values in µM, Mean +/- SEM is shown, n3. 
Figure 17. IC50 values of 2-methoxymethyl- and 2-methyl-3-arylpyrrolidine analogues in 
prostate cancer cell lines. 
 
 Another series of 2,4-substituted pyrrolidine analogues were tested to investigate the 
importance of the relative positions of the phenyl side chain appendage and the 
hydroxymethyl arm (Figure 18). Against prostate cancer cell lines, 1.150, 1.157 and 1.161 
retained as good activities as the 2-hydroxymethyl-3-aryl substituted pyrrolidine analogues, 
and 1.164 was less active. This suggested that the relative position of the substituents on the 
pyrrolidine core could affect the anticancer activity in this series.  
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 1.150 1.157 1.161 1.164 
PC3 6.6 ± 0.1 4.3 ± 0.3 6.4 ± 0.1 9.8 ± 1.3 
DU145 5.8 ± 0.2 4.9 ± 0.1 6.8 ± 0.1 10.6 ± 1.0 
Values in µM, Mean +/- SEM is shown, n3. 
Figure 18. IC50 values of 2-hydroxymethyl-4-arylpyrrolidine analogues in prostate cancer cell 
lines.  
 
 Simplification of the structure by removal of the hydroxymethyl group resulted in 3-
arylpyrrolidine analogues 1.170 and 1.175, which exhibited moderate anti-prostate cancer 
activities (Figure 19). The hydroxyl group was thus not crucial for the anti-cancer activity. In 
general, analogues 1.114, 1.117 and their modified analogue 1.131, that cannot be 
phosphorylated by SphK, have potency that merits be further study in the treatment of prostate 
cancer. 
 
 
 1.170 1.175 
PC3 5.7 ± 0.1 5.5 ± 0.1 
DU145 5.1 ± 0.1 5.0 ± 0.1 
Values in µM, Mean +/- SEM is shown, n3. 
Figure 19. IC50 values of 3-arylpyrrolidine analogues in prostate cancer cell lines.  
 
 The C-aryl substituted pyrrolidine analogues were also evaluated against several other 
cancer cell lines (Table 3). These analogues (1.100, 1.114, 1.117 and 1.131) exhibited as broad 
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anticancer activity as FTY720 (1.8) against colon cancer cell line (SW-620), lung cancer cell 
line (A-549), pancreas cancer cell lines (PANC-1), and breast cancer cell (MDA-MB-231). 
The O-arylmethyl substituted pyrrolidine analogues (e.g., 1.57 and 1.65) were less active in 
these cancer cell lines. Against for the leukemia cell line (SupB-15), the C-aryl substituted 
analogues had activities; however, 1.65 was still the most active analogue in the two series.  
 
Table 3. IC50 values in other cancer cell lines.   
 
 SW-620 A-549 PANC-1 MDA-MB-231 SupB-15 
 Colon Lung Pancreas Breast Leukemia 
FTY720 (1.8) 2.8 ± 0.1 6.0 ± 0.4 4.6 ± 0.5 4.0 ± 0.1 6.8 ± 0.7 
1.100 2.6 ± 0.0 4.7 ± 0.6 3.5 ± 0.3 4.6 ± 0.5 ND 
1.114 2.5 ± 0.1 8.9 ± 1.4 3.3 ± 0.5 2.1 ± 0.2 5.1 ± 0.9 
1.117 2.1 ± 0.2 8.4 ± 1.2 5.0 ± 0.9 4.9 ± 0.6 5.9 ± 0.1 
1.131 2.7 ± 0.2 7.8 ± 1.8 4.8 ± 0.6 4.0 ± 0.0 7.5 ± 0.4 
1.57 7.0 ± 1.2 10.7 ± 0.2 8.0 ± 1.5 9.1 ± 0.3 7.7 ± 0.8 
1.65 4.9 ± 0.9 9.5 ± 1.1 8.8 ± 0.6 6.4 ± 0.4 2.0 ± 0.2 
Values in µM, Mean +/- SEM is shown, n≥3. SupB-15 viability was determined by flow cytometry, Cell Titer 
Glo assays were performed with the other cell lines. ND, not determined. 
 
 Analogues 1.110, 1.114 and 1.117 were tested for the surface expression of 4F2hc at 
their IC50, and at twice this dose (Figure 20). As expected, these analogues, as well as FTY720 
(1.8), triggered down-regulation of the amino acid transporter-associated protein 4F2hc at 
their IC50, and consistently at 2X IC50. This indicated that these C-aryl substituted pyrrolidine 
analogues killed cancer cells through the same “starve to death” mechanism.   
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        2X 1.100 
        1X 1.100 
        2X 1.117 
        1X 1.117 
        2X 1.114 
        1X 1.114 
                 2X FTY720 (1.8) 
                 1X FTY720 (1.8) 
             No Drug (Control) 
                                                                    
                                                   0               20               40              60               80             100 
Surface 4F2 Expression (Percent Control) 
Figure 20. Nutrient transporter down-regulation in PC3 cells at 1X or 2X the IC50. 
 
1-2-5 Discussion 
 Among the O-arylmethylpyrrolidine analogues, 1.57 and 1.65 were found to kill cancer 
cells by down-regulating nutrient transporters to starve cancer cells to death (Figure 13). 
Recent studies from the Huwiler group, in Bern, showed that 1.57 and 1.65 did not activate 
S1P1,2,4, receptors, however, 1.57 could be partially phosphorylated by both SphK1 and SphK2, 
and 1.65 can be efficiently phosphorylated in vivo and in vitro, especially by SphK2. Further 
studies of the corresponding phosphates, 1.75 and 1.77, indicated that these phosphates could 
activate S1P1,2,3,5 receptors in vitro. The phosphates were active against the SupB-15 leukemia 
cell line (Figure 21). Furthermore, in the assay of surface expression of 4F2hc, no down-
regulation of the amino acid transporter-associated protein 4F2hc was observed, up to 20 µM 
dose (Figure 22). Thus, phosphates 1.75 and 1.77 may act through another mechanism to kill 
the leukemia cells. The activity of 1.65 was actually enhanced by phosphorylation. Moreover, 
1.75 and 1.77 could be dephosphorylated by cells, and their anti-leukemia activities may in 
fact be due to corresponding alcohols 1.57 and 1.65, not the phosphates themselves. These 
results demonstrate that the anti-cancer mechanisms of 1.57 and 1.65 are complex, and merit 
study to identify their targets, especially for the most active analogue, 1.65.   
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Figure 21. Cytotoxic action of phosphates 1.75 and 1.77 on Sup-B15 leukemia cells. 
 
 
Figure 22. Nutrient transporter down-regulation of phosphates 1.75 and 1.77 in Sup-B15 
leukemia cells. 
 
1-3 Conclusion 
 In conclusion, we have synthesized two series of constrained FTY720 analogues, 
including all of the diastereomers of 2,3-, 2,4-, and 3-substitituted pyrrolidine analogues, as 
well as a subset of these analogues with modified hydroxymethyl groups to limit the 
possibility of phosphorylation. Many of these analogues exhibited good anticancer activities in 
in vitro studies. The O-arylmethylpyrrolidine analogues were active against the BCR-ABL 
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positive ALL cancer cells, especially compound 1.65, which showed the highest activity 
against the SupB-15 leukemia cell line among all the analogues, with a 3-fold increase in 
efficacy compared to FTY720 (1.8). The C-aryl pyrrolidine series were broadly active against 
human prostate, leukemia, colon, breast, and pancreatic cancer cell lines. Certain analogues 
(e.g., 1.129, 1.131, 1.134 and 1.137) were active without phosphorylation by SphK, exhibiting 
potency to be further studied in the treatment of cancer without inducing bradycardia.  
 
 The mechanistic studies suggested that certain constained analogues killed cancer cells 
through the same bioenergetic mechanism as FTY720 proposed by Edinger.111 By down-
regulation of nutrient transporters, these analogues starved the cancer cells to death; however, 
their mechanism of action is still unclear. Photo-affinity labeling techniques have thus been 
used to find the target protein, and will be discussed in chapter 2. 
 
 The promising in vitro results of analogues 1.65, 1.114, and 1.129 have led to their 
examination in vivo in mice, and these experiments are now in progress.  
 
1-4 Experimental 
 All non-aqueous reactions were run in flame-dried glassware under a positive pressure 
of argon. Anhydrous solvents were distilled under positive pressure of dry argon before use 
and dried by standard methods.135 THF, ether, CH2Cl2 and toluene were dried by passage 
through solvent delivery systems, commercial grade reagents were used without further 
purification. Reactions were monitored by S-2 analytical thin-layer chromatography (TLC) 
performed on pre-coated, glass-backed silica gel plates. Visualization of the developed 
chromatogram was performed by UV absorbance (wave length: 254 nm), and staining TLC 
plates with aqueous cerium ammonium molybdate, or aqueous potassium permanganate 
solution. Flash chromatography136 was performed on 230-400 mesh silica gel with the 
indicated solvent systems. Nuclear magnetic resonance spectra (NMR) were recorded at 300, 
400, 500 and 700 MHz spectrometers. Chemical shifts for 1H NMR spectra are recorded in 
parts per million (ppm) from tetramethylsilane with the solvent resonance as the internal 
standard (CDCl3 δ 7.27 ppm, CD3OD, δ 3.31 ppm, D2O, δ 4.80 ppm). Data are reported as 
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follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = 
quintet, m = multiplet, and br = broad), coupling constants (J) are reported in Hz, and 
integration. Chemical shifts for 13C NMR spectra are recorded in parts per million from 
tetramethylsilane using the central peak of the solvent resonance as the internal standard 
(CDCl3, δ 77.00 ppm, CD3OD, δ 49.00 ppm). All spectra were obtained with complete proton 
decoupling. Optical rotations were determined in a 1 dm cell at 589 nm at 20 °C. Data are 
reported as follows: [α]D, concentration (c in g/100 mL), and solvent. High-resolution mass 
spectra were performed using fast atom bombardment (FAB) or electrospray (ESI) techniques. 
Low-resolution mass spectra were obtained using electrospray ionization technique (ESI). 
Purity analysis was assessed by LC/MS. HPLC conditions: (A) The column used was an YMC 
ODS-AQ, 2.0 x 50 mm, particle size 3u; the eluents were H2O with 0.1 % formic acid and 
ACN 0.1 % formic acid; the gradient started at 20 % organic, then increased to 95 % in 6 
minutes and stays at 95 % for another 1.5 min; the flow was set at 0.35 mL / min; UV det. 214 
nm. (B) The column used was an SUNFIRE™ C18, 2.1 x 50 mm, particle size 3.5 u; the 
eluents were H2O with 0.1 % formic acid and MeOH 0.1 % formic acid; the gradient started at 
80 % organic, then increased to 95 % in 10 minutes and stays at 95 % for another 2.0 min; the 
flow was set at 0.40 mL / min; UV det. 214 nm; (C) The column used was an SUNFIRE™ 
C18, 2.1 x 50 mm, particle size 3.5 u; the gradient started at 50 % organic, then increased 
to 95 % in 10 minutes and stays at 95 % for another 2.0 min; the flow was set at 0.40 mL / 
min; UV det. 214 nm. (D) The column used was an Atlantis C18, 150 x 4.6 mm; the eluents 
were H2O with 0.13 % formic acid and MeOH 0.13 % formic acid; the gradient started at 30 
% organic, then increased to 95 % in 8 minutes and stays at 95 % for another 10 min; flow 
was set at 0.30 mL / min. 
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1-carboxylate (1.29) was synthesized from 1.26 according to the procedure report by 
Evano.121 Spectroscopic data were in agreement with the proposed structures and matched 
those reported in the literature.121,137 
 
 
tert-Butyl (2R,3S)-3-((4-bromobenzyl)oxy)-2-(((tert-butyldimethylsilyl)oxy)methyl) 
pyrrolidine-1-carboxylate (1.30). Alcohol 1.29 (63 mg, 0.19 mmol) was dissolved in dry 
THF (1.3 mL). The solution was purged with argon, cooled to 0°C and treated with NaH (60 
% in mineral oil, 23 mg, 0.57 mmol). The mixture was stirred for 30 min and treated 
sequentially with 4-bromobenzyl bromide (143 mg, 0.57 mmol) and TBAI (7 mg, 0.02 mmol). 
The reaction mixture was allowed to warm to room temperature and was stirred for 2 days.  
The reaction was quenched with water, diluted with EtOAc and washed with water and brine, 
dried over MgSO4 and filtrated. The solvent was removed under reduced pressure and the 
residue was purified by flash chromatography (hexane: EtOAc, 12:1 to 8:1) to give 1.30 (76 
mg, 80 %) as pale yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.47 (d, J = 8.0 Hz, 2H), 7.20 (d, 
J = 8.4 Hz, 2H), 4.48 (m, 2H), 4.07 (m, 1H), 3.94-3.74 (m, 2H), 3.61-3.35 (m, 3H), 1.99 (m, 
2H), 1.46 (s, 9H), 0.87 (d, J = 4.0 Hz, 9H), 0.05 (s, 3H), 0.03 (d, J = 4.0 Hz, 3H); 13C NMR 
(100 MHz, mixture of rotamers, CDCl3): δ 154.8, (154.7), 137.5, 131.6, (129.4), 129.3, 121.5, 
81.3, (80.8), 79.7, (79.3), 69.8, 64.6, (64.2), 62.6, (62.2), (45.5), 45.1, 30.2, 28.8, 28.7, (28.6), 
26.0, -5.6, -5.7; [α]D (-) 11.8° (c 1.60, CHCl3); HRMS (ESI) calcd for C23H38BrNNaO4Si 
[M+Na]+ 522.1646, found 522.1659. 
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tert-Butyl (2R,3S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-((4-octylbenzyl)oxy) 
pyrrolidine-1-carboxylate (1.31). A solution of 1-octyne (31 µL, 0.21 mmol) and 
catecholborane (1.0 M in THF, 0.21 mL, 0.21 mmol) was heated at reflux at 70 °C for 2 h 
under argon atmosphere, and cooled to room temperature. A solution of 1.30 (70 mg, 0.14 
mmol) in DME (1.7 mL) was added to the reaction mixture followed by Pd(PPh3)4 (5.0 mg, 
0.004 mmol) and 1N aqueous NaHCO3 (1.1 mL). The reaction mixture was heated at reflux 
with vigorous stirring for 4 h, cooled to room temperature and treated with a brine solution. 
The mixture was extracted three times with Et2O. The combined organic layers were dried 
over NaSO4 and filtered. The filtrate was evaporated under reduced pressure and the residue 
was purified by flash chromatography (hexane: EtOAc, 10:1 to 8:1) to give pale yellow oil. 
The oil was dissolved in EtOAc (2.6 mL) treated with Pd/C (10 %, 15 mg, 0.014 mmol) and 
placed under an atmosphere of hydrogen by evacuation of the flask and refilling with H2 gas. 
After completion of the hydrogenation as indicated by TLC (Rf: 0.65, hexane: EtOAc, 4:1), 
the reaction mixture was filtered through a pipette containing a layer of CeliteTM over a plus of 
cotton. The filtrate was evaporated under reduced pressure to give alkane 1.31 (53 mg, 69 % 
in two steps) as pale yellow oil. 1H NMR (400 MHz, CDCl3): δ 7.24 (d, J = 8.0 Hz, 2H), 7.15 
(d, J = 7.6 Hz, 2H), 4.50 (m, 2H), 4.10 (m, 1H), 3.81-3.74 (m, 2H), 3.64-3.35 (m, 3H), 2.59 (t, 
J = 7.6 Hz, 2H), 2.01 (m, 2H), 1.60 (m, 2H), 1.46 (d, J = 2.4 Hz, 9H), 1.28 (m, 10H), 0.87 (m, 
12H), 0.05 (s, 3H), 0.03 (d, J = 4.4 Hz, 3H); 13C NMR (100 MHz, mixture of rotamers, 
CDCl3): δ (154.8), 154.7, 142.5, 135.6, 128.6, (127.9), 127.8, 81.1, (80.6), 79.5, (79.2), 70.6, 
64.6, (64.3), 62.8, (62.3), (45.6), 45.2, 35.8, 32.0, (31.7), 30.2, 29.6, 29.5, 29.4, 28.8, 28.7, 
(28.7), 26.0, 22.8, 18.3, 14.2, -5.6, -5.7; [α]D (-) 13.0° (c 1.46, CHCl3); HRMS (ESI) calcd for 
C31H55NNaO4Si [M+Na]+ 556.3793, found 556.3797. 
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(2R,3S)-2-(Hydroxymethyl)-3-((4-octylbenzyl)oxy)pyrrolidin-1-ium chloride (1.32). A 4M 
solution of HCl in 1,4-dioxane (1.4 mL, 5.6 mmol) was added to a flask with 1.31 (15 mg, 
0.028 mmol) and the solution was stirred at room temperature until completion was showed by 
TLC (3h, Rf: 0.42, CH2Cl2: EtOH, 4:1). The volatiles were removed under reduced pressure. 
The residue was dissolved in 1,4-dioxane (2 mL) and the volatiles were evaporated to remove 
the residual HCl. The crude mixture was purified by flash chromatography (CH2Cl2: EtOH, 
4:1 to 1:1) to give yellow oil. The oil was dissolved in water, fitered through a plastic syringe 
filter (pore size: 0.45 µm), and lyophilized to give hydrochloride 1.32 (7.6 mg, 76 %) as pale 
yellow solid. 1H NMR (400 MHz, D2O): δ 7.15 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 8.0 Hz, 2H), 
4.37, 4.34 (ABq, J = 11.8 Hz, 2H), 3.97 (m, 1H), 3.73-3.58 (m, 3H), 3.38-3.24 (m, 2H), 2.37 
(t, J = 7.6 Hz, 2H), 2.07 (m, 1H), 1.94 (m, 1H), 1.38 (m, 2H), 1.23 (s. br, 10H), 0.88 (t, J = 6.4 
Hz, 3H); 13C NMR (100 MHz, D2O): δ 141.4, 134.6, 127.7, 78.2, 70.4, 64.7, 58.4, 43.7, 35.1, 
31.5, 31.0, 29.6, 29.2, 29.1, 29.0, 22.2, 13.5; [α]D (+) 35.0° (c 0.12, MeOH); HRMS (ESI) 
calcd for C20H34NO2 [M+H]+ 320.2584, found 320.2592. HPLC: condition (A), tR = 5.99 min; 
purity: > 99 %. 
 
 
N-(tert-Butoxycarbonyl)-O-(tert-butyldimethylsilyl)-L-serine (1.34) was obtained as pale 
yellow, sticky oil (7.7 g, 99 %) from N-(Boc)-L-serine 1.33 (4.0 g, 0.038 mol).121 
Spectroscopic data were in agreement with the proposed structure and matched those reported 
in the literature.138 
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tert-Butyl ((2S,3R)-1-((tert-butyldimethylsilyl)oxy)-3-hydroxyhex-5-en-2-yl) 
carbamate (1.35) was obtained as colorless oil (0.90 g, 42 % over two steps) from 1.34 (2.0 g, 
6.3 mmol).121 1H NMR (400 MHz, CDCl3): δ5.87-5.79 (m, 1H), 5.24 (d, J = 8.0 Hz, 1H), 5.14 
-5.09 (m, 2H), 3.96 (dd, J = 2.8, 10.4 Hz, 1H), 3.78 (dd, J = 2.0, 10.4 Hz, 1H), 3.71 (quint, J = 
7.2 Hz, 1H), 3.54 (br. m, 1H), 3.07 (d, J = 8.0 Hz, 1H), 2.33 (t, J = 6.4 Hz, 2H), 1.43 (s, 9H), 
0.89 (s, 9H), 0.07 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 155.8, 134.7, 117.9, 79.5, 72.9, 
63.3, 53.8, 39.4, 28.5, 25.9, 18.3, -5.7,-5.7; [α]D (+) 32.2° (c 1.32, CHCl3); HRMS (ESI) calcd 
for C17H35NNaO4Si [M+Na]+ 368.2228, found 368.2238. 
 
 
tert-Butyl (2S,3R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-hydroxypyrrolidine- 
1-carboxylate (1.36) was obtained as white solid (230 mg, 30 %) from 1.35 (800 mg, 2.32 
mmol).121 Spectroscopic data were in agreement with the proposed structures and matched 
those reported in the literature.137 
 
Compound 1.37 was obtained according to the procedure for synthesizing 1.30.  
 
tert-Butyl (2S,3R)-3-((4-bromobenzyl)oxy)-2-(((tert-butyldimethylsilyl)oxy)methyl) 
BocHN
CO2H
OTBS
BocHN OTBS
OH
1.34 1.35
n-BuLi (1 eq),
MgBr
2) NaBH4, EtOH
1)
THF
42% in two steps
(2 eq.)
BocHN OTBS
OH
1.35
OsO4, NaIO41)
2) Et3SiH, BF3 OEt2 N
OTBS
OH
1.36
30% Boc
N
OTBS
OH
Br
Br
NaH, TBAI
N
OTBS
O
Br
THF
1.36 1.37
83%Boc
Boc
  71 
pyrrolidine-1-carboxylate (1.37) was obtained as pale yellow oil (75 mg, 83 %) from 1.36 
(60 mg, 0.18 mmol). 1H NMR (400 MHz, CDCl3): δ 7.45 (d, J = 7.6 Hz, 2H), 7.20 (d, J = 8.4 
Hz, 2H), 4.47 (m, 2H), 4.07 (m, 1H), 3.94-3.73 (m, 2H), 3.60-3.35 (m, 3H), 2.00 (m, 2H), 1.46 
(s, 9H), 0.87 (d, J = 4.4 Hz, 9H), 0.04 (s, 3H), 0.03 (d, J = 4.0 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ (154.8), 154.7, (137.5), 137.4, 131.6, (129.3), 129.2, 121.5, 81.3, (80.8), 79.6, 
(79.3), 69.8, 64.5, (64.2), 62.7, (62.2), (45.5), 45.1, 30.2, 28.8, 28.7, (28.7), 25.9, -5.6, -5.7; 
[α]D (+) 10.6° (c 1.08, CHCl3); HRMS (ESI) calcd for C23H38BrNNaO4Si [M+Na]+ 522.1646, 
found 522.1645. 
 
Compound 1.38 was obtained according to the procedure for synthesizing 1.31.  
 
 
tert-Butyl (2S,3R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-((4-octylbenzyl)oxy) 
pyrrolidine-1-carboxylate (1.38) was obtained as pale yellow oil (55 mg, 73 % over two 
steps) from 1.37 (70 mg, 0.14 mmol). 1H NMR (400 MHz, CDCl3): δ 7.24 (d, J = 8.0 Hz, 2H), 
7.15 (d, J = 7.6 Hz, 2H), 4.50 (m, 2H), 4.10 (m, 1H), 3.97-3.74 (m, 2H), 3.64-3.35 (m, 3H), 
2.59 (t, J = 7.6 Hz, 2H), 2.02 (m, 2H), 1.60 (m, 2H), 1.47 (d, J = 2.8 Hz, 9H), 1.29 (m, 10H), 
0.88 (m, 12H), 0.05 (s, 3H), 0.03 (d, J = 4.4 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ (154.8), 
154.7, 142.5, 135.6, 128.6, (127.9), 127.8, 81.1, (80.6), 79.5, (79.2), 70.6, 64.6, (64.3), 62.8, 
(62.3), (45.6), 45.2, 35.8, 32.1, (31.7), 30.2, 29.6, 29.4, 29.4, 28.8, 28.7, (28.7), 26.0, 22.8, 
18.3, 14.2, -5.6, -5.7; [α]D (+) 14.4° (c 0.45, CHCl3); HRMS (ESI) calcd for C31H55NNaO4Si 
[M+Na]+ 556.3793, found 556.3810. 
 
Compound 1.39 was obtained according to the procedure for synthesizing 1.32.  
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(2S,3R)-2-(Hydroxymethyl)-3-((4-octylbenzyl)oxy)pyrrolidin-1-ium chloride (1.39) was 
obtained as yellow solid (19.0 mg, 95 %) from 1.38 (30 mg, 0.056 mmol). 1H NMR (400 
MHz, D2O): δ 7.10 (d, J = 4.8 Hz, 2H), 6.94 (d, J = 6.8 Hz, 2H), 4.34-4.25 (m, 2H), 3.91 (s. 
br, 1H), 3.69-3.57 (m, 3H), 3.28-3.20 (m, 2H), 2.30 (br, 2H), 2.00 (m, 1H), 1.85 (m, 1H), 1.39 
(br, 2H), 1.21 (br, 10H), 0.87 (t, J = 6.0 Hz, 3H); 13C NMR (100 MHz, D2O): δ 141.0, 134.8, 
127.5, 78.4, 70.3, 64.7, 58.6, 43.7, 35.2, 31.6, 31.1, 29.7, 29.4, 29.3, 29.2, 22.3, 13.5; [α]D (-) 
30.0° (c 0.14, MeOH); HRMS (ESI) calcd for C20H34NO2 [M+H]+ 320.2584, found 320.2591. 
HPLC: condition (A), tR = 6.01 min; purity: > 99 %. 
 
 
tert-Butyl (R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-oxopyrrolidine-1- 
carboxylate (1.40). Solid NaHCO3 (134 mg, 1.60 mmol) followed by Dess–Martin 
periodinane (134 mg, 0.32 mmol) were added to a solution of alcohol 1.29 (70 mg, 0.21 
mmol) in CH2Cl2 (1.0 mL) at room temperature. The resulting mixture was stirred for 1.5 h, 
when no more starting material was observed by TLC (Rf = 0.50hexane: EtOAc, 4:1). A 
saturated aqueous Na2S2O3 solution was added to the mixture. The organic layer was 
separated. The aqueous layer was extracted with CH2Cl2. The combined organic layers were 
washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography (hexane: EtOAc, 12:1 to 8:1) to give ketone 
1.40 (64 mg, 92 %) as pale yellow oil. 1H NMR (400 MHz, CDCl3): δ 4.17-3.77 (m, 4H), 3.63 
(m, 1H), 2.50 (m, 2H), 1.47 (s, 9H), 0.83 (s, 9H), 0.02 (s, 3H) 0.01 (s, 3H); 13C NMR (100 
MHz, CDCl3): δ 213.6, (213.1), 154.3, 80.4, (80.2), 64.3, (64.0), 63.5, (62.5), (43.2), 42.6, 
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(37.1), 36.6, 28.6, 25.9, 18.2, -5.8, -6.0; [α]D (-) 144.9° (c 0.37, CHCl3); HRMS (ESI) calcd 
for C16H31NNaO4Si [M+Na]+ 352.1915, found 352.1921. 
 
 
tert-Butyl (2R,3R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-hydroxypyrrolidine- 
1-carboxylate (1.41). L-Selectride (1M in THF, 0.27 mL, 0.27 mmol) was added to a THF 
(1.8 mL) solution of 1.40 (60 mg, 0.18 mmol) at -78 °C. The resulting solution was stirred for 
1 h at this temperature, when starting material was observed by TLC (Rf = 0.32hexane: 
EtOAc, 4:1). A saturated aqueous NH4Cl was then added to the solution. The organic layer 
was separated. The aqueous layer was extracted with EtOAc. The combined organic layers 
were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. 
The residue was purified by flash chromatography (hexane: EtOAc, 5:1) to give alcohol 1.41 
(45 mg, 75 %) as colorless oil. 1H NMR (400 MHz, CDCl3): δ 4.45 (m, 1H), 4.12-3.76 (m, 
3H), 3.54-3.37 (m, 3H), 2.06 (m, 1H), 1.92 (m, 1H), 1.45 (s, 9H), 0.89 (s, 9H), 0.08 (s, 3H), 
0.07 (s, 3H). 13C NMR (100 MHz, CDCl3): δ = 154.7, (79.8), 79.5, (73.4), 73.0, (62.4), 61.8, 
59.9, 44.6, (44.0), 33.8, (32.8), 28.6, 25.9, 18.1, -5.7; [α]D (-) 61.4° (c 0.28, CHCl3); HRMS 
(ESI) calcd for C16H33NNaO4Si [M+Na]+ 354.2071, found 354.2073. 
 
 
tert-Butyl (2R,3R)-3-((4-bromobenzyl)oxy)-2-(((tert-butyldimethylsilyl)oxy)methyl)-
pyrrolidine-1-carboxylate (1.42) was obtained as colorless oil (46 mg, 77 %) from 1.41 (40 
mg, 0.12 mmol) according to the procedure previously described for synthesizing 1.30. 1H 
NMR (400 MHz, CDCl3): δ 7.46 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 4.54 (m, 2H), 
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4.10 (m, 1H), 3.92-3.85 (m, 3H), 3.41-3.28 (m, 2H), 2.15-2.08 (m, 1H), 2.04-1.97 (m, 1H), 
1.47 (s, 9H), 0.89 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 154.6, 
137.7, 131.5, 129.0, 121.4, 79.6, (79.3), 78.5, (77.7), 71.2, 60.5, 59.8, (59.2), (44.2), 43.8, 
36.7, 29.8, (29.1), (28.7), 26.0, 24.8, (23.5), 18.3, -5.7; [α]D (-) 11.9° (c 0.64, CHCl3); HRMS 
(ESI) calcd for C23H38BrNNaO4Si [M+Na]+ 522.1646, found 522.1658. 
 
 
tert-Butyl (2R,3R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-((4-octylbenzyl)oxy) 
pyrrolidine-1-carboxylate (1.43) was obtained as pale yellow oil (29 mg, 77 % over two 
steps) from 1.42 (35 mg, 0.06 mmol) according to the procedure previously described for 
synthesizing 1.31. 1H NMR (400 MHz, CDCl3): δ 7.25 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 8.0 
Hz, 2H), 4.56 (m, 2H), 4.10 (m, 1H), 3.97-3.81 (m, 3H), 3.51-3.26 (m, 2H), 2.60 (t, J = 7.6 
Hz, 2H), 2.21-2.10 (m, 1H), 2.08-2.00 (m, 1H), 1.61 (m, 2H), 1.47 (s, 9H), 1.28 (m, 10H), 
0.89 (m, 12H), 0.06 (s, 3H), 0.04 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 154.7, 142.5, 135.8, 
128.5, 127.6, 79.5, (79.2), 78.1, 71.9, 60.5, 59.7, (59.1), (44.2), 43.8, 35.8, 32.0, (31.7), 29.8, 
29.6, 29.5, 29.4, 29.1, 28.7, 26.1, (25.9), 22.8, 18.3, 14.3, -5.6; [α]D (-) 9.8° (c 1.33, CHCl3); 
HRMS (ESI) calcd for C31H55NNaO4Si [M+Na]+ 556.3793, found 556.3790. 
 
 
(2R,3R)-2-(Hydroxymethyl)-3-((4-octylbenzyl)oxy)pyrrolidin-1-ium chloride (1.44) was 
obtained as yellow solid (9.3 mg, 99 %) from 1.43 (14 mg, 0.026 mmol) according to the 
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procedure for synthesizing 1.32. 1H NMR (400 MHz, D2O): δ 7.12 (d, J = 7.2 Hz, 2H), 6.94 
(d, J = 7.6 Hz, 2H), 4.42 (d , J = 12.0 Hz, 1H), 4.25 (d , J = 12.0 Hz, 1H), 4.08 (m, 1H), 3.87-
3.79 (m, 2H), 3.61 (m, 1H), 3.36-3.33 (m, 2H), 2.37 (t, J = 7.6 Hz, 2H), 2.10 (m, 1H), 1.97 (m, 
1H), 1.39 (m, 2H), 1.24 (s. br, 10H), 0.88 (t, J = 6.4 Hz, 3H); 13C NMR (100 MHz, D2O): δ 
141.3, 134.9, 127.7, 127.3, 76.6, 70.1, 64.0, 57.2, 42.7, 35.1, 31.5, 31.0, 29.2, 29.2, 29.0, 29.0, 
22.3, 13.5; [α]D (-) 29.0° (c 0.10, MeOH); HRMS (ESI) calcd for C20H34NO2 [M+H]+ 
320.2584, found 320.2587. HPLC: condition (A), tR = 5.97 min; purity: > 99 %. 
 
 
Ketone 1.49 was obtained according to the procedure for synthesizing 1.44. 
 
 
tert-Butyl (S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-oxopyrrolidine-1- 
carboxylate (1.45) was obtained (60 mg, 86 %) as pale yellow oil from alcohol 1.36 (70 mg, 
0.21 mmol). 1H NMR (400 MHz, CDCl3): δ 4.19-3.78 (m, 4H), 3.63 (m, 1H), 2.50 (m, 2H), 
1.49 (s, 9H), 0.85 (s, 9H), 0.02 (s, 3H) 0.01 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 213.6, 
(213.2), 154.3, 80.4, (80.2), 64.3, (64.1), 63.6, (62.6), (43.2), 42.6, (37.1), 36.6, 28.6, 25.9, 
18.2, -5.8, -5.9; [α]D (+) 150.0° (c 0.24, CHCl3); HRMS (ESI) calcd for C16H31NNaO4Si 
[M+Na]+ 352.1915, found 352.1919. 
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tert-Butyl (2S,3S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-hydroxypyrrolidine-1- 
carboxylate (1.46) was obtained (39 mg, 78 %) as colorless oil from 1.45 (50 mg, 0.15 
mmol). 1H NMR (400 MHz, CDCl3): δ 4.45 (m, 1H), 4.12-3.76 (m, 3H), 3.54-3.36 (m, 3H), 
2.06 (m, 1H), 1.92 (m, 1H), 1.45 (s, 9H), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 13C NMR 
(100 MHz, CDCl3): δ 154.6, (154.5), (79.8), 79.4, (73.4), 73.0, (62.4), 61.8, 59.9, (59.8), 44.6, 
(44.0), 33.8, (32.8), 28.6, 25.9, 18.1, -5.8; [α]D (+) 66.7° (c 0.21, CHCl3); HRMS (ESI) calcd 
for C16H33NNaO4Si [M+Na]+ 354.2071, found 354.2080. 
 
 
tert-Butyl (2S,3S)-3-((4-bromobenzyl)oxy)-2-(((tert-butyldimethylsilyl)oxy)methyl) 
pyrrolidine-1-carboxylate (1.47) was obtained as colorless oil (43 mg, 81 %) from 1.46 (35 
mg, 0.11 mmol). 1H NMR (400 MHz, CDCl3): δ 7.46 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.0 Hz, 
2H), 4.54 (m, 2H), 4.10 (m, 1H), 3.92-3.85 (m, 3H), 3.41-3.28 (m, 2H), 2.15-2.08 (m, 1H), 
2.05-2.00 (m, 1H), 1.47 (s, 9H), 0.89 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 154.7, 137.7, 131.5, 129.0, 121.4, 79.6, (79.3), 78.5, (77.8), 71.2, 60.5, 59.8, (59.2), 
(44.2), 43.8, 36.8, 29.8, (29.1), (28.7), 26.0, 24.8, (23.5), 18.3, -5.7; [α]D (+) 10.7° (c 0.30, 
CHCl3); HRMS (ESI) calcd for C23H38BrNNaO4Si [M+Na]+ 522.1646, found 522.1656.  
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pyrrolidine-1-carboxylate (1.48) was obtained as pale yellow oil (30 mg, 81 % over two 
steps) from 1.47 (35 mg, 0.06 mmol). 1H NMR (400 MHz, CDCl3): δ 7.26 (d, J = 8.0 Hz, 2H), 
7.15 (d, J = 8.0 Hz, 2H), 4.56 (m, 2H), 4.10 (m, 1H), 3.92-3.81 (m, 3H), 3.41-3.24 (m, 2H), 
2.60 (t, J = 7.6 Hz, 2H), 2.19-2.09 (m, 1H), 2.04-2.01 (m, 1H), 1.60 (m, 2H), 1.46 (s, 9H), 
1.29 (m, 10H), 0.89 (m, 12H), 0.06 (s, 3H), 0.04 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 
154.7, 142.5, 135.8, 128.5, 127.6, 79.5, (79.2), 78.1, 71.9, 60.5, 59.7, (59.1), (44.2), 43.8, 35.8, 
32.0, (31.7), 29.8, 29.6, 29.5, 29.4, 29.1, 28.7, 26.1, (25.9), 22.8, 18.3, 14.3, -5.6; [α]D (+) 9.5° 
(c 1.37, CHCl3); HRMS (ESI) calcd for C31H55NNaO4Si [M+Na]+ 556.3793, found 556.3789. 
 
 
(2S,3S)-2-(Hydroxymethyl)-3-((4-octylbenzyl)oxy)pyrrolidin-1-ium chloride (1.49) was 
obtained as yellow solid (9.2 mg, 99 %) from 1.48 (14 mg, 0.026 mmol). 1H NMR (400 MHz, 
D2O): δ 7.12 (d, J = 7.2 Hz, 2H), 6.94 (d, J = 7.6 Hz, 2H), 4.44 (d , J = 12.0 Hz, 1H), 4.27 (d , 
J = 12.0 Hz, 1H), 4.08 (m, 1H), 3.87-3.79 (m, 2H), 3.61 (m, 1H), 3.36-3.33 (m, 2H), 2.37 (t, J 
= 7.6 Hz, 2H), 2.10 (m, 1H), 1.97 (m, 1H), 1.39 (m, 2H), 1.24 (s. br, 10H), 0.88 (t, J = 6.4 Hz, 
3H); 13C NMR (100 MHz, D2O): δ 141.6, 135.3, 128.1, 127.7, 77.0, 70.6, 64.4, 57.6, 43.1, 
35.5, 31.9, 31.4, 29.6, 29.5, 29.4, 29.4, 22.6, 13.9; [α]D (+) 29.1° (c 0.11, MeOH); HRMS 
(ESI) calcd for C20H34NO2 [M+H]+ 320.2584, found 320.2586. HPLC: condition (A) tR = 5.97 
min; purity: 95.1 %. 
 
 
(2R,4S)-1-(tert-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (1.59). Saturated 
aqueous NaHCO3 (160 mL) was added to a solution of trans-hydroxyproline 1.58 (4 g, 30.6 
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mmol) in dioxane and water (1:1, 80 mL). The solution was cooled to 0°C and (Boc)2O (7.7 
mL, 33.7 mmol) was added drop wise. The reaction was stirred at room temperature over 
night. The pH was acidified to 3 by addition of 2M HCl and the reaction mixture was 
extracted with EtOAc. The organic layers were combined, dried over MgSO4 and filtered. The 
volatiles were removed under reduced pressure to give alcohol 1.59 (7.1 g, 100 %) as colorless 
oil, which was used in the next step without purification. Spectroscopic data were in 
agreement with the proposed structures and matched those reported in the literature.139 
 
 
tert-Butyl (2R,4S)-4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate (1.60). Acid 
1.59 (3.5g, 15.2 mmol) dissolved in CH2Cl2 (56 mL) on addition of Et3N (2.3 mL, 16.7 
mmol). The solution was cooled to -30°C. Ethyl chloroformate (1.53 mL, 16.0 mmol) was 
added to the mixture, which was stirred for 40 min. To this mixture, TBAB (538 mg, 1.67 
mmol) was added, followed slowly by a suspension of NaBH4 (2.47 g, 65.4 mmol) in ice-cold 
water (4 mL). The reaction mixture was allowed to warm to -10°C, stirred for 1 h, warmed to 
0°C, and stirred for an addition 1 h.  The reaction mixture was acidified to pH 6 with 50 % 
acetic acid. The organic phase and the aqueous phase were separated.  The aqueous phase was 
extracted with CH2Cl2 three times. The organic phases were combined, dried over MgSO4 and 
filtered. The solvent was removed under reduced pressure and the residue purified by flash 
chromatography (hexane: EtOAc, 3:7) to give 1.60 (2.61 g, 79 %) as colorless oil. 
Spectroscopic data were in agreement with the proposed structures and matched those reported 
in the literature.140  
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carboxylate (1.61). DMAP (136 mg, 1.1 mmol), Et3N (3.74 mL, 26.8 mmol) and TBDMSCl 
(3.7 g, 24.5 mmol) were added to a CH2Cl2 solution of diol 1.60 (4.83 g, 22.3 mmol) at 0°C 
under argon atmosphere. The reaction was allowed to warm to room temperature and stirred 
for 2 days when completion was indicated by TLC (Rf : 0.21, hexane: EtOAc, 3:1). The 
reaction was diluted with Et2O and the organic phase was washed with water two times, dried 
over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by 
flash chromatography (hexane: EtOAc, 3:1) to give 1.61 (6.4 g, 87 %) as colorless oil. 
Spectroscopic data were in agreement with the proposed structures and matched those reported 
in the literature.140 
 
 
tert-Butyl (2R,4S)-4-((4-bromobenzyl)oxy)-2-(((tert-butyldimethylsilyl)oxy)methyl) 
pyrrolidine-1-carboxylate (1.62) was obtained as colorless oil (6.94 g, 92 %) from 1.61 (5.0 
g, 15.1 mmol) according to the procedure for synthesizing 1.30. 1H NMR (300 MHz, CDCl3) δ 
7.45 (d, J = 7.9 Hz, 2H), 7.19 (d, J = 8.2 Hz, 2H), 4.55-4.33 (m, 2H), 4.28-4.09 (m, 1H), 4.08-
3.85 (m, 2H), 3.75-3.33 (m, 3H), 2.28 -2.11 (m, 1H), 2.10- 1.94 (m, 1H), 1.54-1.37 (m, 9H), 
0.85 (s, 9H), 0.01 (brs, 6H); 13C NMR (100 MHz, CDCl3) δ (154.7), 154.5, 137.4, 131.7, 
(129.4), 129.3, 121.6, (79.6), 79.4, 76.5, 70.5, 64.4, (63.6), 57.7, 52.5, (51.7), 35.2, 34.1, 28.7, 
26.0, 18.3, -5.3; [α]D (+) 23.2° (c 2.17, CHCl3); HRMS (ESI) calcd for C23H38BrNNaO4Si: 
(M+Na)+ 522.1646, found 522.1655. 
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tert-Butyl (2R,4S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-((4-octylbenzyl)oxy) 
pyrrolidine-1-carboxylate (1.63) was obtained as pale yellow oil (3.25 g, 87 % over two 
steps) from 1.62 (3.5 g, 7.0 mmol) according to the procedure for synthesizing 1.31. 1H NMR 
(400 MHz, CDCl3) δ 7.23 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 7.8 Hz, 2H), 4.54-4.39 (m, 2H), 
4.28-4.16 (m, 1H), 4.05-3.86 (m, 2H), 3.72-3.49 (m, 2H), 3.48-3.37 (m, 1H), 2.63-2.55 (m, 
2H), 2.23-2.14 (m, 1H), 2.12-1.97 (m, 1H), 1.63-1.54 (m, 2H), 1.46, 1.45 (s, 9H), 1.36-1.22 
(m, 10H), 0.93-0.83 (m, 12H), 0.06- -0.02 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 154.7, 
142.6, 135.5, (129.0), 128.6, (128.4), 128.0, 79.5, (79.3), 76.1, (71.2), 71.1, 64.5, (63.6), 
(57.8), 57.7, 52.5, (51.8), 35.8, 35.3, 34.1, 32.0, 31.7, 29.6, 29.5, 29.4, 28.7, 26.0, 22.8, 18.3, 
14.2, -5.3; [α]D (+) 21.2° (c 0.17, CHCl3); HRMS (ESI) calcd for C31H55NNaO4Si: (M+Na)+ 
556.3793, found 556.3808. 
 
 
tert-Butyl (2R,4S)-2-(hydroxymethyl)-4-((4-octylbenzyl)oxy)pyrrolidine-1- 
carboxylate (1.64) A solution of TBAF (1.0 M in THF, 9.8 mL, 9.8 mmol) was added to a 
solution of silyl ether 1.63 (3.0 g, 5.6 mmol) in dry THF (130 mL). The reaction was stirred at 
room temperature for 3 h, when completion was indicated by TLC (Rf : 0.45, hexane: EtOAc, 
1:1). The mixture was quenched with saturated aqueous NaHCO3 and extracted three times 
with CH2Cl2. The organic layers were combined, dried over NaSO4 and filtered. The volatiles 
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were removed under reduced pressure and the residue was purified by flash chromatography 
(hexane: EtOAc, 6:4) to give alcohol 1.64 (2.2 g, 93 %) as pale yellow oil. 1H NMR (400 
MHz, CDCl3) δ 7.22 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 8.1 Hz, 2H), 4.95-2.90 (m, 1H), 4.54-
4.40 (m, 2H), 4.19-4.08 (m, 1H), 4.09-4.00 (m, 1H), 3.78-3.59 (m, 2H), 3.55 (dd, J = 11.4, 7.2 
Hz, 1H), 3.46-3.33 (m, 1H), 2.62-2.54 (m, 2H), 2.23-2.13 (m, 1H), 1.66-1.53 (m, 2H), 1.47 (s, 
9H), 1.35-1.22 (m, 10H), 0.91-0.85 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 157.2, 142.8, 
135.2, 128.7, 127.8, 80.6, 76,0, 70.9, 67.4, 59.3, 53.1, 35.8, 34.7, 32.0, 31.7, 29.6, 29.5, 29.4, 
28.6, 22.8, 14.2; [α]D +20.3° (c 1.3, CHCl3); HRMS (ESI) calcd for C25H41NNaO4: (M+Na)+ 
442.2928, found 442.2939.  
 
 
(2R,4S)-2-(Hydroxymethyl)-4-((4-octylbenzyl)oxy)pyrrolidin-1-ium chloride (1.65) was 
obtained as white solid (759 mg, 90 %) from 1.64 (1.0 g, 2.4 mmol) according to the 
procedure for synthesizing 1.32. 1H NMR (400 MHz, MeOD) δ 7.27 (d, J = 8.0 Hz, 2H), 7.17 
(d, J = 8.1 Hz, 2H), 4.53 (s, 2H), 4.39-4.33 (m, 1H), 3.95-3.83 (m, 2H), 3.63 (dd, J = 11.8, 6.4 
Hz, 1H), 3.46-3.32 (m, 2H), 2.64-2.56 (m, 2H), 2.30 (dd, J = 13.9, 6.6 Hz, 1H), 1.91 (ddd, J = 
14.7, 10.5, 4.5 Hz, 1H), 1.66-1.54 (m, 2H), 1.37-1.20 (m, 10H), 0.89 (t, J = 6.9 Hz, 3H); 13C 
NMR (75 MHz, MeOD) δ 143.9, 136.2, 129.5, 129.1, 78.4, 71.9, 61.5, 61.4, 51.8, 36.6, 33.6, 
33.0, 32.7, 30.6, 30.4, 30.3, 23.7, 14.4; [α]D (-) 4.62° (c 0.26, MeOH); HRMS (ESI) calcd for 
C20H34NO2: (M+H)+ 320.2584, found 320.2594. HPLC: condition (A), tR = 5.99 min; purity: > 
99 %. 
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tert-Butyl (2R,4S)-2-(((methylsulfonyl)oxy)methyl)-4-((4-octylbenzyl)oxy) 
pyrrolidine-1-carboxylate (1.68). Alcohol 1.64 (100 mg, 0.238 mmol) was dissloved in 
CH2Cl2 (0.8 mL), and Et3N (66 µL, 0.476 mmol) was added. The solution was cooled 0 °C. To 
this mixture, MsCl (28 µL, 0.357 mmol) was added. The resulting solution was stirred over 
night. The reaction mixture was poured into water and extracted with EtOAc. The combined 
organic phases were dried over MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography (hexane: EtOAc, 3:1) to give methanesulfonate 
1.68 (112 mg, 95 %) as pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.22 (d, J = 8.0 Hz, 
2H), 7.15 (d, J = 8.0 Hz, 2H), 4.59-4.25 (m, 4H), 4.15 (m, 2H), 3.83-3.56 (m, 1H), 3.44-3.39 
(m, 1H), 2.98 (s, 3H), 2.61-2.57 (t, J = 7.6 Hz, 2H), 2.21 (m, 1H), 2.13-2.08 (m, 1H), 1.61-
1.55 (m, 2H), 1.46 (s, 9H), 1.30-1.27 (m, 10H), 0.83 (t, J = 6.4 Hz 3H); 13C NMR (100 MHz, 
CDCl3, mixture of rotamers) δ 154.8, (154.4), 142.7, 135.0, (129.7), 128.6, 127.8, (127.2), 
(80.5), 80.1, 76.1, (75.6), 71.0, 70.0, 55.0, 52.5, (51.7), (37.4), 36.9, 35.7, (35.3), 34.0, 31.9, 
31.6, 29.5, 29.4, 29.3, 28.5, 22.7, 14.2; [α]D (+) 28.0° (c 0.54, CHCl3); HRMS (ESI) calcd. for 
C26H43NNaO6S: (M+Na)+ 520.2703, found 520.2696. 
 
 
tert-Butyl (2S,4S)-2-methyl-4-((4-octylbenzyl)oxy)pyrrolidine-1-carboxylate (1.69). A 
solution of LiBHEt3 (1 M in THF, 0.644 mL, 0.644 mmol) was added slowly to an ice-cold 
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solution of methanesulfonate 1.68 (80 mg, 0.161 mmol) in THF (0.16 mL). The solution was 
allowed to warm to r.t. and stirred for 2 h, when completion was indicated by TLC (Rf : 0.55, 
hexane: EtOAc, 8:1). The reaction was quenched with water and poured into EtOAc. The 
aqueous and organic phases were separated. The aqueous phase was extracted with EtOAc. 
The combined organic phases were washed with brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(hexane: EtOAc, 16:1) to give pyrrolidine 1.69 (60 mg, 92 %) as pale yellow oil. 1H NMR 
(400 MHz, CDCl3) 7.23 (d, J = 7.6 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 4.48-4.46 (m, 2H), 4.10-
3.97 (m, 2H), 3.68-3.43 (m, 2H), 2.59 (t, J = 8.0 Hz, 2H), 2.17 (m, 1H), 1.75-1.69 (m, 1H), 
1.61-1.57 (m, 2H), 1.48 (s, 9H), 1.31-1.21 (m, 13H), 0.89 (t, J = 6.0 Hz, 3H); 13C NMR (100 
MHz, CDCl3, mixture of rotamers) 154.9, 142.6, 135.3, 128.6, 127.8, 79.2, (76.4), 75.9, 71.0, 
51.9, (51.2), 40.3, (39.3), 35.8, 32.0, 31.6, 29.6, 29.4, 29.4, 28.6, 22.8, 21.5, 20.9, 14.2; [α]D 
(+) 11.1° (c 0.18, CHCl3); HRMS calcd for C25H41NNaO3 : (M+Na)+ 426.2979, found 
426.2963. 
 
 
(2S,4S)-2-Methyl-4-((4-octylbenzyl)oxy)pyrrolidin-1-ium chloride (1.70) was obtained as 
white solid (20.1 mg, 85 %) from 1.69 (28 mg, 0.069 mmol) according to the procedure for 
synthesizing 1.32. 1H NMR (400 MHz, D2O) 7.17 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 8.0 Hz, 
2H), 4.38 (d, J = 12.0 Hz, 1H), 4.29 (d, J = 12.0 Hz, 1H), 4.15 (m, 1H), 3.73-3.64 (m, 1H), 
3.44 (dd, J = 13.2, 5.2 Hz, 1H), 3.30 (d, J = 13.2 Hz, 1H), 2.38 (t, , J = 8.0 Hz, 2H), 2.05 (dd, J 
= 14.0, 6.0 Hz, 1H), 1.58-1.66 (m, 1H), 1.45 (m, 2H), 1.30 (d, J = 6.8 Hz, 3H), 1.25-1.30 (m, 
10H), 0.90 (t, J = 5.2 Hz, 3H); 13C NMR (100 MHz, D2O) 141.6, 135.2, 128.0, 77.0, 70.3, 
54.7, 50.0, 38.0, 35.5, 32.0, 31.5, 29.7, 29.6, 29.5, 22.7, 16.3, 13.9; [α]D (+) 3.5° (c 0.34, 
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MeOH);  HRMS calcd for C20H34NO : (M+H)+ 304.2635, found 304.2644.! HPLC: condition 
(A), tR = 6.20 min; purity: > 99 %. 
 
 
 
tert-Butyl (2R,4S)-2-(((di-tert-butoxyphosphoryl)oxy)methyl)-4-((4-octylbenzyl)oxy) 
pyrrolidine-1-carboxylate (1.76). Di-tert-butyl N,N-diethylphosphoramidite (97 µL, 87 mg, 
0.35 mmol) and 1H-tetrazole (50 mg, 0.71 mmol) were sequentically added to a solution of 
alcohol 1.64 (50 mg, 0.12 mmol) in anhydrous THF (1.6 mL) under argon atmosphere at r.t. 
The mixture was stirred over night and then cooled to -78 °C. A solution of m-CPBA (77%, 83 
mg, 0.35 mmol) in CH2Cl2 (1.6 ml) was added to the mixture and the reaction was warmed 
back to r.t. After 0.5 h, the reaction was quenched with saturated aqueous NaHCO3 and 
extracted three times with EtOAc. The organic layers were washed with brine, dried over 
MgSO4 and filtered. The filtrate was evaporated under reduced pressure and the residue was 
purified by flash chromatography (hexane: EtOAc, 4:1 to 2:1) to give phosphate 1.76 (40 mg, 
55 %) as colorless oil. 1HNMR (400 MHz, CDCl3) δ 7.19 (d, J = 7.6 Hz, 2H), 7.11 (d, J = 7.6 
Hz, 2H), 4.48-4.38 (m, 2H), 4.18-3.92 (m, 4H), 3.74 – 3.36 (m, 2H), 2.55 (t, J = 7.6 Hz, 2H), 
2.13 (m, 2H), 1.56 (m, 2H), 1.49 (s, 9H), 1.44 (m, 18H), 1.26 (m, 10H), 0.85 (m, 3H). 13C 
NMR (100 MHz, CDCl3, mixture of rotamers) δ 154.3, 142.4, 135.0, 128.3, (127.6), 127.6, 
82.7, (82.6), 82.1, (82.0), 79.7, (79.3), 75.7, 70.9, (70.8), 67.8, (67.2), 55.6, 52.1, 51.4, 35.5, 
35.1, 33.7, 31.7, 31.4, 30.2, 30.2, 29.8, 29.7, 29.3, 29.2, 29.1, 28.3, 22.5, 14.0; 31P NMR (162 
MHz, CDCl3, mixture of rotamers) -9.62, -10.01; [α]D (+) 17.0° (c 1.95, CHCl3); HRMS (ESI) 
calcd for C33H58NNaO7P (M+Na)+ 634.3843, found 634.3848.  
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((2R,4S)-4-((4-Octylbenzyl)oxy)pyrrolidin-1-ium-2-yl)methyl hydrogen phosphate (1.77). 
A solution of HCl (4M) in 1,4-dioxane (1.6 mL, 6.4 mmol) was added to a flask containing 
carbamate 1.76 (30 mg, 0.05 mmol) and the solution was stirred overnight at room 
temperature. The volatiles were removed under reduced pressure. 1,4-Dioxane (2 mL) was 
added to the residue and the contents were evaporated to remove residual HCl.  The crude 
mixture was purified by flash chromatography (i-PrOH : NH4OH : H2O, 8 : 2 : 1) to give  a 
colorless oil.  The oil was dissolved in CHCl3, fitered through a plastic syringe filter (pore 
size: 0.45 µm), and lyophilized to give phosphate 1.77 (16.0 mg, 88 %) as while solid. 1H 
NMR (500 MHz, MeOD) δ 7.26 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 4.53 (s, 2H), 
4.37 (t, J = 4.0 Hz, 1H), 4.21 (ddd, J = 12.5, 8.5, 2.5 Hz, 1H), 4.05-3.99 (m, 1H), 3.92 (ddd, J 
= 12.5, 11.0, 5.5 Hz, 1H), 3.44 (m, 1H), 3.31 (m, overlapped with MeOD, 1H), 2.60 (t, J = 7.5 
Hz, 2H), 2.32 (m, 1H), 2.05 (m, 1H), 1.60 (m, 2H), 1.31-1.13 (m, 10H), 0.89 (t, J = 7.0 Hz, 
3H). 13C NMR (100 MHz, D2O) δ 144.0, 136.4, 129.7, 129.3, 78.7, 71.9, 64.1, 60.6, 51.6, 
36.7, 33.3, 33.2, 32.9, 30.7, 30.5, 30.4, 23.9, 14.6; [α]D (-) 20.0° (c 0.05, MeOH); 31P NMR 
(202 MHz, MeOD)  2.36; HRMS (ESI) calcd for C20H34NNaO5P (M+Na)+ 422.2069, found 
422.2064. 
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2,5-dihydro-1H-pyrrole-1-carboxylate (1.103). A solution of lactam 1.23 (257 mg, 0.40 
mmol) in anhydrous THF (4.0 mL) under argon atmosphere was cooled to -78 °C. A solution 
of LiHMDS (1M) in THF (0.44 mL, 0.44 mmol) was added dropwise to the solution. The 
mixture was stirred at -78 °C for 1 h. In another flask under argon atmosphere, a solution of 
PhSeBr (104 mg, 0.44 mmol) in anhydrous THF (1 mL) was cooled to -78 °C, and transferred 
dropwise by canula to the reaction mixture, which was stirred at -78 °C for 2 h. The reaction 
was quenched with saturated aqueous NH4Cl, diluted with CH2Cl2 and the two phases were 
separated. The aqueous phase was extracted twice with CH2Cl2. The combined organic phases 
were dried over MgSO4 and filtered. The volatiles were removed under reduced pressure to a 
residue that was dissolved in CH2Cl2 (2 mL), cooled to -78 °C and treated with a solution of 
hydrogen peroxide  (30 % (w/w) in H2O, 204 µL), followed by pyridine (160 µL, 2.2 mmol). 
The reaction mixture was allowed to warm to room temperature and stirred for 1 h, when 
completion was indicated by TLC (Rf : 0.41, hexane: EtOAc, 4:1). The mixture was quenched 
with saturated aqueous NH4Cl, and extracted three times with CH2Cl2. The organic layers 
were combined, dried over NaSO4 and filtered. The filtrate was evaporated under reduced 
pressure and the residue was purified by flash chromatography (hexane: EtOAc, 6:1) to give 
olefin 1.103 (180 mg, 70 % over two steps) as yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.51-
7.27 (m, 10H), 7.16-7.08 (m, 4H), 6.42 (s, 1H), 5.12 (s, 1H), 4.28 (dd, J = 2.4, 10.4 Hz, 1H), 
3.84 (dd, J = 1.2, 10.4 Hz, 1H), 2.71 (t, 7.6 Hz, 2H), 1.69 (m, 2H), 1.52 (s, 9H), 1.41-1.27 (m, 
10H), 0.90 (m, 12H); 13C NMR (100 MHz, CDCl3) δ 169.4, 159.2, 149.5, 146.2, 135.3, 135.2, 
132.6, 132.6, 129.7, 129.4, 129.1, 128.5, 127.7, 127.4, 127.2, 120.6, 82.6, 63.2, 60.9, 35.9, 
31.8, 31.3, 29.4, 29.3, 29.2, 28.1, 26.4, 22.6, 19.1, 14.1; [α]D (-) 183.8° (c 0.40, CHCl3); 
HRMS (ESI) calcd for C40H53NNaO4Si (M+Na)+ 662.3636, found 662.3616. 
 
 
tert-Butyl (2S,3S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-octylphenyl)-5- 
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oxopyrrolidine-1-carboxylate (1.104). To a solution of olefin 1.103 (300 mg, 0.47 mmol) in 
EtOAc (9.5 mL), Pd/C (10 %, 50 mg, 0.047 mmol) was added. The flask was evacuated under 
vacuum and filled with H2. After stirring overnight, TLC showed complete reaction (Rf : 0.41, 
hexane: EtOAc, 4:1). The reaction mixture was filtered over CeliteTM. The filtrate was 
evaporated under reduced pressure. The residue was purified by flash chromatography 
(hexane: EtOAc, 6:1) to give lactam 1.104 (270 mg, 90 %) as pale yellow oil. 1H NMR (500 
MHz, CDCl3) δ 7.54 (m, 2H), 7.52-7.25 (m, 4H), 7.23-7.19 (m, 8H), 4.36 (d, J = 7.2 Hz, 1H), 
3.87-3.79 (m, 2H), 3.59-3.51 (m, 2H), 2.75-2.67 (m, 3H), 1.68 (m, 2H), 1.43 (s, 9H), 1.43-
1.30 (m, 10H), 1.00 (s, 9H), 0.91 (t, J = 6.8 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ174.0, 
149.6, 141.9, 135.6, 135.4, 133.9, 132.6, 132.1, 129.7, 129.4, 128.6, 127.7, 127.7, 127.4, 82.6, 
62.5, 61.3, 40.3, 37.0, 35.6, 31.8, 31.5, 29.4, 29.3, 29.2, 27.9, 26.7, 22.6, 18.8, 14.0; [α]D (-) 
41.6° (c 1.60, CHCl3); HRMS (ESI) calcd for C40H55NNaO4Si (M+Na)+ 664.3793, found 
664.3799. 
 
 
tert-Butyl (2S,3S,5R)-5-allyl-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-octylphenyl)  
pyrrolidine-1-carboxylate (1.105). Lactam 1.104 (105 mg, 0.16 mmol) was dissolved in 
anhydrous THF (6.0 mL) in a dry flask under argon atmosphere, cooled to -78 °C, treated 
dropwise with lithium triethylborohydride (1.0 M in THF, 180 µL, 0.18 mmol), and stirred for 
1 hat -78 °C. In another dry flask, pyridinium p-toluenesulfonate (48.0 mg, 0.19 mmol) was 
dissolved in anhydrous MeOH (4.0 mL) under argon, cooled to -78°C, then transferred 
dropwise by canula to the reaction mixture. The pH was verified to be slightly acidic (pH~6); 
otherwise, more pyridinium p-toluenesulfonate was added. The mixture was allowed to warm 
to room temperature and stirred overnight. The reaction was quenched with saturated aqueous 
NaHCO3, and extracted three times with CH2Cl2. The organic layers were combined, dried 
over NaSO4 and filtered. The filtrate was evaporated under reduced pressure to give O-methyl 
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aminal product as yellow oil, that was dissolved in anhydrous CH2Cl2 (0.74 mL) under argon 
atmosphere and cooled to -78 °C. Allyltrimethylsilane (128 µL, 0.80 mmol) and titanium 
tetrachloride (1.0 M in CH2Cl2, 180 µL, 0.180 mmol) were added sequentially to the -78 °C 
solution. The resulting orange mixture was stirred for 1 h at -78 °C, quenched with water and 
extracted three times with CH2Cl2. The organic layers were combined, dried over NaSO4 and 
filtered. The filtrate was evaporated under reduced pressure and the residue purified by flash 
chromatography (hexane: EtOAc, 6:1) to give the olefin 1.105 (40 mg, 37 % over two steps) 
as pale yellow oil. 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.51-7.48 (m, 2H), 
7.39-7.10 (m, 12H), 5,87 (m, 1H), 5.10 (m, 2H), 4.20-4.04 (m, 2.5H), 3.78 (dd, J = 2.8, 10.8 
Hz, 0.5H), 3.67 (m, 1H), 3.39 (d, J = 10.4 Hz, 0.5H), 3.29 (d, J =10.8 Hz, 0.5H), 2.94 (m, 
1.5H), 2.74 (dd, J =6.4, 12.8 Hz, 0.5H), 2.65 (m, 2H), 2.29 (m, 1H), 2.01 (td, J =6.4, 11.6 Hz, 
1H), 1.65 (m, 2H), 1.55 (s, 5H), 1.32 (m 10H), 1.26 (s, 4H), 1.00 (s, 5H), 0.98 (s, 4H), 0.91 (t,  
J =7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ (153.8), 153.5, (141.1), 
141.1, (136.1), 135.8, (135.7), 135.7, (135.6), 135.5, 133.4, (133.1), (132.9), 132.8, (129.5), 
129.4, (129.2), 129.2, 128.3, 127.7, (127.4), 127.3, 117.1, (117.0), 79.2, (79.1), (62.4), 62.2, 
61.9, 60.2, 57.1, (56.9), (43.5), 43.0, 39.5, 37.8, 35.6, 32.4, 31.9, (31.7), 31.6, (31.4), 29.5, 
29.4, 29.3, 28.6, (28.4), 26.8, (26.8), 22.7, 19.0, (18.8), 14.1; [α]D (-) 30.2° (c 0.42, CHCl3); 
HRMS (ESI) calcd for C43H61NNaO3Si (M+Na)+ 690.4313, found 690.4297. 
 
 
tert-Butyl (2S,3S,5S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-5-(hydroxymethyl)- 
3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.106). Olefin 1.105 (55 mg, 0.082 mmol) was 
dissolved in anhydrous toluene (1.8 mL) in a dry flask equipped with a condenser, under argon 
atmosphere.  N-Allyltritylamine (49 mg, 0.16 mmol) and Grubb’s catalyst 2nd generation (14 
mg, 0.016 mmol) were sequentially added to the reaction mixture, which was heated to reflux 
for 3 days, cooled to room temperature and quenched with brine. The mixture was extracted 
N
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three times with CH2Cl2. The organic layers were combined, dried over NaSO4 and filtered. 
The filtrate was evaporated under reduced pressure and the residue was purified by flash 
chromatography (hexane: EtOAc, 40:1 to 20:1) to give the disubstituted alkene isomer (40 mg, 
73 %) as yellow oil. The oil (40 mg, 0.06 mmol) was dissolved in a solution of MeOH and 
CH2Cl2 (1:1, 6 mL), cooled to -78 °C, and treated with ozone bubbles until a deep blue color 
persisted. Argon was bubbled through the solution to remove residual ozone until no blue 
color was observed. Dimethyl sulfide (0.4 mL) was added carefully. The reaction was allowed 
to slowly warm to room temperature with stirring overnight. The volatiles were removed 
under reduced pressure. The residue was dissolved in MeOH (1.96 mL), cooled to 0 °C, 
treated with sodium borohydride (6.8 mg, 0.180 mmol) and stirred at 0 °C for 4 h, when 
completion was indicated by TLC (Rf : 0.15, hexane: EtOAc, 8:1). The reaction was quenched 
with saturated aqueous NH4Cl, extracted three times with CH2Cl2. The organic layers were 
combined, dried over NaSO4 and filtered. The filtrate was evaporated under reduced pressure 
and the residue was purified by flash chromatography (hexane: EtOAc, 8:1 to 4:1) to give 
alcohol 1.106 (23.2 mg, 59 % over two steps) as yellow oil (23. 2 mg, 43% over three steps). 
1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.52-7.47 (m, 2H), 7.41-7.06 (m, 12H), 
4.80 (br, 1H), 4.41 (m, 1H), 4.20-3.74 (m, 3H), 3.65 (m, 1H), 3.40-3.29 (m, 1H), 3.16-2.98 (m, 
1H), 2.68-2.59 (m, 2H), 1.93-1.89 (m, 1H), 1.67-1.60 (m, 3H), 1.35-1.26 (m, 19H), 1.10 (s, 
2H), 1.00 (s, 7H), 0.90 (t, J =6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 
156.4, 141.3, (141.1), 135.7, (135.6), (135.5), 135.4, 133.0, 132.7, 129.6, (129.5), 129.4, 
(129.3), 128.4, (128.3), 128.1, 127.7, (127.4), 127.4, 80.6, (79.9), 69.3, (65.3), 63.4, (62.5), 
61.5, 60.4, (59.9), (59.1), 44.5, (43.6), 35.6, (32.1), 31.9, 31.6, (31.5), 29.7, 29.5, 29.4, 29.3, 
28.6, 28.3, 26.8, 22.7, (19.0), 18.8, 14.1; [α]D (-) 31.8° (c 0.78, CHCl3); HRMS (ESI) calcd for 
C41H59NNaO4Si (M+Na)+ 680.4106, found 680.4103.  
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(2S,3S,5S)-2,5-Bis(hydroxymethyl)-3-(4-octylphenyl)pyrrolidin-1-ium chloride (1.100) 
was obtained as a yellow solid (10.6 mg, 85 %) from silyl ether 1.106 (23 mg, 0.035 mmol) 
according to the procedure for synthesizing alcohol 1.32. 1H NMR (400 MHz, D2O) δ 7.09 (d, 
J = 8.0 Hz, 2H), 6.93 (d, J = 7.6 Hz, 2H), 4.01-3.91 (m, 2H), 3.75-3.60 (m, 3H), 3.28-3.19 (m, 
2H), 2.38-2.28 (m, 3H), 1.94-1.90 (m, 1H), 1.47 (br, 2H), 1.27 (br. s, 10H), 0.90 (t, J = 6.8 Hz, 
3H); 13C NMR (100 MHz, D2O) δ 140.9, 134.1, 128.2, 128.1, 63.3, 61.5, 58.8, 58.3, 43.8, 
35.4, 32.0, 31.3, 30.2, 29.8, 29.6, 29.6, 22.7, 13.9; [α]D (+) 37.7° (c 0.22, MeOH); HRMS 
(ESI) calcd for C20H34NO2 (M+H)+ 320.2584, found 320.2586. HPLC: condition (B), tR = 6.05 
min; purity: 95.6 %. 
 
 
tert-Butyl (R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-octylphenyl)-5-oxo- 
2,5-dihydro-1H-pyrrole-1-carboxylate (1.108) was obtained as yellow oil (192 mg, 75 % 
over two steps) from lactam 1.107 (257 mg, 0.40 mmol) according to the procedure for 
synthesizing lactam 1.103. 1H NMR (400 MHz, CDCl3) δ 7.51-7.27 (m, 10H), 7.16-7.08 (m, 
4H), 6.42 (s, 1H), 5.12 (s, 1H), 4.28 (dd, J = 2.4, 10.4 Hz, 1H), 3.84 (dd, J = 1.6, 10.4 Hz, 1H), 
2.71 (t, 7.6 Hz, 2H), 1.68 (m, 2H), 1.53 (s, 9H), 1.37-1.27 (m, 10H), 0.89 (m, 12H); 13C NMR 
(100 MHz, CDCl3) δ 169.4, 159.2, 149.5, 146.2, 135.4, 135.2, 132.6, 132.6, 129.7, 129.4, 
129.2, 128.5, 127.7, 127.4, 127.2, 120.7, 82.6, 63.2, 61.0, 35.9, 31.9, 31.3, 29.5, 29.3, 29.2, 
28.1, 26.4, 22.7, 19.1, 14.1; [α]D (+) 163.0° (c 2.20, CHCl3); HRMS (ESI) calcd for 
C40H53NNaO4Si (M+Na)+ 662.36361, found 662.36401. 
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tert-Butyl (2R,3R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-octylphenyl)-5- 
oxopyrrolidine-1-carboxylate (1.109) was obtained as pale yellow oil (150 mg, 88 %) from 
olefin 1.108 (170 mg, 0.27 mmol) according to the procedure for synthesizing 1.104. 1H NMR 
(500 MHz, CDCl3) δ 7.53 (m, 2H), 7.41-7.32 (m, 4H), 7.25-7.20 (m, 8H), 4.36 (d, J = 6.4 Hz, 
1H), 3.85-3.80 (m, 2H), 3.58-3.51 (m, 2H), 2.74-2.67 (m, 3H), 1.68 (m, 2H), 1.44 (s, 9H), 
1.38-1.31(m, 10H), 1.01 (s, 9H), 0.91 (t, J = 5.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
174.0, 149.6, 141.9, 135.6, 135.4, 133.9, 132.6, 132.1, 129.7, 129.4, 128.6, 127.7, 127.7, 
127.4, 82.6, 62.5, 61.3, 40.3, 37.0, 35.6, 31.8, 31.5, 29.4, 29.3, 29.2, 27.9, 26.7, 22.6, 18.8, 
14.0; [α]D (+) 30.2° (c 1.50, CHCl3); HRMS (ESI) calcd for C40H55NNaO4Si (M+Na)+ 
664.3793, found 664.379. 
 
 
tert-Butyl (2R,3R,5S)-5-allyl-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3- 
(4-octylphenyl)pyrrolidine-1-carboxylate (1.110) was obtained as pale yellow oil (20 mg, 41 
%) from 1.109 (47 mg, 0.073 mmol) according to the procedure for synthesizing 1.105. 1H 
NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.51-7.49 (m, 2H), 7.39-7.10 (m, 12H), 5,88 
(m, 1H), 5.10 (m, 2H), 4.19-4.04 (m, 2.5H), 3.80 (dd, J = 2.8, 10.8 Hz, 0.5H), 3.70 (m, 1H), 
3.39 (d, J = 10.4 Hz, 0.5H), 3.29 (d, J = 10.8 Hz, 0.5H), 2.94 (m, 1.5H), 2.74 (dd, J =5.6, 12.8 
Hz, 0.5H), 2.64 (m, 2H), 2.28 (m, 1H), 2.02 (td, J =6.4, 11.6 Hz, 1H), 1.65 (m, 2H), 1.56 (s, 
5H), 1.31 (m 10H), 1.26 (s, 4H), 1.01 (s, 5H), 0.98 (s, 4H), 0.91 (t, J =7.2 Hz, 3H); 13C NMR 
(100 MHz, CDCl3, mixture of rotamers) δ 153.8, (153.4), (141.1), 141.0, (136.0), 135.8, 
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(135.8), 135.7, (135.7), 135.6, (135.6), 135.5, 133.4, (133.1), (132.8), 132.8, (129.4), 129.4, 
(129.2), 129.2, 128.3, (128.2), 127.7, (127.4), 127.3, 117.1, (117.0), 79.2, (79.1), (62.4), 62.2, 
61.9, 60.1, 57.1, (56.9), (43.4), 43.0, 39.4, 37.7, (35.6), 35.6, (32.3), 31.9, (31.6), 31.6, 31.4, 
(29.5), 29.4, 29.2, 28.6, (28.3), 26.8, (26.7), 22.7, 19.0, (18.8), 14.1; [α]D (+) 43.8° (c 0.16, 
CHCl3); HRMS (ESI) calcd for C43H61NNaO3Si (M+Na)+ 690.4313, found 690.4309. 
 
 
tert-Butyl (2R,3R,5R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-5-(hydroxymethyl)- 
3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.111) was obtained as pale yellow oil (23.8 
mg, 42 % over three steps) from olefin 1.110 (57 mg, 0.085 mmol) according to the procedure 
for synthesizing 1.106. 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.52-7.47 (m, 2H), 
7.41-7.07 (m, 12H), 4.80 (br, 1H), 4.41 (m, 1H), 4.19-3.74 (m, 3H), 3.65 (m, 1H), 3.40-3.29 
(m, 1H), 3.16-3.00 (m, 1H), 2.67-2.59 (m, 2H), 1.93-1.89 (m, 1H), 1.67-1.62 (m, 3H), 1.35-
1.26 (m, 19H), 1.10 (s, 2H), 1.00 (s, 7H), 0.90 (t, J =6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, 
mixture of rotamers) δ156.4, 141.3, (141.1), 135.7, (135.6), (135.5), 135.5, 133.0, 132.7, 
129.6, (129.5), 129.4, (129.3), 128.4, (128.3), 128.1, 127.7, (127.4), 127.4, 80.6, (79.9), 69.4, 
(65.4), 63.4, (62.5), 61.5, 60.4, (59.9), (59.1), 44.5, (43.6), 35.6, (32.1), 31.9, 31.6, (29.7), 
29.6, 29.5, 29.4, (29.3), 29.3, 28.6, 28.3, 26.8, 22.7, (19.0), 18.8, 14.1; [α]D (+) 36.6° (c 0.32, 
CHCl3); HRMS (ESI) calcd for C41H59NNaO4Si (M+Na)+ 680.4106, found 680.4105. 
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(2R,3R,5R)-2,5-Bis(hydroxymethyl)-3-(4-octylphenyl)pyrrolidin-1-ium chloride (1.101) 
was obtained as pale yellow solid (10.0 mg, 88 %) from silyl ether 1.111 (21 mg, 0.032 mmol) 
as yellow solid according to the procedure for synthesizing 1.32. 1H NMR (400 MHz, D2O) δ 
7.08 (d, J = 7.6 Hz, 2H), 6.92 (d, J = 8.0 Hz, 2H), 3.99-3.89 (m, 2H), 3.74-3.58 (m, 3H), 3.27-
3.18 (m, 2H), 2.35-2.29 (m, 3H), 1.92-1.88 (m, 1H), 1.45 (br, 2H), 1.26 (br. s, 10H), 0.89 (t, J 
= 6.8 Hz, 3H); 13C NMR (100 MHz, D2O) δ 140.5, 133.8, 127.8, 127.7, 62.9, 61.1, 58.4, 58.0, 
43.4, 35.0, 31.6, 31.0, 29.8, 29.4, 29.2, 29.2, 22.3, 13.5; [α]D (-) 38.7° (c 0.30, MeOH); HRMS 
(ESI) calcd. for C20H34NO2 (M+H)+ 320.2584, found 320.2587. HPLC: condition (B), tR = 
5.46 min; purity: 93.3 %. 
 
 
 
tert-Butyl (2S,3R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-octylphenyl) 
pyrrolidine-1-carboxylate (1.112) A solution of lactam 1.23 (120 mg, 0.187 mmol) in 
anhydrous THF (2.4 mL) was cooled to 0 °C. Borane dimethyl sulfide complex (2M in THF, 
0.37 mL, 0.748 mmol) was added to the reaction mixture, which was allowed to warm to room 
temperature and stirred overnight, when completion was indicated by TLC (Rf : 0.53, hexane: 
EtOAc, 8:1). The volatiles were removed under reduced pressure. After the residue was co-
evaporated twice with MeOH (2 mL), it was dissolved in CH2Cl2, and washed three times with 
saturated aqueous NaHCO3. The organic layer was washed with brine, dried over MgSO4 and 
filtered. The filtrate was evaporated under reduced pressure and the residue was purified by 
flash chromatography (hexane: EtOAc, 8:1) to give carbamate 1.112 (94.6 mg, 81 %) as pale 
yellow oil. 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.68-7.67 (m, 4H), 7.66-7.37 
(m, 6H), 7.12-7.11 (m, 4H), 4.17 (dd, J =3.6, 10.0 Hz, 0.4H), 3.92-3.57 (m, 4.6H), 3.44 (m, 
1H), 2.59 (t, J =7.2 Hz, 2H), 2.30-2.24 (m, 1H), 1.98-1.90 (m, 1H), 1.61 (br. s, 2H), 1.52 (s, 
3H), 1.35-1.29 (m, 16H), 1.08 (s, 9H), 0.90 (t, J =6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, 
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mixture of rotamers) δ 154.3, 141.2, (140.9), 140.2, 135.6, 133.8, 133.5, (133.4), 129.6, 
(129.5), 128.6, (127.7), 127.7, (127.3), 127.1, 79.3, (79.0), 65.5, (65.3), 63.5, 62.0, 47.2, 
(46.4), 46.2, 45.3, 35.5, 32.9, 31.9, 31.5, 29.5, 29.4, 29.2, 28.6, 28.4, 26.9, 22.7, (19.4), 19.3, 
14.1; [α]D (-) 8.0° (c 1.17, CHCl3); HRMS (ESI) calcd for C40H57NNaO3Si (M+Na)+ 
650.4000, found 650.3998. 
 
 
tert-Butyl (2S,3R)-2-(hydroxymethyl)-3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.113) 
was obtained as colorless oil (155 mg, 92 %) from silyl ether 1.112 (271 mg, 0.432 mmol) 
according to the procedure for synthesizing alcohol 1.64. 1H NMR (400 MHz, CDCl3) δ 7.14 
(s, 4H), 5.10 (br, 1H), 3.93 (m, 1H), 3.90-3.70 (m, 2H), 3.65-3.56 (m, 1H), 3.35 (td, J =6.4, 
10.5 Hz, 1H), 2.86 (m, 1H), 2.58 (t, J =8.0 Hz, 2H), 2.14 (m, 1H), 1.96 (m, 1H), 1.60 (m, 2H), 
1.51 (s, 9H), 1.31-1.23 (m, 10H), 0.89 (t, J =7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
156.9, 141.9, 137.7, 128.7, 127.4, 80.5, 67.1, 66.2, 47.6, 47.1, 35.5, 33.0, 31.9, 31.5, 29.5, 
29.3, 29.2, 28.5, 22.7, 14.1; [α]D (-) 7.6° (c 1.44, CHCl3); HRMS (ESI) calcd for 
C24H39NNaO3 (M+Na)+ 412.2822, found 412.2838. 
 
 
(2S,3R)-2-(Hydroxymethyl)-3-(4-octylphenyl)pyrrolidin-1-ium chloride (1.114) was 
obtained as a pale yellow solid (11.0 mg, 88 %) from carbamate 1.113 (15 mg, 0.039 mmol) 
according to the procedure for synthesizing 1.32. 1H NMR (400 MHz, D2O) δ 7.15 (d, J = 8.0 
N
C8H17
OTBDPSBoc
TBAF
 THF, r.t. N
C8H17
OHBoc
1.112 1.113
92%
N
H2
C8H17
OH
Cl
1.114
      HCl 
in dioxane
N
C8H17
OHBoc
1.113
88%
  95 
Hz, 2H), 6.91 (d, J = 7.6 Hz, 2H), 3.59 (m, 2H), 3.50 (m, 2H), 3.35-3.27 (m, 1H), 3.18-3.11 
(m, 1H), 2.33 (t, J = 7.6 Hz, 2H), 2.15 (m, 1H), 2.06-1.95 (m, 1H), 1.42 (m, 2H), 1.23 (s, 
10H), 0.86 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, D2O) δ141.2, 136.0, 128.5, 127.6, 66.4, 
58.2, 44.7, 44.5, 35.4, 32.4, 31.9, 31.3, 29.7, 29.5, 29.5, 22.6, 13.9; [α]D (+) 20.0° (c 0.06, 
MeOH); HRMS (ESI) calcd for C19H32NO (M+H)+ 290.2478, found 290.2477. HPLC: 
condition (B), tR = 6.00 min; purity: 98.5 %. 
 
Compounds 1.117, 1.120 and 1.123 were prepared according to the procedure for synthesizing 
1.114. 
 
 
tert-Butyl (2R,3S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-octylphenyl) 
pyrrolidine-1-carboxylate (1.115) was obtained as pale yellow oil (120 mg, 82 %) from 
1.107 (150 mg, 0.234 mmol). 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.70-7.69 
(m, 4H), 7.68-7.39 (m, 6H), 7.15-7.11 (m, 4H), 4.18 (dd, J =3.6, 10.0 Hz, 0.4H), 3.92-3.57 (m, 
4.6H), 3.44 (m, 1H), 2.60 (t, J =7.2 Hz, 2H), 2.33-2.25 (m, 1H), 1.99-1.90 (m, 1H), 1.61 (m, 
2H), 1.53 (s, 3H), 1.36-1.30 (m, 16H), 1.09 (s, 9H), 0.91 (t, J =6.8 Hz, 3H); 13C NMR (100 
MHz, CDCl3, mixture of rotamers) δ 154.3, (154.2), 141.2, (140.9), 140.2, 135.6, (133.8), 
133.6, 133.5, (133.4), 129.6, (129.5), 128.6, (127.7), 127.7, (127.2), 127.1, 79.3, (79.0), 65.5, 
(65.3), 63.5, 62.0, 47.2, (46.4), 46.2, 45.4, 35.5, 32.9, 31.9, 31.5, 29.5, 29.4, 29.2, 28.6, 28.4, 
26.9, 22.7, (19.4), 19.3, 14.1; [α]D (+) 7.2° (c 0.60, CHCl3); HRMS (ESI) calcd for 
C40H57NNaO3Si (M+Na)+ 650.4000, found 650.3980. 
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tert-Butyl (2R,3S)-2-(hydroxymethyl)-3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.116) 
was obtained as pale yellow oil (58 mg, 91%) from silyl ether 1.115 (100 mg, 0.159 mmol). 
1H NMR (400 MHz, CDCl3) δ 7.14 (s, 4H), 5.10 (br, 1H), 3.92 (m, 1H), 3.90-3.60 (m, 2H), 
3.65-3.56 (m, 1H), 3.35 (td, J =6.4, 10.5 Hz, 1H), 2.86 (m, 1H), 2.58 (t, J =8.0 Hz, 2H), 2.13 
(m, 1H), 1.95 (m, 1H), 1.60 (m, 2H), 1.51 (s, 9H), 1.31-1.23 (m, 10H), 0.89 (t, J =7.2 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 156.9, 141.8, 137.7, 128.7, 127.4, 80.4, 67.1, 66.1, 47.5, 47.1, 
35.5, 32.9, 31.9, 31.5, 29.4, 29.3, 29.2, 28.4, 22.6, 14.1; [α]D (+) 8.1° (c 1.65, CHCl3); HRMS 
(ESI) calcd for C24H39NNaO3 (M+Na)+ 412.2822, found 412.2807. 
 
 
(2R,3S)-2-(Hydroxymethyl)-3-(4-octylphenyl)pyrrolidin-1-ium chloride (1.117) was 
obtained as yellow solid (10 mg, 89 %) from carbamate 1.116 (15 mg, 0.039 mmol). 1H NMR 
(400 MHz, D2O) δ 7.16 (d, J = 8.0 Hz, 2H), 6.91 (d, J = 8.0 Hz, 2H), 3.60 (m, 2H), 3.51 (m, 
2H), 3.36-3.29 (m, 1H), 3.20-3.13 (m, 1H), 2.33 (t, J = 7.6 Hz, 2H), 2.18-2.12 (m, 1H), 2.06-
1.95 (m, 1H), 1.44 (m, 2H), 1.27 (s, 10H), 0.90 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, D2O) 
δ 141.2, 136.0, 128.5, 127.6, 66.4, 58.2, 44.7, 44.5, 35.4, 32.4, 31.9, 31.3, 29.7, 29.5, 29.5, 
22.7, 13.9; [α]D (-) 19.1° (c 0.11, MeOH); HRMS (ESI) calcd for C19H32NO (M+H)+ 
290.2478, found 290.2473. HPLC: condition (B), tR = 5.56 min; purity: 96.9%. 
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tert-Butyl (2S,3S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-octylphenyl) 
pyrrolidine-1-carboxylate (1.118) was obtained as pale yellow oil (22 mg, 76 %) from 
lactam 1.104 (30 mg, 0.047 mmol). 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.54-
7.52 (m, 2H), 7.39-7.13 (m, 12H), 4.11 (d, J = 7.2 Hz, 0.4H), 3.98 (d, J = 6.8 Hz, 0.6H),  3.90 
(dd, J = 2.8, 11.2 Hz, 0.4H), 3.78-3.70 (m, 1.6H), 3.62-3.49 (m, 2H), 3.36 (dd, J = 10.8, 17.2 
Hz, 1H), 2.86 (m, 1H), 2.65 (m, 2H), 2.17 (m, 1H),  1.65 (m, 2H), 1.54 (s, 4H), 1.41-1.27 (m, 
15H), 0.99 (s, 4.4H), 0.98 (s, 4.6H), 0.90 ((t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, 
mixture of rotamers) δ (154.4), 154.3, 141.2, 136.0, 135.6, 135.5, 135.4, (133.4), 133.1, 132.9, 
129.5, (129.3), 128.3, (127.7), 127.5, 127.4, 79.2, (79.0), 62.4, 61.8, (61.6), 61.5, 46.4, (46.3), 
45.9, 35.7, 31.9, 31.7, 29.5, 29.4, 29.3, (28.6), 28.4, 27.6, 26.7, 22.7, (19.0), 18.8, 14.1; [α]D (-
) 38.2° (c 1.90, CHCl3); HRMS (ESI) calcd for C40H57NNaO3Si (M+Na)+ 650.4000, found 
650.3995. 
 
 
tert-Butyl (2S,3S)-2-(hydroxymethyl)-3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.119) 
A solution of silyl ether 1.118 (22 mg, 0.035 mmol) in anhydrous THF (1.14 mL) was cooled 
to 0 °C. Tetrabutylammonium fluoride solution (1M in THF, 61 µL, 0.061 mmol) was added. 
The reaction was allowed to warm to room temperature and stirred overnight, when 
completion was indicated by TLC (Rf : 0.33, hexane: EtOAc, 4:1). The reaction was heated to 
40 °C for 48 h, quenched with saturated aqueous NaHCO3 extracted three times with CH2Cl2. 
The organic layers were washed with brine, dried over MgSO4 and filtered. The volatiles were 
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removed under reduced pressure. The residue was purified by flash chromatography (hexane: 
EtOAc, 6:1 to 4:1) to give 1.119 (12.2 mg, 90 %) as colorless oil. 1H NMR (400 MHz, CDCl3, 
mixture of rotamers) δ 7.13 (s, 4H), 4.26 (m, 0.7H), 4.07 (m, 0.3H), 3.63 (m, 1H), 3.47 (m, 
2.3H), 3.33 (m, 1.7H), 2.58 (t, J =7.6 Hz, 2H), 2.44-2.28 (m, 1H), 2.15-2.09 (m, 1H), 1.59 (m, 
2H), 1.50 (s, 9H), 1.30-1.26 (m, 10H), 0.88 (t, J =6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, 
mixture of rotamers) δ 157.1, 141.8, 134.9, (134.8), 128.6, (127.7), 127.7, 80.3, 64.7, 62.4, 
(46.2), 45.7, 35.5, 31.9, 31.5, 29.7, 29.5, 29.3, 29.2, 28.5, 28.0, 22.7, 14.1; [α]D (+) 9.8° (c 
1.22, CHCl3); HRMS (ESI) calcd for C24H39NNaO3 (M+Na)+ 412.2822, found 412.2829. 
 
 
(2S,3S)-2-(Hydroxymethyl)-3-(4-octylphenyl)pyrrolidin-1-ium chloride (1.120) was 
obtained as yellow solid (7.0 mg, 84 %) from carbamate 1.119 (10 mg, 0.026 mmol). 1H NMR 
(400 MHz, D2O) δ 7.10 (d, J = 7.6 Hz, 2H), 6.91 (d, J = 7.6 Hz, 2H), 3.99 (m, 1H), 3.59 (m, 
2H), 3.35 (m, 1H), 3.27-3.16 (m, 2H), 2.38 (t, J = 7.2 Hz, 2H), 2.22 (m, 1H), 2.09 (m, 1H), 
1.46 (m, 2H), 1.29 (s, 10H), 0.91 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, D2O) δ 141.1, 
133.6, 128.2, 62.6, 583, 44.3, 44.0, 35.4, 32.0, 31.3, 29.8, 29.6, 29.5, 27.9, 22.7, 13.9; [α]D (+) 
42.9° (c 0.10, MeOH); HRMS (ESI) calcd for C19H32NO (M+H)+ 290.2478, found 290.2478. 
HPLC: condition (B), tR = 5.57 min; purity: 98.0 %. 
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tert-Butyl (2R,3R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(4-octylphenyl) 
pyrrolidine-1-carboxylate (1.121) was obtained as pale yellow oil (22 mg, 76 %) from 
lactam 1.109 (30 mg, 0.047 mmol). 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.54-
7.52 (m, 2H), 7.40-7.13 (m, 12H), 4.11 (d, J = 7.2 Hz, 0.4H), 3.98 (d, J = 6.8 Hz, 0.6H),  3.90 
(dd, J = 2.8, 10.8 Hz, 0.4H), 3.78-3.69 (m, 1.6H), 3.61-3.49 (m, 2H), 3.36 (dd, J = 10.8, 16.8 
Hz, 1H), 2.86 (m, 1H), 2.65 (m, 2H), 2.17 (m, 1H),  1.65 (m, 2H), 1.55 (s, 4H), 1. 42-1.23 (m, 
15H), 0.99 (s, 3.5H), 0.98 (s, 4.5H), 0.90 ((t, J =6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, 
mixture of rotamers) δ (154.4), 154.3, 141.2, 136.0, 135.6, 135.5, 135.4, (133.4), 133.1, 132.8, 
129.5, (129.3), 128.3, 127.7, (127.5), 127.4, 79.2, (79.0), 62.4, 61.8, (61.6), 61.5, 46.4, (46.3), 
45.9, 35.7, 31.9, 31.7, 29.5, 29.4, 29.3, (28.6), 28.4, 27.5, 26.7, 22.7, (19.0), 18.8, 14.1; [α]D 
(+) 34.0° (c 2.10, CHCl3); HRMS (ESI) calcd for C40H57NNaO3Si (M+Na)+ 650.4000, found 
650.4012. 
 
 
tert-Butyl (2R,3R)-2-(hydroxymethyl)-3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.122) 
was obtained as colorless oil (12.5 mg, 92 %) from silyl ether 1.121 (22 mg, 0.035 mmol). 1H 
NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.13 (s, 4H), 4.28 (m, 0.7H), 4.06 (m, 0.3H), 
3.63 (m, 1H), 3.47 (m, 2.3H), 3.33 (m, 1.7H), 2.58 (t, J =7.6 Hz, 2H), 2.43-2.28 (m, 1H), 2.15-
2.09 (m, 1H), 1.61-1.50 (m, 2H), 1.50 (s, 9H), 1.29-1.22 (m, 10H), 0.87 (t, J =6.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 157.1, 141.8, 134.9, 128.6, 127.8, 80.3, 64.7, 62.4, (46.2), 45.7, 
35.5, 31.9, 31.4, 29.7, 29.4, 29.3, 29.2, 28.5, 28.0, 22.6, 14.1; [α]D (-) 9.3° (c 1.25, CHCl3); 
HRMS (ESI) calcd for C24H39NNaO3 (M+Na)+ 412.2822, found 412.2816. 
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(2R,3R)-2-(Hydroxymethyl)-3-(4-octylphenyl)pyrrolidin-1-ium chloride (1.123) was 
obtained as yellow solid (5.4 mg, 65 %) from 1.22 (10 mg, 0.026 mmol). 1H NMR (400 MHz, 
D2O) δ 7.10 (d, J = 7.2 Hz, 2H), 6.91 (d, J = 7.6 Hz, 2H), 3.98 (m, 1H), 3.59 (m, 2H), 3.38-
3.31 (m, 1H), 3.27-3.17 (m, 2H), 2.38 (t, J = 7.2 Hz, 2H), 2.25-2.17 (m, 1H), 2.11 (m, 1H), 
1.47 (m, 2H), 1.27 (s, 10H), 0.90 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, D2O) δ 140.8, 
133.3, 127.8, 127.8, 62.2, 58.0, 43.9, 43.6, 34.9, 31.5, 30.9, 29.3, 29.1, 29.0, 27.6, 22.2, 13.5; 
[α]D (-) 43.2° (c 0.10, MeOH); HRMS (ESI) calcd for C19H32NO (M+H)+ 290.2478, found 
290.2471. HPLC: condition (B), tR = 6.13 min; purity: 94.2%. 
 
 
(4R,5S)-5-(Hydroxymethyl)-4-(4-octylphenyl)pyrrolidin-2-one (1.124). A (9:1) solution of 
trifluoroacetic acid (0.48 mL, 6.2 mmol) and H2O (0.05 mL) was added to a flask containing 
carbamate 1.23 (40 mg, 0.062 mmol) at 0 °C. After 15 min, the solution was warmed to room 
temperature and stirred overnight, when completion was indicated by TLC (Rf : 0.17, CH2Cl2: 
MeOH: NH4OH, 100: 8: 1). The volatiles were removed under reduced pressure. The residue 
was dissolved in CH2Cl2, washed three times with saturated aqueous NaHCO3. The organic 
layer was washed with brine, dried over MgSO4 and filtered. The volatiles were removed 
under reduced pressure and the residue was purified by flash chromatography (CH2Cl2: 
MeOH: NH4OH, 100: 8: 1) to give lactam 1.124 (18.0 mg, 95 %) as white solid. 1H NMR 
(400 MHz, CDCl3) δ 7.38 (s, 1H), 7.16 (s, 4H), 3.93-3.72 (m, 3H), 3.63-3.48 (m, 1H), 3.30 
(m, 1H), 2.81 (dd, J = 17.6, 9.6 Hz, 1H), 2.66-2.51 (m, 3H), 1.60 (p, J = 7.2 Hz, 2H), 1.41-
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1.18 (m, 10H), 0.94-0.81 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 177.9, 142.1, 138.7, 128.9, 
127.1, 64.3, 64.2, 42.0, 39.3, 35.5, 31.9, 31.5, 29.5, 29.3, 29.2, 22.6, 14.1; [α]D (+) 25.8° (c 
0.12, CHCl3); HRMS (ESI) calcd for C19H29NNaO2 (M+Na)+ 326.2091, found. 326.2100. 
 
Compounds 1.125, 1.126 and 1.127 were prepared according to the procedure for synthesizing 
1.124. 
 
 
(4S,5R)-5-(Hydroxymethyl)-4-(4-octylphenyl)pyrrolidin-2-one (1.125) was obtained as 
white solid (12.0 mg, 63 %) from silyl ether 1.107 (40 mg, 0.062 mmol). 1H NMR (400 MHz, 
CDCl3) δ 7.17 (s, 4H), 6.61 (s, 1H), 3.85-3.75 (m, 2H), 3.57 (m, 1H), 3.28 (td, J = 9.0, 6.7 Hz, 
1H), 2.80 (dd, J = 17.3, 9.4 Hz, 1H), 2.69-2.45 (m, 4H), 1.59 (dd, J = 14.9, 7.2 Hz, 2H), 1.37-
1.22 (m, 10H), 0.89 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, D2O) δ 177.2, 142.1, 138.6, 
128.9, 127.1, 64.6, 63.7, 42.2, 39.1, 35.5, 31.9, 31.5, 29.4, 29.3, 29.2, 22.6, 14.1; [α]D (-) 23.0° 
(c 0.60, CHCl3); HRMS (ESI) calcd for C19H29NNaO2 (M+Na)+ 326.2091, found 326.2090. 
HPLC: condition (C), tR = 6.16 min; purity: > 99 %. 
 
 
 
(4S,5S)-5-(Hydroxymethyl)-4-(4-octylphenyl)pyrrolidin-2-one (1.126) was obtained as 
white solid (5.7 mg, 80 %) from silyl ether 1.104 (15 mg, 0.023 mmol). 1H NMR (700 MHz, 
CDCl3) δ 7.16 (s, 4H), 6.22 (m, 1H), 3,99-3.96 (td, J = 7.6, 3.9 Hz, 1H), 3.85-3.82 (dd, J = 
16.9, 8.6 Hz, 1H), 3.36-3.34 (dd, J = 11.3, 3.7 Hz, 1H), 3.24-3.22 (m, 1H), 2.79-2.64 (ddd, J = 
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77.3, 16.8, 8.8 Hz, 2H), 2.60-2.58 (t, J = 7.7 Hz, 2H), 1.61 (m, 2H), 1.32-1.26 (m, 10H), 0.90 
(t, J = 7.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 177.6, 142.3, 134.9, 128.8, 127.6, 63.5, 
59.1, 41.9, 35.6, 35.5, 31.9, 31.4, 29.4, 29.3, 29.2, 22.6, 14.1; [α]D (+) 130.2° (c 0.56, CHCl3); 
HRMS (ESI) calcd for C19H29NNaO2 (M+Na)+ 326.2091, found 326.2095. HPLC: condition 
(C), tR = 6.57 min; purity: > 99 %. 
 
 
 
(4R,5R)-5-(Hydroxymethyl)-4-(4-octylphenyl)pyrrolidin-2-one (1.127) was obtained as 
white solid (6.6 mg, 93 %) from silyl ether 1.109 (15 mg, 0.023 mmol). 1H NMR (700 MHz, 
CDCl3) δ 7.16 (s, 4H), 6.06 (m, 1H), 3,99-3.96 (td, J = 7.8, 3.9 Hz, 1H), 3.86-3.82 (dd, J = 
16.8, 8.7 Hz, 1H), 3.37-3.35 (dd, J = 11.1, 3.8 Hz, 1H), 3.24-3.22 (m, 1H), 2.79-2.65 (ddd, J = 
71.7, 16.8, 8.8 Hz, 2H), 2.60-2.58 (t, J = 7.7 Hz, 2H), 1.59 (m, 2H), 1.31-1.26 (m, 10H), 0.89 
(t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 177.9, 142.3, 134.9, 128.8, 127.6, 63.5, 
59.3, 41.9, 35.6, 35.6, 31.9, 31.5, 29.5, 29.4, 29.3, 22.7, 14.1; [α]D (-) 131.3° (c 0.45, CHCl3); 
HRMS (ESI) calcd for C19H29NNaO2 (M+Na)+ 326.2091, found 326.2095. HPLC: condition 
(C), tR = 5.62 min; purity: > 99 %. 
 
 
 
tert-Butyl (2S,3R)-2-(methoxymethyl)-3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.128) 
A solution of alcohol 1.113 (35 mg, 0.090 mmol) in anhydrous THF (0.75 mL) was cooled to 
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0 °C. Sodium hydride (60 % dispersion in mineral oil, 7.2 mg, 0.180 mmol) was added to the 
solution followed by methyl iodide (26 mg, 12 µL, 0.180 mmol). The reaction was allowed to 
warm to room temperature and stirred overnight. The mixture was poured into water and 
extracted three times with EtOAc. The organic layers were combined, washed with brine, 
dried over MgSO4 and filtered. The filtrate was evaporated under reduced pressure and the 
residue was purified by flash chromatography (hexane: EtOAc, 4:1) to give ether 1.128 (32 
mg, 88 %) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.11 (s, 4H), 3.95-3.86 (br, 1H), 
3.68 (br, 2H), 3.47 (m, 2H), 3.36 (m, 4H), 2.57 (t, J =7.6 Hz, 2H), 2.24 (m, 1H), 1.89 (m, 1H), 
1.59 (m, 2H), 1.49 (s, 9H), 1.29 (m, 10H), 0.88 (m, 3H); 13C NMR (100 MHz, CDCl3,) δ 
154.4, 141.2, 140.6, 128.6, 127.1, 79.4, 72.6, 71.4, 63.5, 59.1, 46.5, 46.0, 35.5, 31.9, 31.5, 
29.5, 29.4, 29.2, 28.5, 22.7, 14.1; [α]D (+) 13.3° (c 0.68, CHCl3); HRMS (ESI) calcd for 
C25H41NNaO3 (M+Na)+ 426.2979, found 426.2981. 
 
 
(2S,3R)-2-(Methoxymethyl)-3-(4-octylphenyl)pyrrolidin-1-ium chloride (1.129) was 
obtained as yellow oil (13.1 mg, 92 %) from ether 1.128 (19 mg, 0.047 mmol) according the 
procedure for synthesizing 1.32. 1H NMR (400 MHz, D2O) δ 7.17 (d, J = 8.0 Hz, 2H), 6.92 (d, 
J = 7.6 Hz, 2H), 3.64 (m, 2H), 3.56 (m, 1H), 3.42-3.30 (m, 2H), 3.18-3.12 (m, 4H), 2.36 (t, J = 
7.6 Hz, 2H), 2.21 (m, 1H), 2.06 (m, 1H), 1.46 (m, 2H), 1.28 (s, 10H), 0.90 (m, 3H); 13C NMR 
(100 MHz, D2O) δ 140.8, 135.7, 128.2, 127.3, 68.5, 64.0, 58.2, 44.7, 44.4, 35.0, 32.3, 31.6, 
31.0, 29.3, 29.2, 29.0, 22.3, 13.5; [α]D (+) 33.5° (c 0.49, MeOH); HRMS (ESI) calcd for 
C20H34NO (M+H)+ 304.2635, found 304.2643. HPLC: condition (B), tR = 7.20 min; purity: 
96.6 %. 
 
Compound 1.131 was prepared according to the procedure for synthesizing 1.129. 
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tert-Butyl (2R,3S)-2-(methoxymethyl)-3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.130) 
was obtained as colorless oil (33 mg, 92 %) from 1.116 (35 mg, 0.090 mmol). 1H NMR (400 
MHz, CDCl3) δ 7.12 (s, 4H), 3.97 (br, 1H), 3.67 (br, 2H), 3.45 (m, 2H), 3.37 (m, 4H), 2.58 (t, 
J =7.6 Hz, 2H), 2.24 (m, 1H), 1.90 (m, 1H), 1.59 (m, 2H), 1.50 (s, 9H), 1.29 (m, 10H), 0.89 
(m, 3H); 13C NMR (100 MHz, CDCl3) δ 154.4, 141.2, 140.6, 128.6, 127.0, 79.4, 72.6, 71.4, 
63.5, 59.1, 46.4, 46.0, 35.5, 31.9, 31.5, 29.4, 29.3, 29.2, 28.5, 22.6, 14.1; [α]D (-) 16.9° (c 1.1, 
CHCl3); HRMS (ESI) calcd for C25H41NNaO3 (M+Na)+ 426.2979, found 426.2988. 
 
 
(2R,3S)-2-(Methoxymethyl)-3-(4-octylphenyl)pyrrolidin-1-ium chloride (1.131) was 
obtained as yellow oil (9.9 mg, 98 %) from carbamate 1.130 (12 mg, 0.030 mmol). 1H NMR 
(400 MHz, D2O) δ 7.17 (d, J = 8.0 Hz, 2H), 6.93 (d, J = 8.0 Hz, 2H), 3.66 (m, 2H), 3.57 (m, 
1H), 3.43-3.31 (m, 2H), 3.17 (m, 4H), 2.37 (m, 2H), 2.22 (m, 1H), 2.06 (m, 1H), 1.47 (m, 2H), 
1.28 (s, 10H), 0.91 (m, 3H); 13C NMR (100 MHz, D2O) δ 141.2, 136.1, 128.6, 127.7, 68.9, 
64.4, 58.5, 45.0, 44.7, 35.4, 32.6, 31.9, 31.4, 29.6, 29.5, 29.4, 22.6, 13.9; [α]D (-) 32.8° (c 0.29, 
MeOH); HRMS (ESI) calcd for C20H34NO (M+H)+ 304.2635, found 304.2640. HPLC: 
condition (B), tR = 6.48 min; purity: 96.8 %. 
 
 
Compounds 1.134 and 1.137 were prepared according to the procedure for synthesizing 1.70. 
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tert-Butyl (2S,3R)-2-(((methylsulfonyl)oxy)methyl)-3-(4-octylphenyl)pyrrolidine- 
1-carboxylate (1.132) was obtained as colorless oil (68 mg, 94 %) from alcohol 1.113 (60 mg, 
0.154 mmol). 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.15 (s, 4H), 4.71 (br, 
0.6H), 4.44 (br, 0.4H), 4.28-4.21 (m, 1H), 3.95 (br, 1H), 3.81-3.69 (br, 1H), 3.44-3.34 (m, 
2H), 2.98 (s, 3H), 2.58 (t, J =7.6 Hz, 2H), 2.24-2.19 (m, 1H), 2.00-1.95 (m, 1H), 1.58 (m, 2H), 
1.50 (s, 9H), 1.31-1.27 (m, 10H), 0.88 (t, J =6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, 
mixture of rotamers) δ 154.4, (153.9), 141.9, 138.1, 128.9, 127.2, (80.6), 80.0, 67.9, 62.9, 
46.9, (46.5), 45.7, (37.5), 36.9, 35.5, 32.6, 31.9, 31.5, 29.4, 29.3, 29.2, 28.4, 22.6, 14.1; [α]D 
(+) 3.0° (c 2.9, CHCl3); HRMS (ESI) calcd for C25H41NNaO5S (M+Na)+ 490.2598, found 
490.2594. 
 
 
tert-Butyl (2R,3R)-2-methyl-3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.133) was 
obtained as colorless oil (33.4 mg, 64 %) from methanesulfonate 1.132 (65 mg, 0.139 mmol). 
1H NMR (400 MHz, CDCl3) δ 7.13 (s, 4H), 3.75 (br, 2H), 3.40-3.34 (m, 1H), 2.92-2.87(m, 
1H), 2.58 (t, J =7.6 Hz, 2H), 2.21-2.13 (m, 1H), 1.96-1.89 (m, 1H), 1.60 (m, 2H), 1.49 (s, 9H), 
1.28 (m, 13H), 0.89 (t, J =6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ154.6, 141.4, 139.5, 
128.6, 127.2, 79.1, 59.9, 52.9, 45.9, 35.5, 32.1, 31.9, 31.5, 29.5, 29.4, 29.2, 28.6, 22.7, 20.2, 
14.1; [α]D (+) 8.8° (c 0.68, CHCl3); HRMS (ESI) calcd for C25H39NNaO2 (M+Na)+ 396.2873, 
found 396.2868.  
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(2R,3R)-2-Methyl-3-(4-octylphenyl)pyrrolidin-1-ium chloride (1.134) was obtained as 
yellow solid (26 mg, 96 %) from carbamate 1.133 (33 mg, 0.088 mmol). 1H NMR (400 MHz, 
D2O) δ 7.10 (d, J = 8.0 Hz, 2H), 6.90 (d, J = 7.6 Hz, 2H), 3.47 (m, 2H), 3.35 (m, 1H), 2.91 (m, 
1H), 2.34 (m, 2H), 2.15 (m, 1H), 1.99 (m, 1H), 1.45 (m, 2H), 1.29 (s, 10H), 1.10 (d, J = 6.4 
Hz, 3H), 0.91 (m, 3H); 13C NMR (100 MHz, D2O) δ 141.0, 136.0, 128.4, 127.6, 61.2, 50.3, 
43.7, 35.5, 32.1, 32.0, 31.4, 29.8, 29.6, 29.6, 22.7, 14.5, 13.9; [α]D (+) 23.3° (c 0.58, MeOH); 
HRMS (ESI) calcd for C19H32N (M+H)+ 274.2529, found 274.2540. HPLC: condition (B), tR = 
6.93 min; purity: 95.6 %. 
 
 
 
tert-Butyl (2R,3S)-2-(((methylsulfonyl)oxy)methyl)-3-(4-octylphenyl)pyrrolidine- 
1-carboxylate (1.135) was obtained as colorless oil (34.0 mg, 94 %) from 1.116 (30 mg, 
0.077 mmol). 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 7.15 (s, 4H), 4.72 (br, 
0.6H), 4.45 (br, 0.4H), 4.27-4.21 (m, 1H), 3.96 (br, 1H), 3.81-3.68 (br, 1H), 3.44-3.34 (m, 
2H), 2.98 (s, 3H), 2.58 (t, J =7.6 Hz, 2H), 2.25-2.21 (m, 1H), 2.00 (m, 1H), 1.62-1.56 (m, 2H), 
1.50 (s, 9H), 1.28 (m, 10H), 0.89 (t, J =6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, mixture of 
rotamers) δ 154.4, (153.9), 141.9, 138.6, 138.1, 128.8, 127.2, (80.5), 79.9, 68.0, 67.9, 62.8, 
46.8, (46.4), 45.6, (37.5), 36.8, 35.5, 32.5, 31.8, 31.4, 29.4, 29.3, 29.2, 28.4, 22.6, 14.1; [α]D (-
) 2.5° (c 1.4, CHCl3); HRMS (ESI) calcd for C25H41NNaO5S (M+Na)+ 490.2598, found 
490.2608. 
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tert-Butyl (2S,3S)-2-methyl-3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.136) was 
obtained as colorless oil (20.7 mg, 89 %) from methanesulfonate 1.135 (29 mg, 0.062 mmol). 
1H NMR (400 MHz, CDCl3) δ 7.13 (s, 4H), 3.75 (br, 2H), 3.41-3.34 (m, 1H), 2.92-2.87(m, 
1H), 2.58 (t, J =7.6 Hz, 2H), 2.21-2.14 (dtd, J =10.8, 6.6, 4.2 Hz, 1H), 1.96-1.87 (m, 1H), 1.61 
(m, 2H), 1.49 (s, 9H), 1.28 (m, 13H), 0.89 (t, J =6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ154.6, 141.4, 139.5, 128.6, 127.2, 79.1, 59.9, 52.9, 45.9, 35.5, 32.1, 31.9, 31.5, 29.5, 29.4, 
29.2, 28.6, 22.7, 20.2, 14.1; [α]D (-) 6.7° (c 0.09, CHCl3); HRMS (ESI) calcd for 
C25H39NNaO2 (M+Na)+ 396.2873, found 396.2877. 
 
 
(2S,3S)-2-Methyl-3-(4-octylphenyl)pyrrolidin-1-ium chloride (1.137) was obtained as 
yellow solid (8.0 mg, 96 %) from carbamate 1.136 (10 mg, 0.027 mmol). 1H NMR (400 MHz, 
D2O) δ 7.10 (d, J = 7.6 Hz, 2H), 6.90 (d, J = 7.6 Hz, 2H), 3.46 (m, 2H), 3.35 (m, 1H), 2.91 (m, 
1H), 2.35 (m, 2H), 2.15 (m, 1H), 1.99 (m, 1H), 1.46 (m, 2H), 1.29 (s, 10H), 1.11 (d, J = 6.4 
Hz, 3H), 0.86 (m, 3H); 13C NMR (100 MHz, D2O) δ 141.1, 136.0, 128.4, 127.6, 61.2, 50.3, 
43.7, 35.4, 32.1, 31.9, 31.3, 29.7, 29.6, 29.5, 22.7, 14.5, 13.9; [α]D (-) 26.2° (c 0.13, MeOH); 
HRMS (ESI) calcd for C19H32N (M+H)+ 274.2529, found 274.2540. HPLC: condition (B), tR = 
5.98 min; purity: 96.2 %. 
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Compounds 1.139 and 1.141 were prepared according to the procedure for synthesizing 1.77. 
 
 
tert-Butyl (2S,3R)-2-(((di-tert-butoxyphosphoryl)oxy)methyl)-3-(4-octylphenyl) 
pyrrolidine-1-carboxylate (1.138) was obtained as colorless oil (10.0 mg, 48 % over two 
steps) from carbamate 1.113 (14 mg, 0.036 mmol). 1HNMR (400 MHz, CDCl3) δ 7.13 (s, 4H), 
4.36 (m, 0.5H), 4.12 (m, 0.5H), 4.01-3.87 (m, 2H), 3.75-3.64 (m, 1H), 3.50 (m, 1H), 3.38 (m, 
1H), 2.58 (m, 2H), 2.24 (m, 1H), 1.94 (m, 1H), 1.60 (m, 2H), 1.49-1.48 (m, 27H), 1.28 (m, 
10H), 0.88 (m, 3H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 154.1, 141.4, 139.9, 
139.5, 128.7, 127.2, 127.1, 82.2, 79.9, 79.3, 65.5, 64.8, 63.8, 63.7, 46.7, 46.2, 46.1, 45.0, 35.5, 
31.9, 31.5, 29.9, 29.8, 29.4, 29.3, 29.2, 28.5, 22.6, 14.1; 31P NMR (162 MHz, CDCl3, mixture 
of rotamers) -9.34, -9.79; [α]D (+) 4.0° (c 0.80, CHCl3); HRMS (ESI) calcd for 
C32H56NNaO6P (M+Na)+ 604.3738, found 604.3732. 
 
((2S,3R)-3-(4-Octylphenyl)pyrrolidin-1-ium-2-yl)methyl hydrogen phosphate (1.139) was 
obtained as white solid (2.5 mg, 78 %) from 1.138 (5 mg, 0.009 mmol). 1H NMR (400 MHz, 
MeOD) δ 7.17 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 8.0 Hz, 2H), 4.05 (ddd, J = 10.4, 7.6, 2.8 Hz, 
1H), 3.79 (ddd, J = 12.8, 10.4, 5.6 Hz, 1H), 3.62 (ddd, J = 8.0, 5.2, 2,4 Hz, 1H), 3.46 (ddd, J = 
11.2, 8.4, 2.4 Hz, 1H), 3.30 (qd, J = 11.2, 7.2Hz, 2H), 2.50 (t, J = 7.6 Hz, 2H), 2.34 (dtd, J = 
13.6, 6.8, 2.8 Hz, 1H), 2.15 (m, 1H), 1.50 (m, 2H), 1.27–1.12 (m, 10H), 0.80 (t, J = 6.8 Hz, 
3H). 13C NMR (100 MHz, MeOD, mixture of rotamers) δ 143.9, 136.8, 130.4, 128.8, 67.4, 
67.4, 62.8, 62.7, 46.2, 46.1, 36.7, 34.2, 33.2, 32.9, 30.8, 30.6, 30.5, 23.9, 14.6; [α]D (+) 52.0° 
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(c 0.05, MeOH); 31P NMR (162MHz, MeOD)  3.65; HRMS (ESI) calcd for C19H33NO4P 
(M+H)+ 370.2142, found 370.2134. HPLC: condition (D), tR = 7.14 min; purity: 94.7 %. 
 
 
tert-Butyl (2R,3S)-2-(((di-tert-butoxyphosphoryl)oxy)methyl)-3-(4-octylphenyl) 
pyrrolidine-1-carboxylate (1.140) was obtained as colorless oil (11.0 mg, 52 % over two 
steps) from 1.116 (14 mg, 0.036 mmol). 1H NMR (400 MHz, CDCl3) δ 7.13 (s, 4H), 4.37 (m, 
0.5H), 4.12 (m, 0.5H), 4.01-3.87 (m, 2H), 3.75-3.62 (m, 1H), 3.50 (m, 1H), 3.38 (m, 1H), 2.58 
(t, J = 8.0 Hz, 2H), 2.24 (m, 1H), 1.94 (m, 1H), 1.60 (m, 2H), 1.49-1.48 (m, 27H), 1.31-1.26 
(m, 10H), 0.89 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 154.2, 
141.4, 139.9, 128.7, 127.2, 127.1, 82.2, 79.9, 79.4, 65.5, 64.8, 63.8, 63.7, 46.7, 46.2, 46.1, 
45.0, 35.5, 31.9, 31.5, 29.9, 29.8, 29.5, 29.4, 29.3, 28.5, 22.7, 14.1; 31P NMR (162 MHz, 
CDCl3, mixture of rotamers) -8.72, -9.18; [α]D (-) 4.2° (c 0.50, CHCl3); HRMS (ESI) calcd for 
C32H56NNaO6P (M+Na)+ 604.3738, found 604.3733. 
 
 
((2R,3S)-3-(4-Octylphenyl)pyrrolidin-1-ium-2-yl)methyl hydrogen phosphate (1.139) was 
obtained as white solid (2.1 mg, 66 %) from 1.140 (5 mg, 0.009 mmol). 1H NMR (400 MHz, 
MeOD) δ 7.17 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 8.0 Hz, 2H), 4.05 (ddd, J = 10.4, 8.0, 2.8 Hz, 
1H), 3.78 (ddd, J = 12.8, 10.4, 5.6 Hz, 1H), 3.61 (ddd, J = 8.0, 5.2, 2,4 Hz, 1H), 3.45 (ddd, J = 
11.2, 8.4, 2.4 Hz, 1H), 3.30 (m, 2H), 2.50 (t, J = 7.6 Hz, 2H), 2.33 (dtd, J = 13.6, 6.8, 2.4 Hz, 
1H), 2.12 (m, 1H), 1.50 (m, 2H), 1.27–1.12 (m, 10H), 0.80 (m, 3H). 13C NMR (100 MHz, 
MeOD, mixture of rotamers) δ 143.8, 136.8, 130.3, 128.8, 67.4, 67.3, 62.7, 62.6, 46.2, 46.0, 
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36.6, 34.2, 33.2, 32.9, 30.7, 30.6, 30.5, 23.9, 14.6; [α]D (-) 55.0° (c 0.10, MeOH); 31P NMR 
(162MHz, MeOD) 2.98; HRMS (ESI) calcd for C19H33NO4P (M+H)+ 370.2142, found 
370.2148. 
 
 
1-Bromo-4-octylbenzene (1.142) was synthesized according to a procedure to generate 1-
bromo-4-dodecylbenzene reported by Dorn et al.125 A solution of octylmagnesium bromide 
(2.0 M) in diethyl ether, (21.2 mL, 42.4 mmol) was added dropwise to a diethyl ether solution 
(25.0 mL) of 1,4-dibromobenzene (10 g, 42.4 mmol) and PdCl2(dppf) at 0 °C under argon. 
After stirring for 48 h at room temperature, the mixture was heated at reflux for 2.5 h, exposed 
to air, poured into water and extracted three times with diethyl ether. The combined organic 
layers were washed with brine, dried over MgSO4 and filtered. The filtrate was evaporated 
under reduced pressure and the residue was purified by preparative thin-layer chromatography 
(20 x 20 cm, 1000 µm, 8 plates in hexane) to give bromide 1.142 (9.9 g, 88 %) as colorless oil. 
The product contained a minor impurity and was used as such in the subsequent reaction. 1H 
NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 2.72 (t, J = 7.6 
Hz, 2H), 1.75 (m, 2H), 1.46 (m, 10H), 1.08 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 141.7, 
131.2, 130.1, 119.2, 35.3, 31.9, 31.3, 29.4, 29.3, 29.2, 22.7, 14.1. 
 
 
(R)-1-(tert-Butoxycarbonyl)-4-oxopyrrolidine-2-carboxylic acid (1.144). Saturated aqueous 
NaHCO3 (120 mL) was added to a solution of cis-4-hydroxy-D-proline (1.143, 3.0 g, 23.0 
mmol) in dioxane and water (1:1, 60 mL). The solution was cooled to 0°C and (Boc)2O (5.52 
g, 5.8 mL, 25.3 mmol) was added drop wise. The reaction was stirred at room temperature 
over night. The pH was adjusted to 3 by addition of 2M HCl and the reaction mixture was 
extracted with EtOAc. The organic layers were combined, dried over MgSO4 and filtered. The 
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filtrate was evaporated under reduced pressure to give a white solid (5.0 g, 94 %). The solid 
(3.0 g, 13.0 mmol) was dissolved in CH2Cl2 (64 mL), treated with trichloroisocyanuric acid 
(3.0 g, 13.0 mmol) in one portion, cooled to 0 °C and treated with TEMPO (102 mg, 0.65 
mmol). The mixture was stirred at 0 °C for 0.5 h, warmed to room temperature, and stirred for 
0.5 h. when completion was indicated by TLC (Rf : 0.30, hexane: EtOAc: AcOH, 10: 10: 1). 
Water (10 mL) was added to the mixture. After stirring for 10 min, the mixture was 
concentrated in vacuo, diluted with ethyl acetate (40 mL), and filtered through CeliteTM. The 
filtrate was acidified with 1N HCl solution (80 mL), washed four times with water (20 mL), 
washed with brine (20 mL), dried over MgSO4 and filtered. The filtrate was evaporated under 
reduced pressure to give ketone 1.144 (2.75 g, 93 %) as white solid (2.75 g, 87 over two 
steps), which was used in the next step without purification. Spectroscopic data were in 
agreement with the proposed structures and matched those reported in the literature.141 
 
 
Di-tert-butyl (R)-4-oxopyrrolidine-1,2-dicarboxylate (1.145). A solution of ketone 1.144 
(2.3 g, 10.0 mmol) in anhydrous CH2Cl2 (46 mL) was cooled to 0 °C. tert-Butyl alcohol (2.9 
mL, 30.0 mmol) and DMAP (122 mg, 1.0 mmol) were added to the solution. After stirring for 
5 min, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (2.0 g, 10.5 mmol) was 
added to the solution. The reaction was allowed to warm to room temperature and stirred 
overnight. The mixture was quenched with saturated aqueous NaHCO3 and extracted three 
times with CH2Cl2. The organic layers were washed with brine, dried over MgSO4 and filtered. 
The filtrate was evaporated under reduced pressure and the residue was purified by flash 
chromatography (hexane: EtOAc, 8:1) to give ester 1.145 (2.41 g, 84 %) as pale yellow oil. 1H 
NMR (400 MHz, CDCl3, mixture of rotamers) δ 4.62-4.53 (dd, J = 29.2, 10.0 Hz, 1H), 3.82 
(m, 2H), 2.93-2.81 (m, 1H), 2.49-2.44 (dd, J = 18.8, 2.0 Hz, 1H), 1.43 (2s, 18H); 13C NMR 
(100 MHz, CDCl3, mixture of rotamers) δ (208.8), 208.0, 170.8, (154.2), 153.6, 82.2, 80.9, 
56.9, (56.5), (52.8), 52.4, 41.3, (40.8), 28.1, 27.8; [α]D (-) 8.9° (c 1.28, CHCl3); HRMS (ESI) 
calcd for C14H23NNaO5 (M+Na)+ 308.1468, found 308.1473. 
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Di-tert-butyl (2R,4S)-4-hydroxy-4-(4-octylphenyl)pyrrolidine-1,2-dicarboxylate (1.146). 
n-BuLi (2.5 M in hexane, 450 µL, 1.12 mmol) was added dropwise to a solution of 1-bromo-
4-octylbenzene (1.142, 288 mg, 1.07 mmol) in THF (2.0 mL) at -78 °C. After stirring for 0.5 
h, a solution of  ketone 1.145 (123 mg, 0.43 mmol) in THF (0.3 mL) was added to the mixture, 
and the solution was stirred for an additional 2 h at -78 °C. The reaction was warmed to -40 °C 
and stirred overnight at this temperature. The reaction mixture was quenched at -40 °C with 
saturated aqueous NH4Cl and allowed to warm to room temperature. The organic layer was 
separated. The aqueous layer was extracted three times with CH2Cl2. The combined organic 
layers were washed with brine, dried over MgSO4 and filtered. The filtrate was evaporated 
under reduced pressure. The residue was purified by flash chromatography (hexane: EtOAc, 
12:1 to 8:1) to give less polar alcohol 1.146 (70 mg, 34 %) as pale yellow oil, and more polar 
product 1.158 (32 mg, 15 %) as pale yellow oil.  
1.146: 1H NMR (400 MHz, CDCl3) δ 7.41 (m, 2H), 7.19 (m, 2H), 4.54 (s, 0.4H), 4.42-4.33 
(dd, J =24.8, 9.6 Hz, 1H), 4.17 (s, 0.6H), 3.97-3.86 (m, 1H), 3.77-3.65 (dd, J =37.6, 11.6 Hz, 
1H), 2.71-2.63 (m, 1H), 2.60 (t, J = 7.6 Hz, 2H), 2.27 (m, 1H), 1.62 (m, 2H), 1.53 (s, 9H), 
1.48-1.47 (m, 9H), 1.29 (m, 10H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, 
mixture of rotamers) δ (174.2), 173.9, (154.3), 153.8, 142.4, 138.7, (138.6), 128.4, 125.2, 
(125.1), (82.8), 82.6, 80.4, (80.2), (80.0), 79.1, (61.4), 60.6, 59.5, (59.4), 44.4, (43.3), 35.5, 
31.9, (31.4), 29.4, 29.3, 29.2, 28.4, 28.0, 27.9, 22.6, 14.1; [α]D (+) 3.5° (c 0.57, CHCl3); 
HRMS (ESI) calcd for C28H45NNaO5 (M+Na)+ 498.3190, found 498.3182. 
1.158: 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J =8.0 Hz, 2H), 7.19 (d, J =8.0 Hz, 2H), 4.51-
4.40 (m, 1H), 4.05-3.87 (m, 1H), 3.86-3.72 (m, 1H), 2,70-2.50 (m, 2H), 2.35-2.18 (m, 1H), 
2.05 (s, 1H), 1.65-1.55 (m, 3H), 1.53 (s, 18H), 1.48 (m, 10H), 0.88 (m, 3H); 13C NMR (100 
MHz, CDCl3,) δ 171.9, 154.3, 143.0, 138.8, 128.7, 125.2, 81.1, 80.2, 79.2, 59.4, 59.0, 44.6, 
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35.5, 31.9, 31.4, 29.4, 29.3, 29.2, 28.4, 28.0, 22.6, 14.1; [α]D (-) 25.2° (c 1.00, CHCl3); HRMS 
(ESI) calcd for C28H45NNaO5 (M+Na)+ 498.3190, found 498.3193. 
 
 
Di-tert-butyl (R)-4-(4-octylphenyl)-2,5-dihydro-1H-pyrrole-1,2-dicarboxylate (1.147). 
Burgess’ reagent (68 mg, 0.286 mmol) was added to a solution of alcohol 1.146 (68 mg, 0.143 
mmol) in toluene (1.1 mL). The mixture was heated at reflux under argon for 4 h, cooled to 
room temperature and diluted with EtOAc. The mixture was washed with water, and brine, 
dried over MgSO4 and filtered. The filtrate was evaporated under reduced pressure and the 
residue was purified by flash chromatography (hexane: EtOAc, 12:1 to 8:1) to give 1.147 (44 
mg, 678%) as pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 8.0 Hz, 2H), 7.18 (d, 
J = 8.4 Hz, 2H), 6.05 (m, 0.3H), 6.00 (0.7H), 5.04 (m, 0.3H), 4.97 (m, 0.7H), 4.67-4.47 (m, 
2H), 2.61 (t, J = 7.6 Hz, 2H), 1.61 (m, 2H), 1.53-1.47 (m, 18H), 1.29 (m, 10H), 0.88 (J = 6.8 
Hz, 3H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 169.6, (169.5), (153.8), 153.5, 
143.8, (143.7), (140.5), 140.4, (130.1), 130.0, 128.7, (128.6), 125.6, (125.5), (117.5), 117.3, 
81.5, (81.5), 80.0, (79.9), 68.0, (67.9), (53.6), 53.5, 35.7, 31.8, (31.3), 29.4, 29.3, 29.2, 28.5, 
28.4, 28.0, (28.0), 22.6, 14.1; [α]D (+) 108.2° (c 0.95, CHCl3); HRMS (ESI) calcd for 
C28H43NNaO4 (M+Na)+ 480.30843, found 480.30792.  
 
 
Di-tert-butyl (2R,4S)-4-(4-octylphenyl)pyrrolidine-1,2-dicarboxylate (1.148) was obtained 
as white solid (30 mg, 94 %) from olefin 1.147 (32 mg, 0.070 mmol) according to a modified 
toluene reflux
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procedure for synthesizing 1.104. To a solution of olefin 1.147 in MeOH (1.6 mL), Pd/C (10 
%, 7.5 mg, 0.007 mmol) was added. The flask was evacuated and filled with H2 atmosphere. 
The reaction was stirred overnight. The mixture was filtered through CeliteTM. The filtrate was 
evaporated under reduced pressure and the residue purified by flash chromatography (hexane: 
EtOAc, 12:1 to 8:1) to give 1.148. m.p. (82.7 - 83.5°C); 1H NMR (400 MHz, CDCl3) δ 7.14 (s, 
4H), 4.22 (m, 1H), 4.07 (m, 0.65H), 3.91 (m, 0.35H), 3.43-3.36 (m, 1H), 3.36-3.24 (m, 1H), 
2.69 (m, 1H), 2.57 (t, J = 7.6 Hz, 2H), 2.02-1.93 (m, 1H), 1.58 (m, 2H), 1.47-1.46 (2s, 18H), 
1.28 (m, 10H), 0.88 (m, 3H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 172.0, 
(171.9), (154.0), 153.7, 141.7, (137.0), 136.9, 128.6, (127.0), 127.0, 80.9, 79.9, (79.6), (60.0), 
60.0, (53.2), 52.4, (43.3), 42.4, 38.5, (37.5), 35.5, 31.8, (31.5), 29.4, 29.3, 29.2, 28.4, 28.3, 
28.0, (27.9), 22.6, 14.1; [α]D (+) 25.4° (c 0.39, CHCl3); HRMS (ESI) calcd for C28H45NNaO4 
(M+Na)+ 482.3241, found 482.3243. 
 
 
tert-Butyl (2R,4S)-2-(hydroxymethyl)-4-(4-octylphenyl)pyrrolidine-1-carboxylate (1.149). 
A mixture of lithium aluminium hydride (2.1 mg, 0.054 mmol) in anhydrous THF (1.5 mL) 
was cooled to 0 °C, treated slowly with ester 1.148 (25 mg, 0.054 mmol) in THF (1.5 mL), 
and stirred at 0 °C for 1 h. The reaction was quenched with water, diluted with CH2Cl2. The 
organic layer was separated, washed with water and brine, dried over MgSO4 and filtered.  The 
filtrate was evaporated under reduced pressure. The residue was purified by flash 
chromatography (hexane: EtOAc, 4:1) to give alcohol 1.149 (19.5 mg, 92 %) as pale yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 7.14 (s, 4H), 5.28 (m, 1H), 4.11-4.06 (m, 1H), 3.97 (m, 
1H), 3.79-3.65 (m, 2H), 3.24 (m, 2H), 2.58 (t, J = 7.6 Hz, 2H), 2.42-2.36 (m, 1H), 1.59 (m, 
2H), 1.49 (s, 9H), 1.28 (m, 10H), 0.89 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
156.9, 141.8, 137.2, 128.6, 126.9, 80.6, 67.7, 61.5, 54.1, 42.2, 36.5, 35.5, 31.9, 31.5, 29.5, 
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29.3, 29.2, 28.4, 22.7, 14.1; [α]D (-) 4.6° (c 0.28, CHCl3); HRMS (ESI) calcd for 
C24H39NNaO3 (M+Na)+ 412.2822, found 412.2836. 
 
 
(2R,4S)-2-(Hydroxymethyl)-4-(4-octylphenyl)pyrrolidin-1-ium chloride (1.150) was 
obtained as pale yellow solid (8.5 mg, 92 %) from 1.149 ( 11 mg, 0.028 mmol) according the 
procedure for synthesizing 1.32. 1H NMR (400 MHz, D2O) δ 7.13 (d, J = 8.0 Hz, 2H), 6.91 (d, 
J = 8.0 Hz, 2H), 3.81 (m, 2H), 3.68-3.57 (m, 2H), 3.46 (m, 1H), 3.09 (m, 1H), 2.32 (m, 2H), 
2.15 (m, 1H), 1.70 (m, 1H), 1.42 (m, 2H), 1.27 (s, 10H), 0.91 (m, 3H); 13C NMR (100 MHz, 
D2O) δ 141.0, 136.3, 128.4, 127.2, 61.3, 59.9, 50.5, 42.5, 35.4, 34.2, 32.0, 31.3, 29.7, 29.6, 
29.5, 22.7, 13.9; [α]D (-) 23.5° (c 0.17, MeOH); HRMS (ESI) calcd. For C19H32NO (M+H)+ 
290.2478, found 290.2469. HPLC: condition (B), tR = 5.97 min; purity: > 99 %. 
 
 
Compound 1.157 was prepared according to the procedure for synthesizing 1.150.  
 
 
(S)-1-(tert-butoxycarbonyl)-4-Oxopyrrolidine-2-carboxylic acid (1.151) was obtained as 
white solid (1.35 g, 83 % over two steps) from 1.50. Spectroscopic data were in agreement 
with the proposed structures and matched those reported in the literature.142,143 
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Di-tert-butyl (S)-4-oxopyrrolidine-1,2-dicarboxylate (1.152) was obtained as pale yellow oil 
(0.96 g, 57 %) from 1.151 (1.35 g, 5.9 mmol). Spectroscopic data were in agreement with the 
proposed structures and matched those reported in the literature.142  
 
 
Di-tert-butyl (2S,4R)-4-hydroxy-4-(4-octylphenyl)pyrrolidine-1,2-dicarboxylate (1.153) 
was obtained as pale yellow oil (21 mg, 32 %) from 1.152 (40 mg, 0.14 mmol). 1H NMR (400 
MHz, CDCl3) δ 7.42 (m, 2H), 7.20 (m, 2H), 4.54 (s, 0.4H), 4.42-4.33 (dd, J =24.8, 10.0 Hz, 
1H), 4.16 (s, 0.6H), 3.97-3.83 (m, 1H), 3.77-3.65 (dd, J =37.2, 11.6 Hz, 1H), 2.71-2.63 (m, 
1H), 2.60 (t, J = 7.6 Hz, 2H), 2.26 (m, 1H), 1.62 (m, 2H), 1.53 (s, 9H), 1.48-1.47 (m, 9H), 1.28 
(m, 10H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 
(174.2), 174.0, (154.3), 153.8, 142.4, (142.4), 138.7, (138.6), 128.4, 125.2, (125.1), (82.8), 
82.6, 80.4, (80.3), (80.0), 79.1, (61.4), 60.6, 59.4, (59.4), 44.3, (43.2), 35.5, 31.9, (31.4), 29.4, 
29.3, 29.2, 28.4, 28.0, 27.9, 22.6, 14.1; [α]D (-) 5.3° (c 0.19, CHCl3); HRMS (ESI) calcd for 
C28H45NNaO5 (M+Na)+ 498.31900, found 498.3188. 
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Di-tert-butyl (S)-4-(4-octylphenyl)-2,5-dihydro-1H-pyrrole-1,2-dicarboxylate (1.154) was 
obtained as pale yellow oil (10 mg, 67 %) from 1.153 (15 mg, 0.032 mmol). 1H NMR (400 
MHz, CDCl3) δ 7.32 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 6.05 (m, 0.3H), 6.00 (0.7H), 
5.04 (m, 0.3H), 4.97 (m, 0.7H), 4.70-4.48 (m, 2H), 2.61 (m, 2H), 1.61 (m, 2H), 1.57-1.47 (m, 
18H), 1.30 (m, 10H), 0.88 (m, 3H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 
169.6, (169.5), (153.8), 153.5, 143.8, (143.7), (140.5), 140.4, (130.1), 130.0, 128.7, (128.6), 
125.6, (125.5), (117.5), 117.2, 81.5, (81.4), 80.0, (79.9), 67.9, (67.9), (53.6), 53.5, 35.7, 31.8, 
(31.3), 29.4, 29.2, 29.2, 28.5, 28.3, 28.0, (28.0), 22.6, 14.1; [α]D (-) 129.1° (c 1.04, CHCl3); 
HRMS (ESI) calcd for C28H43NNaO4 (M+Na)+ 480.3084, found 480.3091. 
 
 
Di-tert-butyl (2S,4R)-4-(4-octylphenyl)pyrrolidine-1,2-dicarboxylate (1.155) was obtained 
as white solid (19 mg, 95 %) from 1.154 (20 mg, 0.044 mmol). m.p. ( 82.5-83.5°C); 1H NMR 
(400 MHz, CDCl3) δ 7.14 (s, 4H), 4.21 (m, 1H), 4.06 (m, 0.65H), 3.91 (m, 0.35H), 3.43-3.34 
(m, 1H), 3.34-3.24 (m, 1H), 2.69 (m, 1H), 2.57 (t, J = 7.6 Hz, 2H), 2.02-1.93 (m, 1H), 1.58 
(m, 2H), 1.47-1.46 (2s, 18H), 1.28 (m, 10H), 0.88 (m, 3H); 13C NMR (100 MHz, CDCl3, 
mixture of rotamers) δ 172.0, (172.0), (154.0), 153.8, 141.8, (137.1), 137.0, 128.6, (127.0), 
127.0, 81.0, 80.0, (79.7), (60.0), 60.0, (53.30, 52.5, (43.3), 42.4, 38.5, (37.5), 35.5, 31.9, 
(31.5), 29.5, 29.3, 29.2, 28.4, 28.4, 28.0, (28.0), 22.7, 14.1; [α]D (-) 24.2° (c 1.08, CHCl3); 
HRMS (ESI) calcd for C28H45NNaO4 (M+Na)+ 482.3241, found 482.3243. 
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tert-Butyl (2S,4R)-2-(hydroxymethyl)-4-(4-octylphenyl)pyrrolidine-1-carboxylate (1.156) 
was obtained as pale yellow oil (11.4 mg, 90 %) from 1.155 (15 mg, 0.033 mmol). 1H NMR 
(400 MHz, CDCl3) δ 7.14 (s, 4H), 5.28 (m, 1H), 4.11-4.04 (m, 1H), 3.97 (m, 1H), 3.79-3.65 
(m, 2H), 3.24 (m, 2H), 2.58 (t, J = 7.6 Hz, 2H), 2.42-2.38 (m, 1H), 1.58 (m, 2H), 1.49 (s, 9H), 
1.28 (m, 10H), 0.89 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 156.9, 141.8, 137.1, 
128.6, 126.9, 80.6, 67.7, 61.5, 54.1, 42.2, 36.5, 35.5, 31.9, 31.5, 29.4, 29.3, 29.2, 28.4, 22.6, 
14.1; [α]D (+)4.31° (c 0.58, CHCl3); HRMS (ESI) calcd for C24H39NNaO3 (M+Na)+ 412.2822, 
found 412.2827. 
 
 
(2S,4R)-2-(hydroxymethyl)-4-(4-octylphenyl)Pyrrolidin-1-ium chloride (1.157) was 
obtained as pale yellow solid (7.0 mg, 93 %) from 1.156 ( 9 mg, 0.023 mmol). 1H NMR (400 
MHz, D2O) δ 7.13 (d, J = 7.2 Hz, 2H), 6.91 (d, J = 7.2 Hz, 2H), 3.81-3.76 (m, 2H), 3.70-3.57 
(m, 2H), 3.46 (m, 1H), 3.13-3.08 (m, 1H), 2.32 (m, 2H), 2.15 (m, 1H), 1.69 (m, 1H), 1.44 (m, 
2H), 1.27 (s, 10H), 0.90 (m, 3H); 13C NMR (100 MHz, D2O) δ 140.7, 135.8, 128.0, 126.8, 
60.9, 59.5, 50.1, 42.1, 34.9, 33.8, 31.5, 30.9, 29.3, 29.1, 29.1, 22.3, 13.5; [α]D (+) 20.0° (c 
0.21, MeOH); HRMS (ESI) calcd for C19H32NO (M+H)+ 290.2478, found 290.2477. HPLC: 
condition (B), tR = 5.93 min; purity: > 99%. 
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1-carboxylate (1.159) was obtained as colorless oil (20.0 mg, 72 %) from 1.147 (33 mg, 
0.072 mmol) according the procedure for synthesizing 1.149. 1H NMR (400 MHz, CDCl3) δ 
7.29 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 6.02 (s, 0.2H), 5.93 (s, 0.8H), 4.91 (m, 1H), 
4.74-4.65 (m, 1H), 4.56-4.43 (m, 2H), 3.85 (m, 1H), 3.78-3.63 (m, 1H), 2.61 (t, J = 7.6 Hz, 
2H), 1.61 (m, 2H), 1.54 (s, 9H), 1.28 (m, 10H), 0.89 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 156.6, 143.6, 138.3, 130.1, 125.4, 119.0, 80.8, 68.6, 67.5, 54.3, 35.7, 31.8, 31.3, 
29.4, 29.2, 29.2, 28.5, 22.6, 14.1; [α]D (+) 34.0° (c 2.0, CHCl3); HRMS (ESI) calcd for 
C24H37NNaO3 (M+Na)+ 410.2666, found 410.2662. 
 
 
tert-Butyl (2R,4R)-2-(hydroxymethyl)-4-(4-octylphenyl)pyrrolidine-1-carboxylate (1.160). 
Crabtree’s catalyst (5.0 mg, 0.006 mmol) was added to a solution of olefin 1.159 (16 mg, 
0.041 mmol) in anhydrous CH2Cl2 (0.8 mL). The resulting light orange mixture was subjected 
to a hydrogen pressure of 70 psi for 72 h. The volatiles were removed under reduced pressure 
and the residue was purified by flash chromatography (hexane: EtOAc, 10:1 to 8:1) to give the 
trans-pyrrolidine 1.160 (11.6 mg, 72 %) as pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 
7.14 (s, 4H), 4.31-3.18 (m, 1H), 3.81-3.67 (m, 3H), 3.41 (m, 2H), 2.59 (t, J = 7.6 Hz, 2H), 
2.21-2.13 (m, 1H), 2.01-1.95 (m, 1H), 1.59 (m, 2H), 1.49 (s, 9H), 1.28 (m, 10H), 0.89 (m, 
3H); 13C NMR (100 MHz, CDCl3) δ 157.1, 141.7, 138.2, 128.6, 126.8, 80.5, 68.0, 59.8, 54.0, 
42.0, 35.9, 35.5, 31.9, 31.5, 29.5, 29.3, 29.2, 28.5, 22.7, 14.1; [α]D (+) 37.2° (c 1.16, CHCl3); 
HRMS (ESI) calcd for C24H39NNaO3 (M+Na)+ 412.2822, found 412.2811. 
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(2R,4R)-2-(Hydroxymethyl)-4-(4-octylphenyl)pyrrolidin-1-ium chloride (1.161) was 
obtained as pale yellow solid (8.5 mg, 88 %) from 1.160 (11.6 mg , 0.030 mmol) according 
the procedure for synthesizing 1.32. 1H NMR (400 MHz, CDCl3) δ 7.15 (dd, J = 8.4, 14.0 Hz, 
4H), 4.14 (m, 1H), 4.08-4.01 (m, 1H), 3.99-3.91 (m, 1H), 3.87-3.83 (m, 1H), 3.67 (m, 1H), 
3.32 (m, 1H),  2.56 (t, J = 7.6 Hz, 2H), 2.31-2.23 (m, 1H), 2.23- 2.14 (m, 1H), 1.58 (m, 2H), 
1.36-1.22 (m, 10H), 0.88 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 142.3, 135.8, 129.0, 127.0, 
61.6, 61.4, 51.5, 42.6, 35.5, 34.4, 31.9, 31.4, 29.4, 29.3, 29.2, 22.6, 14.1 ; [α]D (-) 8.7° (c 0.85, 
CHCl3); HRMS (ESI) calcd for C19H32NO (M+H)+ 290.2478, found 290.2477. HPLC: 
condition (B), tR = 6.30 min; purity: > 99 %. 
 
 
Compound 1.164 was prepared according to the procedure for synthesizing 1.161.  
 
 
tert-Butyl (S)-2-(hydroxymethyl)-4-(4-octylphenyl)-2,5-dihydro-1H-pyrrole- 
1-carboxylate (1.162) was obtained as colorless oil (20.0 mg, 72 %) from 1.154 (38 mg, 
0.083 mmol). 1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.4 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 
6.01 (s, 0.2H), 5.93 (m, 0.8H), 4.91 (m, 1H), 4.70 (m, 1H), 4.49-4.43 (m, 2H), 3.86 (m, 1H), 
3.78-3.63 (m, 1H), 2.61 (t, J = 7.6 Hz, 2H), 1.60 (m, 2H), 1.54 (s, 9H), 1.28 (m, 10H), 0.89 (t, 
J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 156.6, 143.6, 138.3, 130.1, 125.5, 119.1, 80.8, 
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68.6, 67.6, 54.3, 35.7, 31.8, 31.4, 29.4, 29.3, 29.2, 28.5, 22.7, 14.1; [α]D (-) 28.6° (c 0.14, 
CHCl3); HRMS (ESI) calcd for C24H37NNaO3 (M+Na)+ 410.2666, found 410.2657. 
 
 
tert-Butyl (2S,4S)-2-(hydroxymethyl)-4-(4-octylphenyl)pyrrolidine-1-carboxylate (1.163) 
was obtained as pale yellow oil (8.4 mg, 70 %) from 1.162 (12 mg, 0.031 mmol). 1H NMR 
(400 MHz, CDCl3) δ 7.14 (s, 4H), 4.30-3.20 (m, 1H), 3.81-3.69 (m, 3H), 3.43 (m, 2H), 2.58 (t, 
J = 7.6 Hz, 2H), 2.21-2.13 (m, 1H), 1.98 (m, 1H), 1.59 (m, 2H), 1.48 (s, 9H), 1.28 (m, 10H), 
0.89 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 157.1, 141.7, 138.2, 128.6, 126.8, 80.5, 67.9, 
59.8, 54.0, 42.0, 35.8, 35.5, 31.9, 31.5, 29.5, 29.3, 29.2, 28.4, 22.6, 14.1; [α]D (-) 20.0° (c 0.40, 
CHCl3); HRMS (ESI) calcd for C24H39NNaO3 (M+Na)+ 412.2822, found 412.2824. 
 
 
(2S,4S)-2-(Hydroxymethyl)-4-(4-octylphenyl)pyrrolidin-1-ium chloride (1.164) was 
obtained as pale yellow solid (3.2 mg, 80 %) from 1.163 (4.8 mg, 0.012 mmol). 1H NMR (700 
MHz, CDCl3) δ 7.15 (m, 4H), 4.13 (m, 1H), 4.03-3.97 (m, 1H), 3.93-3.88 (m, 1H), 3.86-3.81 
(m, 1H), 3.67 (m, 1H), 3.32 (m, 1H),  2.56 (t, J = 7.7 Hz, 2H), 2.28-2.25 (m, 1H), 2.20- 2.16 
(m, 1H), 1.58 (m, 2H), 1.35-1.22 (m, 10H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (175 MHz, 
CDCl3) δ 142.4, 135.7, 129.0, 127.0, 61.6, 61.4, 51.5, 42.6, 35.5, 34.4, 31.9, 31.4, 29.4, 29.4, 
29.3, 29.2, 22.6, 14.1 ; [α]D (+) 9.4° (c 0.18, CHCl3); HRMS (ESI) calcd for C19H32NO 
(M+H)+ 290.2478, found 290.2482.!HPLC: condition (B), tR = 5.85 min; purity: > 99 %. 
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(S)-3-(4-Bromophenyl)-4-nitrobutanal (1.165) was prepared according the procedure 
reported by List,129 starting from acetaldehyde (5M in CH3CN, 3mL, 15 mmol) and trans-4-
bromo-β-nitrostyrene (684 mg), After 71 h, aldehyde 1.165 was obtained as pale yellow oil 
(180 mg, 22%). 1H NMR (400 MHz, CDCl3) δ 9.69 (s, 1H), 7.47 (d, J = 8.4 Hz, 2H), 7.12 (d, 
J = 8.4 Hz, 2H), 4.70-4.56 (m, 2H), 4.05 (p, J = 7.2 Hz, 1H), 2.94 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 198.4, 137.2, 132.3, 129.1, 122.0, 79.0, 46.2, 37.3; [α]D (-) 6.8° (c 0.47 
CHCl3); HRMS (ESI) calcd for C10H10BrNO3 (M-H)+ 269.9771, found 269.9771. The 
spectroscopic data were in agreement with the proposed structures and matched those reported 
in the literature.144,145  
 
 
tert-Butyl (S)-3-(4-bromophenyl)pyrrolidine-1-carboxylate (1.168) was synthesized 
according the reported procedure.132 Zinc powder was added in three portions over 10 min to a 
solution of aldehyde 1.165 in HOAc/H2O (1:1, 2 mL) at 0 °C. The mixture was stirred at room 
temperature for 3-4 h and filtered, and the filter cake was washed with water. The pH OF THE 
combined filtrate and washings was adjusted to pH = 12 with 4N aqueous KOH. The aqueous 
layer was extracted with CH2Cl2 (5 mL) three times. The organic phases were combined, dried 
over MgSO4 and filtered. The filtrate was evaporated under reduced pressure. The residue was 
directly used without purification. The residue (80 mg, 0.36 mmol) was dissolved in CH2Cl2  
(0.44 mL) and treated with Et3N (57 µL, 41 mg, 0.40 mmol), cooled to 0°C and treated drop-
wise with (Boc)2O (82 µL, 79 mg, 0.36 mmol). The reaction mixture was stirred at room 
temperature for 2 days and then quenched with saturated aqueous NH4Cl. The aqueous layer 
H
O NO2
+
Br
N
H OTMS
Ph
Ph
CH3CN
(20%)
H NO2
O
Br
22%
1.165
(S)
H NO2
O
Br
1) Zn, HOAc/H2O
2) Boc2O, Et3N, CH2Cl2
1.165
N
Br
1.168
57%  in two steps
Boc
  123 
was extracted with CH2Cl2. The organic layers were combined, dried over MgSO4 and filtered. 
The filtrate was evaporated under reduced pressure. The residue was purified by flash 
chromatography (hexane: EtOAc, 1:8 with) to give carbamate 1.168 (68 mg, 57 % in two 
steps) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.4 
Hz, 2H), 3.90-3.70 (m, 1H), 3.70-3.50 (m, 1H), 3.44-3.20 (m, 3H), 2.25 (m, 1H), 1.93 (m, 
1H), 1.47 (s, 9H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 154.4, 140.5, 131.6, 
128.7, 120.4, 79.3, 52.3, (51.6), (45.8), 45.5, 43.7, (42.7), (33.2), 32.3, 28.5; [α]D (-) 17.4° (c 
1.55, CHCl3); HRMS (ESI) calcd for C15H20[79Br]NNaO2 (M+Na)+ 348.0570, found. 
348.0563. SFC conditions: LUX AMYLOSE 2, 150 x 4.6 mm, particle size 3 µm, 10 % 
MeOH, 150 bar CO2, Column temperature: 35 °C, flow rate: 3 mL/min, detection: UV 210 
nm, major tR 2.92 min, minor tR 2.36 min, e.r. = 94.5 : 5.5. 
 
 
tert-Butyl (S)-3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.169) was obtained as colorless 
oil (24 mg, 73% over two steps) from 1.168 (30 mg, 0.092 mmol) according the procedure for 
synthesizing 1.31. 1H NMR (400 MHz, CDCl3) δ 7.15 (m, 4H), 3.90-3.70 (m, 1H), 3.68-3.51 
(m, 1H), 3.45-3.20 (m, 3H), 2.59 (m, 2H), 2.24 (m, 1H), 1.98 (m, 1H), 1.61 (m, 2H), 1.48 (m, 
9H), 1.40-1.20 (m, 10H), 0.89 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 154.5, 141.5, 141.4, 
138.6, 128.6, 126.9, 79.1, 52.7, 51.8, 46.0, 45.6, 44.0, 43.0, 35.5, 33.4, 32.5, 31.9, 31.5, 29.5, 
29.3, 29.2, 28.5, 22.6, 14.1; [α]D (-) 11.6° (c 0.80, CHCl3); HRMS (ESI) calcd for 
C23H37NNaO2 (M+Na)+ 382.2717, found. 382.2704.  
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(S)-3-(4-Octylphenyl)pyrrolidin-1-ium chloride (1.170) was obtained as pale yellow solid 
(12.6 mg, 96 %) from carbamate 1.169 (16 mg, 0.045 mmol) according the procedure for 
synthesizing 1.32. 1H NMR (400 MHz, D2O) δ 7.09 (d, J = 8.0 Hz, 2H), 6.85 (d, J = 8.0 Hz, 
2H), 3.58-3.49 (m, 1H), 3.48-3.39 (m, 1H), 3.38-3.20 (m, 2H), 2.99 (t, J = 11.2 Hz, 1H), 2.29 
(m, 2H), 2.06 (m, 1H), 1.78 (m, 1H), 1.42 (m, 2H), 1.27 (m, 10H), 0.91 (m, 3H); 13C NMR 
(100 MHz, D2O) δ 140.8, 136.6, 128.3, 127.3, 50.5, 45.4, 42.6, 35.4, 32.0, 31.9, 31.4, 29.9, 
29.7, 29.6, 22.7, 13.9; [α]D (-) 8.0° (c 0.40, CHCl3); HRMS (ESI) calcd for C18H30N (M+H)+ 
260.2373, found. 260.2384.  
 
 
Compound 1.175 was prepared according to the procedure for synthesizing 1.170.  
 
 
(R)-3-(4-Bromophenyl)-4-nitrobutanal (1.171). Starting from acetaldehyde (5M in CH3CN, 
3mL, 15 mmol) and trans-4-bromo-β-nitrostyrene (684 mg), After 71 h, 1.171 was obtained as 
pale yellow oil (200 mg, 25%). 1H NMR (400 MHz, CDCl3) δ 9.66 (s, 1H), 7.46 (d, J = 8.4 
Hz, 2H), 7.11 (d, J = 8.4 Hz, 2H), 4.70-4.52 (m, 2H), 4.03 (p, J = 7.2 Hz, 1H), 2.92 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ 198.4, 137.2, 132.2, 129.1, 121.9, 78.9, 46.1, 37.2; [α]D (+) 
6.4° (c 0.45, CHCl3); HRMS (ESI) calcd for C10H10BrNO3 (M-H)+ 269.9771, found 269.9771.  
 
 
tert-Butyl (R)-3-(4-bromophenyl)pyrrolidine-1-carboxylate (1.173) was obtained as 
colorless oil (65 mg, 54 % over two steps) from 1.171 (100 mg, 0.37 mmol). 1H NMR (400 
MHz, CDCl3) δ 7.43 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H), 3.88-3.71 (m, 1H), 3.68-
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3.48 (m, 1H), 3.46-3.18 (m, 3H), 2.24 (m, 1H), 1.94 (m, 1H), 1.47 (s, 9H); 13C NMR (100 
MHz, CDCl3, mixture of rotamers) δ 154.4, 140.4, 131.6, 128.7, 120.4, 79.3, 52.3, (51.6), 
(45.7), 45.5, 43.6, (42.7), (33.2), 32.3, 28.5; [α]D (+) 17.3° (c 1.65, CHCl3); HRMS (ESI) 
calcd for C15H20[79Br]NNaO2 (M+Na)+ 348.0570, found. 348.0563. SFC conditions: LUX 
AMYLOSE 2, 150 x 4.6 mm, particle size 3 µm, 10 % MeOH, 150 bar CO2, Column 
temperature: 35 °C, flow rate: 3 mL/min, detection: UV 210 nm, major tR 2.31 min, minor tR 
3.06 min, e.r. = 94.1: 5.9. 
 
 
tert-Butyl (R)-3-(4-octylphenyl)pyrrolidine-1-carboxylate (1.174) was obtained as colorless 
oil (17 mg, 52 % over two steps) from 1.173 (30 mg, 0.092 mmol). 1H NMR (400 MHz, 
CDCl3) δ 7.15 (m, 4H), 3.88-3.72 (m, 1H), 3.68-3.51 (m, 1H), 3.45-3.22 (m, 3H), 2.59 (m, 
2H), 2.24 (m, 1H), 1.98 (m, 1H), 1.61 (m, 2H), 1.48 (m, 9H), 1.39-1.20 (m, 10H), 0.89 (m, 
3H); 13C NMR (100 MHz, CDCl3) δ 154.5, 141.5, 141.4, 138.6, 128.6, 126.9, 79.1, 52.7, 51.8, 
46.0, 45.7, 44.0, 43.0, 35.5, 33.4, 32.5, 31.9, 31.5, 29.5, 29.4, 29.2, 28.5, 22.7, 14.1; [α]D (+) 
10.8° (c 0.50, CHCl3); HRMS (ESI) calcd for C23H37NNaO2 (M+Na)+ 382.2717, found. 
382.2730.  
 
 
(R)-3-(4-Octylphenyl)pyrrolidin-1-ium chloride (1.175) was obtained as pale yellow solid 
(7.2 mg, 88 %) from 1.174 (10 mg, 0.028 mmol). 1H NMR (400 MHz, D2O) δ 7.09 (d, J = 8.0 
Hz, 2H), 6.85 (d, J = 8.0 Hz, 2H), 3.57-3.49 (m, 1H), 3.48-3.38 (m, 1H), 3.38-3.20 (m, 2H), 
2.98 (t, J = 11.2 Hz, 1H), 2.29 (m, 2H), 2.06 (m, 1H), 1.78 (m, 1H), 1.42 (m, 2H), 1.27 (m, 
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10H), 0.91 (m, 3H); 13C NMR (100 MHz, D2O) δ 140.8, 136.6, 128.3, 127.3, 50.5, 45.4, 42.6, 
35.4, 32.0, 31.9, 31.3, 29.8, 29.6, 29.6, 22.7, 13.9; [α]D (+) 5.9° (c 0.22, CHCl3); HRMS (ESI) 
calcd for C18H30N (M+H)+ 260.2373, found. 260.2363. 
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Chapter 2: Design and Synthesis of Photoaffinity Labeling 
Probe of Amino Alcohol 1.57 and 1.65 
 
2-1 Introduction 
2-1-1 General mechanism of photoaffinity labeling (PAL) 
 Protein–ligand interactions are ubiquitous and essential in living organisms. Study of 
the interactions between bioactive ligands and their corresponding receptor proteins is not only 
required in the fundamental life sciences, but is also helpful for understanding the pathology 
of diseases, to aid drug discovery and medical science.1-3 The major challenges to elucidate the 
structures of the complex biological molecules involved in such processes has led to the 
development of several techniques, 4  such as X-ray crystallography4- 6  and NMR 
spectroscopy.4,7,8 Analysis of structures of crystalline protein-ligand complexes by X-ray 
crystallography can directly provide details of their interactions in three dimensions, but this 
static structural information is usually insufficient for determining or predicting solution-state 
interactions. NMR spectroscopy is a powerful technique for probing protein-ligand 
interactions in solution, because it can provide dynamic structural information of the complex 
by analysis of the resonance signals of the ligand or the protein, but it may be limited by 
macromolecular size.9 Both of these methods require usually protein samples of high purity, 
which may be a challenge due to difficulties in the purification of proteins. In 1962, 
Westheimer and coworkers10 described the successful labeling of chymotrypsin by acylation 
with p-nitrophenyl diazoacetate followed by photolysis. Based on their success, the concept of 
photoaffinity labeling (PAL) was introduced and proposed as a new method for mapping the 
active site of an enzyme.10 With this revolutionary idea, new photoaffinity probes and methods 
for detection of the labeled receptor soon were developed, which led PAL to become one of 
most important techniques in structural biology today.11  
 
 In PAL experiments, a bifunctional ligand probe, possessing a photoreactive group and 
a reporter group, bind to the macromolecule of interest, usually a protein (Figure 23). Upon 
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irradiation with UV light, a highly reactive intermediate (typically a carbene, nitrene or a 
diradical) is generated from the photolabile moiety and inserts into the bounds of the large 
molecule forming a covalent link. Thus, the previously reversible binding is turned to 
permanent binding. The ligand-receptor complex may then be purified by tagging ligand to 
allow identification of the macromolecule, and particularly its binding region. In PAL 
processes, purification of the target macromolecule is initially not needed, and only required 
after tagging of the ligand-receptor complex. Therefore, PAL is advantageous for studies of 
complex systems (e.g. ribosomes and transcription factors) and unknown macromolecules. 
 
Figure 23. General mechanism of a photoaffinity labeling (PAL) process. 
 
2-1-2 Photoaffinity probe (PAP) 
 The design of a suitable photoaffinity probe is a crucial factor for success in PAL 
studies. The PAP is usually prepared by modification of a ligand for the receptor. This 
modification should not decrease the biological activity (including affinity). The photo-
reactive group on the probe should be highly reactive, and activated at mild conditions to 
avoid any damage to the biosystem. The active intermediate after irradiation should readily 
react not only with X-H nucleophiles, but ideally with the C-H bonds of the target protein. The 
reporter group should be easily detected. The crosslinking reaction should give high yield. 
There is no such thing as an ideal PAP; however, many efforts have been made, to create 
diverse photoreactive groups and reporter groups. Design of the most suitable PAP is typically 
done on a case by case basis.11 
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2-1-2-1 Photoreactive groups 
 Since the diazoacetyl group was used by Westheimer and coworkers in the labeling of 
chymotrypsin,10 many other photoreactive groups have been developed.11 Among these, 
benzophenones, aryl azides, and diazirines are among the most widely used in PAL 
experiments (Figure 24). 
 
Figure 24. Photolabeling groups: benzophenones, aryl azides and diazirines. 
 
 Benzophenone11,12 can be photoactivated at wavelengths of 350~360 nm to generate a 
highly reactive triplet state benzhydryl diradical (Figure 25).11d This diradical can exist up to 
120 µs before it converts back to the ground state. It abstracts hydrogen from the nearby X-H 
bonds on a protein, and undergoes fast recombination to form a benzhydrol. Water does not 
deactivate the photochemical reactivity of benzophenone, because the diradical can react with 
water and generate a hydrate, that dehydrats to give back benzophenone. This enhances PAL 
efficiency when using benzophenone.  Benzophenones also have advantages in terms of 
chemical stability and commercial availability; however, they have drawbacks, such as the 
bulkiness of benzophenone may affect the biological activity of the ligand and the interaction 
between the ligand and receptor. Benzophenones often require prolonged irradiation times, 
which may cause damage to biosystems.  
 
 
Figure 25. Possible photochemical processes of benzophenone.11d 
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 Aryl azides11,13 can be irradiated (major wavelengths < 300 nm) to generate the 
reactive singlet state nitrenes, which can directly insert into the X-H bonds of the protein 
receptor (Figure 26). The short-lived nitrene can be transformed to a lower energy triplet state 
nitrene through intersystem crossing, abstract a hydrogen from an X-H bond, and form a 
covalent N-X bond with the protein receptor, the same complex as generated by the singlet 
nitrene. The singlet nitrene can also be converted to a benzazirine, which rearrange to a 
dehydroazepine. Both benzazirine and dehydroazdpine can react with a variety of 
nucleophiles.14 In addition to these possible photolysis reactions, there are many other side 
reactions, including the reduction of aryl azides to the corresponding amines, oxidation of 
triplet nitrenes to nitro intermediates, and dimerization of triplet nitrenes to azobenzene. Due  
to the many reaction pathways, the crosslinking efficiencies of aryl azides in PAL are usually 
low (< 30% yield).15 Irradiating at wavelenghs less than 300 nm may also damage the 
biosystems, which further limits the use of aryl azides in PAL studies. Compared to 
benzophenones, aryl azides are however relatively small in size, and relatively easy to 
synthesize from the corresponding aromatic amines.16 Modification of the substituents on the 
aryl ring may increase crosslinking efficiencies.11a These advantages combined make aryl 
azides one of the most popular photoreactive groups. 
 
 
Figure 26. Possible photochemistry process of aryl azide.11d 
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 Diazirines11,15,17 can be efficiently excited at wavelengths 350-380 nm, and generate a 
singlet carbene and a diazo isomer (> 30 %) (Figure 27). The short-lived singlet carbene can 
directly insert into an X-H bond of the protein, and can also go through intersystem crossing to 
give a lower energy triplet carbene, which could abstract a hydrogen from an X-H bond, and 
recombine to form the ligand-protein complex, the same product generated from the singlet 
carbene. The diazo isomer may also transform into a singlet carbene, but this process is slow, 
and it could lead to the unspecific labeling, or hydrolysis.11d A solution to this problem is to 
use the 3-trifluoromethyl-3-phenyldiazirine (Figure 27),18 because this diazo derivative is 
stabilized due to the strong electron-withdrawing effect of the trifluoromethyl group and 
resists side reactions. Compared to other photoreactive groups, diazirines are more difficult to 
synthesize often requiring more steps.17c,19 Diazirines are relatively small in size, and require 
long wavelengths to activate, which decreases the risk of damaging the target biomolecules. 
They are chemically stable under various conditions (strong acids, bases, etc.). Due to these 
advantages, diazirines have become the most useful photo- reactive groups in PAL studies.  
 
 
Figure 27. Possible photochemistry process of diazirine.11d 
 
2-1-2-2 Reporter groups 
 Reporter groups facilitate the detection of the photolabeled complex, and help isolation 
and identification. A number of reporter groups have been developed based on different 
methods,11e,g, 20 such as radiolabels (radioactive isotopes 125I, 3H), 20  fluorophores (e.g. 
fluorescein, pyrene),21 and affinity tags (e.g. biotin, epitope tags).11d Although widely used, 
radiolabels suffer several significant drawbacks, because they are quickly degradated, harmful, 
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and require special handling techniques. The incorporation of fluorophores and affinity tags 
may augment size, and cell permeablity, and thus alter the biological activities of the probe. In 
the absence of cell permeability, photoaffinity probes are unable to capture receptor targets in 
live cells.  
 
 In 2003, Bertozzi and coworkers coined the term “bioorthogonal chemistry”,22,23 which 
is used to enable the study the biomolecules in living cells. In concept, a chemical reaction 
could occur inside of living systems, but it should neither interact with the biosystem, nor 
interfere with any native biochemical processes.24 This type of reaction was achieved by 
incorporating certain functional groups as reporter groups on biomolecules, which could be 
selectively ligated in a second step (Figure 28). Bioorthogonal chemistry provides a strategy in 
PAL studies, using chemical reporters that perform tandem photoaffinity labeling–
bioorthogonal conjugation to detect the photoaffinity probe-receptor complex,11e and to allow 
the capture of targets in live cells.  
 
 
Figure 28. A general bioorthogonal chemical reaction.  
 
 Bioorthogonal chemistry requires unique reporter and ligation groups. A number of 
bioorthogonal reactions have been developed, 25  including: condensation reactions of 
ketones/aldehydes with amines/hydrazide,26 the Bertozzi-Staudinger ligation of azides and 
triarylphosphines,27 1,3-dipolar cycloaddition between azides and alkynes28-30 Diels−Alder 
cycloadditions between tetrazines and strained alkenes/alkynes,31,32 cross-metathesis,33,34 and 
Suzuki-Miyaura coupling reactions. 35 , 36  Among these reactions, the Bertozzi-Staudinger 
ligation and 1,3-dipolar azide-alkyne cycloaddition have been the most well studied reactions 
in bioorthogonal chemistry. 
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 The Bertozzi-Staudinger ligation was the first successful bioorthogonal reaction in this 
field. 37  In the classic Staudinger reaction, an azide reacts with a phosphine (e.g. 
triphenylphosphine) or a phosphite to generate an unstable aza-ylide intermediate,38,39  which 
then can be hydrolyzed to give the amine (Figure 29). In 2000, Bertozzi and coworkers 
modified this reaction, by introducing an electrophilic trap, a methyl ester group, ortho to the 
phosphorus atom on one of the phenyl rings in triphenylphospine, the generated aza-ylide was 
directed to form a amide bond through intramolecular cyclization, instead of hydrolysis. The 
five-member ring intermediate is then hydrolyzed to afford a stable ligation product (Figure 
29).37   
 
 
 
Figure 29. General mechanisms of the Staudinger reaction and the Bertozzi-Staudinger 
ligation.  
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 Bertozzi-Staudinger ligations have been practically used in living cells40 and animals;41 
however, they suffer drawbacks: aryl azides can be reduced by thiols,23a phosphine reagents 
can be slowly oxidized by air or enzymes,23a,c the kinetics of the reactions are slow (second 
order rate constant: 0.0020 M−1•s−1) resulting in a higher concentration of phosphine reagents, 
which also lead to the problems of phosphine oxidation and high background signals in cell 
fluorescence image applications. 42  Although limited by these problems, the Bertozzi-
Staudinger ligation is a common choice in bioorthogonal chemistry due to high selectivity and 
wide compatibility.25  
 
 1,3-Dipolar azide-alkyne cycloadditions are also commonly considered for 
bioorthogonal chemistry. This [3+2] cycloaddition reaction was first described by Arthur 
Michael in 1893,43 followed by extensive studies by Rolf Huisgen,44 This reaction is presently 
known as “Azide-alkyne Huisgen cycloaddition” (Figure 30). For bioorthogonal chemistry, 
azides are absent in biological systems, both azides and alkynes are small in size, and their 
incorporation should have minimal effect of biological activity, nor perturb biosystems. 
Although there could be many benefits, the classic Huisgen cycloaddition cannot be used as a 
bioorthogonal reaction due to the harsh reaction conditions (high temperature and pressure) 
and the slow kinetics. In 2002, both K. Barry Sharpless45 and Morten Meldal46 reported 
efficient Copper (I) catalyzed 1,3-dipolar cycloaddition reactions between azides and terminal 
alkynes, which overcame these obstacles for use in bioorthogonal chemistry (Figure 30). The 
mechanism of the copper (I) catalyzed 1,3-dipolar azide-alkyne cycloaddition, termed as 
“CuAAC”,47,48 and known as “click chemistry”,49 is different from the standard [3+2] Huisgen 
cycloaddition. The generally recognized mechanism involves dinuclear copper interactions.50-
52 One molecular copper (I) catalyst first interacts with the terminal alkyne substrate to form a 
pi-complex. The terminal hydrogen is then deprotonated by a base to generate a second 
molecular copper (I) species, which binds to the copper acetylide intermediate, and activates 
the azide substrate to generate a copper-azide-acetylide complex. Upon cyclization and 
protonation, the complex transforms to a 1,4-disubstituted triazole as a specific isomer, and  
the copper (I) catalyst was regenerated (Figure 30). 
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Figure 30. General mechanisms of azide-alkyne Huisgen cycloaddition and CuAAC reaction.  
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 The CuAAC reaction has a faster reaction rate compared to Bertozzi-Staudinger 
ligation, is relatively simple and readily occurs in aqueous solution. Widely used as a popular 
bioothogonal reaction in chemical biology studies,47, 53  the CuAAC reaction has wide 
compatibility with biosystems; however, Cu (I) catalysts are toxic to living cells.54 To 
decrease cytotoxicity, a number of ligands have been developed,55-60 which enable labeling 
biomolecules in living cells through the CuAAC reaction.  
 
 To further optimize the CuAAC reaction and avoid the use of Cu (I) completely, 
Bertozzi developed “Cu-free click chemistry” by employing ring strain (cyclooctyne)61-63 to 
facilitate alkyne-azide cycloaddition in the absence of Cu (I) (Figure 31).64 Termed “strain-
promoted alkyne-azide cycloaddition” (SPAAC), the first generation of this method employed 
OCT-botin for labeling glycoproteins without cytotoxicity.64 The reaction suffers from 
drawbacks: the kinetics of the reaction are typically slower than the Bertozzi-Staudinger 
ligation, and significantly slower compared to CuAAC reactions; OCT is poorly water soluble. 
To improve the SPAAC reaction, modified cyclooctynes have been parepared, such as ALO 
(aryl-less octyne),65 which has better solubility in water compared to OCT, but similarly poor 
kinetics. MOFO (monofluorinated cyclooctyne)65 and DIFO (difluorinated cyclooctyne)66 
have enhanced reaction rates due to the electron-withdrawing property of fluoride, DIBO 
(dibenzocyclooctyne) 67  increases reactivity by fusing two aryl rings to increase strain. 
BARAC (biarylazacyclooctynone) 68  and DIBAC (dibenzoazacyclooctyne) 69 , 70  have 
accelerated the reaction rates due in part to an amide bond on the ring. BCN 
(bicycle[6.1.0]nonyne) 71  has improved the kinetics due to the added strain of the 
cyclopropane, and gives a single regioisomer due to symmetry (Figure 31). These modified 
cycloctynes effectively promoted SPAAC in biological systems, especially in vivo imaging 
studies.66,72 , 73 “Click chemistry”, including CuAAC and SPAAC, has become the most 
common and promising reaction in bioorthogonal chemistry, and a popular strategy in PAL 
studies.   
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Figure 31. General reaction of SPAAC and modified octyne analogues. 
 
2-1-3 Design of photoaffinity labeling probes from 1.57 and 1.65 
 In our studies of constrained azacyclic pyrrolidine analogues of FTY720, amino 
alcohol 1.65 exhibited better activity against Sup-B15 leukemia cell line compared to FTY720 
(1.8) and analogues (Tables 2 and 3). Furthermore, 1.65 could trigger down-regulation of the 
nutrient transporter to kill cancer cells (Figure 13). To further understand its anti-cancer 
mechanism, and the affect of stereochemistry compared to its enantiomer 1.57, we decided to 
use PAL to identify the target receptor, and ultimately facilitate design of more effective 
analogues.  
 
 To make photoaffinity labeling probes from 1.57 and 1.65, we chose to incorporate a 
diazirine as the photoreactive group on the C-8 aliphatic long chain (Figure 32). Diazirines are 
usually prepared from the corresponding ketones.17c To determine the best position to install 
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the diazirine, four analogues (2.1, 2.2, 2.3, and 2.4) of 1.65 bearing ketone moieties at the 1-, 
3-, 4-, 7-positions on the chain were respectively prepared (Figure 32).  
 
 For reporter groups, we planed to use “click chemistry”, and install an azide or 
terminal alkyne on the hydroxymethyl arm (Figure 32). In general, these small photo reactive 
groups and reporter groups were expected to not have much negative influence on bioactivity. 
The most suitable reporter group would depend on the bioactivity after modification and the 
difficulty of synthesis.  
 
 
 
Figure 32. Design of photoaffinity labeling (PAL) probes of 1.57 and 1.65, and their ketone 
precursors 2.1, 2.2, 2.3 and 2.4. 
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2-2 Results and Discussion 
2-2-1 Screening of the position of diazirine 
2-2-1-1 Synthesis of ketone 2.1 
 In our initial retrosynthetic analysis (Scheme 37), we envisioned that compound 2.1 
could be easily assembled from the available (2R)-hydroxymethyl-(4S)-hydroxyl-pyrrolidine 
intermediate 1.61 (Scheme 10) and a ketal protected benzyl bromide through a substitution 
reaction. This ketal intermediate could be prepared from the corresponding ketone, which 
could be generated through a Grignard reaction between n-heptylmagnesium bromide and 
phenyl Weinreb amide. The required bromide can be accessed through benzylic bromination 
using NBS. The Weinreb amide intermediate could be easily prepared from the corresponding 
4-methylbenzoyl chloride (2.5). 
 
Scheme 37. Retrosynthetic analysis of ketone 2.1 (route I). 
 
 
 
 Silyl ether 1.61 was available from a previous synthesis (Scheme 10), and to be 
alkylated with benzyl bromide 2.9, in a substitution reaction (Scheme 38). The synthesis of 
bromide 2.9 began by the reaction of N,O-dimethylhydroxylamine hydrochloride, 
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triethylamine and 4-methylbenzoyl chloride (2.5) to provide Weinreb amide 2.6 in 92 % yield. 
The Grignard reagent, n-heptylmagnesium bromide was prepared in situ from 1-bromoheptane 
and magnesium turnings, and reacted with 2.6 to provide the desired ketone 2.7 in 96 % yield. 
Treatment of 2.7 with NBS and AIBN then afforded the required bromide 2.8. Protection of 
ketone 2.8 as the ketal 2.9 left us ready for the substitution reaction using protected prolinol 
1.61. Thus, the reaction of 1.61 and 2.9 in the presence of NaH and TBAI generated 
successfully ether 2.10 in 93 % yield. Global deprotection of 2.10 was accomplished using 
HCl in 1,4-dioxane to remove the ketal, TBS, and Boc groups in one step. The desired ketone 
2.1 was obtained in 90 % yield (Scheme 38).   
 
Scheme 38. Synthesis of ketone 2.1 (route I). 
 
 
 
 Although ketone 2.1 was successfully synthesized, the route was relatively long and 
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FTY720 analogues (Chapter 1). We thought that the aryl ketone side chain in 2.1 could be 
accessed through a palladium-catalyzed cross-coupling reaction74 between octanal and aryl 
bromide intermediate 1.62, which was available from our previous synthesis (see Schemes 10 
and 39).  
 
Scheme 39. Retrosynthetic analysis of ketone 2.1 (route II). 
 
 
  
 Thus, treatment of the bromide 1.62 with octanal in DMF, using Pd(dba)2 and dppp as 
catalysts in the presence of pyrrolidine and 4Å molecular sieves gave aryl ketone 2.11 in 60 % 
yield (Scheme 40). 74 Removal of the TBS and Boc protecting groups in 2.11 using HCl in 1,4-
dioxane provided ketone 2.1 in 92 % yield. This route significantly simplified the synthesis of 
2.1 (two steps from available intermediate 1.62, total 55 % yield).     
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Scheme 40. Synthesis of ketone 2.1 (route II). 
 
 
2-2-1-2 Synthesis of ketone 2.2 
 To make ketone 2.2, we envisioned that a hydrogenation of the olefin from the cross 
metathesis between 1-octen-3-one and a vinyl benzyl hydroxyporlinol (Scheme 41). 1-Octen-
3-one can be easily prepared from 1-octen-3-ol by oxidation.75 Vinyl benzyl hydroxyprolinol 
could be generated from the available intermediate 1.62 and vinyltributylstannane, through a 
Stille coupling reaction (Scheme 41). 
 
Scheme 41. Retrosynthetic analysis of ketone 2.2. 
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 Based on a known procedure,75 1-octen-3-ol was treated with periodic acid and 
TEMPO, and 1-octen-3-one (2.12) was obtained in 80 % yield (Scheme 41). Bromide 1.62 
was transformed to the desired styrene 2.13 by reaction with vinyltributylstannane, which was 
catalyzed by Pd(PPh3)4 (Stille coupling). Olefin 2.13 was mixed with enone 2.12 in 1,2-
dichloroethane in the presence of Grubb’s II catalyst to afford the cross metathesis product, 
which was reduced by hydrogenation to give the ketone 2.14 (53 %, in two steps). Finally, 
deprotection of 2.14 using HCl afforded the required ketone 2.2 in 93 % yield (Scheme 42).    
 
Scheme 42. Synthesis of ketone 2.2. 
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2-2-1-3 Synthesis of ketone 2.3 
 We envisioned that ketone 2.3 could be obtained though our common strategy for 
installing the side chain through a Suzuki coupling reaction with aryl bromide 1.62 followed 
by hydrogenation (Scheme 43). The alkyne could be generated by a Grignard reaction between 
the corresponding Weinreb amide and propylmagnesium chloride. This Weinreb amide could 
be prepared from commercially available 4-pentynoic acid (Scheme 43). 
 
Scheme 43. Retrosynthetic analysis of ketone 2.3. 
 
 
 
 4-Pentynoic acid reacted in the presence of EDC and HOBT with N,O-
dimethylhydroxylamine hydrochloride to give the corresponding Weinreb amide 2.15 in 90 % 
yield (Scheme 44). Treatment of amide 2.15 with propylmagnesium chloride afforded ketone 
2.16 in 95 % yield. Using our Suzuki coupling and hydrogenation strategy, 1.62 was reacted 
with alkyne 2.16 and transformed to ketone 2.17 (48 % yield, in two steps). Finally, HCl was 
used to remove the TBS and Boc protecting groups from 2.17, and provide ketone 2.3 in 95 % 
yield.  
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Scheme 44. Synthesis of ketone 2.3. 
 
2-2-1-4 Synthesis of ketone 2.4 
 Ketone 2.4 was prepared using a similar strategy as for the synthesis of 2.3 (Scheme 
44) from commercially available 6-heptynoic acid (Scheme 45). 
 
Scheme 45. Retrosynthetic analysis of ketone 2.4. 
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 6-Heptynoic acid was transformed to Weinreb amide 2.18 in 95 % yield (Scheme 46), 
which was treated with methylmagnesium bromide to afford ketone 2.19 in 96 % yield. From 
2.19, a two-step sequence of Suzuki coupling and hydrogenation, gave ketone 2.20 in 41 % 
yield. Finally, all the protecting groups were removed from 2.20 using HCl to generate ketone 
2.4 in 63 % yield.  
 
Scheme 46. Synthesis of ketone 2.4. 
 
 
 
2-2-1-5 Biological evaluation of ketones 2.1, 2.2, 2.3 and 2.4 
 With all four ketone analogues in hand, they were tested in a cell viability assay to 
compare their cytotoxic activities on murine hematopoietic FL5.12 cells (Figure 33). 
Preliminary results suggested that all the analogues were less cytotoxic to FL5.12 cells than 
FTY720 (1.8).  Ketone 2.1 was the most active of all four analogues, and 2.2 was less active 
than 2.1, but more active than 2.3 and 2.4. The activities of 2.3 and 2.4 were dramatically 
lower than the activities of 2.1 and 2.2. These results indicated that the closer the side chain 
ketone carbonyl was to the phenyl ring, the more active the analogue. We hypothesized that 
the long aliphatic chain may have interactions with a hydrophobic pocker in the target, such 
that, modification closer to the phenyl ring minimized the negative effect on activity.   
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Figure 33. Cytotoxic action of different ketone side chain substituted analogues 2.1, 2.2, 2.3 
and 2.4 on murine hematopoietic FL5.12 cells. 
 
 The same position-activity trend was also observed in the surface 4F2hc expression 
assay on FL5.12 cells. Although all four analogues induced nutrient transporter down-
regulation, analogue 2.1 was still the most active one, and exhibited almost the same activity 
as FTY720 (1.8). Therefore, the C-1 position on the side chain was considered to be the best 
position to install the diazirine photo-reactive group. 
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Figure 34. Nutrient transporter down-regulation of ketone side-chain substituted analogues 
2.1, 2.2, 2.3, and 2.4 on FL5.12 cells. 
 
2-2-1-6 Synthesis of diazirines 2.21 and 2.22. 
 using ketone 2.1, because it was the most active analogue, we proposed the synthesis 
of diazirine 2.21 (Figure 35). In addition, diazirine 2.22 was prepared from ketone 2.2, and 
tested as well (Figure 35).  
 
Figure 35. Diazirine analogues 2.21 and 2.22. 
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 Diazirines were synthesized from the corresponding ketones by diaziridine formation, 
and oxidation.17c Ketone 2.14 was treated with liquid ammonia and hydroxylamine-O-sulfonic 
acid to generate the corresponding unstable diaziridine intermediate, which was immediately 
oxidized with triethylamine and iodine to give diazirine 2.23 in 15 % yield over two steps 
(Scheme 46). The low yield was due to inefficient diaziridine formation in the first step. With 
diazirine 2.23 in hand, the protecting groups were removed using HCl in 1,4-dioxane to afford 
the desired diazirine analogue 2.22 in 91 % yield (Scheme 47). 
 
Scheme 47. Synthesis of diazirine 2.22. 
 
 
 
 The same synthetic protocol was used to prepare the other diazirine 2.21 (Scheme 48); 
however, treatment of ketone 2.11 with liquid ammonia and hydroxylamine-O-sulfonic acid, 
followed by oxidation using triethylamine and iodine, did not give the expected diazirine 2.24. 
Considering the electrophilicity of the carbonyl was decreased at the benzylic position, ketone 
2.11 was transformed into a more electrophilic benzylimine 2.25, by reaction with 
benzylamine in toluene. Imine 2.25 was submitted to the same reaction conditions as used 
previously, and provided the diazirine 2.24 in 29 % yield over three steps. Finally, 
deprotection of 2.24 afforded the required diazirine 2.21 in 85 % yield (Scheme 48).  
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Scheme 48. Synthesis of diazirine 2.21. 
 
 
 
2-2-1-7 Biological evaluation of diazirines 2.21 and 2.22. 
 Diazirines 2.21 and 2.22 were used in the same cell viability assay as for their 
corrresponding ketones to examine their cytotoxic activities on FL5.12 cells (Figure 36). 
Preliminary results suggested both 2.21 and 2.22 were active against FL5.12 cells as their 
corresponding ketones 2.1 and 2.2 at almost the same concentration, and diazirine 2.21 was 
more active than 2.22, with the same position-activity trend as in the ketones (Figure 33). 
These results suggested that our strategy to use the precursor ketones to predict the activity 
trend was reasonable, and the most suitable position to install a diazirine group on the side 
chain was the C-1 position (the closest carbon to phenyl ring).  
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Figure 36. Cytotoxic action of diazirines 2.21 and 2.22 on FL5.12 cells. 
   
 Diazirines 2.21 and 2.22 were also tested using a surface 4F2hc expression assay, on 
FL5.12 cells (Figure 37). The same activity trend was observed in this test and 2.11 was more 
active than 2.22 in inducing nutrient transporter down-regulation. 
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Figure 37. Nutrient transporter down-regulation of diazirines 2.21 and 2.22 on FL5.12 cells. 
 
2-2-2 Screening of the reporter group 
 “Click chemistry” was explored for use in the reporter groups (Figure 32). To find the 
most suitable reporter alkyne, and the right position to install it. five analogues of 1.65 were 
prepared by Jérémie Tessier in our group (Figure 38). These included analogues 2.26 and 2.27, 
bearing an azide group with different chain lengths, and analogues 2.28, 2.29 and 2.30, 
equipped with a terminal alkyne in different chain lengths. They were tested in the cell 
viability assay to compare their cytotoxic activities on FL5.12 cells (Figure 38). Preliminary 
results suggested azide analogue 2.27 was the most active among all five compounds (Figure 
38). Alkyne analogue 2.30 was slightly less active than 2.27. The other three analogues were 
much less active than 2.27 and 2.30. Although there was not much difference in the activity 
between 2.27 and 2.30, the synthesis of 2.27 was significantly longer than 2.30. Based on this 
information, we decided to employ the terminal alkyne 2.30. 
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Figure 38. Cytotoxic action of azide and alkyne analogues on FL5.12 cells. 
 
 In the surface 4F2hc expression assay on FL5.12 cells (Figure 39), analogues 2.27 and 
2.30 were also the most active compounds, and 2.30 was slightly more active than 2.27 in 
inducing nutrient transporter down-regulation. All of these results suggested that the terminal 
alkyne group in 2.30 should be used in the photoaffinity probe. 
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Figure 39. Nutrient transporter down-regulation of azide and alkyne analogues on FL5.12 
cells. 
 
2-2-3 Synthesis of the photoaffinity probes 2.31 and 2.39 
 Based on the screening results, the diazirine and terminal alkyne functional groups 
were selected to be installed in probe 2.31 (Figure 40). From 2.24, a substitution reaction 
between prolinol 2.32 and propargyl bromide was envisioned to give ether 2.31 after 
carbamate removal (Scheme 48). 
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Figure 40. General structure of the desired photoaffinity probe and its retrosynthetic analysis. 
 
 Silyl ether 2.24 was treated with TBAF to remove the TBS protecting group (Scheme 
49), and prolinol 2.32 was obtained in 84 % yield. Alcohol 2.32 was reacted with propargyl 
bromide in the presence of potassium hydroxide to generate alkyne 2.33 in 67 % yield. 
Finally, removal of the Boc protecting group using HCl in 1,4-dioxane afforded probe 2.31 in 
79 % yield (Scheme 49). 
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Scheme 49. Synthesis of photoaffinity probe 2.31. 
 
 
 
 Using the same synthetic strategy, the enantiomer of compound 2.31 (the photoaffinity 
probe 2.39 for analogue 1.57) was successfully prepared from bromide 1.54 (Scheme 50). 
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Scheme 50. Synthesis of photoaffinity probe 2.39. 
 
 
 
2-2-4 Biological evaluations of photoaffinity probes 2.31 and 2.39 
 With photoaffinity probes 2.31 and 2.39 in hand, a cell viability assay was used to test 
their cytotoxic activities on FL5.12 cells (Figure 41). Preliminary results suggested that both 
2.31 and 2.39 exhibited similar activity in killing the FL5.12 cells as FTY720 (1.8), indicating 
that the positions of the diazirine and alkyne groups were compatible with the expected 
activity.  
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Figure 41. Cytotoxic action of photoaffinity probes 2.31and 2.39 on FL5.12 cells. 
 
 Diazirines 2.31 and 2.39 were also tested in the surface 4F2hc expression assay on 
FL5.12 cells (Figure 42). Both probes induced nutrient transporter down-regulation, further 
indicating that our design was successful, and did not compromise activity.  
 
 
Figure 42. Nutrient transporter down-regulation of photoaffinity probes 2.31 and 2.39 on 
FL5.12 cells. 
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 With these promising results, photoaffinity probes 2.31 and 2.39 were subjected to 
PAL experiments (Figure 43). In general, the probes should bind to the target receptor. Upon 
irradiation, a covalent bond will be formed between the probe and receptor. The terminal 
alkyne on the receptor-probe complex could be “clicked” onto an azide linked to a biotin 
based tag (Figure 43). After generation of the corresponding triazole, the complex would be 
purified using a streptavidin column, which would bind to biotin with high affinity. With the 
avidin-biotin complex in hand, the receptor could be digested into small pieces by trypsin, and 
by analyzed with LC/MS/MS to identify the target receptor and active site (Figure 43). These 
experiments are currently in progress. 
 
 
 
Figure 43. General projected PAL experiments for 2.31 and 2.39.  
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2-3 Conclusion 
 To further understand the anticancer mechanism of amino alcohols 1.57 and 1.65, we 
designed and synthesized successfully photoaffinity probes 2.39 and 2.31 in an effort to fish 
out their target receptors by using PAL techniques.  
 
 Systematic studies on the photoreactive group and receptor group were crucial in 
designing these probes. The position of the diazirine on the side chain was screened using both 
ketone precursors and the corresponding diazirines. Screening was also used to compare azide 
and alkyne groups to determine the best position for their installation.   
 
 Preliminary results indicated probes 2.39 and 2.31 maintained activity, PAL 
experiments using these compounds are in progress now. 
 
2-4 Experimental 
General methods are same as described in the experimental section of Chapter 1.  
 
 
N-Methoxy-N,4-dimethylbenzamide (2.6) was prepared according a reported procedure.76 
Triethylamine (1.67 mL, 1.21 g, 12.0 mmol) was added dropwise to a solution of N,O-
dimethylhydroxylamine hydrochloride (878 mg, 9.0 mmol) in CH2Cl2 (14 mL) at 0 °C. After 
stirring for 10 min, the mixture was treated with a solution of 4-methylbenzoyl chloride (2.5, 
0.53 mL, 927 mg, 6 mmol) in CH2Cl2 (5 mL), allowed to warm to room temperature, stirred 
overnight and quenched by the addition of water. The aqueous layer was extracted three times 
with CH2Cl2 (10 mL). The organic phases were combined, washed with brine, dried over 
MgSO4 and filtered. The volatiles were removed under reduced pressure. The residue was 
purified by flash chromatography (hexane: EtOAc, 4:1 to 2:1) to give hydroxamate 2.6 (990 
mg, 92 %) as colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.51-7.49 (m, 2H), 7.11-7.09 (m, 
NHO HCl
CH2Cl2
92%
Cl
O
Et3N N
O
O
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2H), 3.48-3.43 (m, 3H), 3.27-3.22 (m, 3H), 2.28-2.27 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 
169.5, 140.4, 130.8, 128.2, 127.9, 60.5, 33.4, 21.0; HRMS (ESI) calcd for C10H13NNaO2 
(M+Na)+ 202.0839, found 202.0833. 
 
 
1-(p-Tolyl)octan-1-one (2.7). Magnesium turnings (41 mg, 1.7 mmol) were added to a dry 
flask equipped with condenser, followed by a solution of 1-bromoheptane (304 mg, 1.7 mmol) 
in anhydrous THF (1.7 mL).  1,2-Dibromoethane was then added to the flask to initiate the 
reaction. The mixture was stirred and started to reflux. After stirring for 1 h, the flask was 
cooled to -40 °C, a solution of hydroxamate 2.6 (60 mg, 0.34 mmol) in THF (1.0 mL) was 
added dropwise to the mixture. The reaction was slowly warmed to 0 °C, stirred for 2 h, then 
quenched with saturated aqueous NH4Cl and extracted three times with Et2O. The organic 
layers were washed with brine, dried over MgSO4 and filtered. The filtrate was evaporated 
under reduced pressure and the residue was purified by flash chromatography (hexane: 
EtOAc, 16:1) to give 2.7 (70 mg, 96 %) as colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.86 
(d, J = 8.0 Hz, 2H), 7.25 (d, J = 8.5 Hz, 2H), 2.93 (t, J = 7.5 Hz, 2H), 2.41 (s, 3H), 1.76-1.68 
(m, 2H), 1.42-1.24 (m, 8H), 0.89 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 200.2, 143.5, 134.6, 
129.2, 128.1, 38.5, 31.7, 29.3, 29.1, 24.5, 22.6, 21.5, 14.0; HRMS (ESI) calcd for C15H22NaO 
(M+Na)+ 241.1563, found 241.1560. 
 
 
1-(4-(Bromomethyl)phenyl)octan-1-one (2.8). N-bromosuccinimide (323 mg, 1.82 mmol) 
and AIBN (27 mg, .017 mmol) were added to a solution of ketone 2.7 (360 mg, 1.65 mmol) in 
anhydrous CH3CN (1.8 mL) under argon. The solution was heated to 90 °C, stirred for 14 h, 
and evaporated under reduced pressure. The residue was dissolved in toluene, filtered. The 
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THF
96%
N
O
O
O
C7H15
2.6 2.7
O
C7H15 NBS, AIBN
CH3CN
70%
2.7
O
C7H15
Br
2.8
  171 
filtrate was evaporated under reduced pressure and the residue was purified by flash 
chromatography (hexane: EtOAc, 40:1 to 15:1) to give bromide 2.8 (343 mg, 70 %) as white 
solid. In some cases, bromide 2.8 was purified by preparative thin-layer chromatography 
(hexane: toluene 7:1). m.p. (60.7-61.5 °C); 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 8.4 Hz, 
2H), 7.43 (d, J = 8.4 Hz, 2H), 4.46 (s, 2H), 2.91 (m, 2H), 1.70 (quint., J = 7.3 Hz, 2H), 1.40-
1.21 (m, 8H), 0.86 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 199.4, 142.3, 136.6, 129.0, 128.3, 
38.5, 32.0, 31.5, 29.1, 29.0, 24.1, 22.4, 13.9; HRMS (ESI) calcd for C15H22[79Br]O (M+H)+ 
297.0849, found 297.0843. 
 
 
2-(4-(Bromomethyl)phenyl)-2-heptyl-1,3-dioxolane (2.9). A solution of ketone 2.8 (70 mg, 
0.24 mmol) in toluene and ethylene glycol (40 µL, 45 mg, 0.72 mmol) were added to a flask 
equipped with a Dean-Stark apparatus and condenser. p-Toluenesulfonic acid monohydrate (4 
mg, 0.02 mmol) was added to the reaction mixture, which was heated to reflux and stirred for 
48 h, quenched with saturated aqueous NaHCO3 and concentrated under reduced pressure. The 
reduced volume was extracted with EtOAc (5 mL) three times. The combined organic phases 
were washed with brine, dried over MgSO4 and filtered. The volitiles were removed under 
reduced pressure and the residue was purified by preparative thin-layer chromatography 
(hexane: EtOAc, 16:1) to give acetal 2.9 (68 mg, 87 %) as pale yellow oil. 1HNMR (400 MHz, 
CDCl3) δ 7.43 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 4.48 (s, 2H), 4.03-3.95 (m, 2H), 
3.78-3.70 (m, 2H), 1.91-1.84 (m, 2H), 1.39-1.18 (m, 10H), 0.86 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δ 143.1, 137.0, 128.6, 126.1, 110.1, 64.3, 40.4, 33.0, 31.6, 29.5, 29.0, 23.4, 22.5, 13.9; 
HRMS (ESI) calcd for C17H26[79Br]O2 (M+H)+ 341.1111, found 341.1122. 
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tert-Butyl (2R,4S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-((4-(2-heptyl-1,3- 
dioxolan-2-yl)benzyl)oxy)pyrrolidine-1-carboxylate (2.10). Sodium hydride (60 % in 
mineral oil, 8.3 mg, 0.20 mmol) was added to a solution of alcohol 1.61 (60 mg, 0.18 mmol) 
in anhydrous THF (1.2 mL) at 0 °C. The mixture was warmed to room temperature, stirred for 
30 min, and cooled to 0 °C.  A solution of bromide 2.9 (68 mg, 0.20 mmol) in THF (0.5 mL) 
and TBAI (7 mg, 0.018 mmol) were sequentially added to the mixture, which was warmed to 
room temperature, stirred for 4 h, quenched with saturated aqueous NH4Cl, and extracted three 
times with EtOAc (10 mL). The combined organic phases were washed with brine, dried over 
MgSO4 and filtered. The filtrate was evaporated under reduced pressure. The residue was 
purified by flash chromatography (hexane: EtOAc, 10:1 to 6:1) to give ether 2.10 (100 mg, 93 
%) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 6.8 Hz, 2H), 7.27 (d, J = 8.0 
Hz, 2H), 4.54-4.40 (m, 2H), 4.28-4.14 (m, 1H), 4.04-3.97 (m, 3H), 3.75-3.68 (m, 2H), 3.68-
3.36 (m, 4H), 2.21-2.16 (m, 1H), 2.09-2.00 (m, 1H), 1.86-1.82 (m, 2H), 1.45-1.43 (m, 9H), 
1.29-1.20 (m, 10H), 0.84-0.81 (m, 12H), -0.01 (m, 6H); 13C NMR (100 MHz, CDCl3, mixture 
of rotamers) δ (154.3), 154.2, 142.1, 137.5, (127.2), 127.2, 125.7, 110.3, (79.2), 78.9, 76.8, 
76.2, 70.7, (70.6), 64.3, (64.2), 63.3, 57.5, (57.4), 52.2, (51.5), 40.5, 35.0, 33.8, 31.6, 29.5, 
29.1, 28.4, 25.7, 23.4, 22.5, 18.0, 13.9, (-5.5), -5.6; [α]D (+) 22.8° (c 1.22, CHCl3); HRMS 
(ESI) calcd for C33H57NNaO6Si (M+Na)+ 614.3847, found 614.3847. 
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(2R,4S)-2-(hydroxymethyl)-4-((4-octanoylbenzyl)oxy)Pyrrolidin-1-ium chloride (2.1) was 
obtained as white solid (11 mg, 90 %) from carbamate 2.10 (20 mg, 0.033 mmol) according to 
the procedure for synthesizing 1.32. 1H NMR (400 MHz, D2O) δ 7.90 (d, J = 7.6 Hz, 2H), 7.46 
(d, J = 7.2 Hz, 2H), 4.62 (s, 2H), 4.41 (s, 1H), 3.94-3.87 (m, 2H), 3.71-3.65 (m, 1H), 3.52-3.41 
(m, 2H), 2.96 (m, 2H), 2.29-2.25 (m, 1H), 1.90 (m, 1H), 1.61 (m, 2H), 1.41-1.17 (m, 8H), 0.83 
(m, 3H); 13C NMR (100 MHz, CDCl3) δ 200.3, 142.2, 136.6, 128.3, 127.5, 70.4, 60.6, 60.3, 
50.1, 38.7, 32.8, 31.7, 29.7, 29.3, 29.1, 24.3, 22.6, 14.1; [α]D (-) 8.0° (c 0.20, CHCl3); HRMS 
(ESI) calcd for C20H31NO3 (M+H)+ 334.2377, found 334.2377. 
 
 
tert-Butyl (2R,4S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-((4-octanoylbenzyl) 
oxy)pyrrolidine-1-carboxylate (2.11) was prepared according to a reported procedure for 
similar reactions.74 Starting from bromide 1.62 (250 mg, 0.50 mmol), ketone 2.11 was 
obtained as pale yellow oil (164 mg, 60 %). 1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 5.5 Hz, 
2H), 7.41 (d, J = 7.5 Hz, 2H), 4.62-4.48 (m, 2H), 4.28-4.15 (m, 1H), 4.05-3.98 (m, 0.5H), 
3.97-3.89 (m, 1H), 3.73-3.52 (m, 2H), 3.50-3.38 (m, 1.5H), 2.95 (t, J = 7.5 Hz, 2H), 2.24-2.16 
(m, 1H), 2.14-2.00 (m, 1H), 1.73 (p, J = 7.5 Hz, 2H), 1.50-1.42 (m, 9H), 1.41-1.23 (m, 8H), 
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0.89 (t, J = 6.0 Hz, 3H), 0.88-0.81 (m, 9H), 0.01 (m, 6H); 13C NMR (125 MHz, CDCl3, 
mixture of rotamers) δ 200.2, (154.5), 154.3, 143.5, 136.4, 128.2, (127.4), 127.3, (79.5), 79.2, 
76.6, 70.4, (64.3), 63.4, 57.6, (57.5), 52.3, (51.6), 38.6, (35.1), 33.9, 31.7, 29.3, 29.1, 28.5, 
25.8, 24.4, 22.6, 18.1, 14.1, -5.5; [α]D (+) 21.1° (c 0.47, CHCl3); HRMS (ESI) calcd for 
C31H53NNaO5Si (M+Na)+ 570.3585, found 570.3572. 
 
 
Oct-1-en-3-one (2.12) was synthesized according to a known procedure.75 Staring from oct-1-
en-3-ol (464 µL, 385 mg, 3 mmol), 2.12 was obtained as yellow oil (300mg, 80%). 1H NMR 
(400 MHz, CDCl3) δ 6.37-6.17 (m, 2H), 5.81-5.78 (m, 1H), 2.56  (t, J = 7.5 Hz, 2H), 1.61 
(quint, J = 7.4 Hz, 2H), 1.37-1.22 (m, 4H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 201.0, 136.5, 127.7, 39.6, 31.4, 23.6, 22.4, 13.8; HRMS (ESI) calcd for C8H14O 
(M+H)+ 127.1117, found 127.1112. 
 
 
tert-Butyl (2R,4S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-((4-vinylbenzyl) 
oxy)pyrrolidine-1-carboxylate (2.13). Pd(Ph3)4 (6.9 mg, 0.006 mmol) was added to a 
solution of 1.62 (100 mg, 0.20 mmol) in toluene (2.6 mL). After stirring at room temperature 
for 15 min, a solution of vinyltributylstannane (129 µL, 140 mg, 0.44 mmol) in toluene (1.7 
mL) was added dropwise to the reaction mixture, which was heated to 110 °C and stirred for 
48 h. The flask was then cooled to room temperature, the volatiles were removed under 
reduced pressure and the residue was purified by flash chromatography (hexane: EtOAc, 10:1 
to 8:1) to give olefin 2.13 (52 mg, 58 %) as colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.38 
(d, J = 7.6 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 6.70 (dd, J = 17.6, 6.8 Hz, 1H), 5.74 (d, J = 17.6 
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Hz, 1H), 5.23 (d, J = 10.8 Hz, 1H), 4.54-4.41 (m, 2H), 4.27-4.13 (m, 1H), 4.05-3.97 (m, 0.5 
H), 3.96-3.86 (m, 1H), 3.72-3.49 (m, 2H), 3.47-3.36 (m, 1.5H), 2.21-2.15 (m, 1H), 2.10-2.00 
(m, 1H), 1.47-1.45 (m, 9H), 0.86 (s, 9H), 0.01 (m, 6H); 13C NMR (100 MHz, CDCl3, mixture 
of rotamers) δ (154.5), 154.4, 137.8, (137.7), 137.0, 136.5, (127.9), 127.8, 126.2, 113.7, 
(79.4), 79.1, 76.8, (76.1), 70.8, (70.8), (64.3), 63.4, 57.6, (57.5), 52.3, (51.6), 35.1, 33.9, 28.5, 
25.8, 18.1, (-5.4), -5.5; [α]D (+) 26.2° (c 1.56, CHCl3); HRMS (ESI) calcd for C25H42NO4Si 
(M+H)+ 448.2878, found 448.2872. 
 
 
tert-Butyl (2R,4S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-((4-(3-oxooctyl)benzyl) 
oxy)pyrrolidine-1-carboxylate (2.14). Olefin 2.12 (35 mg, 0.078 mmol) and 2.13 (44 mg, 
0.351 mmol) were dissolved in 1,2-dichloroethane (0.6 mL) in a pressure tube. Grubb’s 2nd 
generation catalyst (2 mg, 0.002 mmol) was then added to the solution. The tube was sealed 
with a PTFE cap, and heated to 40 °C. After stirring for 24 h, the volatiles were removed 
under reduced pressure and the residue was purified by flash chromatography (hexane: 
EtOAc, 8:1 to 7:1) to give the unsaturated ketone (23.4 mg, 54 %) as colorless oil. 
Hydrogenation of the unsaturated ketone was performed according to the procedure for 
synthesizing 1.31. Ketone 2.14 was obtained as a colorless oil (23.0 mg, 98 %). 1H NMR (400 
MHz, CDCl3) δ 7.24 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 7.2 Hz, 2H), 4.52-4.38 (m, 2H), 4.27-
4.13 (m, 1H), 4.05-3.97 (m, 0.5H), 3.96-3.87 (m, 1H), 3.72-3.51 (m, 2H), 3.48-3.36 (m, 1.5H), 
2.86 (t, J = 7.6 Hz, 2H), 2.71 (t, J = 7.6 Hz, 2H), 2.38 (t, J = 7.5 Hz, 2H), 2.21-2.16 (m, 1H), 
2.11-1.99 (m, 1H), 1.56 (quint, J = 7.6 Hz, 2H), 1.47-1.45 (m, 9H), 1.35-1.18 (m, 4H), 0.90-
0.86 (m, 12H), 0.00 (m, 6H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 210.3, 
(154.5), 154.4, 140.7, 135.9, 128.4, (128.0), 127.9, (79.4), 79.1, (76.8), 76.1, 70.8, (64.3), 
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63.4, 57.6, (57.5), 52.4, (51.6), (44.2), 43.0, 35.1, 33.9, 31.4, 29.4, 28.5, 25.8, 23.5, 22.4, 18.1, 
13.9, (-5.4), -5.5; [α]D (+) 22.3° (c 0.80, CHCl3); HRMS (ESI) calcd for C31H53NNaO5Si 
(M+Na)+ 570.3585, found 570.3559. 
 
 
(2R,4S)-2-(Hydroxymethyl)-4-((4-(3-oxooctyl)benzyl)oxy)pyrrolidin-1-ium chloride (2.2) 
was obtained as white solid (10.0 mg, 93 %) from 2.14 (16 mg, 0.029 mmol) according to the 
procedure for synthesizing 1.32. 1H NMR (400 MHz, D2O) δ 7.33 (d, J = 8.4 Hz, 2H), 7.26 (d, 
J = 8.4 Hz, 2H), 4.56 (s, 2H), 4.46 (m, 1H), 4.01-3.88 (m, 2H), 3.70 (dd, J = 12.4, 6.8 Hz, 1H), 
3.54-3.41 (m, 2H), 2.89 (s, 4H), 2.47 (t, J = 7.2 Hz, 2H), 2.31 (dd, J = 14.1, 6.6 Hz, 1H), 1.93 
(ddd, J = 14.8, 10.8, 4.8 Hz, 1H), 1.47 (quint, J = 7.2 Hz, 2H), 1.33-1.09 (m, 4H), 0.82 (t, J = 
7.2 Hz, 3H); 13C NMR (100 MHz, D2O) δ 218.4, 141.0, 134.7, 128.7, 76.9, 70.6, 59.9, 59.8, 
50.2, 43.3, 42.6, 32.3, 30.5, 29.1, 23.0, 21.7, 13.1; [α]D (-) 8.6° (c 0.14, CHCl3); HRMS (ESI) 
calcd for C20H31NO3 (M+H)+ 334.2377, found 334.2378. 
 
 
N-Methoxy-N-methylpent-4-ynamide (2.15). Pent-4-ynoic acid (95 % grade, 1.64 g, 15.85 
mmol) was added to a dried flask with CH2Cl2 (174 mL), followed by EDC·HCl (4.56 g, 23.78 
mmol) and HOBt (3.21g, 23.78 mmol). The mixture was cooled to 0°C, and N,O-
dimethylhydroxylamine hydrochloride (1.7 g, 17.44 mmol) was added. The reaction was 
stirred at room temperature overnight. The volatiles were removed under reduced pressure and 
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the residue was dissolved in EtOAc, and washed three times with brine. The volatiles were 
removed under reduced pressure and the residue was purified by flash chromatography 
(hexane: EtOAc, 2:1 to 1:1) to give 2.15 (2.02 g, 90 %) as colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 3.69 (s, 3H), 3.18 (s, 3H), 2.68 (t, J = 7.4 Hz, 2H), 2.53-2.48 (m, 2H), 1.96 (t, J = 2.6 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 172.3, 83.4, 68.6, 61.2, 32.1, 31.0, 13.8; HRMS 
(ESI) calcd for C7H12NO2 (M+H)+ 142.0863, found 148.0867. 
 
 
Oct-7-yn-4-one (2.16). A solution of hydroxamate 2.15 (700 mg, 4.96 mmol) in THF (17 mL) 
was cooled to 0°C, treated dropwise with n-PrMgCl (2M in Et2O solution, 5.2 mL, 10.4 mmol) 
in 15 min, and the reaction mixture was allowed to warm to room temperature, stirred for 1 h 
and quenched with saturated aqueous NH4Cl (2 mL). The aqueous layer was extracted three 
times with Et2O (10 mL). The organic layers was combined, dried over MgSO4, filtered and 
concentrated under reduced pressure to give ketone 2.16 (585 mg, 95 %) as yellow oil, which 
was used in next step without purification. 1H NMR (500 MHz, CDCl3) δ 2.52 (t, J = 7.3 Hz, 
2H), 2.32 -2.24 (m, 4H), 1.82 (t, J = 3.0 Hz, 1H), 1.47 (sext, J = 7.3 Hz, 2H), 0.77 (t, J = 7.5 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 208.2, 82.8, 68.3, 44.2, 40.8, 16.8, 13.3, 12.5; HRMS 
(ESI) calcd for C8H13O (M+H)+ 125.0961, found 125.0960. 
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oxy)pyrrolidine-1-carboxylate (2.17) was obtained as pale yellow oil (130 mg, 48 % over 
two steps) from 1.62 (250 mg, 0.5 mmol) and 2.16 (249 mmol, 2 mmol) according to the 
procedure for synthesizing 1.31. 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 8.0 Hz, 2H), 7.14 
(d, J = 7.6 Hz, 2H), 4.53-4.39 (m, 2H), 4.28-4.15 (m, 1H), 4.05-3.96 (m, 0.5H), 3.96-3.86 (m, 
1H), 3.72-3.51 (m, 2H), 3.48-3.36 (m, 1.5H), 2.61 (t, J = 6.8 Hz, 2H), 2.43-2.35 (m, 4H), 2.20-
2.16 (m, 1H), 2.11-1.99 (m, 1H), 1.62-1.45 (m, 6H), 1.50-1.44 (m, 9H), 0. 91 (t, J = 7.6 Hz, 
3H), 0.86 (s, 9H), 0.01 (m, 6H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 211.1, 
(154.5), 154.4, 141.7, 135.6, 128.4, (127.9), 127.8, (79.4), 79.1, 76.0, 71.0, (64.3), 63.5, 57.6, 
(57.5), 52.4, (51.6), 44.7, (42.6), 35.5, (35.1), 34.0, 31.1, (30.0), 29.7, 28.5, 25.9, 23.5, 18.2, 
17.3, 13.8, -5.5; [α]D (+) 20.4° (c 0.70, CHCl3); HRMS (ESI) calcd for C31H53NNaO5Si 
(M+Na)+ 570.3585, found 570.3571. 
 
 
(2R,4S)-2-(Hydroxymethyl)-4-((4-(5-oxooctyl)benzyl)oxy)pyrrolidin-1-ium chloride (2.3) 
was obtained as white solid (18.0 mg, 95 %) from 2.17 (28 mg, 0.051 mmol), according to the 
procedure for synthesizing 1.32. 1H NMR (500 MHz, D2O) δ 7.34 (d, J = 8.0 Hz, 2H), 7.28 (d, 
J = 8.0 Hz, 2H), 4.56 (s, 2H), 4.47 (m, 1H), 4.04-3.88 (m, 2H), 3.72 (dd, J = 12.5, 6.5 Hz, 1H), 
3.55-3.43 (m, 2H), 2.63 (t, J = 7.2 Hz, 2H), 2.53 (t, J = 6.9 Hz, 2H), 2.47 (t, J = 7.3 Hz, 2H), 
2.32 (dd, J = 13.5, 6.5 Hz, 1H), 1.95 (ddd, J = 14.6, 10.6, 4.7 Hz, 1H), 1.63-1.48 (m, 6H), 0.84 
(t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, D2O) δ 217.4, 143.0, 134.3, 128.8, 128.6, 76.9, 70.6, 
59.9, 59.8, 50.2, 44.3, 42.1, 34.4, 32.3, 30.1, 22.9, 17.1, 12.9; [α]D (-) 9.2° (c 0.13, CHCl3); 
HRMS (ESI) calcd for C20H31NO3 (M+H)+ 334.2377, found 334.2379. 
 
Compound 2.4 was prepared according to the procedure for synthesizing 2.3. 
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N-Methoxy-N-methylhept-6-ynamide (2.18) was obtained as colorless oil (766 mg, 95 %) 
from hept-6-ynoic acid (0.67 mL, 4.76 mmol). 1H NMR (400 MHz, CDCl3) δ 3.67 (s, 3H), 
3.16 (s, 3H), 2.43 (t, J = 7.5 Hz, 2H), 2.21 (td, J = 7.1, 2.7 Hz, 2H), 1.93 (t, J = 2.6 Hz, 1H), 
1.79-1.69 (m, 2H) 1.64-1.54 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 174.2, 84.1, 68.4, 61.2, 
32.1, 31.2, 28.1, 23.6, 18.2; HRMS (ESI) calcd for C9H15NO2 (M+H)+ 170.1176, found 
170.1176. 
 
 
Oct-7-yn-2-one (2.19) was obtained as colorless oil (510 mg, 96 %) from 2.18 (726 mg, 4.29 
mmol). 1H NMR (400 MHz, CDCl3) δ 2.43 (t, J = 7.2 Hz, 2H), 2.18 (td, J = 7.2, 2.8 Hz, 2H), 
2.12 (s, 3H), 1.93 (t, J = 2.6 Hz, 1H), 1.72-1.62 (m, 2H) 1.55-1.45 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 208.5, 83.9, 68.5, 43.0, 29.8, 27.8, 22.7, 18.1; HRMS (ESI) calcd for C8H12O 
(M+H)+ 125.0961, found 125.0966. 
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oxy)pyrrolidine-1-carboxylate (2.20) was obtained as pale yellow oil (112 mg, 41% over two 
steps) from 1.62 (250 mg, 0.5 mmol) and 2.19 (249 mg, 2 mmol). 1H NMR (400 MHz, CDCl3) 
δ 7.23 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 7.6 Hz, 2H), 4.54-4.39 (m, 2H), 4.28-4.15 (m, 1H), 
4.05-3.96 (m, 0.5H), 3.96-3.87 (m, 1H), 3.72-3.50 (m, 2H), 3.48-3.37 (m, 1.5H), 2.59 (t, J = 
7.7 Hz, 2H), 2.42 (t, J = 7.4 Hz, 2H), 2.24-2.15 (m, 1H), 2.13 (s, 3H), 2.11-2.01 (m, 1H), 1.65-
1.52 (m, 2H), 1.50-1.43 (m, 9H), 1.38-1.25 (m, 6H), 0.86 (s, 9H), 0.01 (m, 6H); 13C NMR 
(100 MHz, CDCl3, mixture of rotamers) δ 209.2, (154.5), 154.4, 142.2, 135.4, 128.4, (127.8), 
127.7, (79.4), 79.1, 76.0, 71.0, (64.3), 63.5, (57.6), 57.5, 52.4, (51.6), 43.7, 35.6, 35.1, 34.0, 
31.3, 29.8, 29.0, 28.5, 25.9, 23.8, 18.2, -5.5; [α]D (+) 19.5° (c 0.98, CHCl3); HRMS (ESI) 
calcd for C31H53NNaO5Si (M+Na)+ 570.3585, found 570.3578. 
 
 
(2R,4S)-2-(Hydroxymethyl)-4-((4-(7-oxooctyl)benzyl)oxy)pyrrolidin-1-ium chloride (2.4) 
was obtained as white solid (8.5 mg, 63%) from 2.20 (20 mg, 0.037 mmol). 1H NMR (400 
MHz, D2O) δ 7.35 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 4.58 (s, 2H), 4.49 (t, J = 4.0 
Hz, 1H), 4.04-3.90 (m, 2H), 3.76-3.68 (m, 1H), 3.56-3.43 (m, 2H), 2.64 (t, J = 7.5 Hz, 2H), 
2.52 (t, J = 7.3 Hz, 2H), 2.34 (dd, J = 14.4, 6.8 Hz, 1H), 2.19 (s, 3H), 1.95 (ddd, J = 14.9, 
11.0, 4.8 Hz, 1H), 1.61 (t, J = 6.8 Hz, 2H), 1.53 (t, J = 6.8 Hz, 2H), 1.30 (m, 4H); 13C NMR 
(100 MHz, D2O) δ 217.4, 143.2, 133.8, 128.5, 128.2, 76.5, 70.2, 59.5, 59.4, 49.8, 42.8, 34.2, 
31.9, 30.0, 28.8, 27.6, 27.5, 22.9; [α]D (-) 6.5° (c 0.40, MeOH); HRMS (ESI) calcd for 
C20H31NO3 (M+H)+ 334.2377, found 334.2389. 
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tert-Butyl (2R,4S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-((4-(2-(3-pentyl-3H- 
diazirin-3-yl)ethyl)benzyl)oxy)pyrrolidine-1-carboxylate (2.23). A solution of ketone 2.14 
(33 mg, 0.060 mmol) in MeOH (1.0 mL) was cooled to 0 °C. Ammonia was bubbled into the 
solution for 5 h. To the solution, NH2OSO3H (7.8 mg, 0.069 mmol) in MeOH (0.5 mL) were 
slowly added over 30 min. The mixture was allowed to warm to room temperature, stirred 
overnight, and filtered. The filter cake was washed with MeOH. The filtrate and washings 
were evaporated under reduced pressure to give a white residue. Methanol (0.5 mL) was added 
to the residue. The resulting mixture was cooled to 0 °C, treated with Et3N (8.4 µL, 6.1 mg, 
0.060 mmol), followed by I2 until a brown color was formed. The reaction was warmed to 
room temperature, stirred for 1 h, and evaporated under reduced pressure. The residue was 
dissolved in EtOAc, washed with brine, dried over MgSO4 and filtered. The filtrate was 
evaporated under reduced pressure. The residue was purified by flash chromatography 
(hexane: EtOAc, 8:1) to give diazirine 2.23 (5.0 mg, 15 % over two steps) as pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 7.2 Hz, 2H), 4.53-4.38 
(m, 2H), 4.26-4.13 (m, 1H), 4.05-3.96 (m, 0.5H), 3.95-3.87 (m, 1H), 3.72-3.51 (m, 2H), 3.48-
3.36 (m, 1.5H), 2.39 (t, J = 8.4 Hz, 2H), 2.21-2.15 (m, 1H), 2.12-1.98 (m, 1H), 1.69-1.65 (m, 
2H), 1.47-1.45 (m, 9H), 1.38-1.34 (m, 2H), 1.29-1.17 (m, 4H), 1.12-1.05 (m, 2H), 0.91-0.86 
(m, 12H), 0.02 (m, 6H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ (154.1), 154.0, 
140.7, 135.6, 127.9, (127.6), 127.5, (79.0), 78.8, 75.7, 70.5, (63.9), 63.1, 57.3, (57.2), 52.0, 
(51.2), 34.7, 33.6, 32.5, 31.0, 29.3, 28.4, 28.2, 25.5, 23.1, 22.0, 17.8, 13.5, -5.8; [α]D (+) 22.0° 
(c 0.50, CHCl3); HRMS (ESI) calcd for C31H53N3NaO4Si (M+Na)+ 582.3698, found 582.3698. 
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(2R,4S)-2-(Hydroxymethyl)-4-((4-(2-(3-pentyl-3H-diazirin-3-yl)ethyl)benzyl)oxy) 
pyrrolidin-1-ium chloride (2.22) was obtained as yellow solid (3.1 mg, 91 %) from 2.23 (5 
mg, 0.009 mmol) according to the procedure for synthesizing 1.32. 1H NMR (700 MHz, 
CDCl3) δ 7.24 (d, J = 7.7 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 4.50 (d, J = 11.9 Hz, 1H), 4.42 (d, 
J = 11.2 Hz, 1H), 4.25 (s, 1H), 4.06-3.97 (m, 2H), 3.77 (dd, J = 12.6, 6.3 Hz, 1H), 3.50 (d, J = 
12.6 Hz, 1H), 3.42 (m, 1H), 2.38 (t, J = 8.4 Hz, 2H), 2.13 (dd, J = 14.0, 6.3 Hz, 1H), 1.98 (m, 
1H), 1.67 (t, J = 8.4 Hz, 2H), 1.36 (t, J = 7.7 Hz, 2H), 1.25 (m, 2H + OH), 1.21 (m, 2H), 1.80 
(m, 2H), 0.87 (t, J = 7.0 Hz, 3H); 13C NMR (175 MHz, CDCl3) δ 140.8, 134.9, 128.5, 128.1, 
76.7, 70.8, 60.7, 60.3, 50.2, 35.0, 32.8, 31.4, 29.7, 28.7, 23.5, 22.4, 13.9; [α]D (-) 9.4° (c 0.16, 
CHCl3); HRMS (ESI) calcd for C20H32N3O2 (M+H)+ 346.2489, found 346.2496. 
 
 
tert-Butyl (2R,4S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-((4-(3-heptyl-3H- 
diazirin-3-yl)benzyl)oxy)pyrrolidine-1-carboxylate (2.24). A solution of ketone 2.11 (40 
mg, 0.073 mmol) and benzyl amine (25 µL, 25 mg, 0.221 mmol) in toluene (1.0 mL) in a dry 
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flask equipped with a Dean-Stark apparatus and condenser, was heated to reflux and stirred for 
48 h. The volatiles were then removed under reduced pressure. To the yellow residue liquid 
ammonia (1 mL) was added at - 60 °C. The reaction mixture was stirred for 30 min, 
NH2OSO3H (12.8 mg, 0.115 mmol) in MeOH (1.0 mL) was added slowly to the reaction 
mixture over 15 min. The mixture was stirred at - 60 °C for 3 h, warmed to room temperature, 
stirred overnight, and filtered. The filtrate was evaporated under reduced pressure to give a 
white residue. Water (2 mL) was added to the residue, and the resulting mixture was extracted 
three times with Et2O (10 mL). The combined organic phases were dried over MgSO4 and 
filtered. The filtrate was evaporated under reduced pressure to give a white residue. MeOH 
(1.1 mL) was added to the residue. The resulting mixture was cooled to 0 °C, and treated with 
Et3N (11.0 µL, 8.0 mg, 0.079 mmol), followed by I2 until a brown color was formed. The 
reaction mixture was warmed to room temperature, stirred for 1 h, an evaporated under 
reduced pressure to a residue that was dissolved in EtOAc, washed with brine, dried over 
MgSO4 and filtered. The filtrate was evaporated under reduced pressure and the residue was 
purified by flash chromatography (hexane: EtOAc, 8:1) to give diazirine 2.24 (12.0 mg, 29 % 
over three steps) as pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.31-7.26 (m, overlapped 
with CDCl3, 2H), 6.92 (d, J = 7.6 Hz, 2H), 4.54-4.42 (m, 2H), 4.25-4.13 (m, 1H), 4.04-3.96 
(m, 0.5H), 3.95-3.86 (m, 1H), 3.72-3.50 (m, 2H), 3.46-3.37 (m, 1.5H), 2.21-2.15 (m, 1H), 
2.11-1.98 (m, 1H), 1.94 (m, 2H), 1.49-1.43 (m, 9H), 1.34-1.18 (m, 10H), 0.93-0.81 (m, 12H), 
0.00 (m, 6H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ (154.5), 154.4, 138.7, 
137.4, (127.6), 127.5, 125.7, (79.4), 79.2, 76.2, 70.6, (64.3), 63.4, 57.6, 52.3, (51.6), 35.1, 
33.9, 31.7, 30.2, 29.2, 29.0, 28.5, 25.8, 24.1, 22.6, 18.1, 14.0, -5.5; [α]D (+) 20.2° (c 0.60, 
CHCl3); HRMS (ESI) calcd for C31H53N3NaO4Si (M+Na)+ 582.3698, found 582.3679. 
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(2R,4S)-4-((4-(3-Heptyl-3H-diazirin-3-yl)benzyl)oxy)-2-(hydroxymethyl)pyrrolidin-1-ium 
chloride (2.21) was obtained as yellow solid (7.0 mg, 85 %) from 2.24 (12 mg, 0.021 mmol) 
according to the procedure for synthesizing 1.32. 1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 
8.4 Hz, 2H), 6.92 (d, J = 8.4 Hz, 2H), 4.53 (d, J = 12.0 Hz, 1H), 4.42 (d, J = 11.6 Hz, 1H), 
4.24 (m, 1H), 4.08-3.97 (m, 2H), 3.77 (dd, J = 12.7, 6.0 Hz, 1H), 3.53 (d, J = 12.4 Hz, 1H), 
3.41 (dd, J = 12.6, 4.3 Hz, 1H), 2.14 (dd, J = 13.8, 6.4 Hz, 1H), 2.02-1.89 (m, 3H), 1.35-1.18 
(m, 10H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 139.1, 136.3, 127.7, 125.8, 
70.5, 60.6, 60.2, 50.2, 32.8, 31.7, 30.1, 29.2, 29.0, 24.0, 22.6, 13.9; [α]D (-) 8.0° (c 0.10, 
CHCl3); HRMS (ESI) calcd for C20H32N3O2 (M+H)+ 346.2489, found 346.2481. 
 
 
tert-Butyl (2R,4S)-4-((4-(3-heptyl-3H-diazirin-3-yl)benzyl)oxy)-2-(hydroxymethyl) 
pyrrolidine-1-carboxylate (2.31) was obtained as pale yellow oil (14.4 mg, 84 %) from 2.24 
(20 mg, 0.036 mmol) according to the procedure for synthesizing 1.64. 1H NMR (400 MHz, 
CDCl3) δ 7.27 (d, J = 8.0 Hz, 2H), 6.93 (d, J = 8.0 Hz, 2H), 4.85 (s, 1H), 4.53-4.40 (m, 2H), 
4.18-3.98 (m, 2H), 3.74-3.48 (m, 3H), 3.42-3.32 (m, 1H), 2.21-2.14 (m, 1H), 1.96-1.89 (m, 
2H), 1.68-1.55 (m, 1H), 1.47 (s, 9H), 1.27 (m, 10H), 0.88 (t, J = 6.4 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 157.0, 138.8, 137.1, 127.4, 125.8, 80.5, 76.2, 70.3, 67.2, 59.1, 52.9, 34.5, 
31.7, 30.1, 29.2, 29.2, 29.0, 28.4, 24.1, 22.6, 14.0; [α]D (+) 20.5° (c 1.44, CHCl3); HRMS 
(ESI) calcd for C25H39N3NaO4 (M+Na)+ 468.2833, found 468.2828. 
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tert-Butyl (2R,4S)-4-((4-(3-heptyl-3H-diazirin-3-yl)benzyl)oxy)-2-((prop-2-yn-1- 
yloxy)methyl)pyrrolidine-1-carboxylate (2.32) was synthesized using a reported procedure 
for similar reactions.77 Potassium hydroxide (9 mg, 0.16 mmol) was added to a solution of 
alcohol 2.31 (14.4 mg, 0.032 mmol) in anhydrous DMF (0.4 mL), followed by propargyl 
bromide (80 % in toluene, 7.1 µL, 9,5 mg, 0.064 mmol) over 5 min.  After stirring at room 
temperature for 18 h, the solution was poured into water (10 mL), and extracted three times 
with CH2Cl2 (10 mL). The organic layers were concentrated under reduce pressure and the 
residue was dissolved in Et2O (15 mL), washed three times by water (20 mL) and brine (10 
mL). The ether solution was dried over MgSO4 and filtered. The filtrate was evaporated under 
reduced pressure and the residue was purified by flash chromatography (hexane: EtOAc, 8:1) 
to give ether 2.32 (10.4 mg, 67 %) as pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.29 (m, 
overlapped with CDCl3, 2H), 6.92 (d, J = 8.4 Hz, 2H), 4.54-4.44 (m, 2H), 4.20-4.08 (m, 4H), 
3.74-3.37 (m, 4H), 2.41 (t, J = 2.4 Hz, 1H), 2.14 (t, J = 6.0 Hz, 2H), 1.94 (m, 2H), 1.47 (s, 
9H), 1.36-1.18 (m, 10H), 0.88 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 154.6, 138.7, 137.3, 
127.5, 125.7, 79.8, 76.2, 74.3, 71.2, 70.7, 70.5, 58.5, 55.6,  52.2, 51.4, 35.6, 34.3, 31.7, 30.2, 
29.2, 29.0, 28.5, 24.1, 22.6, 14.0; [α]D (+) 19.0° (c 1.04, CHCl3); HRMS (ESI) calcd for 
C28H41N3NaO4 (M+Na)+ 506.2989, found 506.2982. 
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(2R,4S)-4-((4-(3-Heptyl-3H-diazirin-3-yl)benzyl)oxy)-2-((prop-2-yn-1-
yloxy)methyl)pyrrolidin-1-ium chloride (2.30) was obtained as pale yellow oil (3.4 mg, 79 
%) from 2.32 (5 mg, 0.010 mmol) according to the procedure for synthesizing 1.32. 1H NMR 
(400 MHz, CDCl3) δ 7.29 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.4 Hz, 2H), 4.47 (ABq, ΔδAB = 
0.02, JAB = 12.0 Hz, 2H), 4.22 (d, J = 2.4 Hz, 2H), 4.17-4.12 (m, 1H), 3.75-3.67 (m, 1H) 3.64 
(dd, J = 9.2, 4.4 Hz, 1H), 3.55 (dd, J = 9.2, 6.4 Hz, 1H), 3.17 (d, J = 4.0 Hz, 2H), 2.44 (t, J = 
2.4 Hz, 1H), 2.10-2.04 (m, 1H), 1.94 (m, 2H), 1.73 (ddd, J = 14.1, 8.8, 5.8 Hz, 1H), 1.35-1.18 
(m, 10H), 0.88 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 138.7, 137.2, 127.5, 125.8, 79.5, 79.0, 
74.7, 71.6, 70.4, 58.5, 56.8, 51.8, 34.7, 31.7, 30.2, 29.2, 29.0, 24.1, 22.6, 14.1; [α]D (-) 13.3° (c 
0.27, CHCl3); HRMS (ESI) calcd for C23H34N3O2 (M+H)+ 384.2646, found 384.2645. 
 
Compound 2.38 was prepared according the procedure for synthesizing 2.30. 
 
 
tert-Butyl (2S,4R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-((4-octanoylbenzyl) 
oxy)pyrrolidine-1-carboxylate (2.33) was obtained as pale yellow oil (84 mg, 77%) from 
1.54 (100 mg, 0.20 mmol) according to the procedure for synthesizing 2.11. 1H NMR (400 
MHz, CDCl3) δ 7.92 (d, J = 7.2 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 4.61-4.45 (m, 2H), 4.28-
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4.15 (m, 1H), 4.05-3.97 (m, 0.5H), 3.97-3.88 (m, 1H), 3.73-3.49 (m, 2H), 3.49-3.38 (m, 1.5H), 
2.95 (t, J = 7.6 Hz, 2H), 2.24-2.15 (m, 1H), 2.14-1.98 (m, 1H), 1.76-1.7 (m, 2H), 1.50-1.40 
(m, 9H), 1.39-1.19 (m, 8H), 0.91-0.78 (m, 12H), 0.00 (s, 6H); 13C NMR (100 MHz, CDCl3, 
mixture of rotamers) δ 200.1, (154.4), 154.3, 143.4, 136.3, 128.2, (127.3), 127.2, (79.4), 79.2, 
76.6, 70.4, (64.2), 63.4, 57.6, (57.5), 52.3, (51.6), 38.6, (35.0), 33.9, 31.6, 29.3, 29.1, 28.5, 
25.8, 24.4, 22.5, 18.1, 14.0, -5.5; [α]D (-) 20.8° (c 0.48, CHCl3); HRMS (ESI) calcd for 
C31H53NNaO5Si (M+Na)+ 570.3585, found 570.3575. 
 
 
tert-Butyl (2S,4R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-((4-(3-heptyl-3H- 
diazirin-3-yl)benzyl)oxy)pyrrolidine-1-carboxylate (2.35) was obtained as pale yellow oil 
(10 mg, 13 % in three steps) from 2.33 (78 mg, 0.143 mmol) according to the procedure for 
synthesizing 2.24. 1H NMR (400 MHz, CDCl3) δ 7.28 (m, overlapped with CDCl3, 2H), 6.92 
(d, J = 7.6 Hz, 2H), 4.54-4.41 (m, 2H), 4.26-4.12 (m, 1H), 4.05-3.97 (m, 0.5H), 3.96-3.88 (m, 
1H), 3.72-3.50 (m, 2H), 3.48-3.36 (m, 1.5H), 2.21-2.15 (m, 1H), 2.12-1.98 (m, 1H), 1.94 (t, J 
= 8.0 Hz, 2H), 1.52-1.43 (m, 9H), 1.34-1.18 (m, 10H), 0.93-0.81 (m, 12H), 0.01 (m, 6H); 13C 
NMR (100 MHz, CDCl3, mixture of rotamers) δ (154.5), 154.4, 138.7, 137.4, (127.6), 127.5, 
125.7, (79.4), 79.2, 76.2, 70.6, (64.3), 63.5, 57.6, 52.3, (51.6), 35.1, 33.9, 31.7, 30.2, 29.2, 
29.0, 28.5, 25.9, 24.1, 22.6, 18.1, 14.0, -5.5; [α]D (-) 20.6° (c 1.01, CHCl3); HRMS (ESI) calcd 
for C31H53N3NaO4Si (M+Na)+ 582.3698, found 582.3695. 
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tert-Butyl (2S,4R)-4-((4-(3-heptyl-3H-diazirin-3-yl)benzyl)oxy)-2-(hydroxymethyl) 
pyrrolidine-1-carboxylate (2.36) was obtained as pale yellow oil (12.6 mg, 89 %) from 2.35 
(18 mg, 0.032 mmol). 1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.0 
Hz, 2H), 4.85 (s, 1H), 4.54-4.43 (m, 2H), 4.17-3.98 (m, 2H), 3.76-3.44 (m, 3H), 3.44-3.35(m, 
1H), 2.23-2.14 (m, 1H), 1.99-1.92 (m, 2H), 1.68-1.58 (m, 1H), 1.47 (s, 9H), 1.27 (m, 10H), 
0.88 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 157.0, 138.8, 137.2, 127.4, 125.8, 80.5, 76.2, 
70.3, 67.2, 59.1, 52.9, 34.5, 31.7, 30.2, 29.2, 29.2, 29.0, 28.4, 24.1, 22.6, 14.0; [α]D (-) 21.0° (c 
1.26, CHCl3); HRMS (ESI) calcd for C25H39N3NaO4 (M+Na)+ 468.2833, found 468.2837. 
 
 
tert-Butyl (2S,4R)-4-((4-(3-heptyl-3H-diazirin-3-yl)benzyl)oxy)-2-((prop-2-yn-1- 
yloxy)methyl)pyrrolidine-1-carboxylate (2.37) was obtained as pale yellow oil (8.0 mg, 62 
%) from 2.36 (12 mg, 0.027 mmol). 1H NMR (400 MHz, CDCl3) δ 7.29 (m, overlapped with 
CDCl3, 2H), 6.92 (d, J = 8.4 Hz, 2H), 4.54-4.44 (m, 2H), 4.21-4.08 (m, 4H), 3.74-3.37 (m, 
4H), 2.41 (s, 1H), 2.14 (t, J = 5.6 Hz, 2H), 1.94 (m, 2H), 1.47 (s, 9H), 1.36-1.18 (m, 10H), 
0.88 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 154.6, 138.7, 137.3, 127.5, 125.7, 79.8, 76.3, 
74.3, 71.2, 70.67, 70.5, 58.5, 55.6, 52.2, 51.4, 35.5, 34.3, 31.7, 30.2, 29.2, 29.0, 28.5, 24.1, 
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22.6, 14.1; [α]D (-) 19.7° (c 0.70, CHCl3); HRMS (ESI) calcd for C28H41N3NaO4 (M+Na)+ 
506.2989, found 506.2969. 
 
 
(2S,4R)-4-((4-(3-Heptyl-3H-diazirin-3-yl)benzyl)oxy)-2-((prop-2-yn-1-
yloxy)methyl)pyrrolidin-1-ium chloride (2.38) was obtained as pale yellow oil (5.1 mg, 86 
%) from 2.37 (7 mg, 0.014 mmol). 1H NMR (700 MHz, CDCl3) δ 7.29 (d, J = 8.4 Hz, 2H), 
6.92 (d, J = 7.7 Hz, 2H), 4.47 (ABq, ΔδAB = 0.02, JAB = 11.9 Hz, 2H), 4.21 (dd, J = 2.4, 1.2 
Hz, 2H), 4.16-4.12 (m, 1H), 3.73-3.67 (m, 1H), 3.63 (dd, J = 9.5, 4.2 Hz, 1H), 3.55 (dd, J = 
9.5, 6.4 Hz, 1H), 3.21-3.14 (m, 2H), 2.44 (t, J = 2.4 Hz, 1H), 2.09-2.03 (m, 1H), 1.94 (m, 2H), 
1.73 (ddd, J = 14.0, 8.9, 5.7 Hz, 1H), 1.33-1.18 (m, 10H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR 
(175 MHz, CDCl3) δ 138.7, 137.2, 127.5, 125.8, 79.5, 79.0, 74.7, 71.5, 70.4, 58.5, 56.8, 51.7, 
34.6, 31.7, 30.2, 29.2, 29.0, 24.1, 22.6, 14.0; [α]D (+) 10.0° (c 0.20, CHCl3); HRMS (ESI) 
calcd for C23H34N3O2 (M+H)+ 384.2646, found 384.2653. 
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Chapter 3: Studies of Unusual Barbier-Grignard Type 
Reactions  
 
3-1 Introduction 
3-1-1 Barbier reaction 
 In 1899, Philippe Barbier reported a reaction forming 2,6-dimethylhept-5-en-2-ol (3.2) 
from 6-methylhept-5-en-2-one (3.1) and methyl iodide, in the presence of metallic magnesium 
(Figure 44).1 This reaction was named after him, as the Barbier reaction. Following this 
discovery, a series of similar reactions, using different metals, were developed, which are also 
referred to as Barbier reactions.2 In general, the Barbier reaction is a one-pot reaction between 
a carbonyl substrate (aldehyde and ketone) and an alkyl halide in the presence of certain 
metals, or their salts. After aqueous workup, the reaction generates the corresponding alcohol 
as the addition product (Figure 44). 
 
 
Figure 44. The first reported Barbier reaction and the general concept of Barbier type 
reaction. 
 
 The Barbier reaction is an important process for the formation of carbon-carbon bonds. 
The advantages of this type of reaction include a one-step procedure that may occur in water,2c 
as environmentally benign solvent. The Barbier reaction may thus be considered as “green 
chemistry”. 3  Applications include Barbier-type allylation,2c, 4  propargylation,2c, 5  alkylation 
using unactivated alkyl halides,6 and arylation of aryl aldehydes7 (Figure 45). 
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Figure 45. Barbier type reactions in aqueous media. 
 
 In addition to its wide use in intermolecular reactions, the Barbier reaction is a useful 
tool for intramolecular cyclizations (Figure 46).2c   Examples include tin/aluminum mediated 
allylic cyclizations in aqueous THF, 8  zinc and indium promoted cyclizations to give 
homoallylic or homoallenic alcohols in five-or six-membered rings, 9  SmI2 mediated 
cyclization to produce tetracyclic polyquinines,10 and CrCl2 with NiCl2 catalyzed Nozaki-
Hiyama-Kishi (NHK) reaction 11  in the synthesis of macrocyclic nature products, 12  e.g. 
bipinnatin J 13 (Figure 46). 
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Figure 46. Intramolecular Barbier type reactions. 
 
 Although the Barbier reaction was discovered more than 100 years ago, its mechanism 
is still widely debated. In the organometallic-pathway, intermediate R3MgX has been 
X
O
M
OH O
M
OH
X
O
CO2Et
Br
Sn/Al
81%
aqueous THF (90%)
CO2Et
OH
66%
THF/H2O (1:2.5)
EtO2CBr
EtO2C
EtO2C
O
Zn
NH4Cl
EtO2C
OH
AcOH
35%
THF/H2O (1:2.5)
CO2Et
EtO2C
EtO2C
Zn
NH4Cl
EtO2C
Br
O
44%
THF/H2O (1:2.5)
In
OH
H
H
OO
Br
Br
H
H
SmI2
THF, HMPA
68%
H
H
HO
OH
H
H
X
O
M
OH
O
O
O
O
Br
CrCl2, NiCl2
59%
O
O
O
OH
H
bipinnatin J
  198 
suggested to be generated in situ and attacks the carbonyl group in the substrate to afford the 
corresponding metal salt, which is transformed to the alcohol product through an aqueous 
workup (Figure 47). Considering organometallic reagents often react violently with water, this 
mechanism is unlikely for aqueous Barbier reactions. Radical mechanisms,14,15 featuring 
single-electron transfer (SET) between metal and halide substrate have been suggested to take 
place on the surface of the metal to generate a radical anion R3·X− that reacts with the carbonyl 
substrate to produce a radical adduct. Following another SET from the metal to the adduct an 
anion ensues. Aqueous workup affords the alcohol (Figure 47).16 Alternatively, a ketyl 
intermediate could be generated through SET between the metal and ketone substrates. This 
reactive species could couple to the radical-anion R3·X−generated from the halide, to give an 
alkoxide intermediate, which would be transformed to the alcohol during aqueous work-up 
(Figure 47). These mechanisms may be applicable to all Barbier reactions with the actual 
pathway being dependent on the reaction conditions, metal, halide and ketone substrates.2c 
 
Figure 47. Proposed mechanisms for Barbier reactions. 
 
3-1-2 Grignard reaction 
 Continuing Barbier’s studies on organomagnesium chemsitry, in 1900, François 
Auguste Victor Grignard, a student of Barbier, reasoned that RMgX was the active 
intermediate in the Barbier reaction.17 He proposed a two-step reaction sequence whereby 
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formation of the RMgX complex occurs first, followed by the addition of this reactive species 
to the carbonyl substrates (Figure 48).17 This novel proposal revolutionized organometallic 
methods for carbon-carbon bond formation. Grignard was awarded the Nobel Prize in 1912 for 
this contribution. Nowadays, the Grignard reaction has become one of the most useful 
reactions, not only in C-C bond formation, but also in the formation of carbon-boron, carbon-
silicon, and other carbon–heteroatom bonds.   
 
 
Figure 48. General concept of the Grignard reaction.  
  
 The active organomagnesium halides (RMgX) are called Grignard reagents18 (Figure 
48). They are usually prepared through the addition of alkyl or aryl halides to magnesium 
metal in ethereal solvent (typically diethyl ether or tetrahydrofuran). A SET mechanism is 
believed to be involved in the formation of Grignard reagents (Figure 49).18e,19 On the surface 
of the magnesium metal, a radical anion (R·X−) is generated through a SET from magnesium to 
the halide. This radical anion then decomposes, and a subsequent combination of radical R·, 
magnesium radical cation (Mg·+) and halide anion X− leads to the organomagnesium halide 
complex (RMgX) (Figure 49). Metallic magnesium is usually covered by a layer of 
Mg(OH)2,19b which results in sluggish formation of Grignard reagents. To accelerate the 
reaction, fresh magnesium metal may be pre-crushed, and iodine, methyl iodide, or 1,2-
dibromoethane may be added as an initiation agent. Sonication and heating is often necessary 
for initiating the reaction in many cases.  
 
 
Figure 49. Proposed mechanism for the formation of Grignard reagents. 
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 In an ether solution, Grignard reagents (RMgX) are stabilized by the formation of a 
tetrahedral magnesium (II) species, in which the ether coordinates to the magnesium in 
complex with the formula RMgX(S)2 (S = ether solvent).  Additionally, an equilibrium has 
been observed between two molecules of RMgX (Grignard complex) and one molecular of  
dialkyl magnesium Mg(R)2 compound with the magnesium halide salt (Figure 50); this was 
named as Schlenk equilibrium.20  The composition of the equilibrium is dependent on the 
solvent, temperature, concentration, organic moiety (R) and halide. 21  For simple 
organomagnesium halides, in mono-ether solvents, the equilibrium usually favors the RMgX 
complex.21,22 In dioxane, MgX2 may precipitate,23 driving the equilibrium to the dialkyl 
magnesium. Grignard reagents have also been found to exist as dimers, and higher-order 
oligomers, in solution.24 For example, alkyl-magnesium chlorides were observed to form 
dimers in diethyl ether25 (Figure 50), with formation of aggregates at high concentration.  
 
 
 Figure 50. Schlenk equilibrium and the dimer complex of alkyl magnesium chlorides. 
 
 Grignard reagents can react with a variety of carbonyl substrates, such as ketones, 
aldehydes, esters, acyl halide, amides and carbon dioxide. The mechanism of the Grignard 
reaction is complex and, so far, there are two widely accepted mechanisms: the polar pathway 
and the SET pathway (Figure 51).24-27 In the polar pathway, one molecule of a Grignard 
reagent RMgX could activate the ketone substrate and form a coordination complex 3.3 
(Figure 51), that reacts with another molecule of RMgX, through a six-membered transition 
state to give the magnesium alkoxide 3.4 and MgX2 salt. Intermediate 3.4 may transformed 
into salt 3.5 by interacting with MgX2 to regenerate one molecule of the Grignard reagent 
(RMgX). Alkoxide 3.5 undergoes hydrolysis to give alcohol product (Figure 51). In the SET 
pathway, one electron is transferred from the Grignard reagent (RMgX) to the ketone substrate 
generating a ketyl radical anion, magnesium halide cation complex 3.6, and the free radical 3.7 
(Figure 51). Coupling of complex 3.6 and radical 3.7 affords the alkoxide intermediate 3.5, 
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2RMgCl Mg
Cl
Mg
Cl
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which is transformed to the corresponding alcohol by hydrolysis (Figure 51). These 
mechanisms are considered to be competitive and suggested to depend on the ketone substrate, 
organic moiety R, solvent and purity of the magnesium metal.27 In relatively non-polar 
solvent, with high purity magnesium metal, the reaction between ketone substrate with a low 
tendency to be reduced and Grignard reagent with a low tendency to be oxidized would favor 
the polar pathway. In polar solvents with magnesium that contains transition metal impurities, 
the Grignard reaction between ketone with a high tendency to be reduced and Grignard 
reagent with a high tendency to be oxidized would favor the SET pathway.27  
 
 
Figure 51. Proposed mechanisms for Grignard reactions. 
 
 The Grignard reaction is well known as an efficient method for obtaining addition 
products from RMgX and carbonyl substrates. However, in some cases, the product of the 
reaction may not be expected.28 Such “unusual” or “abnormal” Grignard reactions include the 
RMgX
R1 R2
O
+
R1 R2
O
Mg
R
X RMgX
R1 R2
O
Mg
R
X
MgR X R1 R
O
R2
MgR
3.3
+  MgX2
R1 R
O
R2
Mg
R
Mg
X
X
R1 R
O
R2
Mg X
RMgX
+
H3O+
R1 R
OH
R2
Polar pathway:
3.4
3.5
RMgX
R1 R2
O
+
SET pathway:
R1 R2
O
R
MgX
R1 R2
O MgX
+
+ R R1 R
O
R2
MgX
3.5
H3O+
R1 R
OH
R2
3.6 3.7
  202 
reduction of carbonyl substrates,28-32 the pinacol coupling of carbonyl substrates28,33 and the 
enolization and condensation of carbonyl substrates.28,30,34,35  
   
 During the discovery of the Grignard reaction, Grignard himself had noticed a 
reduction product, benzyl alcohol, from the reaction of benzaldehyde with isoamylmagnesium 
bromide.36 Further studies on the reduction products in Grignard reactions gave rise to several 
possible mechanisms for this process (Figure 52).28 Whitmore proposed that carbonyl 
substrates could be reduced by a β-hydride attack from a Grignard reagent through a six-
membered transition state (Figure 52).37 Some carbonyl substrates were considered to be 
reduced by magnesium alkoxide38,39 in a manner analogue to the Meerwein-Ponndorf-Verley 
reduction,40 through a six-membered transition state (Figure 52).28 Ashby suggested that 
benzophenone could be reduced by magnesium hydride (MgH2) (Figure 52).25 By using 
deuterated diethyl ether, they could conclude that the hydride involved in the reduction was 
from the solvent, and MgH2 was generated during the formation of the Grignard reagent 
(CH3MgBr).25  
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Figure 52. Proposed mechanisms for reduction reactions occurred in Grignard reactions. 
 
 The pinacol coupling species is a common side product of the Grignard reaction. In 
1906, Schmidlin reported a Grignard reaction between benzophenone and 
triphenylmethylmagnesium chloride, which gave benzopinacol, instead of the expected 
addition product pentaphenylethanol.41 Gomberg continued the study of the Grignard reaction 
with benzophenone and proposed a radical based mechanism (Figure 53). 42  Radical 
magnesium halide ·MgX, generated from MgX2 salt and magnesium metal, could react with 
benzophenone and afford the corresponding benzophenone radicals, which then could be 
coupled to give the pinacol product, benzpinacol (Figure 53). Blicke and Powers43 also studied 
these types of coupling reactions and suggested an alternative radical mechanism: a SET 
between the Grignard reagent (CH3)3CMgCl and benzophenone would generate the 
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magnesium benzophenone ketyl radical anion and a tert-butyl radical. These radical anions 
could couple to give the pinacol product, benzopinacol (Figure 53).25,44-46 Observation of 
pinacol coupling products was important evidence for the SET mechanism in Grignard 
reactions (Figure 51). 
 
 
Figure 53. Proposed mechanisms for pinacol coupling reactions in Grignard reactions. 
 
 Grignard reagents can react as nucleophiles, and as bases. In the case of latter, the first 
example of enolization was described by Grignard.47 ,48  Attempting a Grignard reaction 
between ethyl acetoacetate and methylmagnesium iodide, he observed that considerable 
amounts of methane were liberated and most of the keto-ester was recovered.47,48 Further 
studies indicated that enolization was competitive with the normal addition reaction in 
Grignard reaction, and in certain cases, enolization was favored.28 For example, Whitmore and 
co-workers30,34,35 reported up to quantitative enolization during the reactions between 
sterically hindered methyl dineopentylmethyl ketone and isobutyl-, tert-butyl-, isopropyl-
magnesium halides.35 They suggested that the presence of an acidic α-hydrogen was 
important, otherwise, the addition reaction was favored.35 Although the enolizations occurring 
in Grignard reactions were considered to occur through an acid-base mechanism, the actual 
mechanism for enolization was not clear due to the complicated composition of the Grignard 
reaction components.28 Based on the proposals of Bredt-Savelsburg49 and Arnold,50 in the 
mechanism (Figure 54),28 the ketone interacts with the Grignard reagent to form a complex 
that decomposes to give the corresponding enolate (Figure 54). Enolization may also occur 
through a concerted process, in a six-membered transition state as proposed by Lutz and 
Kibler (Figure 54).51   
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Figure 54. Proposed mechanisms for enolization reactions occurred in Grignard reactions. 
 
 Ketone substrates may be enolized under the Grignard conditions, moreover, aldol 
reaction of ketones to give β-ketols has been reported, initially by Grignard, who noticed 
product form the self-aldol condensation as a side-reaction.36 For example, isoamylmagnesium 
bromide and acetone reacted to give tertiary alcohol, and small quantities of mesityl oxide and 
phorone, which arise from self-aldol reaction of acetone followed by elimination (Figure 55).36 
Other Grignard reactions has led to isolation of the self-aldol condensation products from 
ketone substrates.28 For self-aldol reactions to occur, enolate R1R2C=CR3OMgX should be 
first generated from ketone R1R2CHCR3O by a base, and then react with another molecule of 
the ketone (Figure 55). Grignard realized these reactions were taking place through a base-
catalyzed pathway, and suggested alkoxide ROMgX species to serve as base.52,53 The actual 
base (e.g., ROMgX, Grignard reagent) involved in the enolate formation is difficult to 
identify, due to the complicated composition of Grignard reaction mixtures. 
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Figure 55. Example of self-aldol condensation in Grignard reactions and the possible 
mechanism. 
 
 To inhibit side reactions, additives (e.g. MgBr2, 54 - 56  LiClO4, 57  (n-Bu)4NBr,57 (i-
PrO)3TiCl,58 (n-BuO)3ZrCl,58 CeCl359) have been used to enhance the addition reaction, by 
increasing the electrophilicity of the carbonyl group and decreasing the basicity of the 
organometallic reagent. For example, Imamoto59 reported up to 80 % yield self-aldol reaction 
product from the reaction between cyclopentanone and i-PrMgCl, with addition product 
obtained in only 3 % yield. Employing CeCl3 as additive, the yield of the expected addition 
product was increased to 72 % and only trace amount of ketol was observed (Figure 56). The 
same additive effect was found in the reaction of cyclohexanone and i-PrMgCl (Figure 56).      
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Figure 56. Example of Grignard reaction with and without additive (CeCl3).  
 
3-1-3 An unsuccessful Barbier-Grignard type intramolecular cyclization 
 In a collaboration with Isis Pharmaceuticals to synthesize tricyclic nucleoside 3.8 
(Figure 57) involving Drs. Wagger and Merner,60 we envisioned using a Barbier-Grignard 
type intramolecular cyclization to construct tricycle 3.9 from iodide 3.10. Primary alcohol 3.11 
was converted to iodide 3.10 by the Appel reaction. Alcohol 3.11 was prepared from olefin 
3.12 by hydroboration (Figure 57).  
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Figure 57. Retrosynthetic analysis for synthesizing key intermediate 3.9.  
 
 Treatment of olefin 3.12 with dicyclohexylborane followed by hydrogen peroxide and 
sodium hydroxide gave primary alcohol 3.11 (Scheme 51). Alcohol 3.11 was converted to 
iodide 3.10 using triphenylphosphine and iodine. Treatment of iodide 3.10 with magnesium 
metal in THF, with heating or sonication to initialize the designed Barbier-Grignard type 
reaction provide no cyclization product and iodide starting material 3.10 was recovered 
(Scheme 51).  
 
Scheme 51. Synthesis of key intermediate 3.9 by Barbier-Grignard type reaction. 
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 The unsuccessful Barbier reaction inspired examination of a simpler reaction to 
involving 5-hexen-2-one (3.13), n-butyl iodide (5 equiv.) and magnesium (10 equiv.) in THF 
(Figure 58). Neither heating nor sonication triggered reaction. On the other hand, 1,2-
dibromoethane caused the reaction to occur; however, ketol 3.14a was isolated as the major 
product (44 % yield), instead of the expected addition product 3.15 (5 % yield) (Figure 58).  
 
 
Figure 58. Unusual Barbier reaction between 5-hexen-2-one (3.13) and n-butyl iodide.   
 Faced with no success using the Barbier cyclization strategy, a new route based on 
proline catalyzed intramolecular aldol reaction was proposed and achieved successfully by 
Drs. Jernej Wagger and Bradley L. Merner (Scheme 52).60 Alkene 3.12 was transformed 
methyl ketone 3.16 by a Wacker oxidation. Tricyclic 3.17 was successfully furnished through 
L-proline catalyzed intramolecular aldol reaction. The resulting ketone was reduced, and 
deoxygnated using the by Barton–McCombie reaction to give tricycle 3.9 (Scheme 52). 
 
Scheme 52. Synthesis of key intermediate 3.9 by intramolecular aldol reaction. 
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 Although the Barbier type reaction failed to give tricycle 3.9, the interesting ketol 
product from the model reaction between 5-hexen-2-one (3.13) and n-butyl iodide attracted 
our attention (Figure 58). We decided to expand the scope of this reaction to afford β-ketols in 
one step. 
 
3-2 Results 
3-2-1 Intermolecular reactions 
 Intrigued by the formation of ketol 3.14a from 5-hexen-2-one (3.13) (Figure 58), we 
screened other aliphatic methyl ketone substrates (Table 4, entries 1-10), as well as cyclic 
ketones (Table 4, entries 11-12) and aromatic methyl ketones (Table 4, entries 13-16). Similar 
self-aldol reactions were obtained with these ketones (Table 4). Reducing the amount of n-
butyl iodide from 5 equiv. to 1 equiv., decreased slightly the average yield of β-ketols (Table 
4). The yields of ketol product from cyclohexanone (Table 4, entries 11-12) were similar to 
that reported for the reaction between cyclohexanone and i-PrMgCl (Figure 56).59 For 
aromatic ketones, 2-methoxyacetophenone gave lower yields (Table 4, entries 13-14), 
probably due to the steric bulk inhibiting formation of the ketol compared with the reaction of 
acetophenone (Table 4, entries 15-16).  
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Table 4. Intermolecular reactions under “Barbier conditions” 
 
Entry Substrate 
n-BuI 
(equiv.) 
β-ketol product 
 Yield 
(%)a 
1 
 
1 
 
3.14a 
38 
2 
 
5 
 
44 
3 
 
1 
 
3.14b 
35 
4 
 
5 
 
38 
5 
 
1 
 3.14c 
34 
6 
 
5 
 
40 
7 
 
1 
 
3.14d 
38 
8 
 
5 
 
45 
9 
 
1 
 
3.14e 
48b 
10 
 
5 
 
76b 
11 
 
1 
 
3.14f 
32 
12 
 
5 
 
44 
13 
 
1 
 
3.14g 
22 
14 
 
5 
 
24 
15 
 
1 
 
3.14h 
39 
16 
 
5 
 
42 
The reactions were run with 1 mmol methyl ketone, 10 mmol magnesium turnings in 2 mL THF with heating (<1 
min), then r.t. 2 h. a Average isolated yield. b Calculated from 1H NMR spectra of crude sample. 
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3-2-2 Intramolecular reaction  
 With the promising results in intermolecular reactions (Table 4), we decided to 
investigate intramolecular reactions to form β-ketol. For intramolecular β-ketol formation, we 
selected to study the cyclization of triketone 3.18, a reaction previously made famous by 
Zoltan G. Hajos and David R. Parrish at Hoffmann-La Roche and Schering AG over 40 years 
ago (Figure 59).61,62 In their studies, triketone 3.18 was treated with aqueous piperidinium 
acetate, which gave racemic crystalline [3.2.1]-bicyclooctane: (3.19, m.p. 115 °C). Enolization 
was preferred in the cyclic rather than the aliphatic ketones, and enolate 3.18a, which 
possessed a maximum π-orbital overlap reacted by a favorable alignment of the enolic double 
bond and the side-chain carbonyl group. On treatment with piperidine, followed by 
neutralizing acetic acid, β-ketol 3.19 could be isomerized to a more stable ketol 3.20 (m.p. 164 
°C), in which the hydroxyl group adopted an axial orientation. Ketol 3.20 was considered the 
thermodynamic product compared to 3.19. Enolate 3.18b may thus undergo a retro-aldol 
reaction. In contrast, using piperidinium acetate in ether, the cyclization of 3.18 afforded the β-
ketol 3.21, which could be further dehydrated to give the enone 3.22.61 In an asymmetric 
version, treatment of triketone 3.18 with 3 mol % of L-proline in DMF gave β-ketol 3.23 in 
quantitative yield with an optical purity of > 93 % (Figure 59). The structure of ketol 3.23 was 
characterized by single-crystal X-ray analysis of its racemic mixture. Dehydration of 3.23 led 
to the corresponding α,β-unsaturated diketone 3.24 (Hajos-Parrish diketone), which after 
recrystallization gave a product with an enantiomeric purity of > 97%.62 This remarkable 
success in accessing enantiomerically enriched bicyclic ketol 3.21 through a proline-catalyzed 
intramolecular aldol reaction, is highly recognized as a pioneering example of 
organocatalysis.62,63 
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Figure 59. β-ketol formation from intramolecular cyclization of 3.18. 
 
 In testing triketone 3.18 under our “Barbier conditions”. we hypothesized that β-ketols 
may form by intramolecular and intermolecular reactions. Indeed, the reaction between 
triketone 3.18 and n-butyl iodide generated a complicated mixture from which a major 
component was isolated as white solid in 35 % yield (Figure 60). X-ray analysis of the solid 
confirmed the structure of β-ketol 3.20 bearing an axial hydroxyl group arising from 
intramolecular reaction (Figure 61).   
 
Piperidinium 
acetate in water
3.18
3.18a
O
O
O
XH
3.18b
O
HO
O
O
O
OH
O
O OH
3.21
3.19
(mp. 115 oC)
3.20
(mp. 164 oC)
Piperidinium 
acetate in Ether
O
O
N
  Piperidine,
 then AcOH
O
O
N
O
O
HN
H
CO2H
DMF
O
O
O
3.23
O
O
3.24
O
O
3.22
3.18
O
O
O
O
O OH
- H2O
- H2O
O
OO
XH
H2O
  214 
 
Figure 60. Intramolecular reaction of 3.18 under “Barbier conditions” 
 
Figure 61. X ray structure of 3.20. 
 
3-3 Discussion 
 In self-aldol reactions of ketones, one molecule of ketone is enolized and the enolate 
reacts with another molecule of ketone to yield the ketol product. A base is usually required 
for enolate formation. Under our “Barbier reaction” conditions, the reaction mixture of ketone, 
n-BuI and magnesium metal, is treated with 1,2-dibromoethane in THF. The actual base (e.g., 
ROMgI, Grignard reagent n-BuMgI) responsible for enolization is difficult to identify as 
discussed before in Grignard reactions (Figures 50, 54 and 55). Using commercially available 
Grignard reagents, MeMgBr and EtMgBr, in the presence or absence of magnesium metal, 5-
hexen-2-one (3.13) reacted exclusively to give the addition products, with only trace amount 
ketol products (Figure 62). The Grignard reagent acted as nucleophile rather than a base. 
Although the Grignard reagent was not excluded as base, the magnesium alkoxide (ROMgI) 
generated in the reaction was considered as base (Figure 62). A tertiary magnesium alkoxide, 
t-BuOMgBr was prepared and reacted with ketone 3.13. Ketol 3.14 was isolated in 46 % yield 
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(Figure 62). Similar aldol condensations were performed between a methyl ketone and an α-
bromoketone in the presence of t-BuOMgBr·Et2O in benzene, and a Et2NMgBr·Et2O in 
toluene to give the corresponding bromo β-ketols, as reported by Kulinkovich and Kel’in.64 
 
 
a Calculated from 1H NMR spectra of crude sample. b Isolated yield. 
 Figure 62. Reaction of 3.13 using commercial Grignard reagents, and t-BuOMgBr 
 
 Herein, for the sake of simplicity, R2MI represents any possible base (ROMgI, n-
BuMgI etc.) involved in the self-aldol reaction mechanism (Figure 63). In the presence of 
base, the methyl ketone R1C=OCH3 could be deprotonated to generate a magnesium enolate, 
which attacks another molecule of methyl ketone substrate to lead to the ketol product after 
hydrolysis (Figure 63). A magnesium chelated 6-membered transition state maybe involved in 
the aldol reaction. 
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Figure 63. Plausible mechanism for the intermecular self-aldol reaction of ketones. 
 
 For the intramolecular reaction of triketone 3.18, a similar magnesium chelated 
transition state is proposed, because the hydroxyl group in the major product 3.20 is in the 
axial orientation, parallel to one of the carbonyl groups in the ring (Figure 64). The reaction of 
3.18 with t-BuOMgBr lead to the formation of only 3.20 in 60 % yield (Figure 65), which also 
supports the existence of magnesium chelation.  
 
 
Figure 64. Plausible mechanism for the intramolecular aldol reaction. 
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Figure 65. Reaction of triketone 3.18 with t-BuOMgBr  
 
3-4 Conclusion 
 Intrigued by the discovery of an unusual result in a Bariber reaction, we conducted 
studies of intermolecular and intramolecular reactions to produce β-ketol products in moderate 
yield. We propose a mechanism involving a base promoted, magnesium chelated transition 
state (Figure 63 and 64). Furthermore, based on the selectivity of the intramolecular aldol 
cyclization in the generation of ketol 3.20 from triketone 3.18, we hypothesized that a more 
efficient reaction for the formation of 3.20 could be developed by screening of bases and 
chelating additives. These will be discussed in Chapter four.  
 
 A direct method to access β-ketol is the aldol reaction. In the case of a methyl ketone, 
such as 3.13, addition of a half equiv. of LDA should in principle, generate kinetic enolate to 
attack the ketone (3.13) and produce β-ketol 3.14. Indeed, when such a reaction was tried, the 
β-ketol 3.14 was formed, but accompanied by unreacted ketone 3.13. Organocatalytic aldol 
reactions catalyzed by proline leads to β-ketol; however, self-aldol reaction of ketones has not 
been explored to the best of my knowledge. Such aldol reactions are more common between 
methyl ketones and aldehydes. 
 
 In spite of the modest yields, the Barbier type synthesis of β-ketol as described in this 
thesis appears to be novel. In the original work, Bariber1 had prepared the addition product 3.2 
when using methyl iodide, and magnesium metal in ether (Figure 44). It is therefore curious 
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that using butyl iodide would lead to a β-ketol in substantial amount relative to direct addition. 
A critical experiments to be done is to determine the difference between methyl iodide and  
butyl iodide by using ethyl, propyl, isopropyl iodides to assess the effect of bulk on the 
tendency to promote self-aldol reaction versus direct addition. We have already established 
that a Grignard reactions with MeMgI and EtMgBr with ketone 3.13 led to tertiary alcohol 
addition products (Figure 62). The addition of BuMgCl also led to the tertiary alcohol contrary 
to the presently used Barbier conditions. Several by-products in the Barbier reaction of keonte 
3.13 account for the modest yield of the β-ketol. 
 
 β-Ketol was provided from the reaction of cyclopentanone and i-PrMgBr (Figure 56),59 
however, cyclohexanone gave a lower yield (Figure 56).59 The same results appear to be 
taking place under Barbier condition with butyl iodide (Table 4, entries 11 and 12). 
 
3-5 Experimental 
 General methods are same as described in the experimental section of Chapter 1.  
 
 All the intermolecular reactions of methylketone under Baribier-Grignard type 
conditions were run with 1 mmol methyl ketone, 10 mmol magnesium turnings, in 2 mL THF 
and the typical procedure is shown below:  
 
5-Hexene-2-one (3.13, 101 mg, 1.03 mmol, 120 uL), magnesium turnings (247 mg, 10.3 
mmol) and THF (2 mL) were added to a dried flask equipped with a condenser, following by 
n-butyl iodide (948 mg, 5.15 mmol, 586 uL) and 2 drops of 1,2-dibromoethane at r.t. The 
reaction was initiated using a heat gun and after it was heated to reflux, the mixture was 
cooled to r.t., and stirred for 2 h when the clear solution turned cloudy. The reaction was 
quenched with saturated aqueous NH4Cl and extracted three times with CH2Cl2 (3×10 mL). 
The combined organic phases were washed with brine, dried over MgSO4 and filtered. The 
filtrate was evaporated under reduced pressure and the residue was purified by flash 
chromatography (hexane: EtOAc, 8:1 to 4:1) to give 3.14 (44 mg, 44 %) as pale yellow oil, 
and 3.15 (8.1 mg, 5 %) as pale yellow oil.  
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7-Hydroxy-7-methylundeca-1,10-dien-5-one (3.14a). 1HNMR (400 MHz, CDCl3) δ 5.85-
5.74 (m, 2H), 5.14-4.85 (m, 4H), 2.70-2.44 (m, 4H), 2.32 (q, J = 7.2 Hz, 2H), 2.22-2.00 (m, 
2H), 1.69-1.46 (m, 2H), 1.21 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 212.3, 138.6, 136.6, 
115.5, 114.4, 71.5, 51.6, 43.5, 41.1, 28.2, 27.3, 26.7; FTIR (cm–1) (neat) 3478, 3077, 2976, 
2924, 1699, 1641, 1374, 1132, 996, 910; HRMS (ESI) calcd for C12H21O2 (M+H)+ 197.1536, 
found 197.1546. 
 
 
5-Methylnon-1-en-5-ol (3.15) 1H NMR (400 MHz, CDCl3) δ 5.85 (ddt, J = 16.8, 10.4, 6.4 Hz, 
1H), 5.04 (dq, J = 17.2, 1.6 Hz, 1 H), 4.97-4.93 (m, 1H), 2.15- 2.08 (m, 2H), 1.56-1.52 (m, 
2H), 1.48-1.43 (m, 2H), 1.37-1.28 (m, 5H), 1.17 (s, 3H), 0.92 (t, J = 6.8 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 139.1, 114.3, 72.6, 41.7, 40.7, 28.3, 26.8, 26.1, 23.2, 14.1; FTIR (cm–1) 
(neat) 3383, 3078, 2958, 2931, 2861, 1640, 1465, 1375, 1298, 1260, 1232, 1143, 1088, 1030, 
994, 948, 907. 
 
 
6-Hydroxy-6-methylnonan-4-one (3.14b) was obtained as pale yellow oil (31 mg, 35 %) 
using 1.03 mmol n-butyl iodide [34 mg, 38 % using 5.15 mmol n-butyl iodide]. 1H NMR (400 
MHz, CDCl3) δ 3.88 (s, 1H), 2.56 (q, J = 17.0 Hz, 2H), 2.39 (t, J = 7.3 Hz, 2H), 1.64-1.55 (m, 
2H), 1.48-1.43 (m, 2H), 1.38-1.30 (m, 2H), 1.18 (s, 3H), 0.91 (m, 6H); 13C NMR (100 MHz, 
CDCl3) δ 213.5, 71.7, 51.3, 46.5, 44.5, 26.7, 17.2, 16.9, 14.5, 13.6; FTIR (cm–1) (neat) 3470, 
2960, 2934, 2874, 1697, 1458, 1373, 1148, 1055, 1019, 939, 888.; HRMS (ESI) calcd for 
C10H20NaO2 (M+Na)+ 195.1356, found 195.1356. 
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8-Hydroxy-2,8,12-trimethyltrideca-2,11-dien-6-one (3.14c) was obtained as yellow oil (44 
mg, 34 %) using 1.03 mmol n-butyl iodide [52 mg, 40 % using 5.15 mmol n-butyl iodide]. 1H 
NMR (400 MHz, CDCl3) δ 5.09-5.02 (m, 2H), 3.85 (s, 1H), 2.57 (q, J = 17.0 Hz, 2H), 2.44 (t, 
J = 7.3 Hz, 2H), 2.24 (q, J = 7.2 Hz, 2H), 2.10-1.95 (m, 2H), 1.67 (s, 6H), 1.60 (s, 6H), 1.53-
1.47 (m, 2H), 1.20 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 213.3, 133.2, 131.9, 124.4, 122.5, 
71.8, 51.7, 44.8, 42.1, 26.9, 25.9, 25.8, 22.8, 22.4, 17.8, 17.8; FTIR (cm–1) (neat) 3411, 2971, 
2929, 1706, 1450, 1376, 1147, 1056, 982; HRMS (ESI) calcd for C16H28NaO2 (M+Na)+ 
275.1982, found 275.1982. 
 
 
6-Hydroxy-2,6,8-trimethylnonan-4-one (3.14d) was obtained as pale yellow oil (39 mg, 38 
%) using 1.03 mmol n-butyl iodide, [46 mg, 45 % using 5.15 mmol n-butyl iodide]. 1H NMR 
(400 MHz, CDCl3) δ 3.87 (s, 1H), 2.55 (q, J = 17.2 Hz, 2H), 2.28 (d, J = 6.9 Hz, 2H), 2.18-
2.08 (m, 1H), 1.82-1.72 (m, 1H), 1.40 (qd, J = 14.2, 5.9 Hz, 2H), 1.21 (s, 3H), 1.00-0.91 (m, 
12H); 13C NMR (100 MHz, CDCl3) δ 213.3, 72.2, 53.6, 52.6, 50.5, 27.2, 24.8, 24.5, 24.4, 
24.1, 22.5, 22.4; FTIR (cm–1) (neat) 3489, 2955, 2871, 1697, 1466, 1367, 1152, 1055 947, 
894; HRMS (ESI) calcd for C12H24NaO2 (M+Na)+ 223.1669, found 223.1674. 
 
 
5-Hydroxy-2,2,5,6,6-pentamethylheptan-3-one (3.14e) was obtained as yellow oil (crude 
without purification) (49 mg, 48 %) using 1.03 mmol n-butyl iodide, [78 mg, 76 % using 5.15 
mmol n-butyl iodide]. 1H NMR (400 MHz, CDCl3) δ 1H NMR (400 MHz, CDCl3) δ 4.60 (s, 
1H), 2.86 (d, J = 16.8 Hz, 1H), 2.46 (d, J = 16.8 Hz, 1H), 1.13 (s, 12H), 0.94 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 220.2, 75.5, 45.3, 40.2, 37.7, 26.0, 25.1, 21.9; FTIR (cm–1) (neat) 
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3484, 2958, 2873, 1691, 1478, 1465, 1395, 1369, 1324, 1215, 1155, 1101, 1067, 1008, 939, 
873, 845, 810; HRMS (ESI) calcd for C12H24NaO2 (M+Na)+ 223.1669, found 223.1662. 
 
 
1'-Hydroxy-[1,1'-bi(cyclohexan)]-2-one (3.14f) was obtained as colorless oil (32 mg, 32 %) 
using 1.03 mmol n-butyl iodide, [44 mg, 44 % using 5.15 mmol n-butyl iodide]. 1H NMR (400 
MHz, CDCl3) δ 1H NMR (400 MHz, CDCl3) 3.67 (s, 1H), 2.40-2.31 (m, 3H), 2.20-2.16 (m, 
1H), 2.14-2.07 (m, 1H), 1.96-1.89 (m, 1H), 1.76-1.53 (m, 8H), 1.46-1.35 (m, 3H), 1.33-1.10 
(m, 2H); 13C NMR (100 MHz, CDCl3) δ 216.4, 72.0, 58.9, 43.9, 36.1, 33.2, 29.0, 28.3, 25.9, 
25.5, 21.7, 21.4; FTIR (cm–1) (neat) 3513, 2928, 2858, 1693, 1448, 1395, 1348, 1308, 1258, 
1217, 1179, 1040, 996, 966, 947, 894, 853, 836; HRMS (ESI) calcd for C12H20NaO2 (M+Na)+ 
219.1356, found 219.1364. 
 
 
3-Hydroxy-1,3-bis(2-methoxyphenyl)butan-1-one (3.14g) was obtained as yellow oil (33 
mg, 24 %) using 1.0 mmol n-butyl iodide, [36 mg, 24% using 5.0 mmol n-butyl iodide]. 1H 
NMR (400 MHz, CDCl3) 7.70 (dd, J = 7.7, 1.7 Hz, 1H), 7.43-7.38 (m, 1H), 7.25 (d, J = 1.8 
Hz, 1H), 7.21-7.15 (m, 1H), 6.98 (td, J = 7.6, 1.0 Hz, 1H), 6.93-6.86 (m, 2H), 6.72 (d, J = 8.2 
Hz, 1H), 4.90 (s, 1H), 4.18 (d, J = 16.6 Hz, 1H), 3.89 (s, 3H), 3.63 (s, 3H), 3.39 (d, J = 16.6 
Hz, 1H), 1.63 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 204.9, 158.3, 155.4, 134.8, 133.3, 
129.7, 129.2, 128.0, 127.1, 120.7, 120.5, 111.3, 110.7, 73.5, 55.5, 54.8, 52.3, 28.1; FTIR         
(cm-1) (neat) 3468, 2931, 2837, 1671, 1596, 1485, 1462, 1435, 1357, 1282, 1240, 1179, 1162, 
1124, 1023, 950, 805, 753; HRMS (ESI) calcd for C18H20NaO4 (M+Na)+ 323.1254, found 
323.1258. 
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3-Hydroxy-1,3-diphenylbutan-1-one (3.14h) was obtained as pale yellow oil (47 mg, 39 %) 
using 1.0 mmol n-butyl iodide, [50 mg, 42% using 5.0 mmol n-butyl iodide]. 1H NMR (400 
MHz, CDCl3) δ 7.92 (dd, J = 8.1, 0.8 Hz, 2H), 7.70-7.56 (m, 1H), 7.56-7.37 (m, 4H), 7.37-
7.16 (m, 3H), 4.89 (s, 1H), 3.80 (d, J = 17.4 Hz, 1H), 3.36 (d, J = 17.5 Hz, 1H), 1.64 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 201.3, 147.6, 136.9, 133.7, 128.7, 128.2, 128.0, 126.6, 124.3, 
73.5, 48.8, 30.9; FTIR (cm–1) (neat) 3454, 3058, 3026, 2972, 2927, 1665, 1597, 1579, 1492, 
1447, 1368, 1341, 1282, 1214, 1181, 1071, 1027, 1003, 936, 868, 817, 754, 724, 700, 689; 
HRMS (ESI) calcd for C16H16NaO2 (M+Na)+ 263.1043, found 263.1031. 
 
 
2-Methyl-2-(3-oxobutyl)cyclopentane-1,3-dione (3.18) was prepared according to a known 
procedure.65 The spectroscopic data were in agreement with the proposed structures and 
matched those reported in the literature65,66 1H NMR (400 MHz, CDCl3) δ 2.79-2.50 (m, 4H), 
2.29 (t, J = 7.3 Hz, 2H), 1.94 (s, 3H), 1.70 (t, J = 7.3 Hz, 2H), 0.93 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 215.5, 207.5, 54.7, 37.0, 34.4, 29.6, 27.4, 18.5. 
 
 
(±)-4β-Hydroxy-1β,4α-dimethylbicyclo[3.2.l]octane-7,8-dione (3.20). For intramolecular 
reactions under Baribier conditions, triketone 3.18 (50 mg, 0.28 mmol), magnesium turnings 
(67 mg, 2.8 mmol) and THF (0.5 mL) were added to a dried flask equipped with a condenser, 
following by n-butyl iodide (52mg, 0.28 mmol, 32 uL) and 2 drops of 1,2-dibromoethane at 
r.t. The reaction was initiated using a heat gun and after it was heated to reflux, the mixture 
was cooled to r.t., and stirred for 3 h  when the clear solution turned orange/red. The reaction 
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was quenched by saturated aqueous NH4Cl and extracted three times with CH2Cl2 (3×5 mL). 
The combined organic phases were washed with brine, dried over MgSO4 and filtered. The 
volatiles were removed under reduced pressure and the residue was purified by flash 
chromatography (hexane: EtOAc, 2:1 to 1:1) to give alcohol 3.20 (17.5 mg, 35 %) as white 
solid. m.p. 163-164 °C (lit.67, m.p. 160-161 °C). The spectroscopic data were in agreement 
with the proposed structures and matched those reported in the literature.68 1H NMR (400 
MHz, CDCl3) δ 2.79 (m, 1H), 2.68-2.53 (m, 2H), 2.14 (td, J = 12.6, 6.9 Hz, 1H), 2.06 (s, 1H), 
1.85 (ddd, J = 12.5, 5.3, 1.9 Hz, 1H), 1.80-1.62 (m, 2H), 1.41 (s, 3H), 1.08 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 214.3, 211.3, 80.7, 58.3, 57.5, 42.8, 38.6, 32.3, 28.6, 11.9; FTIR (cm–1) 
(neat) 3465, 2972, 2932, 1763, 1717, 1448, 1402, 1382, 1371, 1357, 1332, 1285, 1247, 1217, 
1185, 1165, 1127, 1106, 1072, 1055, 1018, 978, 957, 942, 919, 858, 809; HRMS (ESI) calcd 
for C10H14NaO3 (M+Na)+ 205.0835, found 205.0833. 
 
Typical procedure for reaction of ketone 3.13 with Grignard reagents:  
5-Hexene-2-one (3.13, 53 mg, 0.54 mmol, 64 uL), with or without magnesium turnings (130 
mg, 5.4 mmol), and THF (1 mL) were added to a dried flask equipped with a condenser, 
following by the addition of methyl magnesium bromide (3M in Et2O, 0.54 mmol, 180 uL) at 
r.t. The reaction was stirred for 0.5 h before being quenched with saturated aqueous NH4Cl. 
The resulting mixture was extracted three times with CH2Cl2 (3×5 mL).The combined organic 
phases were washed with brine, dried over MgSO4 and then filtered. The solvent was removed 
under reduced pressure to give a crude residue, which was directly examined by 1H NMR 
spectroscopy to calculate the ratio of addition product and self-addition product.   
 
 
2-Methylhex-5-en-2-ol (3.25) is a known compound, and the spectroscopic data were in 
agreement with the proposed structures and matched those reported in the literature.69 1H 
NMR (400 MHz, CDCl3) δ 5.83 (ddt, J = 16.8, 10.2, 6.6 Hz, 1H), 5.02 (dd, J = 17.1, 1.4 Hz, 
1H), 4.93 (d, J = 10.1 Hz, 1H), 2.12 (dd, J = 16.2, 6.8 Hz, 2H), 1.70 (s, 1H), 1.63 - 1.45 (m, 
2H), 1.20 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 139.0, 114.2, 70.6, 42.7, 29.1, 28.7. 
OH
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3-Methylhept-6-en-3-ol (3.26). The spectroscopic data were in agreement with the proposed 
structures and matched those reported in the literature (one of its enantiomer).70 1H NMR (400 
MHz, CDCl3) δ 5.85 (ddt, J = 16.8, 10.2, 6.6 Hz, 1H), 5.04 (dd, J = 17.1, 1.7 Hz, 1H), 4.95 
(dd, J = 10.2, 1.8 Hz, 1H), 2.11 (m, 2H), 1.78-1.40 (m, 4H), 1.16 (s, 3H), 0.90 (t, J = 7.5 Hz, 
3H); 13C NMR (100 MHz, CDCl3) δ 139.1, 114.3, 72.8, 40.2, 34.3, 28.3, 26.2, 8.2. 
 
Reaction of trione 3.18 with t-BuOMgBr: 
t-BuOMgBr (0.5 M in THF) was prepared by treating methyl magnesium bromide (3M in 
Et2O, 9 mmol, 3 mL) with anhydrous t-butyl alcohol (0.667 g, 9 mmol, 0.84 mL) in THF 
(14.16 mL) at 0 °C, followed by stirring for 1h at r.t.  
 
To trione 3.18 (50 mg, 0.27 mmol) dissolved in THF (2 mL) freshly prepared t-BuOMgBr (0.5 
M in THF, 0.27 mmol, 0.54 mL) was added at r.t. After stirring for 12 h, one more equivalent 
of t-BuOMgBr (0.5 M in THF, 0.27 mmol, 0.54 mL) was added. The reaction was stirred for 
another 12 h, quenched by the addition of saturated aqueous NH4Cl and extracted with CH2Cl2 
(3×5 mL). The combined organic phases were washed with brine, dried over MgSO4 and then 
filtered. The volatiles were removed under reduced pressure and the residue was purified by 
flash chromatography (hexane: EtOAc, 2:1 to 1:1) to give 3.20 (30 mg, 60 %) as a white solid. 
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Chapter 4: From Synthetic Study of 2-hydroxy-2,5-
dimethylbicyclo[3.2.1]octane-6,8-dione (a constitutional 
isomer of the Hajos-Parrish ketone), to Catalytic Synthesis 
of Tertiary β-Ketols 
 
4-1 Introduction 
4-1-1 β-Ketols from Aldol reaction 
 The aldol reaction, between two aldehydes, was first introduced by Charles-Adolphe 
Wurtz in 18721,2 and has been widely recognized as one of most important methods for the 
construction carbon-carbon bonds.3 Joining two carbonyl compounds (aldehydes, ketones or 
esters) to give a β-ketol product (Figure 66), in the process one of the carbonyl compounds 
bearing an α-proton is enolized and the nucleophlic enolate (basic conditions), or a enol 
(acidic conditions), performs nucleophilic attack on another carbonyl compound (Figure 66).  
 
Figure 66. Aldol reaction under basic and acidic conditions.  
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 The resulting β-hydroxyl carbonyl moiety is a common structural unit exhibited in 
many important natural products and drugs. Such as FK-506,4-6 epothilones A and B,7-10 and 
Taxol11,12 (Figure 67).  
 
 
Figure 67. Examples of β-hydroxyl carbonyl units in natural products and drugs.  
 
 An aldol reaction may generate two new stereogenic centers (at the α and β-positions). 
The challenge of stereoselectively obtaining a specific β-ketol has led to great efforts to 
develop asymmetric aldol reactions, using a variety of chiral auxiliaries, ligands and catalysts.3 
Evans,13 and others,14,15 discovered a series of chiral oxazolidinone auxiliaries, that provide 
high diastereoselectivity in the presence of a Lewis acid (n-Bu2BOTf,13,14 (c-hex)2BCl,16 
Sn(OTf)2,17 TiCl4,15,17 MgCl2,18 MgBr2· (OEt)219 etc.) and base (DIPEA, TEA etc.) (Figure 68). 
Mukaiyama and coworkers discovered a type of aldol reaction, termed Mukaiyama aldol 
reaction, which uses silyl enol ethers as nucleophiles.20 This reaction was widely used in 
synthesis of β-ketols, and chiral catalysts were developed by Mukaiyama, 21  Corey, 22 
Carreira,23 Evans,24 Denmark,25 and Yamamoto26 to achieve asymmetric versions (Figure 69). 
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More recently, organocatalysis has been extensively explored in the aldol reaction.27 As 
mentioned in Chapter 3, in 1974, Hajos and Parrish used proline to catalyze the intramolecular 
aldol reaction of triketone 3.18 (Figure 59).28 Later List29 and Barbas29,30 developed L-proline 
catalyzed asymmetric aldol reactions between acetone and aldehydes (Figure 70). 
MacMillan31 used L-proline successfully to achieve a cross-aldol reaction between aldehydes 
(Figure 70). Based on the success of proline, derivatives were developed to catalyze aldol 
reactions (Figure 70).30,32-36 Although these versatile chiral auxiliaries, ligands, and catalysts 
have advanced the stereoselective synthesis of β-ketols from aldol reactions, catalytic 
asymmetric aldol reactions remain a topic of interest in organic synthesis.      
 
 
Figure 68. Examples of Evans’ oxazolidinone auxiliaries in the aldol reaction.  
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Figure 69. Examples of chiral catalysts used in Mukaiyama aldol reaction. 
 
Figure 70. Examples of proline and its derivatives as catalysts in aldol reaction. 
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4-1-2 Synthetic background of β-ketol 3.20 from triketone 3.18 
 Since Hajos and Parrish disclosed the β-ketol products from triketone 3.18 via 
intramolecular aldol reaction (Figure 59, Chapter 3, section 3-2-1),28, 37  catalytic 
enantioselective synthesis of β-ketol 3.21 has been studied to dertermine the mechanism and 
enhance the methodologies.38 Formation of other ketol products (3.19 and 3.20) has been 
scarcely explored.  
 
 For the synthesis of ketol 3.20, few examples have been reported. Dauben and Bunce39 
studied the reaction between 2-methyl-1,3-cyclopentanedione and methyl vinyl ketone at high 
pressure. Under 15 kbar in the presence of acetonitrile and Et3N, ketol 3.20 was generated in 
52 % yield (Figure 71). Shibasaki and coworkers40 discovered a series of rare earth metal 
alkoxides that catalyze aldol reactions. In the intramolecular aldol cyclization of 3.18 with 10 
mol% Zr(O-t-Bu)4, ketol 3.20 was generated in 30 % yield. Using La3(O-t-Bu)9 as the catalyst, 
both β-ketol 3.19 and 3.20 were obtained in 30 % and 40 % yield respectively. Yttrium 
alkoxide reacted selectively to generate 3.20 in almost quantitative yield. No cyclized product 
was observed using Al(O-t-Bu)3. To achieve enantioselectivity in the synthesis of 3.20, a 
chiral ytterbium alkoxide was prepared and tested. After 6 days at -52 °C, ketol 3.20 was 
obtained in 60 % yield with 52 % e.e. (Figure 72).40 To the best of our knowledge, this is the 
only example of enantioselective synthesis of ketol 3.20. Although Davies and coworkers41 
reported using (1´R, 2´S)-5-(2´-aminocyclopentan-1´-yl) tetrazole as a chiral catalyst in an 
attempt to achieve asymmetric synthesis of 3.20 from 3.18 (Figure 73), they obtained 3.20 in 
67 % yield without enantioselectivity. Mahrwald and coworkers42 employed a tetranuclear 
BINOL-titanium complex as catalyst, obtained racemic 3.20 in 44 % yield (Figure 74). 
 
 
Figure 71. Synthesis of 3.20 by Dauben and Bunce. 
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Figure 72. Synthesis of 3.19 and 3.20 by Shibasaki and coworkers. 
 
Figure 73. Synthesis of 3.20 by Davies and coworkers. 
 
Figure 74. Synthesis of 3.20 by Mahrwald and coworkers. 
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 Our previous study of the cyclization of trione 3.18 under Barbier conditions showed 
that ketol 3.20 was the favored product (Figure 50, Chapter 3, section 3-1-2), and possibly 
formed via a magnesium-chelated transition state (Figure 64, Chapter 3, section 3-3). We 
envisioned that using a suitable base and chelating additives (e.g. magnesium salts), ketol 3.20 
could be generated from 3.18 selectively and efficiently, eventually in an asymmetric or 
catalytic version. 
 
4-2 Results 
4-2-1 Screening of reaction conditions for the synthesis of β-ketol 3.20  
4-2-1-1 Temperature and catalysts loading 
 As described in our hypothesis, a suitable base was needed to promote the cyclization. 
We chose 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), due to its non-nucleophilicity and 
relatively strong basicity (pKa 16.8 in THF).43 Triketone 3.18 was treated with DBU (1 equiv.) 
at room temperature, and converted to all three β-ketol products after 24 h (Table 5, entry 1). 
Decreasing the temperature to -40 °C, the reaction did not reach completion in 24 h, and 3.19, 
3.20 and 3.21 were generated in equal proportion (Table 5, entry 2). Next, we surmised that 
introducing an additive would aid in the forming of a chelated transition state, as proposed in 
Figure 64 (Chapter 3, section 3-3), and lead to β-ketol 3.20 as the major product. Lithium 
bromide is a mild and neutral inorganic salt. The small size of the lithium cation could benefit 
the required chelate model in this intramolecular reaction.44 In the presence of LiBr (1 equiv.) 
and DBU (1 equiv.), the reaction rate was significantly accelerated at -40 °C, and ketol 3.20 
was obtained as the major product as expected (Table 5, entry 3).  In further tests using a 
catalytic amount of DBU and LiBr (5 mol % of each), the reaction proceeded selectively 
affording 3.20 in 88 % isolated yield (Table 5, entry 4). Under the same catalytic conditions, 
lowering the temperature to -78 °C, slowed the reaction rate, and only 6 % of 3.20 was 
observed by 1H NMR spectroscopy of the reaction mixture (Table 5, entry 5). At room 
temperature, the same conditions gave 3.20 as the major product, but less selectively 
compared to at - 40 °C (Table 2, entry 6). Employment of DBU or LiBr used alone yielded 
only a trace amounts of 3.20 (Table 5, entries 7 and 8). The combination of 5 mol% DBU and 
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LiBr in THF at -40 °C promoted the catalytic reaction to give β-ketol 3.20 in high yield and 
excellent selectivity (Table 5, entry 4).  
 
Table 5. Screening of temperature and catalysts loading. 
 
Entry 
Base / Additive 
(equiv.) 
Temperature 
(°C) 
3.18 (%)a 
3.19 
Yield (%)a 
3.20 
Yield (%)a 
3.21 
Yield (%)a 
1 DBU (1) r.t. 4 36 38 22 
2 DBU (1) - 40 69 9 11 11 
3 
DBU (1), 
LiBr (1) 
- 40 2 21 62 15 
4 
DBU (0.05), 
LiBr (0.05) 
- 40 - - 89(88)b 11 
5 
DBU (0.05), 
LiBr (0.05) 
- 78 85 - 6 9 
6 
DBU (0.05), 
LiBr (0.05) 
r.t. 6 13 68 13 
7 DBU (0.05) - 40 94 2 2 2 
8 LiBr (0.05) - 40 93 1 1 5 
Reactions were run with 0.14 mmol triketone in 1 mL THF for 24 h. a Calculated from the 1H NMR spectra of 
crude reaction material. b Isolated yield. 
 
4-2-1-2 Solvents 
 Intrigued by the catalytic effect of DBU and LiBr, a series of solvents were tested in 
the reaction of 3.18 (Table 6). Aprotic solvents (Table 6, entries 1 - 5), favored ketol 3.20; 
THF was the preferred solvent. The reaction in DMF was also selective, and led to 3.20 in 76 
% isolated yield. Protic solvents favored formation of β-ketol 3.19 (72 % isolated yield using 
MeOH) (Table 6, entry 6). 
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Table 6. Screening of solvents. 
 
Entry Solvent 3.18 (%)a 
3.19 
Yield (%)a 
3.20 
Yield (%)a 
3.21 
Yield (%)a 
1 THF - - 89 (88)b 11 
2 Et2O 11 24 53 12 
3 CH2Cl2 27 20 43 10 
4 EtOAc 10 8 73 9 
5 DMF 8 3 82 (76)b 7 
6 MeOH 5 76 (72)b 5 14 
The reactions were run with 0.14 mmol triketone in 1 mL THF for 24 h. a Calculated from 1H NMR spectra of 
crude reaction mixture. b Isolated yield. 
 
4-2-1-3 Additives 
 Based on the success of LiBr as an additive, other inorganic salts were tested as 
chelates. Similar to LiBr, 5 mol % LiCl and DBU gave ketol product 3.20 in 86 % isolated 
yield (Table 7, entry 4). The anion of the lithium salts had little effect on the reaction. 
Switching to magnesium salts, neither MgBr2 nor MgBr2·Et2O with DBU in THF resulted in 
the formation of ketol 3.20 (Table 7, entry 6 and 8). Changing solvent to DMF, which should 
give better solubility for magnesium salts, led to trace amounts of 3.20. Lithium cation 
appeared crucial for catalyzing formation of ketol 3.20 from triketone 3.18. 
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Table 7. Screening of additives. 
 
Entry 
Base / Additive 
(5 %) 
Solvent 
3.18 
(%)a 
3.19  
Yield (%)a 
3.20  
Yield (%)a 
3.21  
Yield (%)a 
1 LiBr THF 93 1 1 5 
2 DBU, LiBr THF - - 89 (88)b 11 
3 LiCl THF 98 - - 2 
4 DBU, LiCl THF - - 84 (86)b 16 
5 MgBr2 THF 92 - - 8 
6 DBU, MgBr2  THF 92 - - 8 
7 MgBr2 ·Et2O THF 93 - - 7 
8 
DBU, 
MgBr2 ·Et2O 
THF 93 - - 7 
9 MgBr2  DMF 95 - 1 4 
10 DBU, MgBr2  DMF 92 - 5 3 
The reactions were run with 0.14 mmol triketone in 1 mL THF for 24 h. a Calculated from 1H NMR spectra of 
crude reaction mixture. b Isolated yield. 
 
4-2-1-4 Achiral bases 
 With the optimized catalyst loading (5 mol %), temperature (-40 oC), solvent (THF), 
and additive (LiBr), we studied a series of bases as catalyst for this reaction (Table 8). Using 
relatively weaker bases (Et3N, TMEDA and pyrrolidine) with and without LiBr, little β-ketol 
3.20 was generated (Table 8, entries 1-6). Switching to piperidine, and stronger bases, with 5 
% LiBr gave ketol 3.20 in excellent yield (Table 8, entries 8, 10, 12, 14 and 16). The presence 
of 5 mol % of 3,3,6,9,9-pentamethyl-2,10-diazabicyclo[4.4.0]dec-1-ene (Eschenmoser’s 
amidine) (Table 8, entries 11)45 gave selectively ketol 3.20 in 35 % yield based on 1H NMR 
spectroscopy of the reaction mixture. Tests with 5 mol% of 1,5,7-triazabicyclo[4.4.0]dec-5-
ene (TBD) (Table 8, entries 15) generated 3.20 in 89 % yield, indicating that TBD alone was 
an efficient catalyst to generate β-ketol 3.20 in high yield and selectivity. Employment of 5 
mol % of TBD with LiBr also led to 3.20 in excellent yield (Table 8, entries 16). The reaction 
O
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O
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O
O
OH
O
HO
O O
O OH
3.203.19 3.21
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Solvent
+ +
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rates were also studied over a 24 h period with DBU, the bicyclic Eschenmoser’s amidine and 
TBD (Figure 75-77). It was clear that LiBr accelerated the reaction with DBU and 
Eschenmoser’s amidine in the formation of 3.20. 
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Table 8. Screening of bases. 
 
Entry 
Base / Additive 
(5%) 
3.20  
Yield (%)a 
pKa (in THF)a 
1 Et3N 1 12.5 
2 Et3N, LiBr 1  
3 TMEDA n.r. 12.8 
4 TMEDA, LiBr 3  
5 Pyrrolidine 1 13.5 
6  Pyrrolidine, LiBr  4  
7                           
8 
Piperidine 
Piperidine, LiBr 
n.r. 
91 (86)b 
14.3 
 
9 
 
4 15.5 
10 
LiBr 
87 (86)b  
11 
 
35 - 
12 
LiBr 
89 (87)b  
13 
 
5 17.9 
14 
LiBr 
92 (88)b  
15 
 
90 (89)b 21.0 
16 
LiBr 
92 (90)b  
The reactions were run with 0.14 mmol triketone in 1 mL THF for 24 h. a Calculated from 1H NMR spectra of 
crude reaction mixture. b Isolated yield. pKa values were taken from references 43 and 46. 
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Figure 75. Kinetic profiles of DBU, with and without LiBr-catalyzed aldol reaction of 3.18 
and the formation of 3.20.  
 
 
Figure 76. Kinetic profiles of Eschenmoser amidine, with and without LiBr-catalyzed aldol 
reaction of 3.18 and the formation of 3.20. 
 
Figure 77. Kinetic profiles of TBD, with and without LiBr catalyzed aldol reaction of 3.18 
and the formation of 3.20. 
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 Thus, we have developed two types of catalysts to synthesize β-ketol 3.20 from 
triketone 3.18 (Figure 78). β-Ketol 3.20 can be selectively generated either by using DBU and 
LiBr, or 5 mol % TBD (Table 8). 
     
 
Figure 78. Catalytic synthesis of β-ketol 3.20 from triketone 3.18 
 
4-2-2 Studies toward an enantioselective synthesis of 3.20 
 Encouraged by the catalytic effect of bases with and without LiBr in the synthesis of 
ketol 3.20 (Table 8), we tested chiral bases for the asymmetric synthesis of 3.20 (Table 9). 
Inspired by the use of sparteine in enantioselective deprotonation,47 we used (-)-sparteine as 
chiral base, with and without LiBr, but no cyclization was observed (Table 9, entries 1 and 2). 
Employing (-)-sparteine as a ligand to generate a chiral lithium complex by mixing it the DBU 
and LiBr conditions had no influence on the stereoselectivity of 3.20 (Table 9, entries 3 and 
4). Treatment of 3.18 with a chiral cyclic guanidine 4.148 and LiBr gave only 20 % of 3.20 
without enantioselectivity (Table 9, entries 5 and 6). Reactions with the thioamidine catalyst, 
(-)-tetramisole (4.2) excluded also enantioselectivity (Table 9, entries 7 and 8).49 Chiral 
amidine 4.350 with LiBr generated 3.20 successfully as the racemate (Table 9, entries 10).  
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Table 9. Chiral bases with and without LiBr. 
 
Entry Base / Additive (5%) 3.20 Yield (%)a 
1 (-)-sparteine n.r. 
2 (-)-sparteine, LiBr n.r. 
3 (-)-sparteine, LiBr, DBU 92 (88)b, c 
4 (-)-sparteine, LiBr, DBU 90 (88)b, c 
5 
 (4.1) 
n.r. 
6 
 LiBr 
20b, c 
7                            (4.2) n.r. 
8 LiBr trace 
9 
(4.3) 
7 
10 
LiBr 
85 (74)b, c 
Entries 1-4, the reactions were run with 0.14 mmol triketone in 1 mL THF at - 40 °C for 24 h. Entry 4, starting 
material, sparteine and LiBr were stirred at - 40 oC for 0.5h, then DBU was added. Entry 5, DBU, sparteine and 
LiBr were stirred at - 40 oC for 0.5h, then starting material was added. Entries 5-10, the reactions were run with 
0.14 mmol triketone in 1 mL THF at - 40 oC for 72 h. a Calculated from 1H NMR spectra of crude reaction 
mixture. b Isolated yield. c Racemic compounds, determined by SFC of 3.20 or GC-MS of the acetate of 3.20. 
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4-3 Discussion 
4-3-1 Proposed mechanisms for catalytic synthesis of 3.20  
4-3-1-1 Mechanism involving LiBr 
 In the reaction catalyzed by a base DBU and LiBr, we hypothesized that LiBr pre-
organized the conformation of triketone 3.18 to place the carbonyl of the side-chain and the 
ketone from cyclopentanedione in a parallel orientation, due to bidentate coordination with 
LiBr (Figure 79). After being activated by LiBr, the most acidic proton at the α- position of 
ketone on the ring was abstracted by DBU to give a lithium enolate, which was readily 
cyclized through an intramolecular aldol reaction with attack of the carbonyl of the side-chain. 
The resulting alkoxide would then abstract a proton from the conjugated base (DBU-H+) to 
give the β-ketol product 3.20, and regenerate the base (DBU) and lithium salt being 
regenerated at the same time.   
 
 
Figure 79. Proposed catalytic cycle in the LiBr pre-coordination model. 
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 In support of lithium chelating pre-organization (Figure 79), indirect evidence was 
provided by study of 3.18 using 13C NMR spectroscopy. In the presence of LiBr in d8-THF, 
the carbonyl peaks of 3.18 were clearly shifted to lower field (Figure 80). Although this does 
not necessarily prove the formation of chelated 3.18-LiBr complex as in Figure 79, the role of 
LiBr for chelating and activation may be inferred from the reaction of 3.18 with catalytic (5 
mol %) DBU alone at -40 °C; without LiBr, only a trace amount of 3.20 was observed (Table 
5, entry 7). Notably, THF as solvent was important, probably due to coordination of Li+ by 
THF in the lithium cheating complexes (Figure 79). In MeOH, the major product was ketol 
3.19 (with the equatorial hydroxyl group), presumably due to solvation of triketone 3.18 by 
MeOH, preventing coordination with LiBr (Table 6, entries 6). 
 
Trione 3.18 (51mg, 0.28 mmol) with LiBr (24 mg, 0.28 mmol) in deuterated THF (0.5 mL) 
Figure 80. 13C NMR spectra study of 3.18. 
 
 Hajos and Parrish demonstrated that ketol 3.19 was the kinetic product, and ketol 3.20, 
generated from 3.19, was the thermodynamic product (Scheme 59).28 Thus, it could be argued 
that in our catalytic synthesis, ketol product 3.20 could also be generated from 3.19 by a retro-
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aldol reaction. To prove that 3.20 was directly formed from triketone 3.18 via the proposed 
lithium-chelating model (Figure 79), kinetic product 3.19 was treated under the same 
conditions (5 mol % DBU and LiBr, at - 40 °C for 24 h), only 4 % of ketol 3.20 and 6 % of 
3.21 were observed from crude 1H NMR spectra (Table 10, entry 1). This indicated that ketol 
3.20 is generated directly from starting triketone 3.19. Warming the reaction to room 
temperature, more ketol products 3.20 and 3.21 were obtained due to the faster equilibrium 
(retro-aldol and aldol) in the reaction (Table 10, entry 2). The equilibrium of ketol 3.20 was 
also tested at room temperature (Table 10). After 24h, 3.20 was transformed to starting 
triketone 3.18, and ketol products 3.19 and 3.21 (Table 10). This confirmed the observation 
that a lower yield of 3.20 was obtained from 3.18 at room temperature compared to the one at 
-40 °C (Compare Table 2, entries 4 and 6). Thus, - 40 °C temperature is crucial for this 
catalytic reaction to produce β-ketol 3.20 as the major product. 
 
Table 10. Equilibration reactions between 3.19 and 3.20. 
 
The reactions were run with 0.14 mmol ketol in 1 mL THF for 24 h. a Calculated from 1H NMR spectra of 
crude reaction mixture. 
  
 To further analyze the proposed LiBr pre-coordination model, a DFT calculation was 
conducted by Dr. Gilles Berger (Figure 81). Theoretical calculations demonstrated that the 
formation of a complex between triketone 3.18 and LiBr (3.18LiBr) was associated with a 
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decrease in the free energy of about 1.6 kcal.mol-1, thus favoring LiBr pre-organization of 3.18 
(Figure 81). In the presence of a base (DBU), the α-proton of the ketone is abstracted, 
followed by generation of the corresponding enolate. Calculation results indicated the 
enolization is highly favored (5 kcal mol-1) for the methylene ketone on the ring (ELi-1) 
compared to the methyl ketone on the side-chain (ELi-2). For the transition states leading to 
ketol products 3.20 and 3.21 respectively, both of the free energies are around 10 kcal.mol-1 
higher than the starting triketone 3.18, and with a ΔΔGǂ of 1.2 kcal.mol-1 favoring the 
formation of 3.20. Also in the more stable transition state (TSLi-1), the length of the forming C-
C bond is significantly shorter (2.13 Å versus 2.23 Å.). Compared to the starting triketone 
3.18, the cyclized ketol products 3.20 and 3.21 are less stable in calculated energy, which is 
consistent with our observation in the equilibration experiment (Table 10) (ketol 3.20 could 
give back 3.18 through a retro-aldol reaction), and in accordance with previous DFT 
studies.51,52  
 
Reaction pathway: enolization of ketone on the 5-membered ring is represented in blue, while the enolization 
occuring on the side-chain is drawn in black. 
Figure 81. Free energy profile of the DBU & LiBr-catalyzed reaction in THF at 233 K. 
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4-3-1-2 Bifunctional H-bonded mechanism  
 In addition to using LiBr and catalytic base, we found that the reaction of 3.18 can be 
catalyzed by Eschenmoser’s amidine alone (Table 8, entry 11), and more efficiently by TBD 
(Table 8, entry 15). A different mechanism was proposed (Figure 82), in which the ketone on 
ring of triketone 3.18 was enolized by 5 mol % TBD, leading to a H-bonded transition state 
with the enol and side chain carbonyl group aligned by a bridging TBD (Figure 82A). 
Intramolecular aldol reaction generated β-ketol 3.20 with recovery of catalytic TBD. A similar 
mechanism could operate in the presence of the Eschenmoser’s amidine (Figure 82B).53 
 
 
Figure 82. Proposed bifunctional H-bonded mechanism. 
 
 Baati, Himo and coworkers52, 54  have reported a DFT study of TBD catalyzed 
intramolecular aldol reactions of acyclic ketoaldehydes. They proposed a proton shuffling 
general base mechanism, in which TBD acts as a bifunctional catalyst, acting as a proton 
donor and acceptor, aiding proton transfer from enol to the aldehyde during C-C bond 
formation (Figure 83). A similar mechanism may be involved in our intramolecular aldol 
reaction of 3.18. Computational analysis of the reaction catalyzed by TBD with DFT was 
conducted by Dr. Gilles Berger (Figure 84). Enolization of 3.18 through a TBD mediated 
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bifunctional H-bonding structure (H-bond lengths between 1.7 and 2.1 Å) was preferred with 
enolization of the methene rather that the methyl ketone. Although the activation energy was 
slightly higher  (around 2 kcal mol-1) compared to the LiBr-catalyzed reaction (Figure 81), the 
intracyclic enolate (TSTBD1) was favored rather than the side-chain enolate (TSTBD2) with a 
energy difference ΔΔGǂ about 1.2 kcal mol-1. The C-C distance was also shorter in the 
transition state (TSTBD1), which leads to ketol product 3.20. Thus, ketol 3.20 was favored due 
to faster enolization and less energetic transition state. 
 
 
Figure 83. Baati’s proton shuffling general base mechanism.52  
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Reaction pathway: enolization of ketone on the 5-membered ring is represented in blue, while the enolization 
occuring on the side-chain is drawn in black. 
Figure 84. Free energy profile of the TBD-catalyzed reaction in THF at 233 K. 
 
 The catalytic effect of TBD with and without LiBr was also observed in other triketone 
substrates (Table 11). Excellent yields of the ketol product were obtained from 2-methyl-2-(3-
oxobutyl)cyclohexane-1,3-dione (4.4) (Table 11, entries 1 and 2). The reaction of phenyl 
trikeone 4.5 and TBD was not completed after 72 h, and gave a modest yield of β-ketol 
product (Table 11, entries 3). The ketone on the side-chain of 4.5 is stabilized by the phenyl 
group, and bulkier than 3.18, which may account for the lower yield. The conversion of 
phenyl triketone 4.5 was not improved using LiBr (Table 11, entries 4). Switching to benzyl 
triketone 4.6, gave the desired axial β-ketol 4.7 in only 30-40 % yield (Table 11, entries 5 and 
6). The efficiency of the TBD reaction was thus dependent on ketone substrate.      
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Table 11. Reactions with other triketones catalyzed by TBD with and without LiBr. 
 
Entry Substrate Base / Additive (5%) Yield (%)a 
1 
(4.4)  
85 
2 
 LiBr 
86 
3 
(4.5)  
50b 
4 
 LiBr 
33b 
5                           
 (4.6) 
 
 
33 
 
6 
 LiBr 
40 
The reactions were run with 0.14 mmol triketone in 1 mL THF at - 40 °C. Entries 1-2, 24 h; entires 3-6, 72h. a 
Isolated yield. b Calculated from 1H NMR spectra of crude reaction mixture. 
 
 Intermolecular self-aldol reactions were studied using 5-hexen-2-one 3.13 in the 
presence of 1 equiv. TBD, but no reaction took place (Table 12, entry 1) in the absence and 
presence of LiBr (1 equiv.) (Table 12, entry 2). Adding stoichiometric amounts of MgBr2 to 
the TBD reaction gave the ketol 3.14a in 48 % yield (Table 12, entry 3), but on decreasing the 
quantities of TBD and MgBr2 to catalytic amounts (5 mol %), 3.14a was no longer observed. 
With stoichiometric amount of TBD serving as base, the β-ketol 3.14a may be generated 
through a magnesium chelated transition state, rather than by a TBD-mediated H-bonding 
mechanism. An indirect evidence of the magnesium chelate was obtained using (1 equiv.) 
Et3N and MgBr2, which gave 3.14a in 51 % yield. 
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Table 12. Intermolecular Reactions in the presence of TBD with and without additives. 
 
Entry Base (equiv.) Additive (equiv.) Time (h) Yield (%)a 
1 
 (1.00) 
- 24 n.r. 
2 
 (1.00) 
LiBr (1.00) 24 n.r. 
3 
 (1.00) 
MgBr2 (1.00) 1 48 
4 
 (0.05) 
MgBr2 (0.05) 24 n.r. 
5 Et3N (1.00)  24 n.r. 
6 Et3N (1.00) LiBr (1.00) 24 n.r. 
7 Et3N (1.00) MgBr2 (1.00) 2 51 
The reactions were run with 0.25 mmol methyl ketone 3.13, in 2 mL THF. a Isolated yield. 
 
4-3-2 Studies toward the symmetric syntheses of β-ketols from benzyl 
triketone 4.6  
 Intrigued by the proposed H-bonded mechanism (Figure 82), we hypothesized that in 
the reaction of benzyl triketone 4.6, chiral naphthyl amidine 4.3 may serve as a bifunctional 
catalyst to generate enantioselectively β-ketol (axial alcohol) 4.7, by a mechanism featuring π-
π stacking of the phenyl ring of 4.6 and naphthyl group in 4.3 (Figure 85). 
 
Figure 85. Hypothesis for enantioselective synthesis of β-ketol 4.7 from benzyl triketone 4.6. 
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 Benzyl triketone 4.6 was treated with amidine catalyst 4.3 at - 40 °C for 72 h, but 
racemic β-ketol 4.7 was obtained in only 4 % yield. The major product, 4.8 was a Hajos-
Parrish type of ketol (Table 13, entry 1). Although a modest improvement in yield of ketol 4.7 
in the presence of LiBr, β-ketol 4.8 remained the major product, and no enantioselectivity was 
observed for 4.7 (Table 13, entry 2). Switching to a catalytic amount DBU at - 40 °C led to the 
formation of diastereomer 4.9 in 83 % yield (Table 13, entry 3). The combination of DBU and 
LiBr gave the ketol 4.7 in 16 % yield, accompanying with 4.8 in 81 % yield (Table 13, entry 
4). Treatment of 4.6 with 5 mol% DBU at - 78 °C produced ketol 4.8 in 82 % yield (Table 13, 
entry 5). The relative configurations of all three ketol products were confirmed by single 
crystal X-ray analysis (Figure 86).  
 
Table 13. Reactions with benzyl triketone 4.6. 
 
Entry 
Base / Additive 
(5 mol %) 
Temperature 
(°C) 
4.7  
Yield (%)a 
4.8  
Yield (%)a 
4.9  
Yield (%)a 
1 
(4.3) 
- 40 4 85 - 
2 
LiBr 
- 40 27 65 - 
3 DBU - 40 - - 83 
4 DBU, LiBr - 40 16 81 - 
5 DBU - 78 - 82 - 
The reactions were run with 0.14 mmol triketone in 1 mL THF for 72 h. a Isolated yield. 
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            4.8                                        4.7                               4.9 
Figure 86. X-ray structure of ketols 4.7, 4.8 and 4.9. 
 
 Although the attempt to enantioselectively synthesize ketol 4.7 was not successful, 
high diastereoselectivity was achieved in forming ketol 4.8 and 4.9. The generation of 4.7 and 
4.8 using base and LiBr, and amide 4.3 at - 40 °C (Table 13, entries 1, 2 and 4) may be 
explained by pre-coordination mechanisms (Figure 79, 82 and 87). The transition structures 
were modeled using DFT calculations in the gas phase at the ωB97x-D/def2-TZVP level by 
Dr. Gilles Berger (Figure 87A). With LiBr and base, ΔΔGǂ was found about 6 kcal mol-1 in 
favor of phenyl ring at the equatorial position. Amidine 4.3 may favour ketol 4.8 by a H-
bonding mechanism (Figure 87B).  
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Figure 87. Proposed Li-coordinated and bifunctional H-bonding transition states model in the 
reaction of benzyl triketone 4.6 at - 40 °C. 
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 Temperature was important for the diastereoselective cyclization of 4.6. Using 5 mol % 
DBU at - 40 °C, a chair conformation may be was preferred to give the more stable ketol 
product 4.9 (Figure 88). At - 78 °C, ketol 4.8 was generated as the kinetic product, through 
another chair transition state (Figure 88). The kinetic property of ketol 4.8 was also confirmed 
by treating it with 5 % DBU at 0 °C, giving the more stable ketol 4.9 in 39 % yield as 
calculated from the 1H NMR spectrum of the crude reaction mixture (Table 14, entry 2). In 
contrast, treatment of ketol 4.9 under the same condition, only 8 % starting benzyl triketone 
4.6 was observed after 12 h, which was generated through a retro-aldol reaction (Table 14). 
 
Figure 88. Proposed transition state model and effect of the temperature in the reaction of 
benzyl triketone 4.6 with DBU.  
Table 14. Equilibrium reactions between ketol 4.8 and 4.9. 
 
Entry Temperature (°C) 4.6 Yield (%)a 
4.7 
Yield (%)a 
4.9 
Yield (%)a 
1 - 40  n.r.  
2 0 27 23 39 
 
The reactions were run with 0.14 mmol ketol in 1 mL THF for 12 h. a Calculated from 1H NMR spectra of crude 
reaction mixture. 
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4-3-3 β-Ketol formation from a benzyl diketone 4.10 
 Based on all the previous observations and mechanistic studies in the β-ketol formation 
from aldol reactions, we hypothesized that if 1-phenylheptane-2,6-dione (4.10) was treated 
with catalytic amount DBU and LiBr, first, there should be no intermolecular aldol reaction 
since it requires a stoichiometric amount base and MgBr2 (Table 12), then in the 
intromolecular reaction, it should give only one β-ketol diastereomer due to the LiBr pre-
organzation. The same result would be expected by using catalytic amount TBD. Thus, to 
prove our hypothesis, benzyl diketone 4.10 was firstly treated with 5 mol% DBU, there was no 
reaction (Table 15, entry 1). Then, upon addition of 5% LiBr, the reaction gave ketol 4.11 as a 
single diastereomer in 74 % yield (Table 12, entry 2). The same ketol product was also 
obtained using 5 mol% TBD as we expected (Table 12, entry 2). The relative configuration of 
4.11 was confirmed by singer crystal x-ray analysis (Figure 89). Treating 4.10 with chiral 
amidine 4.3 with and without LiBr, there was no reaction at - 40 °C. It is notable that under the 
same conditions, benzyl triketone 4.6 was enolized (Table 13, entries 1 and 2). At room 
temperature, with the combination of amidine and LiBr, 23 % ketol product 4.11 was observed 
from 1H NMR of the crude mixture (Table 15, entry 7). Extending the reaction time to 72 h, 
however, no additional ketol 4.11 was obtained (Table 15, entry 8). Therefore, these results 
confirmed our hypothesis, and supported the proposed lithium pre-organization and 
bifunctional H-bonded mechanisms (Figure 90). 
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Table 15. Intramolecular aldol reaction of 1-phenylheptane-2,6-dione (4.10). 
 
Entry Base / Additive (5 %) 
Temperature 
(°C) Time (h) 
4.11  
Yield 
(%)a 
1 DBU - 40 12 n.r. 
2 DBU, LiBr - 40 12 74 
3 
 
- 40 12 85 
4 
 
- 40 12 n.r. 
5 
LiBr 
- 40 12 n.r. 
6 
 
r.t. 12 n.r. 
7 
LiBr 
r.t. 12 23b 
8 
LiBr 
r.t. 72 23b 
The reactions were run with 0.14 mmol diketone in 1 mL THF for 12 h. a Isolated yield. b Calculated from 1H 
NMR spectra of crude reaction mixture. 
 
 
Figure 89. X-ray structure of ketol 4.11. 
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Figure 90. Proposed transition state model in the cyclization of diketone 4.10. 
 
4-4 Conclusion 
 Inspired by the observation of β-ketol product 3.20 from intramolecular cyclization of 
triketone 3.18, we screened reaction temperatures, catalyst loadings, additives, as well as 
chiral and achiral bases. This led to the successful development of a catalytic synthesis of 
ketol 3.20, which can be highly efficiently generated either through a lithium pre-organization 
mechanism, by using a combination of a suitable base (e.g. DBU) and lithium salt (e.g. LiBr) 
as the catalysts, or via a bifunctional H-bonding mechanism, by using TBD as the catalyst. 
These mechanisms were also supported by DFT computational studies. In addition to triketone 
3.18, Our methods of catalytic synthesis of β-ketol were also applicable to other ketone 
substrates (e.g. benzyl trikeone 4.6 and benzyl dikeone 4.10). While, for intermolecular 
reactions, it was found that stoichiometric amount of base and MgBr2 were essential. 
 
 In the efforts of asymmetric synthesis of β-ketol, although so far there was no success 
with chiral amidines, we have designed a new chiral catalyst 4.12 based on the predications by 
DFT calculations (Figure 91). Thus, it is proposed that the π-stacking was not possible due to 
the shorter connecting chain between the naphthyl group and the amidine motif in 4.3 (Figure 
85 and 91). By adding one more carbon to extend the connecting chain, and also changing the 
substitution on the naphthalene to 2-position rather than 1-position, 4.12 could act as 
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bifunctional catalyst through a possible π-stacking and H-bonding transition model and the 
enantioselectivity could be introduced from the chiral methyl group in the catalyst 4.12 
(Figure 91). The synthesis of catalyst 4.12 is currently in progress.  
 
 
Figure 91. Proposed bifunctional chiral amidine catalyst and the transition state model from 
DFT calculations. 
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4-5 Experimental 
  
 General methods are same as described in the experimental section in Chapter 1. 
 
 General procedure: ketone substrate was dissolved in solvent in a dried flask. The 
resulting solution was stirred for 0.5 h, then base or base and additive were added to the 
solution. The reaction mixture was stirred for 24-72h, quenched with saturated aqueous NH4Cl 
and extracted by CH2Cl2. The organic phases were combined, washed with brine, dried over 
MgSO4 and filtered. The solvent was removed under reduced pressure and the residue was 
purified by flash chromatography. 
 
 For screening conditions, all the reactions were run with 3.18 (25 mg, 0.14 mmol) in 
anhydrous solvent (1 mL) for 24 h. Pure reference ketol products 3.19 and 3.21 were 
synthesized according to reported procedures by Hajos and Parrish.37 The spectroscopic data 
were in agreement with the proposed structures and matched those reported in the 
literature.37,41  
 
 
(±)-4α-Hydroxy-1β, 4β-dimethylbicyclo[3.2.l]octane-7,8-dione (3.19). White solid, yield 
(70%). 1H NMR (400 MHz, CDCl3) δ 3.05 (d, J = 19.4 Hz, 1H), 2.80 (d, J = 7.6 Hz, 1H), 2.53 
(dd, J = 19.4, 7.6 Hz, 1H), 1.92-1.69 (m, 4H), 1.62-1.53 (m, 1H), 1.41-1.40 (m, 3H), 1.07 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 213.1, 211.1, 58.5, 58.0, 40.9, 35.5, 32.84, 26.8, 11.5. 
HRMS (ESI) calcd for C10H14NaO3 (M+Na)+ 205.0835, found 205.0835. 
 
 
O
HO
O
3.19
O
O OH
3.21
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(±)-3α,4,7,7α-Tetrahydro-3αβ-hydroxyl-7αβ-methyl-1,5(6H)-indandione (3.21). White 
solid, yield (56%). 1H NMR (400 MHz, CDCl3) δ 2.62 (s, 2H), 2.58-2.51 (m, 1H), 2.47-2.39 
(m, 2H), 2.38-2.25 (m, 1H), 2.02-1.98 (m, 2H), 1.92 (s, 1H), 1.79-1.74 (m, 1H), 1.72-1.67 (m, 
1H), 1.25 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 218.1, 207.9, 81.5, 52.5, 50.4, 36.5, 33.5, 
32.8, 29.7, 13.9; HRMS (ESI) calcd for C10H14NaO3 (M+Na)+ 205.0835, found 205.0839. 
 
Typical procedure of base & additive (e.g. DBU & LiBr) catalyzed reaction of 3.18: (Table 5, 
entry 4) 
 
2-Methyl-2-(3-oxobutyl)cyclopentane-1,3-dione (3.18) (25 mg, 0.14 mmol) was dissolved in 
THF (0.8 mL) in a dried flask at – 40 ºC. The solution was stirred for 0.5 h, DBU (1.1 mg, 
0.007 mmol) as 0.1 mL of a THF solution of DBU (11 mg/mL) and LiBr (0.61 mg, 0.007 
mmol) as 0.1 mL of a THF Solution of LiBr (6.1 mg/mL) were added to the solution. The 
reaction was stirred for 24 h in total, quenched with saturated aqueous NH4Cl and extracted 
with CH2Cl2 (3×10 mL). The organic phases were combined, washed with brine, dried over 
MgSO4 and filtered. The volatiles were removed under reduced pressure. The residue was 
purified by flash chromatography (hexane: EtOAc, 2:1 to 1:1) to give 3.20 (22.0 mg, 88 %) as 
white solid. 
 
Typical procedure of base (e.g. TBD) catalyzed reaction of 3.18: (Table 8, entry 15) 
2-Methyl-2-(3-oxobutyl)cyclopentane-1,3-dione (3.18) (25 mg, 0.14 mmol) was dissolved in 
THF (0.9 mL) in a dried flask at – 40 ºC. The solution was stirred for 0.5 h, TBD (0.97 mg, 
0.007 mmol) as 0.1 mL of a THF solution of DBU (9.7 mg/mL) was added to the solution. 
The reaction was stirred for 24 h in total, quenched with saturated aqueous NH4Cl and 
extracted with CH2Cl2 (3×10 mL). The organic phases were combined, washed with brine, 
dried over MgSO4 and filtered. The volatiles were removed under reduced pressure. The 
residue was purified by flash chromatography (hexane: EtOAc, 2:1 to 1:1) to give 3.20 (22.3 
mg, 89 %) as white solid. 
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1,3-Bis((R)-1-phenylethyl)imidazolidin-2-imine (4.1) was synthesized according a known 
procedure.48a The spectroscopic data were in agreement with the proposed structures and 
matched those reported in the literature.48 Colorless solid, yield (63 %). 1H NMR (400 MHz, 
CDCl3) δ 8.88 (s, 1H), 7.37-7.35 (m, 2H), 7.32-7.18 (m, 6H), 6.01 (q, J = 6.8 Hz, 2H), 3.42-
3.20 (m, 2H), 3.15 - 2.95 (m, 2H), 1.49 (d, J = 6.9 Hz, 6H). [α]D (+) 82.6°, (c 1.00, CHCl3); 
HRMS (ESI) calcd for C19H24N3 (M+H)+ 294.1965, found 294.1973. 
 
 
(S)-N-(1-(naphthalen-1-yl)ethyl)-3,4,5,6-tetrahydropyridin-2-amine hydrochloride salt 
was synthesized according a known procedure from (S)-(−)-1-(1-naphthyl)ethylamine.50 White 
solid, yield (22%). m.p. 257-259 ºC (lit.50, m.p. 258-259 °C). 1H NMR (400 MHz, D2O) δ 
8.09-8.04 (m, 2H), 8.02-7.94 (m, 1H), 7.72-7.63 (m, 2H), 7.62-7.55 (m, 2H), 5.54 (q, J = 6.7 
Hz, 1H), 3.36-3.29 (m, 1H), 3.24-3.18 (m, 1H), 2.75 (t, J = 6.0 Hz, 2H), 1.86-1.76 (m, 4H), 
1.72 (d, J = 6.7 Hz, 3H); 13C NMR (125 MHz, D2O) δ 162.7, 135.4, 133.7, 129.8, 129.2, 
128.8, 127.0, 126.3, 125.8, 122.6, 122.1, 48.3, 41.8, 26.2, 20.6, 20.3, 17.5; [α]D (-) 19.0°, (c 
0.21, CH3OH); FTIR (cm–1) (neat) 3033, 2967, 2874, 1654, 1593, 1450, 1414, 1401, 1371, 
1356, 1332, 1308, 1263, 1210, 1176, 1141, 1110, 1065, 1017, 1000, 922, 805, 783, 758; 
HRMS (ESI) calcd for C17H20N2 (M+H)+ 253.1699, found 253.1702. 
The free amidine 4.3 was then obtained by washing the hydrochloride salt with one equiv. of 
5M NaOH, followed by extracting with CH2Cl2. The organic phases were combined, washed 
with brine, dried over MgSO4 and filtered. The solvent was removed under reduced pressure 
and left on high vacuum for 2h to give 4.3 as colorless oil. 
 
Table 9, the enantiomeric excess was determined by SFC.  
NN
NH
4.1
N
H
N
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SFC conditions: ChiralPAK@AS-H, 250 x 4.6 mm, particle size 5 µm, 10 % MeOH, 150 bar 
CO2, Column temperature: 30 °C, flow rate: 3 mL/min, detection: UV 210 nm, MS.  
(Table 9. Entry 3), e.e. = 10.2 %  
 
 
 
(Table 9. Entry 4), e.e. = 6.6 % 
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(Table 9. Entry 10), e.e. = 11.9 % 
 
 
 
The e.e. of 3.20 (Table 9, entry 6) was determined by chiral GC analysis of the corresponding 
acetate of 3.20. 
 
 
(1SR,2SR,5RS)-2,5-Dimethyl-6,8-dioxobicyclo[3.2.1]octan-2-yl acetate. Et3N (33 mg, 0.33 
mmol, 46 µL) was added to a solution of 3.20 (6 mg, 0.033 mmol) in CH2Cl2 (0.5 mL) at 0 °C, 
followed by addition of Ac2O (34 mg, 0.33 mmol, 31 µL) and DMAP (0.24 mg, 0.002 mmol). 
The reaction was stirred at r.t. for 24 h, quenched with saturated aqueous NH4Cl, and extracted 
O
O
OH
3.20
Ac2O, Et3N
DMAP
CH2Cl2 O
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three time with CH2Cl2 (4 mL). The organic phases were combined, washed with brine, dried 
over MgSO4 and filtered. The volatiles were under reduced pressure. The residue was purified 
by flash chromatography (hexane: EtOAc, 4:1 to 3:1) to give the acetate (5.0 mg, 70 %) as 
white solid. m.p. 99-100 °C. 1H NMR (400 MHz, CDCl3) δ 3.67-3.66 (m, 1H), 2.71-2.50 (m, 
2H), 2.14-2.06 (m 1H), 2.07-1.94 (m, 4H), 1.87-1.82 (m, 1H), 1.76-1.60 (m, 4H), 1.08 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 212.3, 210.5, 170.2, 89.6, 58.2, 52.7, 41.8, 37.9, 31.0, 23.3, 
22.0, 11.7; FTIR (cm–1) (neat) 2928, 1769, 1729, 1454, 1432, 1407, 1371, 1301, 1245, 1200, 
1134, 1065, 1052, 1017, 983, 962, 936, 869, 841, 800; HRMS (ESI) calcd for C12H16NaO4 
(M+Na)+ 247.0941, found 247.0939. 
 
GC conditions: Agilent/HP 6890 GC series with Agilent/HP 7683 automatic liquid sampler, 
fitted with a β-cyclodextrin 120 column, 145 °C isotherm, 40 min.  
 
(Table 9. Entry 6), e.e. = 0.5 % 
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Table 11: 
 
2-Methyl-2-(3-oxobutyl)cyclohexane-1,3-dione (4.4) was synthesized according a known 
procedure.55 The spectroscopic data were in agreement with the proposed structures and 
matched those reported in the literature.56 1H NMR (400 MHz, CDCl3) δ 2.83-2.56 (m, 4H), 
2.34 (t, J = 7.4 Hz, 2H), 2.11 (s, 3H), 2.07-1.89 (m, 4H), 1.24 (s, 3H). 13C NMR (100 MHz, 
CDCl3) δ 210.3, 207.9, 116.2, 64.4, 38.5, 37.8, 30.1, 29.6, 20.2, 17.7; HRMS (ESI) calcd for 
C11H16NaO3 (M+Na)+ 219.0992, found 219.0992. 
 
 
(1RS,5RS,6SR)-6-Hydroxy-1,6-dimethylbicyclo[3.3.1]nonane-2,9-dione was obtained from 
4.4 based on the typical procedures mentioned before.  
Whitle solid. m.p. 110-112 °C. 85 % using TBD, [86 % using TBD & LiBr]. 1H NMR (400 
MHz, CDCl3) δ 2.71-2.64 (m, 1H), 2.61-2.53 (m, 1H), 2.46-2.34 (m, 1H), 2.14-2.01 (m, 3H), 
1.92 (s, 1H), 1.84-1.72 (m, 2H), 1.72-1.60 (m, 1H), 1.39 (s, 3H), 1.17 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 211.5,  211.3, 78.8, 62.4, 56.9, 38.2, 37.0, 32.4, 27.9, 19.2, 16.4; FTIR (cm-1) 
(neat) 3421, 2973, 2935, 1731, 1693, 1467, 1450, 1405, 1378, 1333, 1310, 1293, 1246, 1232, 
1218, 1178, 1150, 1123, 1090, 1066, 1048, 1022, 1009, 945, 924, 876, 815; HRMS (ESI) 
calcd for C11H16NaO3 (M+Na)+ 219.09917, found 219.09855. 
 
 
4.5 was synthesized from acetophenone: 
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1-Phenylprop-2-en-1-one was synthesized according a known procedure.57 The spectroscopic 
data were in agreement with the proposed structures and matched those reported in the 
literature.57 Yield (680 mg, 52 %). 1H NMR (400 MHz, CDCl3) δ 7.99-7.86 (m, 2H), 7.59-7.49 
(m, 1H), 7.49-7.38 (m, 2H), 7.12 (dd, J = 17.1, 10.6 Hz, 1H), 6.40 (dd, J = 17.1, 1.7 Hz, 1H), 
5.88 (dd, J = 10.6, 1.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 190.7, 137.1, 132.8, 132.2, 
129.9, 128.5, 128.4. 
 
 
2-Methyl-2-(3-oxo-3-phenylpropyl)cyclopentane-1,3-dione(4.5). 
1-phenylprop-2-en-1-one (656 mg, 5 mmol) was dissoved in EtOAc (75 mL), followed by 
addition of Et3N (506 mg, 5 mmol, 0.7 mL). The resulting solution was stirred at r.t. for 0.5 h, 
followed by addition of methyl vinyl ketone (374 mg, 3.3 mmol, 445 µL). After stirring for 6 
days, the volatiles were removed under reduced pressure. The residue was purified by flash 
chromatography (hexane: EtOAc, 3:1 to 2:1) to give the 4.5 (540 mg, 67 %) as white solid. 
m.p. 77–80 °C (lit.58, m.p. 80-82 °C). The spectroscopic data were in agreement with the 
proposed structures and matched those reported in the literature.58 1H NMR (400 MHz, 
CDCl3) δ 7.98-7.83 (m, 2H), 7.61-7.38 (m, 3H), 3.00 (t, J = 7.3 Hz, 2H), 2.97-2.72 (m, 4H), 
2.08 (t, J = 7.3 Hz, 2H), 1.18 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 215.7, 199.2, 136.4, 
133.2, 128.6, 127.9, 55.3, 34.7, 32.5, 28.4, 19.1; HRMS (ESI) calcd for C15H17O3 (M+H)+ 
245.1172, found 245.1177. 
 
 
O
Ph
O
O
O
Ph
4.5
Ph ZnCl +
O
Cl
Pd(PPh3)4
THF, 0 oC
O
Ph
O
O
O
4.6
O
O
EtOAc
Et3N
Ph
  269 
 
1-Phenylbut-3-en-2-one was synthesized according a known procedure from benzyl zinc 
chloride solution (18.5 mmol) and acryloyl chloride (1.81 g, 20 mmol).59 Colorless liquid 
(1.75 g, 65 %). The spectroscopic data were in agreement with the proposed structures and 
matched those reported in the literature.59 1H NMR (400 MHz, CDCl3) δ 7.46-7.16 (m, 5H), 
6.44 (dd, J = 17.6, 10.2 Hz, 1H), 6.34 (dd, J = 17.6, 1.4 Hz, 1H), 5.84 (dd, J = 10.2, 1.4 Hz, 
1H), 3.90 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 197.4, 135.4, 133.9, 129.3, 128.8, 128.5, 
126.8, 46.9. 
 
 
2-Methyl-2-(3-oxo-4-phenylbutyl)cyclopentane-1,3-dione (4.6) was synthesized according 
to the procedure for synthesizing 4.5. Starting from 1-phenylbut-3-en-2-one (439 mg, 3 mmol) 
and methyl vinyl ketone (224 mg, 2 mmol, 266 µL). Whitle solid. (450 mg, 87%). m.p. (55-57 
°C), 1H NMR (400 MHz, CDCl3) δ 7.43-7.22 (m, 3H), 7.21-7.11 (m, 2H), 3.64 (s, 2H), 2.87-
2.65 (m, 4H), 2.47 (t, J = 7.1 Hz, 3H), 1.86 (t, J = 7.1 Hz, 2H), 1.07 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 215.4, 207.1, 133.5, 129.1, 128.3, 126.7, 54.7, 49.5, 35.6, 34.3, 27.6, 18.5; 
FTIR (cm-1) (neat) 2949, 1754, 1704, 1601, 1493, 1453, 1418, 1406, 1365, 1329, 1307, 1279, 
1198, 1171, 1132, 1087, 1072, 1046, 1028, 989, 891, 859, 816, 791, 757, 743, 698, 649; 
HRMS (ESI) calcd for C16H19O3 (M+H)+ 259.1329, found 259.1330. 
 
 
(1SR,2RS,5RS)-2-Benzyl-2-hydroxy-5-methylbicyclo[3.2.1]octane-6,8-dione (4.7) was 
obtained from 4.6 (26 mg, 0.10 mmol) based on the typical procedure described before. White 
solid (8.7 mg, 33 % using TBD, [10.4 mg, 40 %, using TBD & LiBr]. m.p. 124-129 °C. 1H 
NMR (400 MHz, CDCl3) δ 7.40-7.29 (m, 3H), 7.18-7.16 (m, 2H), 2.91 (s, 2H), 2.81-2.59 (m, 
O
Ph
O
O
O
4.6
Ph
O
O
OHPh
4.7
  270 
3H), 2.20-2.06 (m, 1H), 1.94-1.77 (m, 3H), 1.73-1.62 (m, 1H), 1.08 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 213.3, 210.8, 134.6, 130.4, 128.8, 127.4, 81.6, 58.6, 54.4, 46.0, 42.1, 38.2, 
31.1, 11.8; FTIR (cm-1) (neat) 3490, 2918, 2850, 1762, 1716, 1498, 1448, 1403, 1373, 1354, 
1324, 1278, 1252, 1213, 1147, 1125, 1104, 1071, 1048, 1034, 1001, 965, 886, 859, 803, 778, 
716, 705, 658; HRMS (ESI) calcd for C16H19O3 (M+H)+ 259.1329, found 259.1330. 
 
 
(3aSR,4RS,7aSR)-3a-Hydroxy-7a-methyl-4-phenylhexahydro-1H-indene-1,5(4H)-dione 
(4.8) was obtained from 4.6 (26 mg, 0.10 mmol) based on the typical procedure of the reaction 
of 3.18. White solid. 22 mg, 85 % using 4.3, [16.8 mg, 65 % using 4.3 & LiBr], [81 %, 21.0 
mg using DBU], [82 %, 21.4 mg using DBU at -78 °C]. m.p. 105-107 °C. 1H NMR (400 MHz, 
CDCl3) δ 7.44-7.35 (m, 3H), 7.28-7.23 (m, 2H), 3.46 (s, 1H), 2.65 (ddd, J = 19.7, 10.0, 2.1 Hz, 
1H), 2.54-2.27 (m, 4H), 2.08 (s, 1H), 1.97 - 1.89 (m, 2H), 1.83-1.75 (m, 1H), 1.19 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 217.8, 207.2, 132.9, 131.0, 128.5, 127.9, 83.7, 61.0, 53.3, 37.4, 
34.6, 31.3, 28.7, 19.3; FTIR (cm-1) (neat) 3505, 2967, 1732, 1716, 1496, 1471, 1450, 1434, 
1410, 1379, 1353, 1320, 1301, 1279, 1263, 1213, 1182, 1127, 1096, 1044, 944, 883, 828, 777, 
748, 727, 701, 673; HRMS (ESI) calcd for C16H19O3 (M+H)+ 259.1329, found 259.1331. 
 
 
(3aSR,4SR,7aSR)-3a-hydroxy-7a-methyl-4-phenylhexahydro-1H-indene-1,5(4H)-dione 
(4.9) was obtained from 4.6 (26 mg, 0.10 mmol) based on the typical procedure of the reaction 
of 3.16. White solid (21.5 mg, 83%). m.p. 162-164 °C; 1H NMR (400 MHz, CDCl3) δ 7.42-
7.34 (m, 3H), 7.30-7.25 (m, 2H), 3.94 (s, 1H), 2.78-2.65 (m, 1H), 2.57-2.27 (m, 4H), 2.17-
2.09 (m, 1H), 1.98-1.68 (m, 3H), 1.44 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 217.5, 205.4, 
131.4, 131.3, 128.4, 128.1, 83.9, 63.2, 53.2, 36.9, 32.7, 31.0, 29.8, 12.5; FTIR (cm-1) (neat) 
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3480, 2970, 2938, 2874, 1734, 1710, 1499, 1474, 1455, 1418, 1405, 1376, 1345, 1311, 1265, 
1231, 1209, 1136, 1060, 1017, 975, 954, 873, 800, 769, 726, 703; HRMS (ESI) calcd for 
C16H19O3 (M+H)+ 259.1329, found 259.1328. 
 
Table 13, the enantiomeric excess of 4.7 was determined by SFC. 
SFC conditions: ChiralPAK@AS-H, 250 x 4.6 mm, particle size 5 µm, 10 % MeOH, 150 bar 
CO2, Column temperature: 30 °C, flow rate: 3 mL/min, detection: UV 210 nm, MS.  
 
(Table 13 entry 1) e.e < 1 %, racemic  
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(Table 13 entry 2) e.e < 1 %, racemic 
 
 
  
 
Table 15: 
 
1-Phenylheptane-2,6-dione (4.10) was prepared according to a known procedure from benzyl 
magnesium chloride solution (2.25 mmol) and 3,4-dihydro-6-methyl-2H-pyran -2-one (0.5 g, 
4.5 mmol).60 The spectroscopic data were in agreement with the proposed structures and 
matched those reported in the literature.60 Colorless solid, (50 mg, 11 %). 1H NMR (400 MHz, 
CDCl3) δ 7.37-7.31 (m, 2H), 7.29-7.25 (m, 1H), 7.23-7.19 (m, 2H), 3.67 (s, 2H), 2.49 (t, J = 
7.0 Hz, 2H), 2.40 (t, J = 7.1 Hz, 2H), 2.07 (s, 3H), 1.81 (p, J = 7.0 Hz, 2H); 13C NMR (101 
MHz, CDCl3) δ 208.3, 207.8, 134.1, 129.3, 128.7, 127.0, 50.1, 42.3, 40.6, 29.8, 17.6; HRMS 
(ESI) calcd for C13H16NaO2 (M+Na)+ 227.1043, found 227.1045. 
 
O O
4.10
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PhCH2MgClO O
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(2RS,3RS)-3-Hydroxy-3-methyl-2-phenylcyclohexan-1-one (4.11) was obtained from 4.10 
(29 mg, 0.14 mmol) based on the typical procedure of the reaction of 3.18. White solid, 21.0 
mg, 72 % using DBU & LiBr, [24.7 mg, 85 % using TBD]. m.p. 109-110 °C. 1H NMR (400 
MHz, CDCl3) δ 7.42-7.28 (m, 3H), 7.28-7.22 (m, 2H), 3.59 (s, 1H), 2.60-2.54 (m, 1H), 2.50-
2.40 (m, 1H), 2.33-2.15 (m, 1H), 2.11-1.91 (m, 3H), 1.57 (s, 1H), 1.08 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 207.9, 134.2, 130.9, 128.1, 127.3, 76.6, 66.5, 41.1, 39.0, 29.9, 21.3; FTIR (cm-
1) (neat) 3451, 3028, 2974, 2955, 2912, 1698, 1497, 1445, 1426, 1371, 1353, 1318, 1272, 
1244, 1217, 1181, 1143, 1118, 1066, 1038, 998, 960, 943, 930, 912, 888, 868, 853, 801, 
785,743, 700; HRMS (ESI) calcd for C13H17O2 (M+H)+ 205.1223, found 205.1224. 
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Annex 1: 1H and 13C NMR Spectra of Compound 1.32 
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Annex 2: 1H and 13C NMR Spectra of Compound 1.39 
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Annex 5: 1H and 13C NMR Spectra of Compound 1.65 
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Annex 6: 1H and 13C NMR Spectra of Compound 1.70 
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Annex 7: 1H, 13C and 31P NMR Spectra of Compound 
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Annex 10: 1H and 13C NMR Spectra of Compound 
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Annex 15: 1H and 13C NMR Spectra of Compound 
1.125 
 
  309 
 
 
 
 
  310 
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Annex 17: 1H and 13C NMR Spectra of Compound 
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Annex 19: 1H and 13C NMR Spectra of Compound 
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Annex 20: 1H and 13C NMR Spectra of Compound 
1.134 
 
  321 
 
 
 
 
  322 
Annex 21: 1H and 13C NMR Spectra of Compound 
1.137 
 
  323 
 
 
 
 
  324 
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Annex 28: 1H and 13C NMR Spectra of Compound 
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Annex 30: 1H and 13C NMR Spectra of Compound 2.1 
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Annex 31: 1H and 13C NMR Spectra of Compound 2.2 
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Annex 32: 1H and 13C NMR Spectra of Compound 2.3 
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Annex 33: 1H and 13C NMR Spectra of Compound 2.4 
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Annex 35: 1H and 13C NMR Spectra of Compound 2.21 
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Annex 36: 1H and 13C NMR Spectra of Compound 2.22 
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Annex 37: 1H and 13C NMR Spectra of Compound 2.30 
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Annex 38: 1H and 13C NMR Spectra of Compound 2.38 
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Annex 47: 1H and 13C NMR Spectra of Compound 3.15 
 
  375 
 
 
 
 
  376 
Annex 48: 1H and 13C NMR Spectra of Compound 3.19 
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Annex 50: 1H and 13C NMR Spectra of Compound 3.21 
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Annex 51: 1H and 13C NMR Spectra of Compound 4.3 
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Annex 52: 1H and 13C NMR Spectra of Compound 4.6 
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Annex 53: 1H and 13C NMR Spectra of Compound 4.7 
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Annex 55: 1H and 13C NMR Spectra of Compound 4.9 
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Annex 56: 1H and 13C NMR Spectra of Compound 4.10 
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Annex 57: 1H and 13C NMR Spectra of Compound 4.11 
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Annex 58: X-Ray Data for Compound 1.148 
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Table 1.  Crystal data and structure refinement for C28 H45 N1 O4. 
 
   
Identification code robe26 
Empirical formula C28H45NO4 
Formula weight 459.65 
Temperature/K 100.15 
Crystal system monoclinic 
Space group C2 
a/Å 26.5372(15) 
b/Å 5.5899(4) 
c/Å 20.8906(12) 
α/° 90 
β/° 118.206(3) 
γ/° 90 
Volume/Å3 2730.9(3) 
Z 4 
ρcalcg/cm3 1.118 
µ/mm‑1 0.576 
F(000) 1008.0 
Crystal size/mm3 0.23 × 0.06 × 0.04 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 4.8 to 142.454 
Index ranges -31 ≤ h ≤ 32, -6 ≤ k ≤ 6, -24 ≤ l ≤ 25 
Reflections collected 10895 
Independent reflections 4622 [Rint = 0.0436, Rsigma = 0.0563] 
Data/restraints/parameters 4622/29/325 
Goodness-of-fit on F2 1.005 
Final R indexes [I>=2σ (I)] R1 = 0.0635, wR2 = 0.1578 
Final R indexes [all data] R1 = 0.0714, wR2 = 0.1628 
Largest diff. peak/hole / e Å-3 0.31/-0.37 
Flack parameter 0.0(2) 
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Table 2.  Fractional atomic coordinates (× 104) and equivalent isotropic 
displacement parameters (Å2 x 103) for C28 H45 N1 O4.  
   
Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
   
Atom x y z U(eq) 
C1 830.1(15) 3805(8) 3470.3(19) 24.1(8) 
C2 1122.4(15) 2867(9) 4259.9(19) 27.7(8) 
C3 643.3(15) 2748(8) 4476.4(19) 25.0(8) 
C4 269.9(14) 4883(8) 4064.6(19) 24.9(8) 
C5 -88.3(15) 5962(8) 2787.4(19) 24.5(8) 
C6 -282.4(16) 6974(8) 1550(2) 27.1(9) 
C7 -904.0(16) 6218(9) 1166(2) 34.9(10) 
C8 -204.3(19) 9626(10) 1696(2) 37.7(10) 
C9 23.7(17) 6194(9) 1121(2) 32.9(10) 
C10 1200.8(15) 5745(8) 3396.1(19) 25.2(8) 
C11 2141.1(16) 6155(9) 3443(2) 34.2(10) 
C12 2571(2) 4271(11) 3508(3) 54.5(15) 
C13 2377.2(18) 7730(12) 4112(2) 44.3(12) 
C14 1942.7(19) 7564(11) 2746(2) 40(1) 
C15 851.5(15) 2740(8) 5284.7(19) 25.2(8) 
C16 732.1(15) 807(8) 5615(2) 26.4(8) 
C17 915.6(15) 771(8) 6360(2) 26.4(8) 
C18 1229.0(15) 2651(8) 6799.1(19) 26.5(8) 
C19 1360.6(15) 4581(8) 6475(2) 26.8(8) 
C20 1169.6(15) 4617(8) 5731(2) 25.9(8) 
C21 1431.4(17) 2601(9) 7605(2) 31.7(9) 
C22 1828.6(16) 488(9) 7996(2) 30.9(9) 
C23 2087.4(17) 631(9) 8816(2) 33.8(9) 
C24 2450.5(18) -1500(9) 9225(2) 35.4(10) 
C25 2937.2(19) -2073(12) 9049(2) 44.0(12) 
C26 3344.4(18) -3972(11) 9538(2) 41.9(11) 
C27A 3736(2) -5069(11) 9261(3) 37.1(14) 
C27B 3927(9) -3600(80) 9537(17) 44(6) 
C28A 4134(3) -3207(14) 9214(5) 64(2) 
C28B 3870(20) -3850(100) 8770(20) 66(7) 
N1 291.0(12) 4812(7) 3380.0(16) 25.5(7) 
O1 -491.0(11) 7126(6) 2749.8(15) 30.2(7) 
O2 32.3(10) 5628(5) 2228.8(13) 25.9(6) 
O3 1118.4(12) 7856(6) 3382.2(16) 34.1(7) 
O4 1658.8(11) 4685(6) 3396.1(15) 30.9(6) 
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Table 3.  Hydrogen atom coordinates (× 104) and isotropic displacement 
parameters (Å2 x 103) for C28 H45 N1 O4.  
   
Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
   
Atom x y z U(eq) 
H1 760 2476 3117 29 
H2A 1290 1263 4287 33 
H2B 1429 3969 4584 33 
H3 419 1251 4268 30 
H4A -126 4688 3985 30 
H4B 429 6400 4327 30 
H7A -928 4471 1124 52 
H7B -1094 6931 680 52 
H7C -1093 6763 1446 52 
H8A -403 10118 1969 57 
H8B -364 10494 1234 57 
H8C 204 9990 1980 57 
H9A 429 6623 1393 49 
H9B -149 7000 649 49 
H9C -13 4458 1048 49 
H12A 2701 3402 3967 82 
H12B 2899 5040 3498 82 
H12C 2393 3148 3101 82 
H13A 2106 9023 4040 66 
H13B 2743 8414 4195 66 
H13C 2435 6772 4534 66 
H14A 1768 6474 2330 60 
H14B 2271 8369 2746 60 
H14C 1661 8760 2710 60 
H16 521 -511 5325 32 
H17 825 -561 6569 32 
H19 1583 5875 6767 32 
H20 1258 5955 5522 31 
H21A 1094 2523 7688 38 
H21B 1636 4112 7821 38 
H22A 1610 -1020 7826 37 
H22B 2141 444 7864 37 
H23A 2326 2090 8985 41 
H23B 1774 805 8943 41 
H24A 2200 -2922 9112 43 
H24B 2617 -1191 9753 43 
H25A 2770 -2618 8539 53 
H25B 3156 -590 9095 53 
H26A 3118 -5270 9601 50 
H26B 3586 -3259 10022 50 
H26C 3191 -5587 9354 50 
H26D 3396 -3813 10037 50 
H27A 3965 -6369 9592 45 
H27B 3498 -5774 8774 45 
H27C 4077 -1988 9729 53 
H27D 4207 -4793 9862 53 
H28A 3908 -1966 8864 97 
H28B 4388 -3973 9055 97 
H28C 4363 -2481 9693 97 
H28D 3756 -2306 8523 99 
H28E 3573 -5046 8499 99 
H28F 4233 -4360 8810 99 
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Table 4.  Anisotropic displacement parameters (Å2 x 103) for C28 H45 N1 O4.  
   
The anisotropic displacement factor exponent takes the form: 
-2π2[h2a*2U11 + ... + 2hka*b*U12] 
   
Atom U11 U22 U33 U23 U13 U12 
C1 20.0(15) 34(2) 23.9(17) 0.7(16) 14.7(13) 3.6(16) 
C2 20.9(15) 42(2) 24.5(17) 2.1(18) 14.4(14) 5.3(19) 
C3 22.7(16) 32(2) 24.7(17) -1.9(17) 15.0(14) -1.0(18) 
C4 23.1(16) 32(2) 23.7(17) 0.0(17) 14.8(14) -2.4(18) 
C5 26.5(17) 30(2) 21.5(16) -0.1(17) 15.0(14) -1.7(18) 
C6 27.6(17) 36(2) 22.8(16) 2.6(18) 15.9(14) 3.9(18) 
C7 31.1(19) 46(3) 28.0(18) 3.9(19) 14.6(16) 2(2) 
C8 46(2) 37(2) 36(2) 4(2) 24.6(19) -1(2) 
C9 39(2) 43(3) 26.8(18) 2.3(19) 23.3(16) 3(2) 
C10 22.0(16) 32(2) 24.6(16) 2.6(17) 13.7(13) 6.1(18) 
C11 24.6(18) 41(3) 46(2) 1(2) 23.8(17) -6(2) 
C12 39(2) 55(3) 91(4) 13(3) 48(3) 0(3) 
C13 29.2(19) 66(3) 40(2) 0(3) 17.9(17) -11(2) 
C14 36(2) 51(3) 42(2) -1(2) 25.8(18) -8(2) 
C15 22.0(16) 33(2) 24.3(17) 2.9(18) 13.8(14) 6.0(18) 
C16 24.7(16) 31(2) 28.6(18) -3.1(18) 17.0(14) -0.6(18) 
C17 26.4(17) 31(2) 28.4(18) 5.7(18) 18.8(15) 5.4(18) 
C18 24.8(16) 35(2) 25.3(18) 2.4(17) 16.4(14) 9.3(18) 
C19 24.8(16) 32(2) 27.0(18) -1.7(18) 14.9(14) 3.5(18) 
C20 24.3(16) 31(2) 28.5(18) 5.0(18) 17.4(14) 3.5(18) 
C21 38(2) 38(2) 25.9(18) 1.4(19) 20.8(16) 5(2) 
C22 30.7(18) 41(2) 26.2(18) 3.5(18) 18.1(15) 7.1(19) 
C23 34.7(19) 45(3) 25.9(19) 0(2) 17.7(16) 2(2) 
C24 32(2) 51(3) 28.4(19) 2.7(19) 18.2(16) 2(2) 
C25 36(2) 69(3) 34(2) 9(2) 22.2(18) 8(3) 
C26 34(2) 62(3) 36(2) 7(2) 21.1(17) 8(2) 
C27A 40(3) 38(3) 38(3) -2(3) 22(2) 3(3) 
C27B 47(11) 45(12) 41(11) -1(10) 21(9) 0(11) 
C28A 57(4) 57(4) 110(6) 0(5) 65(5) -1(4) 
C28B 63(12) 59(12) 98(13) -1(11) 55(10) 5(11) 
N1 23.6(14) 34.7(18) 24.3(15) -0.6(15) 16.3(12) 3.5(16) 
O1 27.2(12) 38.7(17) 31.4(13) 4.4(13) 19.2(11) 9.1(13) 
O2 26.4(11) 35.7(15) 22.0(12) 2.1(12) 16.6(10) 5.4(13) 
O3 29.4(14) 34.5(16) 43.5(16) -1.1(15) 21.4(12) 0.7(14) 
O4 23.8(12) 36.1(16) 42.7(15) 1.6(15) 24.0(11) 1.0(14) 
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Table 5.  Bond lengths [Å] for C28 H45 N1 O4.  
   
Atom Atom Length/Å  Atom Atom Length/Å 
C1 C2 1.545(5)  C11 C14 1.515(6) 
C1 C10 1.520(5)  C11 O4 1.484(4) 
C1 N1 1.464(4)  C15 C16 1.396(6) 
C2 C3 1.539(4)  C15 C20 1.393(6) 
C3 C4 1.530(6)  C16 C17 1.394(5) 
C3 C15 1.508(5)  C17 C18 1.385(6) 
C4 N1 1.458(4)  C18 C19 1.403(6) 
C5 N1 1.335(5)  C18 C21 1.507(5) 
C5 O1 1.221(5)  C19 C20 1.387(5) 
C5 O2 1.361(4)  C21 C22 1.536(6) 
C6 C7 1.514(5)  C22 C23 1.517(5) 
C6 C8 1.508(7)  C23 C24 1.516(7) 
C6 C9 1.529(5)  C24 C25 1.534(5) 
C6 O2 1.469(5)  C25 C26 1.514(7) 
C10 O3 1.198(6)  C26 C27A 1.536(6) 
C10 O4 1.352(4)  C26 C27B 1.562(13) 
C11 C12 1.511(7)  C27A C28A 1.519(8) 
C11 C13 1.514(7)  C27B C28B 1.53(2) 
 
 
 
Table 6.  Bond angles [Å] for C28 H45 N1 O4.  
   
Atom Atom Atom Angle/˚  Atom Atom Atom Angle/˚ 
C10 C1 C2 109.2(3)  O4 C11 C14 109.1(3) 
N1 C1 C2 103.6(3)  C16 C15 C3 120.4(4) 
N1 C1 C10 110.7(3)  C20 C15 C3 122.2(4) 
C3 C2 C1 105.1(3)  C20 C15 C16 117.3(3) 
C4 C3 C2 101.9(3)  C17 C16 C15 121.4(4) 
C15 C3 C2 114.4(3)  C18 C17 C16 120.8(4) 
C15 C3 C4 115.4(3)  C17 C18 C19 118.1(3) 
N1 C4 C3 102.4(3)  C17 C18 C21 120.8(4) 
N1 C5 O2 110.5(3)  C19 C18 C21 121.0(4) 
O1 C5 N1 124.7(3)  C20 C19 C18 120.6(4) 
O1 C5 O2 124.8(3)  C19 C20 C15 121.6(4) 
C7 C6 C9 111.0(3)  C18 C21 C22 113.7(3) 
C8 C6 C7 113.1(4)  C23 C22 C21 113.0(3) 
C8 C6 C9 109.8(3)  C24 C23 C22 115.0(4) 
O2 C6 C7 110.4(3)  C23 C24 C25 114.3(4) 
O2 C6 C8 110.3(3)  C26 C25 C24 113.5(4) 
O2 C6 C9 101.7(3)  C25 C26 C27A 114.8(4) 
O3 C10 C1 125.8(3)  C25 C26 C27B 107.3(15) 
O3 C10 O4 125.8(4)  C28A C27A C26 111.4(5) 
O4 C10 C1 108.2(4)  C28B C27B C26 112(2) 
C12 C11 C13 110.9(4)  C4 N1 C1 111.8(3) 
C12 C11 C14 110.6(4)  C5 N1 C1 124.6(3) 
C13 C11 C14 112.9(4)  C5 N1 C4 122.3(3) 
O4 C11 C12 102.2(4)  C5 O2 C6 120.1(3) 
O4 C11 C13 110.6(3)  C10 O4 C11 120.3(3) 
 
  
Table 7.  Torsion angles [°] for C28 H45 N1 O4.  
  
A B C D Angle/˚  A B C D Angle/˚ 
C1 C2 C3 C4 -33.9(4)  C16 C17 C18 C19 -0.6(5) 
C1 C2 C3 C15 -159.2(4)  C16 C17 C18 C21 -179.5(3) 
C1 C10 O4 C11 -170.7(3)  C17 C18 C19 C20 1.4(5) 
C2 C1 C10 O3 -102.2(4)  C17 C18 C21 C22 60.3(5) 
C2 C1 C10 O4 73.9(4)  C18 C19 C20 C15 -1.1(5) 
C2 C1 N1 C4 8.3(4)  C18 C21 C22 C23 172.8(3) 
C2 C1 N1 C5 175.8(4)  C19 C18 C21 C22 -118.6(4) 
C2 C3 C4 N1 38.1(4)  C20 C15 C16 C17 1.0(5) 
C2 C3 C15 C16 -119.1(4)  C21 C18 C19 C20 -179.6(3) 
C2 C3 C15 C20 60.5(5)  C21 C22 C23 C24 176.0(4) 
C3 C4 N1 C1 -29.8(4)  C22 C23 C24 C25 55.1(5) 
C3 C4 N1 C5 162.4(4)  C23 C24 C25 C26 171.8(4) 
C3 C15 C16 C17 -179.4(3)  C24 C25 C26 C27A 164.5(5) 
C3 C15 C20 C19 -179.7(3)  C24 C25 C26 C27B -156.1(15) 
C4 C3 C15 C16 123.2(4)  C25 C26 C27A C28A 63.2(7) 
C4 C3 C15 C20 -57.3(4)  C25 C26 C27B C28B -60(4) 
C7 C6 O2 C5 -66.7(4)  C27A C26 C27B C28B 48(3) 
C8 C6 O2 C5 59.1(4)  C27B C26 C27A C28A -23(2) 
C9 C6 O2 C5 175.5(3)  N1 C1 C2 C3 16.6(4) 
C10 C1 C2 C3 134.5(3)  N1 C1 C10 O3 11.2(5) 
C10 C1 N1 C4 -108.5(4)  N1 C1 C10 O4 -172.7(3) 
C10 C1 N1 C5 58.9(5)  N1 C5 O2 C6 -172.1(3) 
C12 C11 O4 C10 174.1(4)  O1 C5 N1 C1 -167.8(4) 
C13 C11 O4 C10 56.0(5)  O1 C5 N1 C4 -1.7(6) 
C14 C11 O4 C10 -68.7(5)  O1 C5 O2 C6 8.7(6) 
C15 C3 C4 N1 162.7(3)  O2 C5 N1 C1 13.0(6) 
C15 C16 C17 C18 -0.7(5)  O2 C5 N1 C4 179.2(3) 
C16 C15 C20 C19 -0.1(5)  O3 C10 O4 C11 5.4(6) 
 
 
Table 8.  Atomic accompancy for C28 H45 N1 O4.  
   
Atom Occupancy  Atom Occupancy  Atom Occupancy 
H26A 0.859(10)  H26B 0.859(10)  H26C 0.141(10) 
H26D 0.141(10)  C27A 0.859(10)  H27A 0.859(10) 
H27B 0.859(10)  C27B 0.141(10)  H27C 0.141(10) 
H27D 0.141(10)  C28A 0.859(10)  H28A 0.859(10) 
H28B 0.859(10)  H28C 0.859(10)  C28B 0.141(10) 
H28D 0.141(10)  H28E 0.141(10)  H28F 0.141(10) 
 
 
 
  
404 
  
Experimental 
Single crystals of C28H45NO4 [robe26] were prepared by slow recrystallized 
from chloroform–hexanes. A suitable crystal was selected and mounted on a 
loop fiber on a 'Bruker APEX-II CCD' diffractometer. The crystal was kept 
at 100.15 K during data collection. Using Olex2 [1], the structure was 
solved with the olex2.solve [2] structure solution program using Charge 
Flipping and refined with the ShelXL [3] refinement package using Least 
Squares minimization. 
 
1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & Puschmann, 
H. (2009), J. Appl. Cryst. 42, 339-341. 
2. Bourhis, L.J., Dolomanov, O.V., Gildea, R.J., Howard, J.A.K., Puschmann, 
H. (2013). in preparation. 
3. Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122. 
4. APEX2 (2008), Bruker AXS Inc., Madison, WI 53719-1173. 
5. SAINT (2009) V7.60A, Bruker AXS Inc., Madison, WI 53719-1173. 
6. XPREP (2013); X-ray data Preparation and Reciprocal space Exploration 
Program.  Bruker AXS Inc., Madison, WI 53719-1173. 
 
Crystal structure determination of ROBE26: 
Crystal Data for C28H45NO4 (M =459.65 g/mol): monoclinic, space group C2 (no. 5), 
a = 26.5372(15) Å, b = 5.5899(4) Å, c = 20.8906(12) Å, β = 118.206(3)°, V = 
2730.9(3) Å3, Z = 4, T = 100.15 K, µ(CuKα) = 0.576 mm-1, Dcalc = 1.118 g/cm3, 
10895 reflections measured (4.8° ≤ 2Θ ≤ 142.454°), 4622 unique (Rint = 0.0436, 
Rsigma = 0.0563) which were used in all calculations. The final R1 was 0.0635 (I > 
2σ(I)) and wR2 was 0.1628 (all data). 
 
Refinement model description 
Number of restraints - 29, number of constraints - unknown. 
Details: 
1. Fixed Uiso 
 At 1.2 times of: 
  All C(H) groups, All C(H,H) groups, All C(H,H,H,H) groups 
 At 1.5 times of: 
  All C(H,H,H) groups 
2. Restrained distances 
 C27A-C28A 
 1.54 with sigma of 0.02 
 C26-C27A 
 1.54 with sigma of 0.02 
 C27B-C28B 
 1.54 with sigma of 0.02 
 C26-C27B 
 1.54 with sigma of 0.01 
3. Uiso/Uaniso restraints and constraints 
C27A ≈ C27B: within 1.7A with sigma of 0.01 and sigma for terminal atoms of 
0.01 
C28A ≈ C28B: within 1.7A with sigma of 0.01 and sigma for terminal atoms of 
0.01 
Uanis(C28A) ≈ Ueq, Uanis(C28B) ≈ Ueq: with sigma of 0.005 and sigma for 
terminal atoms of 0.02 
4. Others 
 Sof(H26C)=Sof(H26D)=Sof(C27B)=Sof(H27C)=Sof(H27D)=Sof(C28B)=Sof(H28D)= 
 Sof(H28E)=Sof(H28F)=1-FVAR(1) 
 Sof(H26A)=Sof(H26B)=Sof(C27A)=Sof(H27A)=Sof(H27B)=Sof(C28A)=Sof(H28A)= 
 Sof(H28B)=Sof(H28C)=FVAR(1) 
5.a Ternary CH refined with riding coordinates: 
 C1(H1), C3(H3) 
5.b Secondary CH2 refined with riding coordinates: 
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 C2(H2A,H2B), C4(H4A,H4B), C21(H21A,H21B), C22(H22A,H22B), C23(H23A,H23B), 
 C24(H24A,H24B), C25(H25A,H25B), C26(H26A,H26B), C26(H26C,H26D), C27A(H27A, 
 H27B), C27B(H27C,H27D) 
5.c Aromatic/amide H refined with riding coordinates: 
 C16(H16), C17(H17), C19(H19), C20(H20) 
5.d Idealised Me refined as rotating group: 
 C7(H7A,H7B,H7C), C8(H8A,H8B,H8C), C9(H9A,H9B,H9C), C12(H12A,H12B,H12C), 
 C13(H13A,H13B,H13C), C14(H14A,H14B,H14C), C28A(H28A,H28B,H28C),    
 C28B(H28D,H28E,H28F)
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ORTEP view of the C28 H45 N1 O4 compound with the numbering 
scheme adopted. Ellipsoids are drawn at the 50% probability 
level. Hydrogen atoms are represented by spheres of arbitrary 
size.  
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Annex 59: X-Ray Data for Compound 3.20 
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      Table 1.  Crystal data and structure refinement for C10 H14 O3.  
   
   
      Identification code               bent63  
   
      Empirical formula                 C10 H14 O3  
   
      Formula weight                    182.21  
   
      Temperature                       200K  
   
      Wavelength                        1.54178 Å  
   
      Crystal system                    Orthorhombic  
   
      Space group                       Pna21  
   
      Unit cell dimensions              a = 12.0380(3) Å    α = 90°  
                                        b = 10.6966(2) Å    β = 90°  
                                        c = 7.1306(2) Å    γ = 90°  
   
      Volume                            918.18(4)Å3  
   
      Z                                 4  
   
      Density (calculated)              1.318  g/cm3  
   
      Absorption coefficient            0.793 mm-1  
   
      F(000)                            392  
   
      Crystal size                      0.18 x 0.11 x 0.09 mm  
   
      Theta range for data collection   5.53 to 72.28°  
   
      Index ranges                      -14 ≤ h ≤ 14, -12 ≤ k ≤ 13, -8 ≤  ≤ 8  
   
      Reflections collected             12321  
   
      Independent reflections           1774 [Rint = 0.031]  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9311 and 0.8101  
   
      Refinement method                 Full-matrix least-squares on F2  
   
      Data / restraints / parameters    1774 / 1 / 122  
   
      Goodness-of-fit on F2             1.091  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0303, wR2 = 0.0788  
   
      R indices (all data)              R1 = 0.0307, wR2 = 0.0795  
   
      Absolute structure parameter      0.03(17)  
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      Extinction coefficient            0.0107(9)  
   
      Largest diff. peak and hole       0.151 and -0.225 e/Å3  
 
 
 
 
         Table 2.  Atomic coordinates (x 104) and equivalent isotropic  
         displacement parameters (Å2 x 103) for C10 H14 O3.  
   
         Ueq is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          O(1)         3821(1)       4490(1)       4720(2)       39(1)  
          O(2)         3328(1)       8720(1)       5183(2)       33(1)  
          O(3)          868(1)       8131(1)       6169(1)       28(1)  
          C(1)         3441(1)       5482(1)       5263(2)       27(1)  
          C(2)         3156(1)       6582(1)       4010(2)       26(1)  
          C(3)         3076(1)       7636(1)       5432(2)       24(1)  
          C(4)         2562(1)       7066(1)       7177(2)       23(1)  
          C(5)         1292(1)       6932(1)       6741(2)       24(1)  
          C(6)         1147(1)       6066(1)       5048(2)       29(1)  
          C(7)         1912(1)       6386(1)       3402(2)       30(1)  
          C(8)         3165(1)       5795(1)       7286(2)       27(1)  
          C(9)         3920(1)       6795(2)       2351(2)       38(1)  
          C(10)         652(1)       6470(1)       8448(2)       31(1)  
         ________________________________________________________________  
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         Table 3. Hydrogen coordinates (x 104) and isotropic displacement  
         parameters (Å2 x 103) for C10 H14 O3.  
   
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          H(3)          952          8648          7044          42  
          H(4)         2700          7589          8316          28  
          H(6A)        1293          5195          5446          35  
          H(6B)         366          6111          4617          35  
          H(7A)        1640          7158          2790          36  
          H(7B)        1877          5703          2467          36  
          H(8A)        3849          5862          8051          32  
          H(8B)        2676          5149          7842          32  
          H(9A)        3847          6099          1466          57  
          H(9B)        4691          6846          2789          57  
          H(9C)        3718          7578          1724          57  
          H(10A)       -128          6340          8108          47  
          H(10B)        700          7093          9452          47  
          H(10C)        972          5679          8882          47  
         ________________________________________________________________  
 
 
         Table 4.  Anisotropic parameters (Å2 x 103) for C10 H14 O3.  
   
         The anisotropic displacement factor exponent takes the form:  
   
                 -2 π2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
   
_______________________________________________________________________ 
 
U11        U22        U33        U23        U13        U12 
_______________________________________________________________________ 
 
O(1)     46(1)      31(1)      41(1)     -10(1)      -3(1)      11(1) 
O(2)     32(1)      24(1)      42(1)       4(1)       1(1)      -4(1) 
O(3)     31(1)      23(1)      30(1)      -1(1)      -2(1)       3(1) 
C(1)     25(1)      26(1)      29(1)      -3(1)      -2(1)      -1(1) 
C(2)     28(1)      29(1)      22(1)      -2(1)      -2(1)       2(1) 
C(3)     21(1)      25(1)      26(1)       0(1)      -3(1)       0(1) 
C(4)     25(1)      22(1)      22(1)      -1(1)      -1(1)      -2(1) 
C(5)     23(1)      22(1)      28(1)       1(1)       0(1)       0(1) 
C(6)     26(1)      27(1)      36(1)      -7(1)      -5(1)      -2(1) 
C(7)     31(1)      34(1)      27(1)      -8(1)      -7(1)       2(1) 
C(8)     27(1)      28(1)      25(1)       3(1)      -1(1)       2(1) 
C(9)     39(1)      50(1)      25(1)       1(1)       7(1)       0(1) 
C(10)    29(1)      29(1)      35(1)       6(1)       5(1)       1(1) 
_______________________________________________________________________ 
  
  
412 
      Table 5.  Bond lengths [Å] and angles [°] for C10 H14 O3  
    
______________________________________________________________________________ 
 
 
O(1)-C(1)              1.2185(15) 
O(2)-C(3)              1.2119(15) 
O(3)-C(5)              1.4394(13) 
C(1)-C(2)              1.5171(17) 
C(1)-C(8)              1.5186(18) 
C(2)-C(9)              1.5160(19) 
C(2)-C(3)              1.5194(17) 
C(2)-C(7)              1.5728(16) 
C(3)-C(4)              1.5170(17) 
C(4)-C(8)              1.5425(17) 
C(4)-C(5)              1.5667(17) 
C(5)-C(10)             1.5229(18) 
C(5)-C(6)              1.5321(18) 
C(6)-C(7)              1.5313(19) 
 
O(1)-C(1)-C(2)         125.00(12) 
O(1)-C(1)-C(8)         125.22(12) 
C(2)-C(1)-C(8)         109.78(10) 
C(9)-C(2)-C(1)         116.02(11) 
C(9)-C(2)-C(3)         116.62(11) 
 
 
C(1)-C(2)-C(3)         101.37(10) 
C(9)-C(2)-C(7)         112.49(11) 
C(1)-C(2)-C(7)         105.92(10) 
C(3)-C(2)-C(7)         102.86(9) 
O(2)-C(3)-C(4)         127.38(12) 
O(2)-C(3)-C(2)         126.59(12) 
C(4)-C(3)-C(2)         105.96(10) 
C(3)-C(4)-C(8)         101.78(9) 
C(3)-C(4)-C(5)         105.79(10) 
C(8)-C(4)-C(5)         112.86(9) 
O(3)-C(5)-C(10)        109.66(10) 
O(3)-C(5)-C(6)         105.95(10) 
C(10)-C(5)-C(6)        112.07(10) 
O(3)-C(5)-C(4)         108.72(9) 
C(10)-C(5)-C(4)        111.41(10) 
C(6)-C(5)-C(4)         108.84(10) 
C(7)-C(6)-C(5)         113.59(10) 
C(6)-C(7)-C(2)         113.05(11) 
C(1)-C(8)-C(4)         104.45(10) 
 
______________________________________________________________________________ 
 
      
 
 
      Table 6.  Torsion angles [°] for C10 H14 O3.  
  ______________________________________________________________________________  
  
 
  O(1)-C(1)-C(2)-C(9)      -35.89(18)  
  C(8)-C(1)-C(2)-C(9)      145.06(12)  
  O(1)-C(1)-C(2)-C(3)     -163.25(12)  
  C(8)-C(1)-C(2)-C(3)       17.71(12)  
  O(1)-C(1)-C(2)-C(7)       89.69(15)  
  C(8)-C(1)-C(2)-C(7)      -89.36(11)  
  C(9)-C(2)-C(3)-O(2)       19.28(18)  
  C(1)-C(2)-C(3)-O(2)      146.25(12)  
  C(7)-C(2)-C(3)-O(2)     -104.31(13)  
  C(9)-C(2)-C(3)-C(4)     -163.58(11)  
  C(1)-C(2)-C(3)-C(4)      -36.62(11)  
  C(7)-C(2)-C(3)-C(4)       72.83(11)  
  O(2)-C(3)-C(4)-C(8)     -141.48(12)  
  C(2)-C(3)-C(4)-C(8)       41.41(11)  
  O(2)-C(3)-C(4)-C(5)      100.40(13)  
  C(2)-C(3)-C(4)-C(5)      -76.71(11)  
  C(3)-C(4)-C(5)-O(3)      -54.18(12)  
   
 
  C(8)-C(4)-C(5)-O(3)     -164.63(10)  
  C(3)-C(4)-C(5)-C(10)    -175.14(9)  
  C(8)-C(4)-C(5)-C(10)      74.41(13)  
  C(3)-C(4)-C(5)-C(6)       60.80(12)  
  C(8)-C(4)-C(5)-C(6)      -49.66(13)  
  O(3)-C(5)-C(6)-C(7)       69.20(12)  
  C(10)-C(5)-C(6)-C(7)    -171.23(10)  
  C(4)-C(5)-C(6)-C(7)      -47.56(14)  
  C(5)-C(6)-C(7)-C(2)       48.06(14)  
  C(9)-C(2)-C(7)-C(6)      175.40(11)  
  C(1)-C(2)-C(7)-C(6)       47.68(13)  
  C(3)-C(2)-C(7)-C(6)      -58.31(13)  
  O(1)-C(1)-C(8)-C(4)     -172.07(12)  
  C(2)-C(1)-C(8)-C(4)        6.97(12)  
  C(3)-C(4)-C(8)-C(1)      -28.79(11)  
  C(5)-C(4)-C(8)-C(1)       84.13(12)  
   
  
  ______________________________________________________________________________  
 
   
  
   Table 7. Bond lengths [Å] and angles [°] related to the hydrogen  
   bonding for C10 H14 O3.  
   ______________________________________________________________________  
   
        D-H         ..A       d(D-H)      d(H..A)     d(D..A)     <DHA  
   
     O(3)-H(3)      O(1)#1     0.84        2.13       2.9433(14)  163.8  
   
   ______________________________________________________________________  
   
    Symmetry transformations used to generate equivalent atoms:  
   
         #1 -x+1/2,y+1/2,z+1/2      
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   ORTEP view of the C10 H14 O3 compound with the numbering scheme adopted. 
Ellipsoids drawn at 30% probability level. Hydrogen atoms are represented by 
sphere of arbitrary size. 
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      Table 1.  Crystal data and structure refinement for C16 H18 O3.  
   
   
      Identification code               bent93  
   
      Empirical formula                 C16 H18 O3  
   
      Formula weight                    258.30  
   
      Temperature                       100K  
   
      Wavelength                        1.54178 Å  
   
      Crystal system                    Orthorhombic  
   
      Space group                       P212121  
   
      Unit cell dimensions              a = 11.8790(2) Å    α = 90°  
                                        b = 12.1705(2) Å    β = 90°  
                                        c = 37.5309(8) Å    γ = 90°  
   
      Volume                            5425.97(17)Å3  
   
      Z                                 16  
   
      Density (calculated)              1.265  g/cm3  
   
      Absorption coefficient            0.697 mm-1  
   
      F(000)                            2208  
   
      Crystal size                      0.10 x 0.06 x 0.04 mm  
   
      Theta range for data collection   2.35 to 70.91°  
   
      Index ranges                      -14 ≤ h ≤ 14, -14 ≤ k ≤ 14, -45 ≤  ≤ 45  
   
      Reflections collected             80689  
   
      Independent reflections           10395 [Rint = 0.041]  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9725 and 0.9124  
   
      Refinement method                 Full-matrix least-squares on F2  
   
      Data / restraints / parameters    10395 / 1 / 694  
   
      Goodness-of-fit on F2             0.939  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0300, wR2 = 0.0663  
   
      R indices (all data)              R1 = 0.0362, wR2 = 0.0677  
  419 
   
      Absolute structure parameter      0.00(9)  
   
      Extinction coefficient            0.00017(2)  
   
      Largest diff. peak and hole       0.156 and -0.165 e/Å3  
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         Table 2.  Atomic coordinates (x 104) and equivalent isotropic  
         displacement parameters (Å2 x 103) for C16 H18 O3.  
   
         Ueq is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          O(11)        1935(1)       4998(1)       7963(1)       31(1)  
          O(12)        5655(1)       5294(1)       7710(1)       28(1)  
          O(13)        2177(1)       7424(1)       8285(1)       25(1)  
          C(11)        2798(1)       5526(1)       7934(1)       22(1)  
          C(12)        3956(1)       5209(1)       8070(1)       22(1)  
          C(13)        4697(1)       5580(1)       7762(1)       22(1)  
          C(14)        4045(1)       6396(1)       7535(1)       24(1)  
          C(15)        2951(1)       6614(1)       7746(1)       22(1)  
          C(16)        3099(1)       7502(1)       8040(1)       21(1)  
          C(17)        4151(1)       7246(1)       8260(1)       21(1)  
          C(18)        4196(1)       6044(1)       8379(1)       24(1)  
          C(19)        4098(1)       4032(1)       8193(1)       31(1)  
          C(110)       3136(1)       8636(1)       7862(1)       24(1)  
          C(111)       3313(1)       9602(1)       8107(1)       24(1)  
          C(112)       4391(1)       9978(1)       8184(1)       29(1)  
          C(113)       4552(2)      10879(1)       8404(1)       34(1)  
          C(114)       3642(2)      11414(1)       8550(1)       36(1)  
          C(115)       2572(2)      11063(1)       8472(1)       36(1)  
          C(116)       2404(1)      10165(1)       8252(1)       30(1)  
          O(21)       10115(1)       8483(1)       7975(1)       36(1)  
          O(22)        6409(1)       8415(1)       7697(1)       33(1)  
          O(23)        9878(1)       6047(1)       8209(1)       28(1)  
          C(21)        9241(1)       8009(1)       7920(1)       27(1)  
          C(22)        8089(1)       8304(1)       8064(1)       27(1)  
          C(23)        7339(1)       8047(1)       7746(1)       26(1)  
          C(24)        7954(1)       7252(1)       7501(1)       27(1)  
          C(25)        9068(1)       6986(1)       7698(1)       25(1)  
          C(26)        8941(1)       6025(1)       7970(1)       23(1)  
          C(27)        7903(1)       6228(1)       8202(1)       24(1)  
          C(28)        7856(1)       7398(1)       8351(1)       29(1)  
          C(29)        7968(2)       9449(1)       8214(1)       39(1)  
          C(210)       8893(1)       4939(1)       7763(1)       25(1)  
          C(211)       8702(1)       3927(1)       7985(1)       22(1)  
          C(212)       7611(1)       3583(1)       8066(1)       25(1)  
          C(213)       7430(1)       2672(1)       8278(1)       30(1)  
          C(214)       8325(2)       2084(1)       8412(1)       33(1)  
          C(215)       9406(2)       2399(1)       8326(1)       35(1)  
          C(216)       9596(1)       3312(1)       8116(1)       29(1)  
          O(31)        7681(1)       5566(1)       9578(1)       33(1)  
          O(32)        7262(1)       1894(1)       9775(1)       37(1)  
          O(33)        5267(1)       5416(1)       9243(1)       28(1)  
          C(31)        7135(1)       4729(1)       9600(1)       25(1)  
          C(32)        7434(1)       3615(1)       9450(1)       26(1)  
          C(33)        7009(1)       2853(1)       9742(1)       28(1)  
          C(34)        6183(1)       3477(1)       9976(1)       29(1)  
          C(35)        6010(1)       4576(1)       9783(1)       25(1)  
          C(36)        5117(1)       4502(1)       9478(1)       23(1) 
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         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
  
          C(37)        5351(1)       3499(1)       9249(1)       26(1)  
          C(38)        6589(1)       3435(1)       9134(1)       29(1)  
          C(39)        8645(1)       3449(1)       9333(1)       35(1)  
          C(310)       3939(1)       4505(1)       9644(1)       26(1)  
          C(311)       2974(1)       4423(1)       9383(1)       24(1)  
          C(312)       2459(1)       3421(1)       9312(1)       29(1)  
          C(313)       1569(1)       3360(2)       9072(1)       36(1)  
          C(314)       1198(1)       4281(2)       8897(1)       36(1)  
          C(315)       1703(1)       5277(2)       8962(1)       35(1)  
          C(316)       2576(1)       5354(1)       9207(1)       30(1)  
          O(41)        4142(1)       7274(1)       9674(1)       45(1)  
          O(42)        3978(1)      11005(1)       9784(1)       41(1)  
          O(43)        6460(1)       7592(1)       9347(1)       35(1)  
          C(41)        4538(1)       8188(1)       9686(1)       31(1)  
          C(42)        4067(1)       9201(1)       9511(1)       32(1)  
          C(43)        4392(1)      10096(1)       9773(1)       29(1)  
          C(44)        5324(1)       9670(1)      10012(1)       30(1)  
          C(45)        5628(1)       8538(1)       9855(1)       27(1)  
          C(46)        6494(1)       8603(1)       9540(1)       25(1)  
          C(47)        6099(1)       9476(1)       9278(1)       29(1)  
          C(48)        4850(1)       9351(2)       9180(1)       37(1)  
          C(49)        2835(1)       9166(2)       9404(1)       49(1)  
          C(410)       7657(1)       8824(1)       9693(1)       32(1)  
          C(411)       8606(1)       8934(1)       9427(1)       27(1)  
          C(412)       9147(1)       8016(1)       9292(1)       36(1)  
          C(413)      10016(1)       8123(2)       9049(1)       45(1)  
          C(414)      10372(1)       9151(2)       8942(1)       44(1)  
          C(415)       9848(2)      10069(2)       9079(1)       44(1)  
          C(416)       8974(1)       9961(1)       9318(1)       35(1)  
         ________________________________________________________________  
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         Table 3. Hydrogen coordinates (x 104) and isotropic displacement  
         parameters (Å2 x 103) for C16 H18 O3.  
   
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          H(13)        1580          7615          8182          38  
          H(14A)       3874          6081          7297          29  
          H(14B)       4478          7084          7502          29  
          H(15)        2304          6785          7585          26  
          H(17A)       4166          7727          8472          25  
          H(17B)       4827          7412          8115          25  
          H(18A)       3635          5930          8571          29  
          H(18B)       4949          5890          8480          29  
          H(19A)       3927          3532          7995          46  
          H(19B)       3584          3885          8391          46  
          H(19C)       4876          3915          8271          46  
          H(11A)       3749          8632          7683          29  
          H(11B)       2420          8747          7732          29  
          H(112)       5024          9612          8085          34  
          H(113)       5293         11128          8453          41  
          H(114)       3754         12023          8704          43  
          H(115)       1942         11440          8569          43  
          H(116)       1659          9930          8200          36  
          H(23)       10452          5801          8105          42  
          H(24A)       8107          7597          7267          32  
          H(24B)       7504          6577          7463          32  
          H(25)        9705          6860          7529          30  
          H(27A)       7905          5700          8402          29  
          H(27B)       7218          6091          8058          29  
          H(28A)       8419          7468          8544          35  
          H(28B)       7103          7525          8456          35  
          H(29A)       8468          9534          8420          58  
          H(29B)       7187          9569          8288          58  
          H(29C)       8171          9988          8031          58  
          H(21A)       8282          4990          7584          30  
          H(21B)       9610          4849          7631          30  
          H(212)       6986          3980          7974          30  
          H(213)       6683          2448          8331          36  
          H(214)       8199          1469          8562          40  
          H(215)      10026          1985          8412          41  
          H(216)      10346          3521          8060          35  
          H(33)        5165          6004          9355          43  
          H(34A)       6498          3595         10217          35  
          H(34B)       5463          3073          9997          35  
          H(35)        5841          5187          9953          29  
          H(37A)       4867          3525          9034          31  
          H(37B)       5154          2829          9385          31  
          H(38A)       6730          3999          8949          35  
          H(38B)       6731          2706          9026          35  
          H(39A)       8842          4002          9154          52  
          H(39B)       8729          2713          9230          52  
          H(39C)       9144          3523          9539          52  
          H(31A)       3887          3881          9813          31  
          H(31B)       3849          5189          9784          31  
          H(312)       2718          2774          9427          35  
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         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
 
          H(313)       1214          2673          9029          43  
          H(314)        594          4231          8731          43  
          H(315)       1455          5915          8839          42  
          H(316)       2906          6049          9255          36  
          H(43)        6849          7119          9454          52  
          H(44A)       5058          9599         10260          36  
          H(44B)       5982         10169         10006          36  
          H(45)        5877          8011         10044          33  
          H(47A)       6559          9429          9059          35  
          H(47B)       6221         10211          9385          35  
          H(48A)       4763          8707          9021          45  
          H(48B)       4606         10010          9046          45  
          H(49A)       2719          8579          9229          73  
          H(49B)       2620          9873          9298          73  
          H(49C)       2371          9024          9614          73  
          H(41A)       7621          9510          9835          38  
          H(41B)       7846          8219          9859          38  
          H(412)       8919          7305          9367          44  
          H(413)      10371          7485          8956          54  
          H(414)      10969          9225          8775          52  
          H(415)      10092         10780          9009          53  
          H(416)       8618         10600          9410          42  
         ________________________________________________________________  
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    Table 4.  Anisotropic parameters (Å2 x 103) for C16 H18 O3.  
   
         The anisotropic displacement factor exponent takes the form:  
   
                 -2 π2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    O(11)    20(1)      25(1)      47(1)      -3(1)       1(1)      -4(1)  
    O(12)    19(1)      32(1)      34(1)      -7(1)      -1(1)       3(1)  
    O(13)    18(1)      27(1)      30(1)       2(1)       5(1)       2(1)  
    C(11)    20(1)      22(1)      24(1)      -5(1)       2(1)       1(1)  
    C(12)    19(1)      19(1)      28(1)       1(1)      -1(1)       1(1)  
    C(13)    20(1)      20(1)      25(1)      -7(1)      -4(1)      -1(1)  
    C(14)    24(1)      25(1)      24(1)      -1(1)       1(1)       2(1)  
    C(15)    17(1)      24(1)      25(1)       0(1)      -5(1)       2(1)  
    C(16)    18(1)      22(1)      24(1)       2(1)       2(1)       1(1)  
    C(17)    19(1)      23(1)      22(1)       0(1)      -1(1)      -2(1)  
    C(18)    22(1)      26(1)      24(1)       3(1)      -3(1)       2(1)  
    C(19)    30(1)      24(1)      39(1)       4(1)      -4(1)       2(1)  
    C(110)   26(1)      23(1)      24(1)       4(1)      -1(1)       3(1)  
    C(111)   30(1)      18(1)      23(1)       8(1)       2(1)      -1(1)  
    C(112)   31(1)      26(1)      29(1)       5(1)       9(1)      -4(1)  
    C(113)   38(1)      29(1)      35(1)       5(1)       0(1)     -15(1)  
    C(114)   57(1)      17(1)      35(1)       1(1)       2(1)      -3(1)  
    C(115)   42(1)      27(1)      39(1)      -2(1)       4(1)      10(1)  
    C(116)   30(1)      26(1)      34(1)       4(1)      -2(1)       3(1)  
    O(21)    23(1)      26(1)      58(1)       2(1)      -8(1)      -4(1)  
    O(22)    22(1)      38(1)      40(1)      -2(1)      -5(1)       7(1)  
    O(23)    19(1)      28(1)      37(1)      -5(1)      -6(1)       3(1)  
    C(21)    22(1)      21(1)      39(1)       6(1)      -5(1)      -1(1)  
    C(22)    22(1)      21(1)      39(1)      -6(1)      -5(1)       0(1)  
    C(23)    23(1)      23(1)      34(1)       2(1)       0(1)      -3(1)  
    C(24)    24(1)      26(1)      29(1)       1(1)       1(1)       0(1)  
    C(25)    20(1)      23(1)      31(1)       1(1)       3(1)      -1(1)  
    C(26)    17(1)      22(1)      28(1)      -3(1)      -3(1)       0(1)  
    C(27)    20(1)      26(1)      26(1)      -2(1)      -1(1)      -2(1)  
    C(28)    23(1)      32(1)      32(1)      -7(1)      -2(1)       3(1)  
    C(29)    35(1)      28(1)      52(1)     -12(1)     -10(1)       6(1)  
    C(210)   25(1)      24(1)      26(1)      -3(1)       2(1)      -2(1)  
    C(211)   25(1)      19(1)      23(1)      -7(1)      -2(1)       0(1)  
    C(212)   24(1)      25(1)      26(1)      -3(1)      -3(1)       1(1)  
    C(213)   33(1)      27(1)      30(1)      -3(1)       2(1)      -7(1)  
    C(214)   51(1)      19(1)      30(1)      -1(1)      -1(1)      -2(1)  
    C(215)   37(1)      24(1)      42(1)      -4(1)     -11(1)       9(1)  
    C(216)   25(1)      26(1)      38(1)      -9(1)      -1(1)       1(1)  
    O(31)    26(1)      26(1)      48(1)       1(1)      -2(1)      -3(1)  
    O(32)    39(1)      25(1)      46(1)      -1(1)      -5(1)       6(1)  
    O(33)    29(1)      25(1)      31(1)       2(1)       1(1)       0(1)  
    C(31)    23(1)      25(1)      26(1)       2(1)      -4(1)       2(1)  
    C(32)    21(1)      28(1)      28(1)      -3(1)       0(1)       2(1)  
    C(33)    26(1)      26(1)      32(1)      -4(1)      -6(1)       0(1)  
    C(34)    31(1)      30(1)      26(1)       1(1)       1(1)       2(1)  
    C(35)    25(1)      22(1)      26(1)      -6(1)       1(1)       0(1)  
    C(36)    22(1)      23(1)      25(1)       1(1)       0(1)       1(1)  
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    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
 
    C(37)    25(1)      28(1)      23(1)      -3(1)      -1(1)      -2(1)  
    C(38)    28(1)      32(1)      27(1)      -7(1)       4(1)       3(1)  
    C(39)    24(1)      39(1)      42(1)      -7(1)       3(1)       5(1)  
    C(310)   23(1)      29(1)      26(1)      -2(1)       4(1)       2(1)  
    C(311)   18(1)      29(1)      25(1)      -3(1)       7(1)      -1(1)  
    C(312)   25(1)      29(1)      34(1)       0(1)       8(1)      -2(1)  
    C(313)   27(1)      39(1)      42(1)     -12(1)       8(1)     -12(1)  
    C(314)   20(1)      57(1)      31(1)      -7(1)       1(1)      -2(1)  
    C(315)   24(1)      44(1)      37(1)       7(1)       3(1)       7(1)  
    C(316)   25(1)      28(1)      38(1)      -4(1)       5(1)      -1(1)  
    O(41)    38(1)      32(1)      67(1)      -7(1)      13(1)     -12(1)  
    O(42)    42(1)      33(1)      48(1)      -2(1)       4(1)      12(1)  
    O(43)    29(1)      27(1)      48(1)      -8(1)      -3(1)       1(1)  
    C(41)    27(1)      28(1)      36(1)      -3(1)       7(1)      -5(1)  
    C(42)    24(1)      38(1)      33(1)      -4(1)      -5(1)       2(1)  
    C(43)    26(1)      29(1)      31(1)       3(1)       3(1)      -1(1)  
    C(44)    28(1)      34(1)      27(1)      -2(1)       0(1)      -2(1)  
    C(45)    29(1)      25(1)      28(1)       7(1)      -1(1)      -1(1)  
    C(46)    24(1)      24(1)      27(1)      -1(1)      -3(1)      -2(1)  
    C(47)    31(1)      33(1)      25(1)       3(1)       2(1)       2(1)  
    C(48)    36(1)      49(1)      27(1)       1(1)      -6(1)      10(1)  
    C(49)    27(1)      65(1)      54(1)     -13(1)     -10(1)       7(1)  
    C(410)   27(1)      38(1)      30(1)       0(1)      -6(1)      -2(1)  
    C(411)   21(1)      28(1)      32(1)      -2(1)      -8(1)      -1(1)  
    C(412)   26(1)      28(1)      55(1)      -2(1)      -8(1)      -1(1)  
    C(413)   23(1)      57(1)      55(1)     -20(1)      -5(1)       6(1)  
    C(414)   21(1)      75(2)      35(1)       3(1)      -1(1)      -5(1)  
    C(415)   31(1)      46(1)      54(1)      16(1)      -5(1)      -8(1)  
    C(416)   28(1)      30(1)      48(1)      -3(1)      -5(1)       1(1)  
    _______________________________________________________________________  
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Table 5.  Bond lengths [Å] and angles [°] for C16 H18 O3 
     ______________________________________________________________________  
  
 
    O(11)-C(11)            1.2143(17)  
    O(12)-C(13)            1.2058(16)  
    O(13)-C(16)            1.4314(16)  
    C(11)-C(15)            1.511(2)  
    C(11)-C(12)            1.5177(19)  
    C(12)-C(19)            1.515(2)  
    C(12)-C(13)            1.522(2)  
    C(12)-C(18)            1.569(2)  
    C(13)-C(14)            1.520(2)  
    C(14)-C(15)            1.5447(19)  
    C(15)-C(16)            1.556(2)  
    C(16)-C(17)            1.5284(19)  
    C(16)-C(110)           1.5341(19)  
    C(17)-C(18)            1.531(2)  
    C(110)-C(111)          1.507(2)  
    C(111)-C(112)          1.390(2)  
    C(111)-C(116)          1.391(2)  
    C(112)-C(113)          1.385(2)  
    C(113)-C(114)          1.376(2)  
    C(114)-C(115)          1.373(2)  
    C(115)-C(116)          1.384(2)  
    O(21)-C(21)            1.2062(17)  
    O(22)-C(23)            1.2065(17)  
    O(23)-C(26)            1.4301(16)  
    C(21)-C(25)            1.511(2)  
    C(21)-C(22)            1.514(2)  
    C(22)-C(29)            1.510(2)  
    C(22)-C(23)            1.520(2)  
    C(22)-C(28)            1.566(2)  
    C(23)-C(24)            1.522(2)  
    C(24)-C(25)            1.551(2)  
    C(25)-C(26)            1.559(2)  
    C(26)-C(27)            1.5297(19)  
    C(26)-C(210)           1.534(2)  
    C(27)-C(28)            1.531(2)  
    C(210)-C(211)          1.504(2)  
    C(211)-C(216)          1.389(2)  
    C(211)-C(212)          1.395(2)  
    C(212)-C(213)          1.381(2)  
    C(213)-C(214)          1.377(2)  
    C(214)-C(215)          1.378(2)  
    C(215)-C(216)          1.382(2)  
    O(31)-C(31)            1.2110(17)  
    O(32)-C(33)            1.2120(18)  
    O(33)-C(36)            1.4316(17)  
    C(31)-C(32)            1.510(2)  
    C(31)-C(35)            1.515(2)  
    C(32)-C(39)            1.516(2)  
    C(32)-C(33)            1.522(2)  
    C(32)-C(38)            1.570(2)  
    C(33)-C(34)            1.521(2)  
    C(34)-C(35)            1.534(2)  
    C(35)-C(36)            1.564(2)  
    C(36)-C(37)            1.517(2)  
     
    C(36)-C(310)           1.533(2)  
    C(37)-C(38)            1.535(2)  
    C(310)-C(311)          1.512(2)   
    C(311)-C(312)          1.391(2)  
    C(311)-C(316)          1.393(2)  
    C(312)-C(313)          1.390(2)  
    C(313)-C(314)          1.373(2)  
    C(314)-C(315)          1.374(2)  
    C(315)-C(316)          1.390(2)  
    O(41)-C(41)            1.2089(18)  
    O(42)-C(43)            1.2115(18)  
    O(43)-C(46)            1.4272(18)  
    C(41)-C(42)            1.505(2)  
    C(41)-C(45)            1.505(2)  
    C(42)-C(43)            1.517(2)  
    C(42)-C(49)            1.518(2)  
    C(42)-C(48)            1.561(2)  
    C(43)-C(44)            1.516(2)  
    C(44)-C(45)            1.540(2)  
    C(45)-C(46)            1.571(2)  
    C(46)-C(47)            1.519(2)  
    C(46)-C(410)           1.522(2)  
    C(47)-C(48)            1.537(2)  
    C(410)-C(411)          1.513(2)  
    C(411)-C(412)          1.384(2)  
    C(411)-C(416)          1.385(2)  
    C(412)-C(413)          1.383(3)  
    C(413)-C(414)          1.381(3)  
    C(414)-C(415)          1.378(3)  
    C(415)-C(416)          1.379(2)  
   
    O(11)-C(11)-C(15)      127.39(13)  
    O(11)-C(11)-C(12)      126.89(14)  
    C(15)-C(11)-C(12)      105.70(12)  
    C(19)-C(12)-C(11)      116.36(12)  
    C(19)-C(12)-C(13)      116.59(13)  
    C(11)-C(12)-C(13)      101.06(12)  
    C(19)-C(12)-C(18)      111.59(12)  
    C(11)-C(12)-C(18)      104.43(11)  
    C(13)-C(12)-C(18)      105.39(11)  
    O(12)-C(13)-C(14)      125.48(14)  
    O(12)-C(13)-C(12)      125.51(14)  
    C(14)-C(13)-C(12)      108.99(11)  
    C(13)-C(14)-C(15)      104.65(12)  
    C(11)-C(15)-C(14)      100.96(11)  
    C(11)-C(15)-C(16)      106.96(12)  
    C(14)-C(15)-C(16)      112.90(12)  
    O(13)-C(16)-C(17)      105.51(11)  
    O(13)-C(16)-C(110)     111.20(11)  
    C(17)-C(16)-C(110)     113.29(12)  
    O(13)-C(16)-C(15)      108.83(11)  
    C(17)-C(16)-C(15)      109.40(11)  
    C(110)-C(16)-C(15)     108.51(12)  
    C(16)-C(17)-C(18)      112.41(12)  
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    C(17)-C(18)-C(12)      113.32(12)  
    C(111)-C(110)-C(16)    116.03(12)  
    C(112)-C(111)-C(116)   118.16(14)  
    C(112)-C(111)-C(110)   120.84(13)  
    C(116)-C(111)-C(110)   120.97(14)  
    C(113)-C(112)-C(111)   120.79(15)  
    C(114)-C(113)-C(112)   120.25(16)  
    C(115)-C(114)-C(113)   119.64(16)  
    C(114)-C(115)-C(116)   120.44(16)  
    C(115)-C(116)-C(111)   120.69(16)  
    O(21)-C(21)-C(25)      127.23(15)  
    O(21)-C(21)-C(22)      127.15(15)  
    C(25)-C(21)-C(22)      105.61(12)  
    C(29)-C(22)-C(21)      115.97(13)  
    C(29)-C(22)-C(23)      115.24(13)  
    C(21)-C(22)-C(23)      101.60(13)  
    C(29)-C(22)-C(28)      112.13(14)  
    C(21)-C(22)-C(28)      103.74(12)  
    C(23)-C(22)-C(28)      106.92(12)  
    O(22)-C(23)-C(22)      125.48(15)  
    O(22)-C(23)-C(24)      125.60(15)  
    C(22)-C(23)-C(24)      108.93(12)  
    C(23)-C(24)-C(25)      104.64(12)  
    C(21)-C(25)-C(24)      101.94(12)  
    C(21)-C(25)-C(26)      105.75(12)  
    C(24)-C(25)-C(26)      112.75(12)  
    O(23)-C(26)-C(27)      105.50(12)  
    O(23)-C(26)-C(210)     111.30(12)  
    C(27)-C(26)-C(210)     113.45(12)  
    O(23)-C(26)-C(25)      108.71(11)  
    C(27)-C(26)-C(25)      109.16(12)  
    C(210)-C(26)-C(25)     108.60(12)  
    C(26)-C(27)-C(28)      112.83(12)  
    C(27)-C(28)-C(22)      113.37(13)  
    C(211)-C(210)-C(26)    115.45(12)  
    C(216)-C(211)-C(212)   118.09(14)  
    C(216)-C(211)-C(210)   121.43(14)  
    C(212)-C(211)-C(210)   120.48(13)  
    C(213)-C(212)-C(211)   120.75(14)  
    C(214)-C(213)-C(212)   120.52(15)  
    C(213)-C(214)-C(215)   119.26(16)  
    C(214)-C(215)-C(216)   120.64(15)  
    C(215)-C(216)-C(211)   120.70(15)  
    O(31)-C(31)-C(32)      127.14(14)  
    O(31)-C(31)-C(35)      127.41(14)  
    C(32)-C(31)-C(35)      105.45(12)  
    C(31)-C(32)-C(39)      116.78(13)  
    C(31)-C(32)-C(33)      101.56(12)  
    C(39)-C(32)-C(33)      116.22(13)  
    C(31)-C(32)-C(38)      104.86(12)  
    C(39)-C(32)-C(38)      111.68(13)  
    C(33)-C(32)-C(38)      104.25(12)  
    O(32)-C(33)-C(34)      125.57(15)  
    O(32)-C(33)-C(32)      125.38(15)  
    C(34)-C(33)-C(32)      109.01(12)  
    C(33)-C(34)-C(35)      104.42(12)  
    C(31)-C(35)-C(34)      101.71(12)  
    C(31)-C(35)-C(36)      105.86(12)  
    C(34)-C(35)-C(36)      112.73(12)  
    O(33)-C(36)-C(37)    104.71(12)  
    O(33)-C(36)-C(310)     111.27(12)  
    C(37)-C(36)-C(310)     113.54(13)  
    O(33)-C(36)-C(35)      108.82(12)  
    C(37)-C(36)-C(35)      109.71(12)  
    C(310)-C(36)-C(35)     108.66(12)  
    C(36)-C(37)-C(38)      112.04(13)  
    C(37)-C(38)-C(32)      113.16(12)  
    C(311)-C(310)-C(36)    115.30(12)  
    C(312)-C(311)-C(316)   118.23(14)  
    C(312)-C(311)-C(310)   121.01(14)  
    C(316)-C(311)-C(310)   120.76(14)  
    C(313)-C(312)-C(311)   120.36(16)  
    C(314)-C(313)-C(312)   120.74(16)  
    C(313)-C(314)-C(315)   119.64(16)  
    C(314)-C(315)-C(316)   120.20(16)  
    C(315)-C(316)-C(311)   120.81(15)  
    O(41)-C(41)-C(42)      126.36(16)  
    O(41)-C(41)-C(45)      127.68(16)  
    C(42)-C(41)-C(45)      105.85(13)  
    C(41)-C(42)-C(43)      102.17(13)  
    C(41)-C(42)-C(49)      116.82(15)  
    C(43)-C(42)-C(49)      115.89(14)  
    C(41)-C(42)-C(48)      102.80(13)  
    C(43)-C(42)-C(48)      106.20(14)  
    C(49)-C(42)-C(48)      111.53(14)  
    O(42)-C(43)-C(44)      125.97(15)  
    O(42)-C(43)-C(42)      125.17(15)  
    C(44)-C(43)-C(42)      108.86(13)  
    C(43)-C(44)-C(45)      104.62(13)  
    C(41)-C(45)-C(44)      102.23(12)  
    C(41)-C(45)-C(46)      104.95(13)  
    C(44)-C(45)-C(46)      113.30(12)  
    O(43)-C(46)-C(47)      105.52(12)  
    O(43)-C(46)-C(410)     111.72(13)  
    C(47)-C(46)-C(410)     113.65(13)  
    O(43)-C(46)-C(45)      108.68(12)  
    C(47)-C(46)-C(45)      108.68(12)  
    C(410)-C(46)-C(45)     108.45(12)  
    C(46)-C(47)-C(48)      112.55(13)  
    C(47)-C(48)-C(42)      113.34(13)  
    C(411)-C(410)-C(46)    116.14(13)  
    C(412)-C(411)-C(416)   118.27(15)  
    C(412)-C(411)-C(410)   121.09(15)  
    C(416)-C(411)-C(410)   120.62(15)  
    C(413)-C(412)-C(411)   120.77(17)  
    C(414)-C(413)-C(412)   120.40(18)  
    C(415)-C(414)-C(413)   119.11(17)  
    C(414)-C(415)-C(416)   120.42(17)  
    C(415)-C(416)-C(411)   121.01(17)  
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Table 6.  Torsion angles [°] for C16 H18 O3. 
  ______________________________________________________________________________  
  
 
  O(11)-C(11)-C(12)-C(19)   12.3(2)  
  C(15)-C(11)-C(12)-C(19) -166.12(13)  
  O(11)-C(11)-C(12)-C(13)  139.61(15)  
  C(15)-C(11)-C(12)-C(13)  -38.82(14)  
  O(11)-C(11)-C(12)-C(18) -111.15(16)  
  C(15)-C(11)-C(12)-C(18)   70.41(14)  
  C(19)-C(12)-C(13)-O(12)  -35.8(2)  
  C(11)-C(12)-C(13)-O(12) -162.95(14)  
  C(18)-C(12)-C(13)-O(12)   88.55(17)  
  C(19)-C(12)-C(13)-C(14)  145.81(13)  
  C(11)-C(12)-C(13)-C(14)   18.67(14)  
  C(18)-C(12)-C(13)-C(14)  -89.83(13)  
  O(12)-C(13)-C(14)-C(15) -171.12(14)  
  C(12)-C(13)-C(14)-C(15)    7.26(15)  
  O(11)-C(11)-C(15)-C(14) -134.79(16)  
  C(12)-C(11)-C(15)-C(14)   43.63(14)  
  O(11)-C(11)-C(15)-C(16)  106.95(17)  
  C(12)-C(11)-C(15)-C(16)  -74.63(13)  
  C(13)-C(14)-C(15)-C(11)  -30.28(14)  
  C(13)-C(14)-C(15)-C(16)   83.57(14)  
  C(11)-C(15)-C(16)-O(13)  -53.14(14)  
  C(14)-C(15)-C(16)-O(13) -163.31(11)  
  C(11)-C(15)-C(16)-C(17)   61.67(14)  
  C(14)-C(15)-C(16)-C(17)  -48.49(16)  
  C(11)-C(15)-C(16)-C(110) -174.28(11)  
  C(14)-C(15)-C(16)-C(110)  75.56(15)  
  O(13)-C(16)-C(17)-C(18)   68.48(15)  
  C(110)-C(16)-C(17)-C(18) -169.65(12)  
  C(15)-C(16)-C(17)-C(18)  -48.45(16)  
  C(16)-C(17)-C(18)-C(12)   48.30(17)  
  C(19)-C(12)-C(18)-C(17)  175.52(12)  
  C(11)-C(12)-C(18)-C(17)  -57.97(15)  
  C(13)-C(12)-C(18)-C(17)   48.07(15)  
  O(13)-C(16)-C(110)-C(111) 62.21(16)  
  C(17)-C(16)-C(110)-C(111) -56.43(17)  
  C(15)-C(16)-C(110)-C(111) -178.13(12)  
  C(16)-C(110)-C(111)-C(112) 90.45(17)  
  C(16)-C(110)-C(111)-C(116) -91.73(17)  
  C(116)-C(111)-C(112)-C(113) 0.9(2)  
  C(110)-C(111)-C(112)-C(113) 178.76(14)  
  C(111)-C(112)-C(113)-C(114) 0.2(2)  
  C(112)-C(113)-C(114)-C(115) -1.3(2)  
  C(113)-C(114)-C(115)-C(116) 1.2(3)  
  C(114)-C(115)-C(116)-C(111) 0.0(2)  
  C(112)-C(111)-C(116)-C(115) -1.0(2)  
 C(110)-C(111)-C(116)-C(115) -178.86(14)  
  O(21)-C(21)-C(22)-C(29)   16.3(3)  
  C(25)-C(21)-C(22)-C(29) -164.59(14)  
  O(21)-C(21)-C(22)-C(23)  142.03(17)  
  C(25)-C(21)-C(22)-C(23)  -38.84(15)  
  O(21)-C(21)-C(22)-C(28) -107.11(18)  
  C(25)-C(21)-C(22)-C(28)   72.01(14)  
  C(29)-C(22)-C(23)-O(22)  -32.6(2)  
   
  C(21)-C(22)-C(23)-O(22) -158.85(16)  
  C(28)-C(22)-C(23)-O(22)   92.73(18)  
  C(29)-C(22)-C(23)-C(24)  147.21(14)  
  C(21)-C(22)-C(23)-C(24)   20.99(16) 
  C(28)-C(22)-C(23)-C(24)  -87.43(14)  
  O(22)-C(23)-C(24)-C(25) -176.46(15)  
  C(22)-C(23)-C(24)-C(25)    3.70(16)  
  O(21)-C(21)-C(25)-C(24) -139.39(17)  
  C(22)-C(21)-C(25)-C(24)   41.48(15)  
  O(21)-C(21)-C(25)-C(26)  102.55(18)  
  C(22)-C(21)-C(25)-C(26)  -76.58(14)  
  C(23)-C(24)-C(25)-C(21)  -26.97(15)  
  C(23)-C(24)-C(25)-C(26)   85.96(15)  
  C(21)-C(25)-C(26)-O(23)  -52.57(14)  
  C(24)-C(25)-C(26)-O(23) -163.15(11)  
  C(21)-C(25)-C(26)-C(27)   62.03(14)  
  C(24)-C(25)-C(26)-C(27)  -48.54(16)  
  C(21)-C(25)-C(26)-C(210) -173.81(12)  
  C(24)-C(25)-C(26)-C(210)  75.61(15)  
  O(23)-C(26)-C(27)-C(28)   68.70(15)  
  C(210)-C(26)-C(27)-C(28) -169.22(13)  
  C(25)-C(26)-C(27)-C(28)  -47.97(16)  
  C(26)-C(27)-C(28)-C(22)   47.31(17)  
  C(29)-C(22)-C(28)-C(27)  176.55(13)  
  C(21)-C(22)-C(28)-C(27)  -57.58(16)  
  C(23)-C(22)-C(28)-C(27)   49.33(16)  
  O(23)-C(26)-C(210)-C(211) 63.86(16)  
  C(27)-C(26)-C(210)-C(211) -54.94(17)  
  C(25)-C(26)-C(210)-C(211) -176.51(12)  
  C(26)-C(210)-C(211)-C(216) -92.43(17)  
  C(26)-C(210)-C(211)-C(212) 87.41(17)  
  C(216)-C(211)-C(212)-C(213) 1.6(2)  
  C(210)-C(211)-C(212)-C(213) -178.29(13)  
  C(211)-C(212)-C(213)-C(214) -0.1(2)  
  C(212)-C(213)-C(214)-C(215) -1.6(2)  
  C(213)-C(214)-C(215)-C(216) 1.8(2)  
  C(214)-C(215)-C(216)-C(211) -0.3(2)  
  C(212)-C(211)-C(216)-C(215) -1.3(2)  
  C(210)-C(211)-C(216)-C(215) 178.51(14)  
  O(31)-C(31)-C(32)-C(39)   15.1(2)  
  C(35)-C(31)-C(32)-C(39) -165.08(13)  
  O(31)-C(31)-C(32)-C(33)  142.54(16)  
  C(35)-C(31)-C(32)-C(33)  -37.61(14)  
  O(31)-C(31)-C(32)-C(38) -109.14(17)  
  C(35)-C(31)-C(32)-C(38)   70.71(14)  
  C(31)-C(32)-C(33)-O(32) -164.12(15)  
  C(39)-C(32)-C(33)-O(32)  -36.3(2)  
  C(38)-C(32)-C(33)-O(32)   87.09(18)  
  C(31)-C(32)-C(33)-C(34)   17.96(15)  
  C(39)-C(32)-C(33)-C(34)  145.79(14)  
  C(38)-C(32)-C(33)-C(34)  -90.84(14)  
  O(32)-C(33)-C(34)-C(35) -170.26(15)  
  C(32)-C(33)-C(34)-C(35)    7.66(16)  
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  O(31)-C(31)-C(35)-C(34) -137.27(16)  
  C(32)-C(31)-C(35)-C(34)   42.88(14)  
  O(31)-C(31)-C(35)-C(36)  104.76(18)  
  C(32)-C(31)-C(35)-C(36)  -75.09(14)  
  C(33)-C(34)-C(35)-C(31)  -30.07(15)  
  C(33)-C(34)-C(35)-C(36)   82.85(15)  
  C(31)-C(35)-C(36)-O(33)  -51.02(15)  
  C(34)-C(35)-C(36)-O(33) -161.38(12)  
  C(31)-C(35)-C(36)-C(37)   63.00(15)  
  C(34)-C(35)-C(36)-C(37)  -47.36(16)  
  C(31)-C(35)-C(36)-C(310)-172.34(12)  
  C(34)-C(35)-C(36)-C(310)  77.31(15)  
  O(33)-C(36)-C(37)-C(38)   67.15(15)  
  C(310)-C(36)-C(37)-C(38) -171.28(13)  
  C(35)-C(36)-C(37)-C(38)  -49.49(17)  
  C(36)-C(37)-C(38)-C(32)   47.99(18)  
  C(31)-C(32)-C(38)-C(37)  -57.54(17)  
  C(39)-C(32)-C(38)-C(37)  175.08(14)  
  C(33)-C(32)-C(38)-C(37)   48.80(17)  
  O(33)-C(36)-C(310)-C(311) 60.87(17)  
  C(37)-C(36)-C(310)-C(311) -56.96(18)  
  C(35)-C(36)-C(310)-C(311) -179.34(13)  
  C(36)-C(310)-C(311)-C(312) 97.48(17)  
  C(36)-C(310)-C(311)-C(316) -82.60(18)  
  C(316)-C(311)-C(312)-C(313) -0.3(2)  
  C(310)-C(311)-C(312)-C(313) 179.65(14)  
  C(311)-C(312)-C(313)-C(314) 1.3(2)  
  C(312)-C(313)-C(314)-C(315) -0.7(2)  
  C(313)-C(314)-C(315)-C(316) -0.8(2)  
  C(314)-C(315)-C(316)-C(311) 1.8(2)  
  C(312)-C(311)-C(316)-C(315) -1.3(2)  
  C(310)-C(311)-C(316)-C(315) 178.83(14)  
  O(41)-C(41)-C(42)-C(43)  146.93(17)  
  C(45)-C(41)-C(42)-C(43)  -36.73(16)  
  O(41)-C(41)-C(42)-C(49)   19.4(3)  
  C(45)-C(41)-C(42)-C(49) -164.28(15)  
  O(41)-C(41)-C(42)-C(48) -103.09(19)  
  C(45)-C(41)-C(42)-C(48)   73.26(15)  
  C(41)-C(42)-C(43)-O(42) -162.36(16)  
  C(49)-C(42)-C(43)-O(42)  -34.2(2)  
  C(48)-C(42)-C(43)-O(42)   90.26(19)  
  C(41)-C(42)-C(43)-C(44)   18.32(17)  
  C(49)-C(42)-C(43)-C(44)  146.48(16)  
  C(48)-C(42)-C(43)-C(44)  -89.06(15)  
  O(42)-C(43)-C(44)-C(45) -173.30(16)  
  C(42)-C(43)-C(44)-C(45)    6.01(16)  
  O(41)-C(41)-C(45)-C(44) -142.93(17)  
  C(42)-C(41)-C(45)-C(44)   40.79(15)  
  O(41)-C(41)-C(45)-C(46)   98.60(19)  
  C(42)-C(41)-C(45)-C(46)  -77.68(15)  
  C(43)-C(44)-C(45)-C(41)  -27.93(15)  
  C(43)-C(44)-C(45)-C(46)   84.45(15)  
  C(41)-C(45)-C(46)-O(43)  -51.89(15)  
  C(44)-C(45)-C(46)-O(43) -162.61(12)  
  C(41)-C(45)-C(46)-C(47)   62.46(15)  
  C(44)-C(45)-C(46)-C(47)  -48.25(16)  
  C(41)-C(45)-C(46)-C(410) -173.54(13)  
  C(44)-C(45)-C(46)-C(410)  75.75(16)  
  O(43)-C(46)-C(47)-C(48)   67.79(16)  
   
  C(410)-C(46)-C(47)-C(48) -169.47(14)  
  C(45)-C(46)-C(47)-C(48)  -48.62(17)  
  C(46)-C(47)-C(48)-C(42)   48.44(19)  
  C(41)-C(42)-C(48)-C(47)  -58.29(18)  
  C(43)-C(42)-C(48)-C(47)   48.64(18)  
  C(49)-C(42)-C(48)-C(47)  175.76(15)  
  O(43)-C(46)-C(410)-C(411) 61.26(18)  
  C(47)-C(46)-C(410)-C(411) -58.01(19)  
  C(45)-C(46)-C(410)-C(411) -178.98(13)  
  C(46)-C(410)-C(411)-C(412) -83.53(19)  
  C(46)-C(410)-C(411)-C(416) 98.19(18)  
  C(416)-C(411)-C(412)-C(413) -1.4(2)  
  C(410)-C(411)-C(412)-C(413) -179.76(15)  
  C(411)-C(412)-C(413)-C(414) 1.2(3)  
  C(412)-C(413)-C(414)-C(415) -0.1(3)  
  C(413)-C(414)-C(415)-C(416) -0.7(3)  
  C(414)-C(415)-C(416)-C(411) 0.3(3)  
  C(412)-C(411)-C(416)-C(415) 0.7(2)  
  C(410)-C(411)-C(416)-C(415) 179.02(15)  
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   Table 7. Bond lengths [Å] and angles [°] related to the hydrogen  
   bonding for C16 H18 O3.  
   ______________________________________________________________________  
   
        D-H         ..A       d(D-H)      d(H..A)     d(D..A)     <DHA  
   
     O(13)-H(13)    O(21)#1    0.84        2.18       3.0019(14)  166.4  
     O(23)-H(23)    O(11)#2    0.84        2.08       2.9078(15)  166.3  
     O(33)-H(33)    O(41)      0.84        2.3        3.0841(16)  155.5  
     O(33)-H(33)    O(43)      0.84        2.47       3.0288(15)  124.7  
     O(43)-H(43)    O(31)      0.84        2.18       2.9885(15)  160.7  
   
   ______________________________________________________________________  
   
    Symmetry transformations used to generate equivalent atoms:  
   
         #1 x-1,y,z    #2 x+1,y,z      
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   ORTEP (Asymmetric unit) view of the C16 H18 O3 compound with the numbering 
scheme adopted. Ellipsoids drawn at 30% probability level. Hydrogen atoms 
are represented by sphere of arbitrary size.  
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   ORTEP 1 view of the C16 H18 O3 compound with the numbering scheme adopted. 
Ellipsoids drawn at 30% probability level. Hydrogen atoms are represented by 
sphere of arbitrary size.    
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   ORTEP 2 view of the C16 H18 O3 compound with the 
numbering scheme adopted. Ellipsoids drawn at 30% 
probability level. Hydrogen atoms are represented by 
sphere of arbitrary size.    
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ORTEP 3 view of the C16 H18 O3 compound with the numbering scheme adopted. 
Ellipsoids drawn at 30% probability level. Hydrogen atoms are represented by 
sphere of arbitrary size.   
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ORTEP 4 view of the C16 H18 O3 compound with the numbering scheme adopted. 
Ellipsoids drawn at 30% probability level. Hydrogen atoms are represented by 
sphere of arbitrary size.  
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Annex 61: X-Ray Data for Compound 4.8 
 
 
Table 1 Crystal data and structure refinement for han470. 
 
Identification code han470 
Empirical formula C16H18O3 
Formula weight 258.30 
Temperature/K 100 
Crystal system orthorhombic 
Space group Pna21 
a/Å 13.0120(7) 
b/Å 6.5847(3) 
c/Å 15.4360(8) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 1322.56(12) 
Z 4 
ρcalcg/cm3 1.297 
µ/mm‑1 0.459 
F(000) 552.0 
Crystal size/mm3 0.24 × 0.16 × 0.12 
Radiation GaKα (λ = 1.34139) 
2Θ range for data 
collection/° 12.846 to 121.428 
Index ranges -16 ≤ h ≤ 16, -8 ≤ k ≤ 8, -20 ≤ l ≤ 20 
Reflections collected 56212 
Independent reflections 3007 [Rint = 0.0263, Rsigma = 0.0150] 
Data/restraints/parameters 3007/1/177 
Goodness-of-fit on F2 1.143 
Final R indexes [I>=2σ (I)] R1 = 0.0278, wR2 = 0.0769 
Final R indexes [all data] R1 = 0.0291, wR2 = 0.0848 
Largest diff. peak/hole / e 
Å-3 0.28/-0.21 
Flack parameter 0.02(2) 
  
 
 
 
O
OHO Ph
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for han470. Ueq is defined as 1/3 of of the 
trace of the orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
C1 5829.8(11) 8757(2) 5952.0(9) 18.8(3) 
C2 4884.9(12) 10090(2) 5828.6(13) 23.8(3) 
C3 3968.1(11) 8622(2) 5793.1(10) 20.0(3) 
C4 4454.8(11) 6547(2) 5584.6(9) 16.0(3) 
C5 4705.1(11) 6443(2) 4584.7(9) 16.9(3) 
C6 5381.6(12) 4586(2) 4429.3(10) 19.7(3) 
C7 6411.6(12) 4731(2) 4875.6(11) 23.4(3) 
C8 6254.6(11) 4960(2) 5857.1(11) 19.5(3) 
C9 5477.1(11) 6582(2) 6103.5(10) 17.2(3) 
C10 5271.6(13) 6450(3) 7087.7(10) 24.7(3) 
C11 3772.4(11) 6607(2) 4002.8(10) 18.6(3) 
C12 3019.2(13) 5089(2) 3963.0(11) 22.7(3) 
C13 2167.4(13) 5307(3) 3424.2(12) 27.8(3) 
C14 2064.3(13) 7025(3) 2908.2(12) 30.5(4) 
C15 2806.2(14) 8539(3) 2935.7(11) 28.9(4) 
C16 3653.7(13) 8330(2) 3482.4(11) 23.6(3) 
O1 6711.2(8) 9345.1(19) 5934.0(8) 26.1(3) 
O4 3857.2(8) 4851.8(16) 5834.9(8) 19.7(2) 
O6 5108.5(9) 3117.6(17) 4018.5(8) 25.3(3) 
 
Table 3 Anisotropic Displacement Parameters (Å2×103) for han470.  
The Anisotropic displacement factor exponent takes the form:  
-2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
C1 17.4(6) 23.4(6) 15.6(6) -2.7(5) 0.4(5) -1.7(5) 
C2 20.2(7) 20.6(6) 30.6(8) -3.3(6) 0.0(7) 0.1(5) 
C3 15.2(6) 23.0(6) 22.0(7) -1.5(6) 0.8(5) 2.1(5) 
C4 11.9(6) 19.5(6) 16.6(7) 0.9(5) -0.2(5) -1.5(5) 
C5 13.1(6) 20.8(6) 16.7(7) 0.4(5) -0.2(5) -1.4(5) 
C6 18.2(7) 25.3(7) 15.7(6) 0.4(5) 2.1(5) 2.0(5) 
C7 15.9(7) 30.6(7) 23.7(8) -5.1(6) 0.5(6) 4.8(6) 
C8 13.2(6) 22.3(6) 23.1(7) 1.2(5) -2.9(6) 1.0(5) 
C9 12.8(6) 22.4(6) 16.6(6) 1.0(5) -0.6(5) -1.1(5) 
C10 20.8(7) 36.3(8) 17.0(7) 1.5(6) -1.4(6) -1.8(6) 
C11 15.4(6) 25.2(7) 15.3(6) -0.5(5) -0.5(5) 0.4(5) 
C12 20.5(7) 26.7(7) 20.8(7) -0.1(6) -1.0(6) -2.9(5) 
C13 20.2(7) 37.5(8) 25.8(8) -4.4(7) -3.1(6) -3.8(6) 
C14 23.7(8) 47.1(10) 20.6(7) -1.0(7) -7.1(6) 5.1(7) 
C15 29.4(8) 37.8(8) 19.6(7) 5.4(6) -1.1(7) 5.2(7) 
C16 22.1(7) 27.5(7) 21.1(7) 3.2(6) 1.0(6) 0.7(5) 
O1 17.5(5) 30.6(6) 30.3(6) -4.9(5) 1.2(5) -6.3(4) 
O4 12.6(5) 23.5(5) 22.9(5) 4.1(4) 1.2(4) -3.2(4) 
O6 28.5(6) 26.8(6) 20.7(5) -4.5(4) -3.3(5) 3.6(4) 
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Table 4 Bond Lengths for han470. 
 
Atom Atom Length/Å Atom Atom Length/Å 
C1 C2 1.522(2) C6 O6 1.209(2) 
C1 C9 1.522(2) C7 C8 1.536(2) 
C1 O1 1.2109(19) C8 C9 1.520(2) 
C2 C3 1.536(2) C9 C10 1.545(2) 
C3 C4 1.5402(19) C11 C12 1.401(2) 
C4 C5 1.579(2) C11 C16 1.398(2) 
C4 C9 1.5529(18) C12 C13 1.393(2) 
C4 O4 1.4141(16) C13 C14 1.390(3) 
C5 C6 1.526(2) C14 C15 1.388(3) 
C5 C11 1.5137(19) C15 C16 1.395(2) 
C6 C7 1.510(2)       
 
Table 5 Bond Angles for han470. 
 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C9 C1 C2 108.55(12) C6 C7 C8 109.77(12) 
O1 C1 C2 125.29(14) C9 C8 C7 113.86(13) 
O1 C1 C9 126.16(14) C1 C9 C4 101.14(11) 
C1 C2 C3 105.60(12) C1 C9 C10 104.86(12) 
C2 C3 C4 104.26(11) C8 C9 C1 114.97(12) 
C3 C4 C5 109.11(12) C8 C9 C4 115.51(12) 
C3 C4 C9 103.36(11) C8 C9 C10 108.76(13) 
C9 C4 C5 109.16(11) C10 C9 C4 110.98(12) 
O4 C4 C3 114.65(11) C12 C11 C5 122.41(14) 
O4 C4 C5 110.26(11) C16 C11 C5 119.16(13) 
O4 C4 C9 110.00(11) C16 C11 C12 118.43(14) 
C6 C5 C4 107.90(11) C13 C12 C11 120.62(15) 
C11 C5 C4 114.31(12) C14 C13 C12 120.16(15) 
C11 C5 C6 115.24(12) C15 C14 C13 120.00(15) 
C7 C6 C5 112.93(13) C14 C15 C16 119.80(16) 
O6 C6 C5 123.62(14) C15 C16 C11 120.99(15) 
O6 C6 C7 123.41(14)     
 
Table 6 Hydrogen Bonds for han470. 
 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O4 H4 O11 0.80(3) 2.05(3) 2.8461(15) 172(2) 
1-1/2+X,3/2-Y,+Z 
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Table 7 Torsion Angles for han470. 
 
A B C D Angle/˚ A B C D Angle/˚ 
C1 C2 C3 C4 -18.82(16) C7 C8 C9 C1 -71.01(16) 
C2 C1 C9 C4 29.57(14) C7 C8 C9 C4 46.27(17) 
C2 C1 C9 C8 154.73(14) C7 C8 C9 C10 171.80(12) 
C2 C1 C9 C10 -85.89(15) C9 C1 C2 C3 -7.07(17) 
C2 C3 C4 C5 -78.75(14) C9 C4 C5 C6 56.06(14) 
C2 C3 C4 C9 37.32(15) C9 C4 C5 C11 -174.33(12) 
C2 C3 C4 O4 157.04(13) C11 C5 C6 C7 167.00(13) 
C3 C4 C5 C6 168.35(12) C11 C5 C6 O6 -15.6(2) 
C3 C4 C5 C11 -62.04(15) C11 C12 C13 C14 1.0(3) 
C3 C4 C9 C1 -40.72(13) C12 C11 C16 C15 0.0(2) 
C3 C4 C9 C8 -165.52(13) C12 C13 C14 C15 -0.7(3) 
C3 C4 C9 C10 70.10(14) C13 C14 C15 C16 0.0(3) 
C4 C5 C6 C7 -63.91(15) C14 C15 C16 C11 0.3(3) 
C4 C5 C6 O6 113.53(16) C16 C11 C12 C13 -0.7(2) 
C4 C5 C11 C12 -67.76(19) O1 C1 C2 C3 173.13(14) 
C4 C5 C11 C16 112.38(15) O1 C1 C9 C4 -150.63(14) 
C5 C4 C9 C1 75.31(13) O1 C1 C9 C8 -25.5(2) 
C5 C4 C9 C8 -49.49(16) O1 C1 C9 C10 93.91(16) 
C5 C4 C9 C10 -173.87(12) O4 C4 C5 C6 -64.88(14) 
C5 C6 C7 C8 59.31(17) O4 C4 C5 C11 64.73(15) 
C5 C11 C12 C13 179.44(14) O4 C4 C9 C1 -163.59(11) 
C5 C11 C16 C15 179.89(15) O4 C4 C9 C8 71.61(15) 
C6 C5 C11 C12 58.09(19) O4 C4 C9 C10 -52.77(15) 
C6 C5 C11 C16 -121.76(15) O6 C6 C7 C8 -118.14(16) 
C6 C7 C8 C9 -48.60(17)      
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Table 8 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for han470. 
 
Atom x y z U(eq) 
H2A 4937 10876 5284 29 
H2B 4810 11050 6318 29 
H3A 3477 9029 5335 24 
H3B 3604 8583 6356 24 
H5 5142 7654 4454 20 
H7A 6796 5915 4649 28 
H7B 6819 3492 4755 28 
H8A 6025 3641 6097 23 
H8B 6923 5296 6128 23 
H10A 4857 7616 7270 37 
H10B 5927 6458 7400 37 
H10C 4900 5191 7217 37 
H12 3090 3901 4307 27 
H13 1656 4278 3409 33 
H14 1486 7163 2537 37 
H15 2737 9714 2583 35 
H16 4158 9373 3501 28 
H4 3260(20) 5180(30) 5834(18) 29(6) 
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Experimental 
 
Single crystals of C16H18O3 [han470] were slow recrystallized from 
chloroform–hexanes. A suitable crystal was selected and mounted on a loop 
fiber on a Bruker Venture Metaljet diffractometer. The crystal was kept at 
100 K during data collection. Using Olex2 [1], the structure was solved with 
the XT [2] structure solution program using Direct Methods and refined with 
the XL [3] refinement package using Least Squares minimisation. 
1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & 
 Puschmann, H. (2009), J. Appl. Cryst. 42, 339-341. 
2. Bourhis, L.J., Dolomanov, O.V., Gildea, R.J., Howard, J.A.K., 
Puschmann, H. (2013). in preparation. 
3. Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122. 
4. APEX2 (2008), Bruker AXS Inc., Madison, WI 53719-1173. 
5. SAINT (2009) V7.60A, Bruker AXS Inc., Madison, WI 53719-1173. 
6. XPREP (2013); X-ray data Preparation and Reciprocal space Exploration 
Program.  Bruker AXS Inc., Madison, WI 53719-1173. 
 
Crystal structure determination of [han470] 
 
Crystal Data for C16H18O3 (M =258.30 g/mol): orthorhombic, space group 
Pna21 (no. 33), a = 13.0120(7) Å, b = 6.5847(3) Å, c = 15.4360(8) Å, V = 
1322.56(12) Å3, Z = 4, T = 100 K, µ(GaKα) = 0.459 mm-1, Dcalc = 1.297 g/cm3, 
56212 reflections measured (12.846° ≤ 2Θ ≤ 121.428°), 3007 unique (Rint = 
0.0263, Rsigma = 0.0150) which were used in all calculations. The final R1 was 
0.0278 (I > 2σ(I)) and wR2 was 0.0848 (all data). 
 
Refinement model description 
 
Number of restraints - 1, number of constraints - unknown. 
Details: 
1. Fixed Uiso 
 At 1.2 times of: 
  All C(H) groups, All C(H,H) groups 
 At 1.5 times of: 
  All C(H,H,H) groups 
2.a Ternary CH refined with riding coordinates: 
 C5(H5) 
2.b Secondary CH2 refined with riding coordinates: 
 C2(H2A,H2B), C3(H3A,H3B), C7(H7A,H7B), C8(H8A,H8B) 
2.c Aromatic/amide H refined with riding coordinates: 
 C12(H12), C13(H13), C14(H14), C15(H15), C16(H16) 
2.d Idealised Me refined as rotating group: 
 C10(H10A,H10B,H10C) 
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Annex 62: X-Ray Data for Compound 4.9 
 
 
Table 1 Crystal data and structure refinement for han477. 
 
Identification code han477 
Empirical formula C16H18O3 
Formula weight 258.30 
Temperature/K 110 
Crystal system orthorhombic 
Space group Pca21 
a/Å 20.6653(5) 
b/Å 6.1757(2) 
c/Å 10.3155(3) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 1316.49(7) 
Z 4 
ρcalcg/cm3 1.303 
µ/mm‑1 0.461 
F(000) 552.0 
Crystal size/mm3 0.22 × 0.16 × 0.08 
Radiation GaKα (λ = 1.34139) 
2Θ range for data 
collection/° 7.444 to 121.25 
Index ranges -26 ≤ h ≤ 26, -8 ≤ k ≤ 8, -13 ≤ l ≤ 13 
Reflections collected 45195 
Independent reflections 2986 [Rint = 0.0229, Rsigma = 0.0145] 
Data/restraints/parameters 2986/1/174 
Goodness-of-fit on F2 1.058 
Final R indexes [I>=2σ (I)] R1 = 0.0285, wR2 = 0.0746 
Final R indexes [all data] R1 = 0.0286, wR2 = 0.0748 
Largest diff. peak/hole / e 
Å-3 0.27/-0.14 
Flack parameter 0.06(2) 
 
O
OHO Ph
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for han477. Ueq is defined as 1/3 of of the 
trace of the orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
C1 4972.0(7) 7559(2) 2508.1(15) 20.6(3) 
C2 4755.0(7) 8318(3) 3840.9(15) 27.1(3) 
C3 5363.6(7) 8204(3) 4694.1(14) 21.8(3) 
C4 5821.1(6) 6646(2) 3968.3(13) 17.1(3) 
C5 6543.8(6) 6818(2) 4375.0(14) 18.7(3) 
C6 6863.7(7) 8900(2) 3884.5(15) 22.5(3) 
C7 6733.4(8) 9438(3) 2476.7(17) 32.7(4) 
C8 6006.4(8) 9384(3) 2169.7(16) 25.1(3) 
C9 5702.6(7) 7172(2) 2519.4(13) 18.4(3) 
C10 5906.1(8) 5416(3) 1570.1(15) 25.9(3) 
C11 6648.1(6) 6413(2) 5810.6(14) 18.8(3) 
C12 6879.1(7) 4396(2) 6212.1(16) 22.2(3) 
C13 6965.4(7) 3945(3) 7526.7(17) 26.2(3) 
C14 6831.5(7) 5517(3) 8448.8(15) 26.8(3) 
C15 6604.2(8) 7531(3) 8058.9(16) 25.4(3) 
C16 6512.2(7) 7987(2) 6750.7(15) 21.8(3) 
O1 4622.5(6) 7331.0(19) 1581.3(11) 26.6(3) 
O4 5600.4(6) 4466.9(16) 4117.8(10) 22.5(2) 
O6 7220.4(6) 9982.1(18) 4546.7(12) 27.5(3) 
 
Table 3 Anisotropic Displacement Parameters (Å2×103) for han477. The 
Anisotropic displacement factor exponent takes the form:  
-2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
C1 23.6(7) 18.1(6) 19.9(7) 1.6(5) -0.8(6) -1.7(5) 
C2 21.3(6) 39.4(9) 20.7(7) -3.9(6) -1.7(6) 6.0(6) 
C3 19.6(6) 27.8(7) 18.0(6) -4.2(6) -0.4(5) 4.1(5) 
C4 19.5(6) 16.7(6) 15.1(6) -0.3(5) 0.4(5) -1.1(5) 
C5 18.5(6) 19.2(6) 18.3(6) -1.1(5) 0.3(5) 0.4(5) 
C6 19.0(6) 23.4(6) 25.3(7) 0.2(6) 2.7(5) -0.2(5) 
C7 28.6(8) 40.0(9) 29.6(8) 12.2(7) -1.0(7) -12.6(7) 
C8 28.4(7) 22.9(7) 24.0(7) 7.4(6) -2.5(6) -4.4(6) 
C9 22.1(6) 17.9(6) 15.1(6) 0.9(5) 0.0(5) 0.0(5) 
C10 32.9(8) 27.3(7) 17.5(7) -3.2(6) 0.4(6) 5.3(6) 
C11 15.7(6) 21.8(7) 18.7(6) -0.2(5) -1.3(5) -0.6(5) 
C12 18.9(6) 21.4(7) 26.2(7) -0.2(6) -0.3(5) 1.4(5) 
C13 20.3(6) 28.2(7) 30.1(8) 6.8(7) -1.7(6) 2.3(6) 
C14 18.9(6) 42.1(9) 19.4(7) 3.9(6) -0.9(5) 1.8(6) 
C15 18.8(7) 36.2(8) 21.2(7) -6.2(6) -0.4(5) 2.4(6) 
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C16 18.2(6) 23.2(7) 24.0(7) -2.6(6) -2.1(6) 2.7(5) 
O1 27.9(5) 30.5(6) 21.5(5) -0.4(4) -6.3(4) -1.1(4) 
O4 31.0(5) 19.6(5) 17.1(5) 2.7(4) -2.0(4) -6.1(4) 
O6 25.9(5) 26.2(5) 30.4(6) -5.3(5) 3.5(4) -5.9(4) 
Table 4 Bond Lengths for han477. 
 
Atom Atom Length/Å Atom Atom Length/Å 
C1 C2 1.520(2) C6 O6 1.2069(19) 
C1 C9 1.5287(19) C7 C8 1.536(2) 
C1 O1 1.2063(19) C8 C9 1.546(2) 
C2 C3 1.537(2) C9 C10 1.520(2) 
C3 C4 1.5428(19) C11 C12 1.3971(19) 
C4 C5 1.5549(18) C11 C16 1.401(2) 
C4 C9 1.5489(18) C12 C13 1.396(2) 
C4 O4 1.4295(15) C13 C14 1.387(2) 
C5 C6 1.5320(19) C14 C15 1.389(2) 
C5 C11 1.5172(19) C15 C16 1.392(2) 
C6 C7 1.514(2)    
 
Table 5 Bond Angles for han477. 
 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C2 C1 C9 109.42(12) C6 C7 C8 111.54(13) 
O1 C1 C2 125.17(14) C7 C8 C9 111.60(13) 
O1 C1 C9 125.40(14) C1 C9 C4 101.32(11) 
C1 C2 C3 105.21(12) C1 C9 C8 105.15(12) 
C2 C3 C4 104.61(12) C8 C9 C4 110.25(12) 
C3 C4 C5 114.54(11) C10 C9 C1 112.30(12) 
C3 C4 C9 103.93(11) C10 C9 C4 115.36(12) 
C9 C4 C5 113.45(11) C10 C9 C8 111.57(13) 
O4 C4 C3 109.84(11) C12 C11 C5 118.99(13) 
O4 C4 C5 109.95(11) C12 C11 C16 118.81(14) 
O4 C4 C9 104.54(11) C16 C11 C5 122.20(13) 
C6 C5 C4 112.48(11) C13 C12 C11 120.62(14) 
C11 C5 C4 112.87(11) C14 C13 C12 120.10(14) 
C11 C5 C6 113.53(12) C13 C14 C15 119.70(15) 
C7 C6 C5 115.11(13) C14 C15 C16 120.54(15) 
O6 C6 C5 122.78(14) C15 C16 C11 120.22(14) 
O6 C6 C7 122.01(14)     
 
Table 6 Hydrogen Bonds for han477. 
 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O4 H4 O11 0.84 2.00 2.8112(15) 162.9 
    11-X,1-Y,1/2+Z 
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Table 7 Torsion Angles for han477. 
 
A B C D Angle/˚ A B C D Angle/˚ 
C1 C2 C3 C4 -19.85(16) C7 C8 C9 C1 165.35(13) 
C2 C1 C9 C4 26.65(15) C7 C8 C9 C4 56.89(17) 
C2 C1 C9 C8 -88.18(14) C7 C8 C9 C10 -72.66(17) 
C2 C1 C9 C10 150.31(13) C9 C1 C2 C3 -4.53(17) 
C2 C3 C4 C5 161.10(12) C9 C4 C5 C6 46.95(15) 
C2 C3 C4 C9 36.77(15) C9 C4 C5 C11 177.00(11) 
C2 C3 C4 O4 -74.60(15) C11 C5 C6 C7 -176.11(13) 
C3 C4 C5 C6 -72.16(15) C11 C5 C6 O6 7.5(2) 
C3 C4 C5 C11 57.89(16) C11 C12 C13 C14 -1.0(2) 
C3 C4 C9 C1 -38.37(13) C12 C11 C16 C15 -0.3(2) 
C3 C4 C9 C8 72.60(14) C12 C13 C14 C15 0.7(2) 
C3 C4 C9 C10 -159.92(12) C13 C14 C15 C16 -0.2(2) 
C4 C5 C6 C7 -46.39(17) C14 C15 C16 C11 0.0(2) 
C4 C5 C6 O6 137.19(14) C16 C11 C12 C13 0.8(2) 
C4 C5 C11 C12 101.39(14) O1 C1 C2 C3 176.58(15) 
C4 C5 C11 C16 -77.72(17) O1 C1 C9 C4 -154.46(14) 
C5 C4 C9 C1 -163.40(11) O1 C1 C9 C8 90.71(17) 
C5 C4 C9 C8 -52.43(15) O1 C1 C9 C10 -30.8(2) 
C5 C4 C9 C10 75.05(16) O4 C4 C5 C6 163.61(11) 
C5 C6 C7 C8 51.19(19) O4 C4 C5 C11 -66.34(15) 
C5 C11 C12 C13 -178.37(13) O4 C4 C9 C1 76.81(12) 
C5 C11 C16 C15 178.82(14) O4 C4 C9 C8 -172.22(11) 
C6 C5 C11 C12 -129.10(14) O4 C4 C9 C10 -44.74(15) 
C6 C5 C11 C16 51.80(18) O6 C6 C7 C8 -132.37(16) 
C6 C7 C8 C9 -56.2(2)      
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Table 8 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for han477. 
 
Atom x y z U(eq) 
H2A 4411 7363 4187 33 
H2B 4587 9819 3800 33 
H3A 5258 7636 5566 26 
H3B 5563 9653 4788 26 
H5 6770 5606 3918 22 
H7A 6961 8383 1917 39 
H7B 6906 10897 2281 39 
H8A 5941 9672 1235 30 
H8B 5785 10542 2663 30 
H10A 6373 5168 1645 39 
H10B 5803 5876 685 39 
H10C 5674 4073 1769 39 
H12 6978 3320 5584 27 
H13 7116 2560 7790 31 
H14 6895 5217 9343 32 
H15 6511 8606 8690 30 
H16 6357 9370 6494 26 
H4 5548 4197 4909 34 
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Experimental 
 
Single crystals of C16H18O3 [han477] were slow recrystallized from 
chloroform–hexanes. A suitable crystal was selected and mounted on a loop 
fiber on a Bruker Venture Metaljet diffractometer. The crystal was kept at 
110 K during data collection. Using Olex2 [1], the structure was solved with 
the XT [2] structure solution program using Direct Methods and refined with 
the XL [3] refinement package using Least Squares minimisation. 
1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & 
 Puschmann, H. (2009), J. Appl. Cryst. 42, 339-341. 
2. Bourhis, L.J., Dolomanov, O.V., Gildea, R.J., Howard, J.A.K., 
Puschmann, H. (2013). in preparation. 
3. Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122. 
4. APEX2 (2008), Bruker AXS Inc., Madison, WI 53719-1173. 
5. SAINT (2009) V7.60A, Bruker AXS Inc., Madison, WI 53719-1173. 
6. XPREP (2013); X-ray data Preparation and Reciprocal space Exploration 
Program.  Bruker AXS Inc., Madison, WI 53719-1173. 
 
 
Crystal structure determination of [han477] 
Crystal Data for C16H18O3 (M =258.30 g/mol): orthorhombic, space group 
Pca21 (no. 29), a = 20.6653(5) Å, b = 6.1757(2) Å, c = 10.3155(3) Å, V = 
1316.49(7) Å3, Z = 4, T = 110 K, µ(GaKα) = 0.461 mm-1, Dcalc = 1.303 g/cm3, 
45195 reflections measured (7.444° ≤ 2Θ ≤ 121.25°), 2986 unique (Rint = 
0.0229, Rsigma = 0.0145) which were used in all calculations. The final R1 was 
0.0285 (I > 2σ(I)) and wR2 was 0.0748 (all data). 
 
Refinement model description 
Number of restraints - 1, number of constraints - unknown. 
Details: 
1. Fixed Uiso 
 At 1.2 times of: 
  All C(H) groups, All C(H,H) groups 
 At 1.5 times of: 
  All C(H,H,H) groups, All O(H) groups 
2.a Ternary CH refined with riding coordinates: 
 C5(H5) 
2.b Secondary CH2 refined with riding coordinates: 
 C2(H2A,H2B), C3(H3A,H3B), C7(H7A,H7B), C8(H8A,H8B) 
2.c Aromatic/amide H refined with riding coordinates: 
 C12(H12), C13(H13), C14(H14), C15(H15), C16(H16) 
2.d Idealised Me refined as rotating group: 
 C10(H10A,H10B,H10C) 
2.e Idealised tetrahedral OH refined as rotating group: 
 O4(H4) 
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Annex 63: X-Ray Data for Compound 4.11 
 
 
Table 1 Crystal data and structure refinement for han479. 
 
Identification code han479 
Empirical formula C13H16O2 
Formula weight 204.26 
Temperature/K 110 
Crystal system monoclinic 
Space group P21/c 
a/Å 18.7276(4) 
b/Å 7.4816(2) 
c/Å 15.9354(4) 
α/° 90 
β/° 100.5880(10) 
γ/° 90 
Volume/Å3 2194.73(9) 
Z 8 
ρcalcg/cm3 1.236 
µ/mm‑1 0.419 
F(000) 880.0 
Crystal size/mm3 0.2 × 0.12 × 0.04 
Radiation GaKα (λ = 1.34139) 
2Θ range for data 
collection/° 8.358 to 121.324 
Index ranges -24 ≤ h ≤ 24, -9 ≤ k ≤ 9, -20 ≤ l ≤ 20 
Reflections collected 35407 
Independent reflections 5040 [Rint = 0.0238, Rsigma = 0.0164] 
Data/restraints/parameters 5040/0/281 
Goodness-of-fit on F2 1.035 
Final R indexes [I>=2σ (I)] R1 = 0.0357, wR2 = 0.0919 
Final R indexes [all data] R1 = 0.0382, wR2 = 0.0944 
Largest diff. peak/hole / e 
Å-3 0.37/-0.16 
 
 
 
 
 
 
 
 
OH
Ph
O
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic 
Displacement Parameters (Å2×103) for han479. Ueq is defined as 1/3 of of the 
trace of the orthogonalised UIJ tensor. 
 
Atom x y z U(eq) 
C11 4386.0(5) 5968.9(13) 2998.2(6) 20.09(19) 
C12 4706.0(6) 4955.8(14) 3800.6(6) 25.7(2) 
C13 4188.1(5) 3490.1(14) 3996.6(6) 24.8(2) 
C14 3953.1(5) 2291.8(13) 3223.1(6) 22.7(2) 
C15 3616.1(5) 3317.8(12) 2419.1(6) 19.36(18) 
C16 4146.7(5) 4800.5(12) 2215.3(5) 17.87(18) 
C17 3414.9(6) 2037.0(14) 1672.5(7) 27.6(2) 
C18 3861.7(5) 5803.7(12) 1398.2(6) 19.22(18) 
C19 3293.2(5) 7038.1(13) 1324.7(6) 24.2(2) 
C110 3013.7(6) 7822.5(14) 540.9(7) 30.3(2) 
C111 3307.7(7) 7417.5(14) -175.1(7) 31.4(2) 
C112 3881.9(6) 6228.0(15) -108.1(6) 29.0(2) 
C113 4154.1(5) 5425.7(14) 671.6(6) 23.6(2) 
O11 4346.9(4) 7588.8(9) 2980.4(4) 25.85(16) 
O12 2969.9(4) 4154.9(10) 2613.6(5) 24.49(16) 
C21 917.5(5) 4909.7(13) 4387.9(6) 20.31(19) 
C22 916.9(5) 3996.7(14) 5233.6(6) 23.8(2) 
C23 1594.9(5) 2826.7(14) 5474.8(6) 24.1(2) 
C24 1659.3(5) 1509.1(13) 4765.1(6) 23.5(2) 
C25 1679.8(5) 2442.4(13) 3913.8(6) 20.38(19) 
C26 985.1(5) 3637.5(12) 3657.4(6) 18.56(18) 
C27 1726.5(6) 1056.4(14) 3224.8(7) 27.0(2) 
C28 928.8(5) 4564.9(12) 2804.8(6) 18.71(18) 
C29 1384.6(5) 5986.3(13) 2683.5(6) 20.39(19) 
C210 1325.8(5) 6791.7(13) 1885.3(6) 22.9(2) 
C211 807.4(6) 6202.9(13) 1199.8(6) 24.0(2) 
C212 346.0(5) 4813.8(13) 1318.7(6) 23.7(2) 
C213 405.5(5) 3998.6(13) 2114.0(6) 20.93(19) 
O21 859.8(4) 6517.1(10) 4301.6(5) 28.34(17) 
O22 2312.1(4) 3559.6(10) 4059.7(5) 23.38(15) 
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Table 3 Anisotropic Displacement Parameters (Å2×103) for han479. 
The Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
C11 17.2(4) 22.7(5) 21.0(4) -1.7(3) 5.3(3) -4.2(3) 
C12 26.1(5) 26.3(5) 22.3(4) -0.5(4) -1.7(4) -4.6(4) 
C13 26.1(5) 25.7(5) 21.4(4) 3.9(4) 1.0(4) -1.7(4) 
C14 21.5(4) 19.3(4) 26.1(5) 3.2(4) 0.8(3) -0.6(3) 
C15 16.8(4) 18.2(4) 22.7(4) 0.2(3) 2.5(3) 0.1(3) 
C16 16.3(4) 18.1(4) 19.3(4) -1.2(3) 3.6(3) 0.0(3) 
C17 29.4(5) 22.4(5) 28.4(5) -3.4(4) -2.0(4) -4.5(4) 
C18 20.2(4) 17.6(4) 19.8(4) -1.4(3) 3.4(3) -2.8(3) 
C19 27.2(5) 20.1(4) 25.6(5) -0.8(4) 5.6(4) 2.1(4) 
C110 34.0(5) 21.0(5) 33.4(5) 2.7(4) -0.1(4) 4.2(4) 
C111 43.5(6) 24.8(5) 22.7(5) 4.3(4) -2.1(4) -6.5(4) 
C112 37.9(6) 29.4(5) 20.4(4) -2.6(4) 7.1(4) -8.4(4) 
C113 25.3(5) 23.4(5) 22.9(4) -3.7(4) 6.5(4) -2.5(4) 
O11 32.4(4) 20.4(3) 25.5(3) -2.8(3) 7.2(3) -5.7(3) 
O12 17.3(3) 28.6(4) 28.4(4) 7.0(3) 6.4(3) 3.1(3) 
C21 16.4(4) 23.7(5) 21.0(4) 0.7(4) 3.9(3) 0.7(3) 
C22 25.8(5) 26.3(5) 20.2(4) 1.0(4) 6.7(3) 0.0(4) 
C23 21.6(4) 27.0(5) 22.6(4) 5.5(4) 1.8(3) -3.5(4) 
C24 21.2(4) 21.9(5) 27.7(5) 6.1(4) 4.8(4) 0.5(4) 
C25 18.1(4) 18.6(4) 24.8(4) 1.4(3) 5.1(3) -0.8(3) 
C26 16.7(4) 19.0(4) 20.3(4) 0.3(3) 4.2(3) -2.4(3) 
C27 29.5(5) 21.1(5) 32.1(5) -1.6(4) 10.0(4) 1.4(4) 
C28 17.9(4) 19.1(4) 19.5(4) -0.6(3) 4.3(3) 2.1(3) 
C29 18.9(4) 20.6(4) 21.5(4) -0.2(3) 3.2(3) 0.6(3) 
C210 24.4(4) 20.0(4) 25.8(5) 2.4(4) 8.7(4) 2.3(4) 
C211 29.8(5) 23.3(5) 19.6(4) 1.7(4) 6.1(4) 8.8(4) 
C212 24.8(4) 24.3(5) 20.4(4) -5.0(4) 0.2(3) 6.4(4) 
C213 19.2(4) 19.6(4) 24.0(4) -3.1(3) 3.9(3) 0.8(3) 
O21 37.6(4) 22.9(4) 26.1(3) 0.2(3) 9.8(3) 5.1(3) 
O22 17.0(3) 26.7(4) 26.9(3) 2.9(3) 5.5(3) -3.1(3) 
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Table 4 Bond Lengths for han479. 
 
Atom Atom Length/Å Atom Atom Length/Å 
C11 C12 1.5123(13) C21 C22 1.5111(13) 
C11 C16 1.5218(12) C21 C26 1.5268(13) 
C11 O11 1.2141(12) C21 O21 1.2129(12) 
C12 C13 1.5337(14) C22 C23 1.5319(14) 
C13 C14 1.5224(13) C23 C24 1.5217(14) 
C14 C15 1.5269(12) C24 C25 1.5325(13) 
C15 C16 1.5627(12) C25 C26 1.5697(13) 
C15 C17 1.5203(13) C25 C27 1.5244(13) 
C15 O12 1.4459(11) C25 O22 1.4331(11) 
C16 C18 1.5126(12) C26 C28 1.5119(12) 
C18 C19 1.3980(13) C28 C29 1.3991(13) 
C18 C113 1.3977(13) C28 C213 1.3982(13) 
C19 C110 1.3921(14) C29 C210 1.3934(13) 
C110 C111 1.3884(16) C210 C211 1.3928(14) 
C111 C112 1.3848(17) C211 C212 1.3867(15) 
C112 C113 1.3896(14) C212 C213 1.3924(13) 
 
Table 5 Bond Angles for han479. 
 
Atom Atom Atom Angle/˚ Atom Atom Atom Angle/˚ 
C12 C11 C16 114.61(8) C22 C21 C26 114.32(8) 
O11 C11 C12 122.20(9) O21 C21 C22 122.32(9) 
O11 C11 C16 123.15(8) O21 C21 C26 123.36(8) 
C11 C12 C13 111.31(8) C21 C22 C23 110.23(8) 
C14 C13 C12 110.83(8) C24 C23 C22 111.03(8) 
C13 C14 C15 113.38(8) C23 C24 C25 112.40(8) 
C14 C15 C16 110.53(7) C24 C25 C26 109.60(7) 
C17 C15 C14 110.16(8) C27 C25 C24 109.98(8) 
C17 C15 C16 111.12(8) C27 C25 C26 110.76(8) 
O12 C15 C14 105.73(7) O22 C25 C24 106.05(7) 
O12 C15 C16 109.04(7) O22 C25 C26 109.31(7) 
O12 C15 C17 110.11(8) O22 C25 C27 111.02(7) 
C11 C16 C15 109.87(7) C21 C26 C25 109.72(7) 
C18 C16 C11 115.14(8) C28 C26 C21 113.40(8) 
C18 C16 C15 113.20(7) C28 C26 C25 114.39(7) 
C19 C18 C16 122.87(8) C29 C28 C26 121.96(8) 
C113 C18 C16 118.86(8) C213 C28 C26 119.43(8) 
C113 C18 C19 118.20(9) C213 C28 C29 118.60(8) 
C110 C19 C18 120.58(9) C210 C29 C28 120.46(9) 
C111 C110 C19 120.31(10) C211 C210 C29 120.39(9) 
C112 C111 C110 119.77(9) C212 C211 C210 119.47(9) 
C111 C112 C113 119.91(9) C211 C212 C213 120.33(9) 
C112 C113 C18 121.20(9)     
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Table 6 Hydrogen Bonds for han479. 
 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O22 H22 O12 0.875(16) 1.975(16) 2.8407(10) 170.0(14) 
 
Table 7 Torsion Angles for han479. 
A B C D Angle/˚ A B C D Angle/˚ 
C11 C12 C13 C14 52.56(11) C21 C22 C23 C24 -54.61(10) 
C11 C16 C18 C19 -54.97(12) C21 C26 C28 C29 55.53(11) 
C11 C16 C18 C113 128.09(9) C21 C26 C28 C213 -124.24(9) 
C12 C11 C16 C15 53.81(10) C22 C21 C26 C25 -54.98(10) 
C12 C11 C16 C18 -176.97(8) C22 C21 C26 C28 175.74(7) 
C12 C13 C14 C15 -55.01(11) C22 C23 C24 C25 57.41(10) 
C13 C14 C15 C16 55.33(10) C23 C24 C25 C26 -56.67(10) 
C13 C14 C15 C17 178.52(8) C23 C24 C25 C27 -178.67(8) 
C13 C14 C15 O12 -62.54(10) C23 C24 C25 O22 61.22(10) 
C14 C15 C16 C11 -52.81(10) C24 C25 C26 C21 53.85(10) 
C14 C15 C16 C18 176.92(7) C24 C25 C26 C28 -177.41(8) 
C15 C16 C18 C19 72.59(11) C25 C26 C28 C29 -71.33(11) 
C15 C16 C18 C113 -104.34(10) C25 C26 C28 C213 108.90(9) 
C16 C11 C12 C13 -54.07(11) C26 C21 C22 C23 55.18(10) 
C16 C18 C19 C110 -174.99(9) C26 C28 C29 C210 178.94(8) 
C16 C18 C113 C112 176.03(9) C26 C28 C213 C212 -179.29(8) 
C17 C15 C16 C11 -175.44(8) C27 C25 C26 C21 175.38(8) 
C17 C15 C16 C18 54.29(10) C27 C25 C26 C28 -55.89(10) 
C18 C19 C110 C111 -1.46(16) C28 C29 C210 C211 0.64(14) 
C19 C18 C113 C112 -1.05(14) C29 C28 C213 C212 0.93(14) 
C19 C110 C111 C112 -0.02(16) C29 C210 C211 C212 0.40(14) 
C110 C111 C112 C113 0.94(16) C210 C211 C212 C213 -0.76(14) 
C111 C112 C113 C18 -0.39(15) C211 C212 C213 C28 0.09(14) 
C113 C18 C19 C110 1.96(14) C213 C28 C29 C210 -1.29(13) 
O11 C11 C12 C13 128.16(10) O21 C21 C22 C23 -125.69(10) 
O11 C11 C16 C15 -128.44(9) O21 C21 C26 C25 125.90(10) 
O11 C11 C16 C18 0.77(13) O21 C21 C26 C28 -3.38(13) 
O12 C15 C16 C11 63.01(9) O22 C25 C26 C21 -61.99(9) 
O12 C15 C16 C18 -67.26(9) O22 C25 C26 C28 66.75(10) 
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Table 8 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement 
Parameters (Å2×103) for han479. 
 
Atom x y z U(eq) 
H12A 4806 5798 4287 31 
H12B 5172 4408 3729 31 
H13A 4434 2761 4483 30 
H13B 3755 4047 4161 30 
H14A 3596 1411 3357 27 
H14B 4381 1622 3109 27 
H16 4593 4161 2117 21 
H17A 3856 1469 1549 41 
H17B 3174 2699 1169 41 
H17C 3085 1118 1818 41 
H19 3096 7344 1814 29 
H110 2620 8639 496 36 
H111 3116 7955 -709 38 
H112 4089 5961 -594 35 
H113 4546 4605 711 28 
H12 2716(9) 4560(20) 2158(10) 50(4) 
H22A 476 3248 5194 29 
H22B 908 4908 5682 29 
H23A 2032 3596 5585 29 
H23B 1569 2162 6006 29 
H24A 1241 678 4690 28 
H24B 2108 795 4933 28 
H26 560 2810 3600 22 
H27A 2158 312 3401 41 
H27B 1759 1664 2689 41 
H27C 1291 302 3141 41 
H29 1737 6405 3149 24 
H210 1641 7748 1808 27 
H211 770 6749 655 29 
H212 -12 4416 855 28 
H213 87 3047 2188 25 
H22 2464(8) 3710(20) 3577(10) 45(4) 
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Experimental 
 
Single crystals of C13H16O2 [han479] were slow recrystallized from ethyl 
acetate–hexanes. A suitable crystal was selected and mounted on a loop fiber 
on a Bruker Venture Metaljet diffractometer. The crystal was kept at 110 K 
during data collection. Using Olex2 [1], the structure was solved with the 
XT [2] structure solution program using Direct Methods and refined with the 
XL [3] refinement package using Least Squares minimisation. 
1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & 
 Puschmann, H. (2009), J. Appl. Cryst. 42, 339-341. 
2. Bourhis, L.J., Dolomanov, O.V., Gildea, R.J., Howard, J.A.K., 
Puschmann, H. (2013). in preparation. 
3. Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122. 
4. APEX2 (2008), Bruker AXS Inc., Madison, WI 53719-1173. 
5. SAINT (2009) V7.60A, Bruker AXS Inc., Madison, WI 53719-1173. 
6. XPREP (2013); X-ray data Preparation and Reciprocal space Exploration 
Program.  Bruker AXS Inc., Madison, WI 53719-1173. 
 
Crystal structure determination of [han479] 
 
Crystal Data for C13H16O2 (M =204.26 g/mol): monoclinic, space group 
P21/c (no. 14), a = 18.7276(4) Å, b = 7.4816(2) Å, c = 15.9354(4) Å, β = 
100.5880(10)°, V = 2194.73(9) Å3, Z = 8, T = 110 K, µ(GaKα) = 0.419 mm-1, 
Dcalc = 1.236 g/cm3, 35407 reflections measured (8.358° ≤ 2Θ ≤ 121.324°), 
5040 unique (Rint = 0.0238, Rsigma = 0.0164) which were used in all 
calculations. The final R1 was 0.0357 (I > 2σ(I)) and wR2 was 0.0944 (all 
data). 
 
Refinement model description 
 
Number of restraints - 0, number of constraints - unknown. 
Details: 
1. Fixed Uiso 
 At 1.2 times of: 
  All C(H) groups, All C(H,H) groups 
 At 1.5 times of: 
  All C(H,H,H) groups 
2.a Ternary CH refined with riding coordinates: 
 C16(H16), C26(H26) 
2.b Secondary CH2 refined with riding coordinates: 
 C12(H12A,H12B), C13(H13A,H13B), C14(H14A,H14B), C22(H22A,H22B), C23(H23A, 
 H23B), C24(H24A,H24B) 
2.c Aromatic/amide H refined with riding coordinates: 
 C19(H19), C110(H110), C111(H111), C112(H112), C113(H113), C29(H29), 
 C210(H210), C211(H211), C212(H212), C213(H213) 
2.d Idealised Me refined as rotating group: 
 C17(H17A,H17B,H17C), C27(H27A,H27B,H27C) 
 
 
 
 
